US20220236284A1 - Therapeutically Triggering an Innate Immune Response in a Target Tissue - Google Patents
Therapeutically Triggering an Innate Immune Response in a Target Tissue Download PDFInfo
- Publication number
- US20220236284A1 US20220236284A1 US17/542,820 US202117542820A US2022236284A1 US 20220236284 A1 US20220236284 A1 US 20220236284A1 US 202117542820 A US202117542820 A US 202117542820A US 2022236284 A1 US2022236284 A1 US 2022236284A1
- Authority
- US
- United States
- Prior art keywords
- spp
- prr
- colon
- ssi
- streptococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015788 innate immune response Effects 0.000 title description 12
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 55
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims description 43
- 241000588748 Klebsiella Species 0.000 claims description 26
- 230000002238 attenuated effect Effects 0.000 claims description 13
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 12
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 10
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 241001014264 Klebsiella variicola Species 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 206010061598 Immunodeficiency Diseases 0.000 claims description 6
- VYMCYRPQICLHKC-WCCKRBBISA-N acetic acid;(2s)-2-amino-5-[[amino-(hydroxyamino)methylidene]amino]pentanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)NO VYMCYRPQICLHKC-WCCKRBBISA-N 0.000 claims description 6
- 208000004235 neutropenia Diseases 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 150000003505 terpenes Chemical class 0.000 claims description 3
- 101710081722 Antitrypsin Proteins 0.000 claims description 2
- 230000001475 anti-trypsic effect Effects 0.000 claims description 2
- 206010033675 panniculitis Diseases 0.000 claims description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 2
- 239000002753 trypsin inhibitor Substances 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims 1
- 230000003039 myelosuppressive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 118
- 108010089193 pattern recognition receptors Proteins 0.000 abstract description 99
- 102000007863 pattern recognition receptors Human genes 0.000 abstract description 98
- 239000000556 agonist Substances 0.000 abstract description 83
- 244000052769 pathogen Species 0.000 abstract description 39
- 230000028993 immune response Effects 0.000 abstract description 31
- 210000002865 immune cell Anatomy 0.000 abstract description 11
- 208000015181 infectious disease Diseases 0.000 description 111
- 210000004027 cell Anatomy 0.000 description 110
- 206010028980 Neoplasm Diseases 0.000 description 103
- 230000001580 bacterial effect Effects 0.000 description 97
- 238000011282 treatment Methods 0.000 description 92
- 241000699670 Mus sp. Species 0.000 description 91
- 210000001072 colon Anatomy 0.000 description 79
- 108090000623 proteins and genes Proteins 0.000 description 78
- 241000894007 species Species 0.000 description 78
- 241000588724 Escherichia coli Species 0.000 description 73
- 239000000902 placebo Substances 0.000 description 68
- 229940068196 placebo Drugs 0.000 description 68
- 210000001519 tissue Anatomy 0.000 description 58
- 210000004072 lung Anatomy 0.000 description 54
- 244000052613 viral pathogen Species 0.000 description 52
- 238000009472 formulation Methods 0.000 description 51
- 230000014509 gene expression Effects 0.000 description 51
- 201000011510 cancer Diseases 0.000 description 48
- 239000000779 smoke Substances 0.000 description 45
- 235000019504 cigarettes Nutrition 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 36
- 210000000440 neutrophil Anatomy 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 36
- 108090000695 Cytokines Proteins 0.000 description 35
- 230000008938 immune dysregulation Effects 0.000 description 35
- 102000004127 Cytokines Human genes 0.000 description 34
- 150000007523 nucleic acids Chemical class 0.000 description 34
- 230000000813 microbial effect Effects 0.000 description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
- 241000194017 Streptococcus Species 0.000 description 30
- 241000701161 unidentified adenovirus Species 0.000 description 30
- 241000894006 Bacteria Species 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 27
- 210000000056 organ Anatomy 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 27
- 208000009889 Herpes Simplex Diseases 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 108020004707 nucleic acids Proteins 0.000 description 26
- 239000000427 antigen Substances 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 201000010099 disease Diseases 0.000 description 25
- 230000002163 immunogen Effects 0.000 description 25
- 210000004379 membrane Anatomy 0.000 description 25
- 239000012528 membrane Substances 0.000 description 25
- 210000001616 monocyte Anatomy 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 241001529936 Murinae Species 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 238000002347 injection Methods 0.000 description 24
- 210000002540 macrophage Anatomy 0.000 description 24
- 206010061218 Inflammation Diseases 0.000 description 23
- 241000605861 Prevotella Species 0.000 description 23
- 208000006673 asthma Diseases 0.000 description 23
- 230000004054 inflammatory process Effects 0.000 description 23
- 230000004044 response Effects 0.000 description 23
- 238000002560 therapeutic procedure Methods 0.000 description 23
- 241000191967 Staphylococcus aureus Species 0.000 description 22
- 241000193996 Streptococcus pyogenes Species 0.000 description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 21
- 241000701022 Cytomegalovirus Species 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 21
- 150000004676 glycans Chemical group 0.000 description 21
- 229920001282 polysaccharide Polymers 0.000 description 21
- 239000005017 polysaccharide Substances 0.000 description 21
- 239000003981 vehicle Substances 0.000 description 21
- 239000000304 virulence factor Substances 0.000 description 21
- 230000007923 virulence factor Effects 0.000 description 21
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 20
- 108020000411 Toll-like receptor Proteins 0.000 description 20
- 244000005700 microbiome Species 0.000 description 20
- 241000709687 Coxsackievirus Species 0.000 description 19
- 102000002689 Toll-like receptor Human genes 0.000 description 19
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 18
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 18
- 241000605909 Fusobacterium Species 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 241000193403 Clostridium Species 0.000 description 17
- 208000001382 Experimental Melanoma Diseases 0.000 description 17
- 238000010171 animal model Methods 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 206010022000 influenza Diseases 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 241001148536 Bacteroides sp. Species 0.000 description 15
- 241000588914 Enterobacter Species 0.000 description 15
- 208000007514 Herpes zoster Diseases 0.000 description 15
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 15
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 15
- 241000193998 Streptococcus pneumoniae Species 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 230000027455 binding Effects 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 208000020816 lung neoplasm Diseases 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 15
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 15
- 230000009885 systemic effect Effects 0.000 description 15
- 208000011231 Crohn disease Diseases 0.000 description 14
- 108090000176 Interleukin-13 Proteins 0.000 description 14
- 108090000978 Interleukin-4 Proteins 0.000 description 14
- 108090001005 Interleukin-6 Proteins 0.000 description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 14
- -1 c-di-IMP Chemical compound 0.000 description 14
- 201000005202 lung cancer Diseases 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 108010002616 Interleukin-5 Proteins 0.000 description 13
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 13
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- 206010009887 colitis Diseases 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 201000005404 rubella Diseases 0.000 description 13
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 12
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 12
- 241000709661 Enterovirus Species 0.000 description 12
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 12
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 12
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 12
- 108010013639 Peptidoglycan Proteins 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- 101100478426 Streptomyces albogriseolus ssi gene Proteins 0.000 description 12
- 101100366698 Streptomyces violaceus vsi gene Proteins 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 210000002175 goblet cell Anatomy 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 12
- 210000001165 lymph node Anatomy 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 11
- 108700028369 Alleles Proteins 0.000 description 11
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 11
- 108050003558 Interleukin-17 Proteins 0.000 description 11
- 102000013691 Interleukin-17 Human genes 0.000 description 11
- 208000005647 Mumps Diseases 0.000 description 11
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 11
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 11
- 230000001363 autoimmune Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000009826 distribution Methods 0.000 description 11
- 208000010805 mumps infectious disease Diseases 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 241000606124 Bacteroides fragilis Species 0.000 description 10
- 241000589876 Campylobacter Species 0.000 description 10
- 241000194033 Enterococcus Species 0.000 description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 10
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 10
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 10
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 10
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 10
- 241000191992 Peptostreptococcus Species 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 229950009571 murabutide Drugs 0.000 description 10
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 9
- 241000606125 Bacteroides Species 0.000 description 9
- 206010009900 Colitis ulcerative Diseases 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 108090000174 Interleukin-10 Proteins 0.000 description 9
- 241000186660 Lactobacillus Species 0.000 description 9
- 241000204031 Mycoplasma Species 0.000 description 9
- 241001263478 Norovirus Species 0.000 description 9
- 241000589516 Pseudomonas Species 0.000 description 9
- 241000702670 Rotavirus Species 0.000 description 9
- 241000607762 Shigella flexneri Species 0.000 description 9
- 208000000453 Skin Neoplasms Diseases 0.000 description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 description 9
- 241000607447 Yersinia enterocolitica Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000002095 exotoxin Substances 0.000 description 9
- 231100000776 exotoxin Toxicity 0.000 description 9
- 230000001613 neoplastic effect Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000001018 virulence Effects 0.000 description 9
- 229940098232 yersinia enterocolitica Drugs 0.000 description 9
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 8
- 241000193468 Clostridium perfringens Species 0.000 description 8
- 241001466953 Echovirus Species 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102100023688 Eotaxin Human genes 0.000 description 8
- 241000606768 Haemophilus influenzae Species 0.000 description 8
- 101001125032 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 1 Proteins 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 8
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 8
- 102100029424 Nucleotide-binding oligomerization domain-containing protein 1 Human genes 0.000 description 8
- 241000588769 Proteus <enterobacteria> Species 0.000 description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 8
- 241000607142 Salmonella Species 0.000 description 8
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 8
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 8
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- 210000000436 anus Anatomy 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 244000000010 microbial pathogen Species 0.000 description 8
- 108700017543 murabutide Proteins 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 238000000513 principal component analysis Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000000664 rectum Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000012552 review Methods 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 201000000849 skin cancer Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 7
- 241000193163 Clostridioides difficile Species 0.000 description 7
- 241000711573 Coronaviridae Species 0.000 description 7
- 206010014950 Eosinophilia Diseases 0.000 description 7
- 101710139422 Eotaxin Proteins 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 7
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 7
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 7
- 201000005505 Measles Diseases 0.000 description 7
- 101150058357 Muc2 gene Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 7
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
- 241000725643 Respiratory syncytial virus Species 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 7
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 7
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 7
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 7
- 241000589884 Treponema pallidum Species 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 244000309743 astrovirus Species 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000002421 cell wall Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 102000054765 polymorphisms of proteins Human genes 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000004853 protein function Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 6
- 241000606215 Bacteroides vulgatus Species 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 6
- 101710183446 C-type lectin domain family 4 member E Proteins 0.000 description 6
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 6
- 108010055166 Chemokine CCL5 Proteins 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 241000186216 Corynebacterium Species 0.000 description 6
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 6
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 6
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 6
- 108091005686 NOD-like receptors Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 241000588770 Proteus mirabilis Species 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 241000191940 Staphylococcus Species 0.000 description 6
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 6
- 241001312524 Streptococcus viridans Species 0.000 description 6
- 239000013566 allergen Substances 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- ISYJGPYKJNWIQE-BNOMVYTKSA-N butyl (2r)-2-[[(2s)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoate Chemical compound CCCCOC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O ISYJGPYKJNWIQE-BNOMVYTKSA-N 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 108010025838 dectin 1 Proteins 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 208000026278 immune system disease Diseases 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 6
- 229940124530 sulfonamide Drugs 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 150000003952 β-lactams Chemical class 0.000 description 6
- 241000186046 Actinomyces Species 0.000 description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 5
- 108090000342 C-Type Lectins Proteins 0.000 description 5
- 102000003930 C-Type Lectins Human genes 0.000 description 5
- 101100355609 Caenorhabditis elegans rae-1 gene Proteins 0.000 description 5
- 241000606153 Chlamydia trachomatis Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000991587 Enterovirus C Species 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 5
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 5
- 101001017828 Homo sapiens Leucine-rich repeat flightless-interacting protein 1 Proteins 0.000 description 5
- 101000595918 Homo sapiens Phospholipase A and acyltransferase 4 Proteins 0.000 description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102100033303 Leucine-rich repeat flightless-interacting protein 1 Human genes 0.000 description 5
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 5
- 102000012064 NLR Proteins Human genes 0.000 description 5
- 206010029098 Neoplasm skin Diseases 0.000 description 5
- 241000206591 Peptococcus Species 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 108010079723 Shiga Toxin Proteins 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 241000193985 Streptococcus agalactiae Species 0.000 description 5
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 5
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 5
- 241000589886 Treponema Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 102100040310 Z-DNA-binding protein 1 Human genes 0.000 description 5
- 101710181770 Z-DNA-binding protein 1 Proteins 0.000 description 5
- 229940126575 aminoglycoside Drugs 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940038705 chlamydia trachomatis Drugs 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- QIFGMZZTJRULMA-XLPZGREQSA-N gamma-D-glutamyl-meso-diaminopimelic acid Chemical compound OC(=O)[C@@H](N)CCC[C@H](C(O)=O)NC(=O)CC[C@@H](N)C(O)=O QIFGMZZTJRULMA-XLPZGREQSA-N 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 5
- 208000037841 lung tumor Diseases 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000000737 periodic effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 5
- 229960001082 trimethoprim Drugs 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 4
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 4
- 108060000255 AIM2 Proteins 0.000 description 4
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 4
- 108020003591 B-Form DNA Proteins 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- 241000190890 Capnocytophaga Species 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 108010040721 Flagellin Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108010015899 Glycopeptides Proteins 0.000 description 4
- 102000002068 Glycopeptides Human genes 0.000 description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 4
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 4
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 4
- 241000342334 Human metapneumovirus Species 0.000 description 4
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 108010002335 Interleukin-9 Proteins 0.000 description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 description 4
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 4
- 241000588754 Klebsiella sp. Species 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 206010054949 Metaplasia Diseases 0.000 description 4
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 4
- 241000588771 Morganella <proteobacterium> Species 0.000 description 4
- 201000002481 Myositis Diseases 0.000 description 4
- 241000192001 Pediococcus Species 0.000 description 4
- 206010034277 Pemphigoid Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 4
- 241000605894 Porphyromonas Species 0.000 description 4
- 241000607720 Serratia Species 0.000 description 4
- 239000000589 Siderophore Substances 0.000 description 4
- 108010015795 Streptogramin B Proteins 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 4
- 239000011612 calcitriol Substances 0.000 description 4
- 235000020964 calcitriol Nutrition 0.000 description 4
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 4
- 229960005084 calcitriol Drugs 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 229940124307 fluoroquinolone Drugs 0.000 description 4
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 4
- 229960000308 fosfomycin Drugs 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 4
- 229960004675 fusidic acid Drugs 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 229940047650 haemophilus influenzae Drugs 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 230000006054 immunological memory Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000005007 innate immune system Anatomy 0.000 description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 description 4
- 230000015689 metaplastic ossification Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001855 preneoplastic effect Effects 0.000 description 4
- YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 229960003127 rabies vaccine Drugs 0.000 description 4
- 208000002574 reactive arthritis Diseases 0.000 description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 3
- 102100022410 ATP-dependent DNA/RNA helicase DHX36 Human genes 0.000 description 3
- 241000379991 Anaerococcus Species 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000193755 Bacillus cereus Species 0.000 description 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 3
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 241001647372 Chlamydia pneumoniae Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108010005843 Cysteine Proteases Proteins 0.000 description 3
- 102000005927 Cysteine Proteases Human genes 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 241000192128 Gammaproteobacteria Species 0.000 description 3
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 3
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 101000901942 Homo sapiens ATP-dependent DNA/RNA helicase DHX36 Proteins 0.000 description 3
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 3
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 3
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 101000720958 Homo sapiens Protein artemis Proteins 0.000 description 3
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 108010034143 Inflammasomes Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 3
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 241000186779 Listeria monocytogenes Species 0.000 description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
- 241000203736 Mobiluncus Species 0.000 description 3
- 241000588655 Moraxella catarrhalis Species 0.000 description 3
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 3
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 3
- 241000588650 Neisseria meningitidis Species 0.000 description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 102100025067 Potassium voltage-gated channel subfamily H member 4 Human genes 0.000 description 3
- 101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100025918 Protein artemis Human genes 0.000 description 3
- 241000588768 Providencia Species 0.000 description 3
- 206010037742 Rabies Diseases 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 208000033464 Reiter syndrome Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 241000194008 Streptococcus anginosus Species 0.000 description 3
- 101710147244 TIR domain-containing protein Proteins 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 3
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000005006 adaptive immune system Anatomy 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 101150055997 capD gene Proteins 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000004953 colonic tissue Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229920003045 dextran sodium sulfate Polymers 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000002074 inflammatory monocyte Anatomy 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 230000004682 mucosal barrier function Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical class C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 2
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 2
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 description 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 2
- ADHSUZMEJHOWOL-UHFFFAOYSA-N 73120-97-5 Chemical compound OC1C2OP(O)(=O)OCC3OC(N4C(NC(=O)C=C4)=O)C(O)C3OP(O)(=O)OCC2OC1N1C=CC(=O)NC1=O ADHSUZMEJHOWOL-UHFFFAOYSA-N 0.000 description 2
- 102100030088 ATP-dependent RNA helicase A Human genes 0.000 description 2
- 102100033391 ATP-dependent RNA helicase DDX3X Human genes 0.000 description 2
- 241000201860 Abiotrophia Species 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- 241001291962 Actinobaculum Species 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 229940080328 Arginase inhibitor Drugs 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193818 Atopobium Species 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 241001464894 Blautia producta Species 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 108700012434 CCL3 Proteins 0.000 description 2
- 241000589877 Campylobacter coli Species 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 101150107838 Capg gene Proteins 0.000 description 2
- 241000046135 Cedecea Species 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 description 2
- 108010055165 Chemokine CCL4 Proteins 0.000 description 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 2
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241000024397 Dysgonomonas Species 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 241001126301 Echinostoma Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010061075 Enterobactin Proteins 0.000 description 2
- SERBHKJMVBATSJ-UHFFFAOYSA-N Enterobactin Natural products OC1=CC=CC(C(=O)NC2C(OCC(C(=O)OCC(C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-UHFFFAOYSA-N 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 241001617393 Finegoldia Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 241000193789 Gemella Species 0.000 description 2
- 241000720942 Globicatella Species 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 241000607259 Grimontia hollisae Species 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 2
- 241000588729 Hafnia alvei Species 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 101000864670 Homo sapiens ATP-dependent RNA helicase A Proteins 0.000 description 2
- 101000870662 Homo sapiens ATP-dependent RNA helicase DDX3X Proteins 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 2
- 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 2
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 2
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 2
- 101000628968 Homo sapiens Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 2
- 101001005550 Homo sapiens Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 description 2
- 101001055092 Homo sapiens Mitogen-activated protein kinase kinase kinase 7 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 description 2
- 101000973618 Homo sapiens NF-kappa-B essential modulator Proteins 0.000 description 2
- 101000979338 Homo sapiens Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 description 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
- 101000874165 Homo sapiens Probable ATP-dependent RNA helicase DDX41 Proteins 0.000 description 2
- 101000952078 Homo sapiens Probable ATP-dependent RNA helicase DDX60 Proteins 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 2
- 101000708741 Homo sapiens Transcription factor RelB Proteins 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- 101000807668 Homo sapiens Uracil-DNA glycosylase Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000702617 Human parvovirus B19 Species 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 description 2
- 102000001284 I-kappa-B kinase Human genes 0.000 description 2
- 101150106931 IFNG gene Proteins 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 201000004029 Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 2
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 2
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000712890 Junin mammarenavirus Species 0.000 description 2
- 241000588749 Klebsiella oxytoca Species 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 241001622839 Leminorella Species 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108700012928 MAPK14 Proteins 0.000 description 2
- 241000712898 Machupo mammarenavirus Species 0.000 description 2
- 101150003941 Mapk14 gene Proteins 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 102100026930 Mitogen-activated protein kinase 13 Human genes 0.000 description 2
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 description 2
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000588621 Moraxella Species 0.000 description 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 description 2
- 241000498270 Necator americanus Species 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000713112 Orthobunyavirus Species 0.000 description 2
- 241000702244 Orthoreovirus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241000193465 Paeniclostridium sordellii Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
- 102100035727 Probable ATP-dependent RNA helicase DDX41 Human genes 0.000 description 2
- 102100037439 Probable ATP-dependent RNA helicase DDX60 Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241001472782 Proteus penneri Species 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010056342 Pulmonary mass Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 2
- 241001443208 Retortamonas Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241001453443 Rothia <bacteria> Species 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 229940044665 STING agonist Drugs 0.000 description 2
- 101100421548 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) sipB gene Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 description 2
- 241000607694 Serratia odorifera Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000607766 Shigella boydii Species 0.000 description 2
- 241000607760 Shigella sonnei Species 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 241000605008 Spirillum Species 0.000 description 2
- 208000006045 Spondylarthropathies Diseases 0.000 description 2
- 101100059003 Staphylococcus aureus (strain COL) capA gene Proteins 0.000 description 2
- 101100344096 Staphylococcus aureus (strain MSSA476) lukDv gene Proteins 0.000 description 2
- 101100227488 Staphylococcus aureus (strain USA300) fnbB gene Proteins 0.000 description 2
- 101100219468 Staphylococcus aureus capF gene Proteins 0.000 description 2
- 101100112129 Staphylococcus aureus capM gene Proteins 0.000 description 2
- 241001291896 Streptococcus constellatus Species 0.000 description 2
- 241000194049 Streptococcus equinus Species 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 241000194023 Streptococcus sanguinis Species 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 241000123710 Sutterella Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 2
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 2
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 2
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 2
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 2
- 241000711517 Torovirus Species 0.000 description 2
- 102100032727 Transcription factor RelB Human genes 0.000 description 2
- ZLJJDBSDZSZVTF-LXOQPCSCSA-N Trehalose-6,6'-dibehenate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)O1 ZLJJDBSDZSZVTF-LXOQPCSCSA-N 0.000 description 2
- 241000242541 Trematoda Species 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 241001148134 Veillonella Species 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 241000607291 Vibrio fluvialis Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000010817 Wright-Giemsa staining Methods 0.000 description 2
- 101100440252 Xenopus laevis ncapg gene Proteins 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 2
- 108020005172 Z-Form DNA Proteins 0.000 description 2
- 241000985249 [Clostridium] indolis Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008372 airway inflammatory response Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229940065181 bacillus anthracis Drugs 0.000 description 2
- 108010056458 bacterial fibronectin-binding proteins Proteins 0.000 description 2
- 244000000007 bacterial human pathogen Species 0.000 description 2
- 229960001212 bacterial vaccine Drugs 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 235000020299 breve Nutrition 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 208000002849 chondrocalcinosis Diseases 0.000 description 2
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002153 concerted effect Effects 0.000 description 2
- 201000003278 cryoglobulinemia Diseases 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- SERBHKJMVBATSJ-BZSNNMDCSA-N enterobactin Chemical compound OC1=CC=CC(C(=O)N[C@@H]2C(OC[C@@H](C(=O)OC[C@@H](C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-BZSNNMDCSA-N 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 101150026034 esxC gene Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 101150104841 hlgB gene Proteins 0.000 description 2
- 229930186900 holotoxin Natural products 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 231100000043 nose-only exposure Toxicity 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000005868 ontogenesis Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 229950010550 resiquimod Drugs 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 229940115939 shigella sonnei Drugs 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 101150113992 sspB gene Proteins 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 238000011421 subcutaneous treatment Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- LJUIOEFZFQRWJG-GHYFRYPYSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)CSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O LJUIOEFZFQRWJG-GHYFRYPYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- ICZSAXDKFXTSGL-UHFFFAOYSA-N 1-[4-[5-carbamoyl-2-[(2-ethyl-5-methylpyrazole-3-carbonyl)amino]benzimidazol-1-yl]butyl]-2-[(2-ethyl-5-methylpyrazole-3-carbonyl)amino]benzimidazole-5-carboxamide Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC=C2N1CCCCN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC=C12)C(N)=O)C(N)=O ICZSAXDKFXTSGL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000009069 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Human genes 0.000 description 1
- 108010073030 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Proteins 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- MCVICBSLLMHLBJ-UHFFFAOYSA-N 6-amino-9-benzyl-7h-purin-8-one Chemical compound OC1=NC=2C(N)=NC=NC=2N1CC1=CC=CC=C1 MCVICBSLLMHLBJ-UHFFFAOYSA-N 0.000 description 1
- 108010029988 AICDA (activation-induced cytidine deaminase) Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000203024 Acholeplasma Species 0.000 description 1
- 241000604451 Acidaminococcus Species 0.000 description 1
- 241000604450 Acidaminococcus fermentans Species 0.000 description 1
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 208000002485 Adiposis dolorosa Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 241001464907 Anaerococcus hydrogenalis Species 0.000 description 1
- 241001464884 Anaerococcus lactolyticus Species 0.000 description 1
- 241001464890 Anaerococcus prevotii Species 0.000 description 1
- 241000246073 Anaerorhabdus Species 0.000 description 1
- 241000246079 Anaerorhabdus furcosa Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001147672 Ancylostoma caninum Species 0.000 description 1
- 241000498253 Ancylostoma duodenale Species 0.000 description 1
- 241000359199 Angiostrongylus costaricensis Species 0.000 description 1
- 241000244023 Anisakis Species 0.000 description 1
- 108050009514 Antigen peptide transporter 1 Proteins 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000001839 Antisynthetase syndrome Diseases 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000244185 Ascaris lumbricoides Species 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000588732 Atlantibacter hermannii Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000217846 Bacteroides caccae Species 0.000 description 1
- 241001135322 Bacteroides eggerthii Species 0.000 description 1
- 241001135228 Bacteroides ovatus Species 0.000 description 1
- 241001235572 Balantioides coli Species 0.000 description 1
- 201000002827 Balo concentric sclerosis Diseases 0.000 description 1
- 208000012904 Bartter disease Diseases 0.000 description 1
- 208000010062 Bartter syndrome Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001495171 Bilophila Species 0.000 description 1
- 241001495172 Bilophila wadsworthia Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000726108 Blastocystis Species 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 241000605902 Butyrivibrio Species 0.000 description 1
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 102100028699 C-type lectin domain family 4 member E Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- FWPKHBSTLJXXIA-CATQOQJWSA-N CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O FWPKHBSTLJXXIA-CATQOQJWSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 101150062345 CX3CR1 gene Proteins 0.000 description 1
- 101100095643 Caenorhabditis elegans set-26 gene Proteins 0.000 description 1
- 102100033093 Calcium/calmodulin-dependent protein kinase type II subunit alpha Human genes 0.000 description 1
- 241000589873 Campylobacter concisus Species 0.000 description 1
- 241000589985 Campylobacter curvus Species 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241000606208 Campylobacter gracilis Species 0.000 description 1
- 241000589996 Campylobacter rectus Species 0.000 description 1
- 241000589992 Campylobacter showae Species 0.000 description 1
- 241000589990 Campylobacter sputorum Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000190885 Capnocytophaga ochracea Species 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 241000207206 Cardiobacterium Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241001633683 Centipeda <firmicute> Species 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- 108010090591 Cloacin Proteins 0.000 description 1
- 241001327965 Clonorchis sinensis Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193470 Clostridium sporogenes Species 0.000 description 1
- 241000186524 Clostridium subterminale Species 0.000 description 1
- 101710198480 Clumping factor A Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000702669 Coltivirus Species 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 206010010252 Concentric sclerosis Diseases 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 1
- 241000918600 Corynebacterium ulcerans Species 0.000 description 1
- 241001135265 Cronobacter sakazakii Species 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 101150030419 Cx3cl1 gene Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 241000179197 Cyclospora Species 0.000 description 1
- 241000016605 Cyclospora cayetanensis Species 0.000 description 1
- 241000205707 Cystoisospora belli Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101710121036 Delta-hemolysin Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 241000604463 Desulfovibrio piger Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100221536 Dictyostelium discoideum comA gene Proteins 0.000 description 1
- 101100129336 Dictyostelium discoideum malA gene Proteins 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000024134 Diffuse cutaneous systemic sclerosis Diseases 0.000 description 1
- 241001137876 Diphyllobothrium Species 0.000 description 1
- 241000935792 Dipylidium caninum Species 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 108091034946 ESAT-6 family Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 241000588877 Eikenella Species 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 241000146368 Endolimax nana Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000146407 Entamoeba coli Species 0.000 description 1
- 241000204733 Entamoeba dispar Species 0.000 description 1
- 241000146401 Entamoeba hartmanni Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000982938 Enterobacter cancerogenus Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 241001442406 Enterocytozoon bieneusi Species 0.000 description 1
- 101710204426 Enterotoxin type A Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000007985 Erythema Infectiosum Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 108700035708 EsaB Proteins 0.000 description 1
- 101100042406 Escherichia coli O6:K15:H31 (strain 536 / UPEC) sfaS gene Proteins 0.000 description 1
- 241000023505 Escherichia coli SE15 Species 0.000 description 1
- 101100223892 Escherichia coli sulI gene Proteins 0.000 description 1
- 241000588720 Escherichia fergusonii Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 241000131486 Ewingella Species 0.000 description 1
- 101710146375 Exfoliative toxin A Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 241001126302 Fasciolopsis buski Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- KDHHWXGBNUCREU-HOTGVXAUSA-N Ferric-aerobactin Chemical compound CC(=O)N(O)CCCC[C@@H](C(O)=O)NC(=O)CC(O)(C(O)=O)CC(=O)N[C@H](C(O)=O)CCCCN(O)C(C)=O KDHHWXGBNUCREU-HOTGVXAUSA-N 0.000 description 1
- 101710128530 Fibrinogen-binding protein Proteins 0.000 description 1
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000605908 Fusobacterium gonidiaformans Species 0.000 description 1
- 241000605956 Fusobacterium mortiferum Species 0.000 description 1
- 241001303074 Fusobacterium naviforme Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 241000605978 Fusobacterium russii Species 0.000 description 1
- 241000605975 Fusobacterium varium Species 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 241001147749 Gemella morbillorum Species 0.000 description 1
- 101100010809 Geobacillus thermodenitrificans (strain NG80-2) eccC gene Proteins 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 241000235796 Granulicatella Species 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 101150063370 Gzmb gene Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000122047 Helcococcus kunzii Species 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 241001491880 Heterophyes Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 1
- 101000777599 Homo sapiens C-C chemokine receptor type 2 Proteins 0.000 description 1
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000944249 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit alpha Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101001011442 Homo sapiens Interferon regulatory factor 5 Proteins 0.000 description 1
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101000945492 Homo sapiens Killer cell immunoglobulin-like receptor 3DS1 Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 1
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 1
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 1
- 101000721642 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 description 1
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101000755690 Homo sapiens Single-stranded DNA cytosine deaminase Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 101000637726 Homo sapiens Toll/interleukin-1 receptor domain-containing adapter protein Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000611185 Homo sapiens Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
- 101000620751 Homo sapiens mRNA export factor RAE1 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241000244166 Hymenolepis diminuta Species 0.000 description 1
- 241001464384 Hymenolepis nana Species 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 102000028555 IgG binding proteins Human genes 0.000 description 1
- 108091009325 IgG binding proteins Proteins 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 101710085994 Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
- 102100039068 Interleukin-10 Human genes 0.000 description 1
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 241001162603 Iodamoeba Species 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100034833 Killer cell immunoglobulin-like receptor 3DS1 Human genes 0.000 description 1
- 241001454354 Kingella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 208000017119 Labyrinth disease Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 241001647840 Leclercia Species 0.000 description 1
- 241001647841 Leclercia adecarboxylata Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000222734 Leishmania mexicana Species 0.000 description 1
- 241001453171 Leptotrichia Species 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 101710170970 Leukotoxin Proteins 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 241000132887 Lomentospora prolificans Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 208000009777 Majeed syndrome Diseases 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000604449 Megasphaera Species 0.000 description 1
- 241000604448 Megasphaera elsdenii Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010058780 Meningitis neonatal Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001660194 Metagonimus yokogawai Species 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000243190 Microsporidia Species 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241000509624 Mitsuokella Species 0.000 description 1
- 241000509622 Mitsuokella multacida Species 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 241000203732 Mobiluncus mulieris Species 0.000 description 1
- 241000043364 Moellerella Species 0.000 description 1
- 241000043363 Moellerella wisconsensis Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 101710090077 NF-kappa-B essential modulator Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001135232 Odoribacter splanchnicus Species 0.000 description 1
- 241000242716 Opisthorchis Species 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000604373 Ovatus Species 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000606210 Parabacteroides distasonis Species 0.000 description 1
- 241000204306 Parabacteroides merdae Species 0.000 description 1
- 241000593811 Paracapillaria philippinensis Species 0.000 description 1
- 241000193157 Paraclostridium bifermentans Species 0.000 description 1
- 241001480233 Paragonimus Species 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 241000122116 Parvimonas Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 241000224539 Pentatrichomonas hominis Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000351207 Peptoniphilus Species 0.000 description 1
- 241000192013 Peptoniphilus asaccharolyticus Species 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 1
- 102100025058 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Human genes 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 241001492235 Picobirnavirus Species 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 241000606999 Plesiomonas shigelloides Species 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 241000881813 Pluralibacter gergoviae Species 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 101710199994 Poly-beta-1,6-N-acetyl-D-glucosamine N-deacetylase Proteins 0.000 description 1
- 101710111390 Poly-beta-1,6-N-acetyl-D-glucosamine synthase Proteins 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 241001135211 Porphyromonas asaccharolytica Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241001135223 Prevotella melaninogenica Species 0.000 description 1
- 241001135261 Prevotella oralis Species 0.000 description 1
- 241001135262 Prevotella oris Species 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 101710146876 Probable poly-beta-1,6-N-acetyl-D-glucosamine export protein Proteins 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102100035251 Protein C-ets-1 Human genes 0.000 description 1
- 102100024740 Protein unc-93 homolog B1 Human genes 0.000 description 1
- 241000588777 Providencia rettgeri Species 0.000 description 1
- 241000588778 Providencia stuartii Species 0.000 description 1
- 241000588733 Pseudescherichia vulneris Species 0.000 description 1
- 101100180956 Pseudomonas putida (strain ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950 / KT2440) gmk gene Proteins 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 238000012193 PureLink RNA Mini Kit Methods 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 102100025234 Receptor of activated protein C kinase 1 Human genes 0.000 description 1
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037886 Regenerating islet-derived protein 3-gamma Human genes 0.000 description 1
- 101710086144 Regenerating islet-derived protein 3-gamma Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 101150055297 SET1 gene Proteins 0.000 description 1
- 101150104646 SET4 gene Proteins 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 101150063267 STAT5B gene Proteins 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 241000224003 Sarcocystis Species 0.000 description 1
- 241000242687 Schistosoma intercalatum Species 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 241001520868 Schistosoma mekongi Species 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 102100023152 Scinderin Human genes 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000605036 Selenomonas Species 0.000 description 1
- 241001067759 Senta Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710152520 Serine protease SplA Proteins 0.000 description 1
- 101710152518 Serine protease SplB Proteins 0.000 description 1
- 101710152517 Serine protease SplC Proteins 0.000 description 1
- 101710152532 Serine protease SplE Proteins 0.000 description 1
- 101710152528 Serine protease SplF Proteins 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 101100190460 Shigella flexneri pic gene Proteins 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 101710190410 Staphylococcal complement inhibitor Proteins 0.000 description 1
- 101100438292 Staphylococcus aureus (strain Newman) cap5A gene Proteins 0.000 description 1
- 101100326706 Staphylococcus aureus cap8A gene Proteins 0.000 description 1
- 101710145796 Staphylokinase Proteins 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 241000194046 Streptococcus intermedius Species 0.000 description 1
- 101100114721 Streptococcus pneumoniae cpsB gene Proteins 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 101100043719 Streptomyces griseus strB1 gene Proteins 0.000 description 1
- 241000244177 Strongyloides stercoralis Species 0.000 description 1
- 241001648295 Succinivibrio Species 0.000 description 1
- 241001648293 Succinivibrio dextrinosolvens Species 0.000 description 1
- 208000002286 Susac Syndrome Diseases 0.000 description 1
- 241000722075 Suttonella Species 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 241000244157 Taenia solium Species 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 241000131405 Tissierella Species 0.000 description 1
- 241000167944 Tissierella praeacuta Species 0.000 description 1
- 108010060826 Toll-Like Receptor 6 Proteins 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100032120 Toll/interleukin-1 receptor domain-containing adapter protein Human genes 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 241000243774 Trichinella Species 0.000 description 1
- 241000486415 Trichiura Species 0.000 description 1
- 241000243797 Trichostrongylus Species 0.000 description 1
- 241000203807 Tropheryma Species 0.000 description 1
- 241000203826 Tropheryma whipplei Species 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 101150041147 Unc93b1 gene Proteins 0.000 description 1
- 101710160987 Uracil-DNA glycosylase Proteins 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241001148070 Vibrio furnissii Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 108091034940 WXG100 family Proteins 0.000 description 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- JHYVWAMMAMCUIR-UHFFFAOYSA-N Yersiniabactin Natural products CC(C)(C(O)C1CSC(N1)C1CSC(=N1)c1ccccc1O)C1=NC(C)(CS1)C(O)=O JHYVWAMMAMCUIR-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 101150042295 arfA gene Proteins 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000001974 autoimmune enteropathy Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 208000007456 balantidiasis Diseases 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 101150031494 blaZ gene Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 230000035571 calor Effects 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 101150002095 capB gene Proteins 0.000 description 1
- 101150118250 capC gene Proteins 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001228 classical NK T cell Anatomy 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 108010004171 colibactin Proteins 0.000 description 1
- ZWKHDAZPVITMAI-ROUUACIJSA-N colibactin Chemical compound C[C@H]1CCC(=N1)C1=C(CC(=O)NCC(=O)c2csc(n2)C(=O)C(=O)c2csc(CNC(=O)CC3=C(C(=O)NC33CC3)C3=N[C@@H](C)CC3)n2)C2(CC2)NC1=O ZWKHDAZPVITMAI-ROUUACIJSA-N 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000008867 communication pathway Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000003056 complement component 2 deficiency Diseases 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000008243 diversion colitis Diseases 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 230000035620 dolor Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 101150032154 ebpS gene Proteins 0.000 description 1
- 108010064033 elastin-binding proteins Proteins 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 206010014910 enthesopathy Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 101150022827 esaA gene Proteins 0.000 description 1
- 101150079475 esaB gene Proteins 0.000 description 1
- 101150102084 essA gene Proteins 0.000 description 1
- 101150043366 essB gene Proteins 0.000 description 1
- 101150018154 essC gene Proteins 0.000 description 1
- 101150016690 esxA gene Proteins 0.000 description 1
- 101150079015 esxB gene Proteins 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 125000001924 fatty-acyl group Chemical group 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 244000000050 gastrointestinal parasite Species 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000446 genotoxin Toxicity 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 108010008486 gp100 Melanoma Antigen Proteins 0.000 description 1
- 102000007192 gp100 Melanoma Antigen Human genes 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 101150048127 hlgA gene Proteins 0.000 description 1
- 101150057138 hlgC gene Proteins 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 101150086151 hrdB gene Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
- 208000018949 hyper-IgM syndrome type 2 Diseases 0.000 description 1
- 208000025762 hyper-IgM syndrome type 4 Diseases 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 101150032134 icaA gene Proteins 0.000 description 1
- 101150103684 icaB gene Proteins 0.000 description 1
- 101150045118 icaR gene Proteins 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 201000001373 immunodeficiency with hyper-IgM type 2 Diseases 0.000 description 1
- 201000001399 immunodeficiency with hyper-IgM type 4 Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 208000027138 indeterminate colitis Diseases 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000023002 juvenile spondyloarthropathy Diseases 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 102100022885 mRNA export factor RAE1 Human genes 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 206010072221 mevalonate kinase deficiency Diseases 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 101150087557 omcB gene Proteins 0.000 description 1
- 101150115693 ompA gene Proteins 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 201000005580 palindromic rheumatism Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 101150107865 prf1 gene Proteins 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 101150110106 rmpA gene Proteins 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 101150102864 rpoD gene Proteins 0.000 description 1
- 230000036185 rubor Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 101150064504 sdrC gene Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 101150117326 sigA gene Proteins 0.000 description 1
- 101150100487 sipA gene Proteins 0.000 description 1
- 101150105615 sipC gene Proteins 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 101150095667 splA gene Proteins 0.000 description 1
- 101150040819 splB gene Proteins 0.000 description 1
- 101150101154 splC gene Proteins 0.000 description 1
- 101150017378 splE gene Proteins 0.000 description 1
- 101150081576 splF gene Proteins 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 101150059275 sspA gene Proteins 0.000 description 1
- 101150054014 sspC gene Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- 229950008737 vadimezan Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 101150076562 virB gene Proteins 0.000 description 1
- 244000000009 viral human pathogen Species 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 244000000057 wild-type pathogen Species 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- JHYVWAMMAMCUIR-VQNLDRKJSA-N yersiniabactin Chemical compound C([C@@H](N=1)C2SC[C@H](N2)[C@@H](O)C(C)(C)C=2SC[C@@](C)(N=2)C(O)=O)SC=1C1=CC=CC=C1O JHYVWAMMAMCUIR-VQNLDRKJSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/065—Poxviridae, e.g. avipoxvirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Definitions
- an important aspect of immunological regulation involves the concerted activity of the innate immune system and the adaptive immune system.
- This concerted activity involves metabolic, enzymatic and molecular genetic changes within immune cells, orchestrating an elaborate system of cellular, cytokine and chemokine communication pathways mediating the coordinated activity of the disparate components of these complementary systems (see Iwasaki & Madzhitov, 2015, Nature Immunology 16:343-353; WO0209748; WO03051305; Turner et al., 2014, BBA-Molecular Cell Research 1843:11 2563-2582).
- An aspect of this coordinated activity underlies the recognition that ligands of the pattern recognition receptors (PRRs) of the innate immune system may be used as vaccine adjuvants to improve an adaptive immune response (see Maisonneuve et al., 2014, PNAS 111(34), 12294-9; WO2007035368).
- PRRs pattern recognition receptors
- Immunological memory involving the recognition of specific antigens by B and T cell receptors, is a long recognized and central feature of the adaptive immune system, and the basis for vaccine efficacy (see Nature Immunology, Focus on immunological memory: June 2011, Volume 12 No 6 pp 461-575). Innate immune memory is a more recently recognized and less well understood characteristic of the immune system (see Netea et al., 2015, Nature Immunology 16, 675-679; and Bordon, 2014, Nature Reviews Immunology 14, 713).
- tissue homeostasis A wide variety of innate and adaptive immune cells are understood to be resident in non-lymphoid tissues, with diverse roles in tissue homeostasis (see Nature Immunology, Focus on tissue-resident leukocytes, October 2013, Volume 14 No 10 pp 977-1100). The complexities of this homeostasis are evident in the observation that even the ontogeny of tissue resident immune cells may in some cases be distinct from the ontogeny of similar immune cells that are not tissue resident (Italiani and Boraschi, Frontiers in Immunology, October 2014, Vol 5, article 514).
- Immunomodulatory or immunogenic compositions are provided that constitute an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists.
- the PRR agonist repertoire is selected so that it in effect recapitulates a distinct portion of a PRR agonist signature of a microbial pathogen, and more specifically a pathogen that is pathogenic in a selected target tissue.
- the PRR agonist signature is distinct in the sense that it is different from PRR agonist signatures of microbes that are not pathogenic in the target tissue, and it is also distinct in the sense that it is different from the native PRR agonist signature of the wild-type pathogen.
- This distinct artificial repertoire of PRR agonists may then be formulated so that the PRR agonists are presented together in a therapeutic vehicle, for example so that the PRR agonist repertoire may be presented in combination.
- the therapeutic vehicle may for example be a recombinant microbe, a cellular fraction of a microbial cell, a microparticle or a liposome.
- the composition may for example comprise microbial agonists for at least a minimum number of distinct mammalian PRRs, for example at least 5, as described in more detail herein.
- the vehicle may then be delivered, for example systemically, so that the PRR agonist repertoire is presented to an innate immune cell resident in the target tissue in a host, such as a mammalian host.
- the therapeutic vehicle may for example aggregate the artificial repertoire of PRR agonists, so that the proximity of the plurality of PRR agonists is maintained during systemic distribution in a host.
- Compositions of this kind may be used to treat a wide variety of diseases characterized by immune dysregulation, including neoplastic diseases and auto-immune diseases.
- compositions in methods of treating an immune dysregulation in a target tissue in a mammalian host, wherein the composition comprises the foregoing artificial repertoire of mammalian PRR.
- the artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation following administration to a mammalian host.
- Composition may for example include components of the microbial mammalian pathogen that are agonists for a select number of distinct mammalian PRRs, as discussed in more detail below, for example at least 5.
- Compositions may for example be adapted for use so as to modulate an innate immune response in the target tissue.
- the therapeutic vehicle may for example include a recombinant microbe, a cellular fraction of the recombinant microbe, a cellular fraction of a microbial cell, a microparticle or a liposome, each comprising components of the microbial mammalian pathogen that provide the PRR agonists that together make up the artificial repertoire of PRR agonists.
- a recombinant microbe may for example include a recombinant gene encoding a component of at least one of the PRR agonists.
- the therapeutic vehicle may for example include a whole killed or attenuated cell of the recombinant microbe.
- the cellular fraction of the microbial mammalian pathogen may be used, for example, a bacterial outer membrane fraction; a bacterial inner membrane fraction; a pellet from a gradient centrifugation of microbial cell components; or chromosomal DNA.
- the therapeutic vehicle may for example be formulated for use for delivering the PRR agonists to the target tissue.
- the PRRs and the corresponding PRR agonists may for example be selected from the group consisting of:
- PRR PRR Agonist TLR2 Microbial cell wall components/preparations Pam2C- Aca-Benzyl-Murabutide (Pam2C- conjugated murabutide) TLR3 Polyadenylic-polyuridylic acid, Polyinosine-polycytidylic acid TLR4 Lipopolysaccharide, Monophosphoryl Lipid A TLR5 Flagellin TLR7/8 Single-stranded RNAs, Nucleoside analogs, Imidazoquinolines/Thiazoquinolines TLR9 unmethylated CpG DNA motifs NOD1 iE-DAP, Acylated iE-DAP, D-gamma- Glu-mDAP, L-Ala-gamma-D-Glu-mDAP NOD2 MDP (MurNAc-L-Ala-D-isoGln, muramyl dipeptide), N-glycolylated muramyldipeptide, N-Acetyl-mura
- the therapeutic vehicle may for example include additional therapeutic moieties, such as one or more of: GMCSF, vitamin D, NOHA, alph1 antitrypsin, glutathione, an isoprenoid, or ⁇ -galactosylceramide.
- the therapeutic vehicle further comprises an antigen, such as a cancer antigen.
- the therapeutic vehicle may further include a heterologous PRR agonist, such as a PRR agonist that is not a component of the microbial mammalian pathogen.
- the subject of treatment such as a mammalian host or human patient, may for example be suffering from a disease or condition characterized by the immune dysregulation in the target tissue, such as a cancer or an inflammatory disorder.
- the composition may be adapted for use in an amount effective to modulate a biomarker, for example one or more of PD1, PDL1, IP-10, MIG, RANTES, neutrophils, Ly6C monocytes, and NKG2D.
- a biomarker for example one or more of PD1, PDL1, IP-10, MIG, RANTES, neutrophils, Ly6C monocytes, and NKG2D.
- the composition may for example be adapted for use in an amount effective to down-regulate PD1 and/or PDL1 expression in cells present in the target tissue.
- the composition may accordingly be adapted for use so as to modulate an adaptive immune response in the host, for example as a concomitant of modulating an innate immune response.
- the therapeutic vehicle is for administration at an administration site that is not the target tissue, and the site may for example be the skin, subcutaneous tissue, the respiratory tract. Administration may be enteric, or non-enteric.
- the therapeutic vehicle may be formulated for systemic distribution of the PRR agonists following administration at a localized administration site.
- the therapeutic vehicle may be administered in a plurality of doses over a dosage duration, and the dosage duration may for example be at least two weeks, or any of other wide range of dosage regimens disclosed herein or known in the art.
- human patient treated in accordance with the invention may for example be immunosuppressed or immunocompromised, or may be geriatric or pediatric patients.
- FIG. 1 is a schematic timeline of a site specific immunotherapy (SSI) in accordance with one aspect of the invention, illustrating intra-tracheal (IT) instillation of a K. pneumoniae (KPN) whole killed cell SSI at day ⁇ 31, and subcutaneous (SQ) injections of SSI or saline (placebo) every other day starting on day ⁇ 10, with intravenous (IV) Lewis lung carcinoma (LLC) administration on day 0, followed by sacrifice (sac) on day 18.
- SSI site specific immunotherapy
- FIG. 2 is a graph illustrating therapeutic efficacy of alternative SSI formulations in a murine cancer model.
- FIG. 3 is a schematic timeline illustrating a murine pre-infection model of SSI-mediated anti-tumour efficacy.
- FIG. 4 is a graph illustrating anti-cancer efficacy of an SSI after pre-infection in a murine Lewis lung carcinoma (LLC) cancer model.
- FIG. 5 is a line graph illustrating tumour volume over time for alternative SSI therapies in a murine B16 skin cancer model. 10 ⁇ QBSAU and 1 ⁇ QBSAU are denoted as QBSAUR and QBSAU, respectively, herein.
- FIG. 6 is a bar graph illustrating tumour volume at day 7 for alternative SSI therapies in a murine B16 skin cancer model.
- FIG. 7 is a bar graph illustrating tumour volume at day 8 for alternative SSI therapies in a murine B16 skin cancer model.
- FIG. 8 is a bar graph illustrating tumour volume at day 10 for alternative SSI therapies in a murine B16 skin cancer model.
- FIG. 9 is a bar graph illustrating tumour volume at day 12 for alternative SSI therapies in a murine B16 skin cancer model.
- FIG. 10 is a bar graph illustrating tumour volume at day 14 for alternative SSI therapies in a murine B16 skin cancer model.
- FIG. 11 is a schematic illustration, top panel, showing an SSI administration schedule, and a bar graph, bottom panel, illustrating therapeutic efficacy of an SSI in a murine cancer model.
- FIG. 12 is a chart illustrating the efficacy of various SSI co-formulations in a murine cancer model.
- FIG. 13 is an alternative bar graph representation of the efficacy of various SSI co-formulations in a murine cancer model.
- FIG. 14 is a series of graphs illustrating efficacy of SSI treatment in alternative model animals in the colitis model: a logarithmic Y axis scale illustrating relative levels of IFN-gamma (A) and IL-17A expression (B), and cumulative data for IL-17A expression (C), as well as site-specific evidence of QBECO efficacy in increasing IL-18 gene expression in colon tissue, compared to QBKPN (D).
- FIG. 15 is a series of graphs illustrating efficacy of SSI treatment in alternative model animals in the colitis model: microbiome (A and B) and histology (C).
- FIG. 16 is a bar graph illustrating efficacy of an SSI in a murine asthma/allergy model.
- FIG. 17 includes two bar graphs illustrating efficacy of an SSI in a murine asthma/allergy model, showing counts of A) Eosinophils, B) Lymphocytes.
- FIG. 18 includes two bar graphs illustrating efficacy of an SSI in a murine asthma/allergy model, showing A) IL-4 and B) IL-5 concentrations.
- FIG. 19 is a bar graph illustrating results of ex-vivo imaging of Cy5.5 labelled KPN SSI (QBKPN) measured in organs (heart, lungs and spleen) 24 hours after a third SQ SSI injection.
- QBKPN Cy5.5 labelled KPN SSI
- FIG. 20 is a bar graph illustrating house dust mite (HDM)-specific IgE responses following saline or HDM exposure, treated with either Placebo or QBKPN.
- HDM house dust mite
- FIG. 21 is a series of bar graphs (A-E) illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly BAL cell counts and differentials in Saline or HDM exposed mice treated with Placebo or QBKPN SSI.
- FIG. 22 includes two bar graphs illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly serum (A) and BAL (B) mediators that are linked to eosinophilia.
- FIG. 23 is a series of bar graphs illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly Th1 (A) and Th2 (B and C) lung gene expression following HDM exposure and QBPKN treatment.
- FIG. 24 is a series of bar graphs illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly the effects of HDM exposure and QBKPN treatment on Th1- (A-C) and Th2- (D-F) mediated BAL fluid cytokine levels.
- FIG. 25 is a graph illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly a principal component analysis (PCA) of BAL cytokines showing partial normalization of overall cytokine profile.
- PCA principal component analysis
- FIG. 26 is a bar graph illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly illustrating airway goblet cell quantification following HDM exposure and QBPKN treatment.
- FIG. 27A is a bar graph illustrating aspects of an anti-inflammatory SSI treatment for COPD from an animal model, particularly BAL cell differential.
- FIG. 27B reflects this data, illustrating that a KPN SSI intervention attenuated cigarette smoke exposure induced increases in lung macrophages and lymphocytes but not total cells or neutrophils.
- FIG. 27B illustrates BAL cell counts and differentials following placebo and KPN SSI treatment in filtered air or cigarette smoke-exposed groups: (a) BAL total cells, (b) lymphocytes, (c), macrophages (d), and neutrophils. *p ⁇ 0.05 comparing to the groups relative control; #p ⁇ 0.05 comparing KB group to relative placebo control. Data are means ⁇ SD of 9-10 mice per group.
- FIGS. 28A-28D illustrates data showing that a KPN SSI intervention attenuated cigarette smoke exposure induced increases Th1-skewed lung inflammatory responses, as follows.
- IFN ⁇ IFN ⁇
- CXCL9 CXCL9
- CXCL10 CCL5
- CCL5 CCL5
- CCL5 CCL5
- IL-6 IL-6
- G-CSF G-CSF
- Data are means ⁇ SD of 10 mice per group.
- FIG. 28B provides data illustrating that KPN SSI intervention differentially modulates cigarette smoke exposure induced changes in serum immune mediators, as follows. Serum analysis following placebo and KPN treatment in filtered air or cigarette smoke-exposed groups: (a) VEGF, (b) IL-1 ⁇ , (c) CCL2, (d) CXCL9, (e) CXCL10 and (f) CCL5. *p ⁇ 0.05 comparing to the groups relative control; #p ⁇ 0.05 comparing KB group to relative placebo control. Data are means ⁇ SD of 9-10 mice per group.
- FIG. 28C provides data illustrating that KPN SSI intervention increased blood and lung Ly6CHI monocytes and neutrophils, as follows.
- FIG. 28D is series of bar graphs (A-C) illustrating aspects of an anti-inflammatory SSI treatment for COPD from an animal model, particularly select lung gene expression profiles.
- FIG. 29 is a series of bar graphs (A-G) illustrating aspects of an anti-inflammatory SSI treatment for COPD from an animal model, particularly select BAL cytokine expression profiles.
- FIG. 30 is a series of bar graphs (A-C) illustrating aspects of an anti-inflammatory SSI treatment for COPD from an animal model, particularly serum cytokine expression profiles.
- FIG. 31 is a bar graph illustrating reduced tumour burden in a B16 melanoma model of metastases to the lung using a Klebsiella variicola SSI.
- FIG. 32 is a bar graph illustrating QBKPN SSI efficacy in reducing lung nodules in the absence of CD25 positive cells.
- FIG. 33 includes three bar graphs:
- FIG. 33A is a bar graph illustrating delta C t (cycle threshold) values associated with a KPN SSI formulation (QBKPN) administered in a B16 melanoma model of metastases to the lung, with progressive dilutions of the KPN SSI (10 ⁇ , 100 ⁇ and 1000 ⁇ ). Delta C t values are inversely proportional to the amount of target nucleic acid in the sample. As illustrated, tumour burden increased with increasing dilution of the SSI.
- FIG. 33B is a bar graph illustrating a similar dose-dependent effect of the KPN SSI as measured by the number of B16 tumour nodules in the lung.
- FIG. 33C is a bar graph illustrating that a variety of dosing regimes provide a therapeutic effect, with intervals between injections varying from 1 to 7 days all providing a therapeutic effect.
- FIG. 34 includes two bar graphs illustrating that the proportion of cells that express Rae-1 was inversely correlated with tumour burden in a B16 melanoma model of metastases to the lung (A) and this is dependent on NKG2D expression (B).
- FIG. 35 is a bar graph illustrating that a QBKPN SSI provided a markedly stronger effect in reducing tumour nodules in the lung in a Lewis lung carcinoma (LLC)-RFP model.
- LLC Lewis lung carcinoma
- FIG. 36 is a bar graph illustrating a concomitant reduction in the number of LLC-RFP cells in the lungs at day 15 after inoculation with LLC.
- FIG. 37 is a line graph showing that a QBECO SSI conferred a greater survival advantage than did either QBKPN or QBSAU in an MC38 colon cancer model.
- FIG. 38 is a bar graph illustrating that mice treated with a QBKPN SSI, but not 10 ⁇ QBSAU, exhibited elevated lung-specific Rae-1 expression in a skin and lung tumour model.
- FIG. 39 is a bar graph illustrating decreased PD-1 expression in the lung of QBKPN-treated mice as compared to placebo-treated mice in the skin and lung tumour model.
- FIG. 40 is a bar graph illustrating that treating mice with 10 ⁇ QBSAU, but not QBKPN, led to a decrease in the skin tumour burden as compared to placebo control in the B16 skin and lung tumour model.
- FIG. 41 is a bar graph illustrating that both intravenous (IV) SSI and subcutaneous (SQ) SSI treatments provide therapeutic benefit in a B16 lung metastasis model.
- FIG. 42 is a schematic time line illustrating the study design for an example based on efficacy of QBKPN in a treatment and prophylaxis of cancer in a B16 lung cancer model.
- FIG. 43 includes 4 bar graphs illustrating efficacy of QBKPN in a treatment and prophylaxis of cancer in a B16 lung cancer model.
- FIG. 44 is a bar graph illustrating aspects of the efficacy of QBKPN in a treatment and prophylaxis of cancer in a B16 lung cancer model.
- FIG. 45 is a bar graph illustrating aspects of how quickly SSI therapies have detectable therapeutic effects involving myeloid cell populations, particularly neutrophils.
- FIG. 46 is a bar graph illustrating aspects of how quickly SSI therapies have detectable therapeutic effects involving myeloid cell populations, particularly Ly6C monocytes.
- FIGS. 47A and 47D are a series of graphs illustrating efficacy of alternative cellular fractions in a B16 melanoma model in the lung, including dose-dependent and site-specific efficacy.
- FIG. 47A includes three bar graphs illustrating that both 1 ⁇ and 0.01 ⁇ KPN outer membrane fractions (i) were efficacious, in a dose-dependent manner, with the 1 ⁇ fraction having comparable efficacy to the whole killed cell formulation, as were the 1 ⁇ and 4 ⁇ DNA fractions (ii), while the inner membrane fraction showed a dose dependent trend that lacked strong statistical significance (iii).
- FIG. 47B is a bar graph illustrating results following 10 injections of outer membrane SSI, showing that Rae-1 expression was elevated by the outer membrane fraction in a dose dependent manner.
- FIG. 47C includes two bar graphs illustrating OM dose-dependent elevated neutrophil and monocyte blood counts after 4 injections of QBKPN SSI, placebo, or various concentrations of OM fraction (0.01 ⁇ , 1 ⁇ , 10 ⁇ or 20 ⁇ ) in blood collected 2 days prior to tumour implant.
- FIG. 47D is a column scatter graph plot illustrating the site-specific efficacy of KPN fractions compared to E. coli fractions in the B16 lung cancer model.
- FIG. 48 is a bar graph illustrating that a QBKPN SSI increases NCI-H358 cancer cell death at high doses (1/20, 1/200 dilution) in a 24-hour killing assay.
- FIG. 49 is a bar graph illustrating that a KPN SSI increases ⁇ T cell mediated killing of NCI-H358 cancer cells at alternative doses (1/20 dilution, 1/200 dilution) in a 24 hour cell killing assay.
- FIG. 50 is a bar graph illustrating that a KPN SSI (QBKPN) potentiated the effect of zoledronate in inducing ⁇ T cell mediated cancer cell lysis, at 1/200 and 1/2000 dilutions in a 24 hour cell killing assay.
- QBKPN KPN SSI
- FIG. 51 is a line graph illustrating the therapeutic efficacy of a QBECO SSI in a MC-38 colon cancer model.
- FIG. 52 is a line graph illustrating that NKG2D expression is correlated with QBECO efficacy in a MC-38 colon cancer model using NKG2D knockout mice.
- FIG. 53 is a schematic representation of a treatment schema in a model neutropenia system.
- FIG. 54 is a series of 4 graphs that depict the results of flow cytometry in the neutropenia model, illustrating counts of particular cell populations from lung samples, gated on live, CD45+CD11b+ cells.
- FIG. 55 includes two column scatter graph plots illustrating the proportion (A) and number (B) of neutrophils in lung samples in the neutropenia model.
- FIG. 56 includes two plots illustrating the proportion (A) and number (B) of neutrophils in spleen samples in the neutropenia model.
- FIG. 57 is a bar graph illustrating the proportion of cells having the denoted characteristics in blood samples from lung cancer patients segregated into a neoplastic patient population and a pre-neoplastic patient population, showing elevated PDL1 and PD1 expression in the neoplastic patient population compared to the pre-neoplastic patients.
- FIG. 58 is a bar graph illustrating the relative number of cells having the denoted characteristics in blood samples from lung cancer patients segregated into a neoplastic patient population and a pre-neoplastic patient population, showing elevated PDL1 and PD1 expression in the neoplastic patient population compared to the pre-neoplastic patients.
- FIGS. 59A and 59B include two bar graphs illustrating the SSI mediated reduction of PD-L1 expression in neoplastic lung cancer in two patients, Patient 01-001 ( FIG. 59A ) and Patient 01-002 ( FIG. 59B ), at: week 1, day 4 (W1D4); week 1, day 5 (W1D5); week 2 (W2); week 4 (W4), week 12 (W12) and week 16 (W16)
- FIGS. 60A and 60B include two bar graphs illustrating the SSI mediated reduction in PD-1 expression in two neoplastic lung cancer patients, Patient 01-001 ( FIG. 60A ) and Patient 01-002 ( FIG. 60B ).
- FIGS. 61A and 61B include two bar graphs illustrating the increase in the proportion of M1 macrophages in two neoplastic lung cancer patients, Patient 01-001 ( FIG. 61A ) and Patient 01-002 ( FIG. 61B ).
- FIGS. 62A and 62B include two bar graphs, showing RT-qPCR fold changes in ( FIG. 62A ) GzmA, GzmB, Prf1, and ( FIG. 62B ) Tyr in lungs of B16 inoculated mice with differing QBKPN doses. Data points are mean+/ ⁇ SD. Significance was calculated using a one-way Tukey's multiple comparison ANOVA test. **p ⁇ 0.01, p ⁇ 0.001 and ****p ⁇ 0.0001.
- FIG. 63 includes three bar graphs illustrating the activation of pattern recognition receptors in HEK cells after QBECO or QBKPN stimulation, showing respectively: A) Toll-like receptor (TLR) activation as measured by NK- ⁇ B activation; B) NOD2 and C-type lectin receptors (CTL) as measured by NK- ⁇ B activation; and, C) RLR (Rig-1-like receptors) as measured by IRF3 activation.
- TLR Toll-like receptor
- CTL C-type lectin receptors
- FIG. 64 is a PRR repertoire fingerprint bar graph, in which a PRR fingerprint was constructed for QBECO and QBKPN SSIs from the 1/10 dilution data, after subtracted the negative control data. Bars, in order, represent TLR2, 3, 4, 5, 7, 8, 9, NOD1, NOD2, Dectin 1a, Dectin 1b and Mincle. RIG-1 and MDA5 are not shown. The positive control is specific for each PRR (ie LPS for TLR4).
- FIG. 65 is a PRR fingerprint radar graph, in which a PRR fingerprint was constructed for QBECO and QBKPN SSIs from the 1/10 dilution data, after subtracted the negative control data, and plotted on a radar graph.
- QBKPN is a bacterial SSI derived from Klebsiella .
- Rabies is the Imrab 3TF Rabies Vaccine which contains killed rabies virus.
- FIG. 67 is a bar graph illustrating Ly6C HI monocyte levels in the blood at day 7 after treatment with Placebo, QBKPN or Rabies Vaccine.
- Ly6C HI monocyte levels were measured by flow cytometry and were assessed as the percentage of Ly6C HI monocyte (Ly6C HI Ly6G ⁇ ) of total CD45+ cells.
- N 4-5 mice per group. * is P ⁇ 0.05 compared to placebo as assessed by Student's t-test. Average ⁇ standard deviation shown.
- QBKPN is a bacterial SSI derived from Klebsiella .
- Rabies is the Imrab 3TF Rabies Vaccine which contains killed rabies virus.
- Fel-O-Vac is Feline Rhinotracheitis-Calici-Panleukopenia Vaccine which contains the three killed viruses.
- Nobivac is Canine Influenza H3H8 which contains killed influenza H3H8.
- FIG. 68 is a column scatter plot illustrating cancer antigen potentiation using QBKPN to potentiate the effect of the melanoma-associated antigen gp100.
- the anti-tumour efficacy of QBKPN SSI in combination with gp100 is compared to the irrelevant control antigen OVA (SIINFEKL), including OVA adjuvanted with CpG.
- FIG. 69 is a column scatter plot illustrating surface metastatic-like tumour nodules in mice challenged with B16 melanoma, evidencing enhanced efficacy of the microbial SSI QBKPN augmented with an additional PRR agonist, the STING agonist 2′2′-cGMAP.
- FIG. 70 is a column scatter plot illustrating treatment-induced IFN- ⁇ levels in plasma in mice challenged with B16 melanoma, evidencing enhanced IFN- ⁇ levels when the microbial SSI QBKPN is augmented with a STING agonist.
- FIG. 71A is a violin plot representing the log distribution of risk scores, comparing last recorded response for all CD subjects using risk scores based on 112 IBD SNPs (P-value: 2.430E-05).
- FIG. 71B is a violin plot representing the log distribution of risk scores, comparing last recorded response for all CD subjects using risk scores based on 3 IBD SNPs (P-value: 1.385E-04).
- FIG. 72 is a violin plot representing the log distribution of risk scores, comparing last recorded response for all UC subjects using risk scores based on 84 IBD SNPs (P-value: 1.255E-02).
- FIG. 73 is a violin plot representing the log distribution of risk scores, comparing last recorded response for all CD and UC subjects using risk scores based on 112 IBD SNPs (P-value: 8.184E-07).
- FIG. 74 is a graph illustrating the change in serum IL-18 levels in patients treated with QBECO vs. Placebo.
- FIG. 75 is a set of 4 graphs illustrating serum immune cytokine changes with QBECO treatment that associated with clinical response.
- FIG. 76 is a set of 3 graphs illustrating baseline levels of Eotaxin-1, IL-10 and IL-12p40 by patient response to QBECO.
- FIG. 77 is a graph illustrating the change in body weight over time in a murine DSS colitis model.
- FIG. 78 is a graph illustrating change in disease activity index over time in a murine DSS colitis model.
- FIG. 79 is a graph illustrating change in the FITC-dextran assay over time in a murine DSS colitis model.
- FIG. 82 is a graph illustrating the pharmacokinetics of QBKPN, in which QBKPN SSI was fluorescently labelled and subcutaneously injected into disease-free mice. Mice were bled at different timepoints over 48 hours and the blood cell count was quantified.
- FIG. 83 includes 6 bar graphs, illustrating gene expression in the lung tissues for CXCL10 (IP-10), CCL2 (MCP-1) and CCR2. Mice were treated every second day for 10 days with Placebo, QBKPN or QBECO before B16F10 tumour implantation into the lungs via tail vein injection. Treatment continued every second day after tumour inoculation. Mice were euthanized on day 5 (A, C, E) or day 17 (B, D, F).
- an “immunogen” refers to a molecule, or a composition comprising the molecule, that is capable of eliciting an immune response by an organism's immune system.
- An “antigen” refers to a molecule that is capable of binding to the product of an immune response.
- “Pathogenic” agents are agents, such as microbes, such as bacteria or viruses, which are known to cause infection in a host in nature, and in this sense, “pathogenic” is used in the context of the present invention to mean “naturally pathogenic”. Although a wide variety of microbes may be capable of causing infection under artificial conditions, such as artificial inoculations of a microbe into a tissue, the range of microbes that naturally cause infection is necessarily limited, and well established by medical practice.
- An “infection” is the state or condition in which the body or a part of it is invaded by a pathogenic agent (e.g., a microbe, such as a bacterium) which, under favorable conditions, multiplies and produces effects that are injurious (Taber's Cyclopedic Medical Dictionary, 14th Ed., C. L. Thomas, Ed., F. A. Davis Company, PA, USA).
- a pathogenic agent e.g., a microbe, such as a bacterium
- An infection may not always be apparent clinically and may result in only localized cellular injury. Infections may remain subclinical, and temporary if the body's defensive mechanisms are effective. Infections may spread locally to become clinically apparent as an acute, a subacute, or a chronic clinical infection or disease state.
- a local infection may also become systemic when the pathogenic agent gains access to the lymphatic or vascular. Infection is usually accompanied by inflammation, but inflammation may occur without infection.
- Inflammation is the characteristic tissue reaction to injury (marked by swelling, redness, heat, and pain), and includes the successive changes that occur in living tissue when it is injured. Infection and inflammation are different conditions, although one may arise from the other (Taber's Cyclopedic Medical Dictionary, supra). Accordingly, inflammation may occur without infection and infection may occur without inflammation (although inflammation typically results from infection by pathogenic bacteria or viruses). Inflammation is characterized by the following symptoms: redness (rubor), heat (calor), swelling (tumour), pain (dolor). Localized visible inflammation on the skin may be apparent from a combination of these symptoms, particularly redness at a site of administration.
- a “subject” is an animal, for e.g., a vertebrate or a mammal. Accordingly, a subject may be a patient, e.g., a human, suffering from an immune dysregulation. A subject may also be an experimental animal, e.g., an animal model of an immune dysregulation. In some embodiments, the terms “subject” and “patient” may be used interchangeably, and may include a human, a non-human mammal, a non-human primate, a rat, mouse, or dog.
- a healthy subject may be a human who is not suffering from a disease, such as a cancer or immune dysfunction, or suspected of having the disease, or who is not suffering from a chronic disorder or condition.
- a “healthy subject” may also be a subject who is not immunocompromised.
- immunocompromised is meant any condition in which the immune system functions in an abnormal or incomplete manner. Immunocompromisation may be due to disease, certain medications, or conditions present at birth. Immunocompromised subjects may be found more frequently among infants, the elderly, and individuals undergoing extensive drug or radiation therapy.
- sample from a subject may include any relevant biological material, including for example a cell, tissue or bodily fluid sample taken from a patient.
- a sample may conveniently include samples of skin, cheek, blood, stool, hair or urine.
- Sample nucleic acids for use in diagnostic and prognostic methods can for example be obtained from a selected cell type or tissue of a subject.
- a subject's bodily fluid e.g. blood
- nucleic acid tests can be performed on dry samples (e.g., hair or skin).
- polymorphism refers to a location within a biological sequence, such as a genomic sequence, which varies within a population. Polymorphisms are comprised of different “alleles”.
- genotyp refers to the specific alleles in a genome, for example in a cell, tissue sample or an individual.
- the location of a polymorphism may be identified by its position, for example within the genome or within a sequence such as a protein that is reflective of a genomic locus. This may for example be provided in the form of a characterization of the different amino acids or bases that are found at a designated location.
- the genotype is typically comprised of at least two alleles, which may be the same (homozygous) or different (heterozygous).
- Individual polymorphisms are typically assigned unique identifiers in the art (such as “Reference SNP”, “refSNP” or “rs#”), for example in the Single Nucleotide Polymorphism Database (dbSNP) of Nucleotide Sequence Variation available on the NCBI website.
- Characterization of polymorphisms, alleles or a genotype may be performed by any of very wide variety of methods. These methods may for example variously involve hybridization, labeling, cloning, sequencing and/or amplification of nucleic acids, such as genomic DNA, for example using PCR, LCR, xMAP, invader assays, mass spectrometry, pyrosequencing, selective oligonucleotide hybridization, selective amplification, selective primer extension or probes.
- probes includes naturally occurring or recombinant single- or double-stranded nucleic acids or chemically synthesized nucleic acids.
- a probe can for example be a polynucleotide of a length suitable for selective hybridization to a nucleic acid containing a polymorphic region. Labeled probes also can be used in conjunction with amplification of a polymorphism.
- DNA microarray technologies sometimes referred to as DNA chips or gene chips, may for example be used for genomic characterization, for example to characterize point mutations, single nucleotide polymorphisms (SNPs), and/or short tandem repeats (STRs).
- SNPs single nucleotide polymorphisms
- STRs short tandem repeats
- several probes capable of hybridizing specifically to an allelic variant may be attached to a solid phase support by a variety of processes, including lithography.
- Allele specific hybridization may for example make use of probes overlapping the polymorphic site and having about 5, or alternatively 10, or alternatively 20, or alternatively 25, or alternatively 30 nucleotides around the polymorphic region.
- the presence of the specific allele in DNA from a subject can in some case be characterized by restriction enzyme analysis.
- cleavage agents such as a nuclease, hydroxylamine or osmium tetroxide
- protection from cleavage agents can be used to detect mismatched bases in RNA/RNA DNA/DNA, or RNA/DNA heteroduplexes, using technique that may be described as “mismatch cleavage” assays.
- Alterations in electrophoretic mobility may be used to characterize allelic variants, for example to detect single strand conformation polymorphisms.
- kits for example comprising at least one probe or primer nucleic acid, or one of more of the compositions described herein and instructions for use of the kit.
- Kits can for example comprise at least one probe or primer which is capable of specifically hybridizing to a polymorphic region or adjacent to the polymorphic region, so that the oligonucleotides are “specific for” the polymorphic region.
- Kits may also comprise at least one reagent necessary to perform a particular assay.
- Kits can also include positive controls, negative controls, sequencing markers, or antibodies, for example for determining a subject's genotype or biological marker profile.
- an “immune response” includes, but is not limited to, one or more of the following responses in a mammal: induction or activation of antibodies, neutrophils, monocytes, macrophages (including both M1-like macrophages and M2-like macrophages as described herein), B cells, or T cells (including helper T cells, natural killer cells, cytotoxic T cells, gamma-delta ( ⁇ ) T cells), such as induction or activation by one or more immunogens in an immunogenic composition, following administration of the composition.
- An immune response to a composition thus generally includes the development in the host animal of a cellular and/or antibody-mediated response to the composition.
- the immune response is such that it will also result in slowing or stopping the progression of an immune dysregulation, or a disease characterized by immune dysregulation.
- An immune response may accordingly include one or both of a cellular immune response and/or a humoral immune response, and may be an adaptive response or an innate immune response.
- Immuno dysregulation is an inappropriately regulated immune response, such as an inappropriately restrained or inappropriately robust immune response.
- the immune dysregulation may for example be in the context of an autoimmune, inflammatory, or degenerative disease (such as rheumatoid arthritis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, neurodegenerative disease, or allergies) or a neoplastic disease, such as a cancer, or a host defense against pathogens.
- IBD Inflammatory bowel disease
- IBD Crohn's disease and ulcerative colitis.
- IBD may also include conditions recognized as any one of the following: collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behget's syndrome or indeterminate colitis. The difference between these conditions relate primarily to the location and nature of the inflammatory changes in the gastrointestinal tract (GIT).
- GIT gastrointestinal tract
- Crohn's disease for example, is generally recognized as potentially affecting any part of the gastrointestinal tract, from mouth to anus, with a majority of the cases marked by relapsing and remitting granulomatous inflammation of the alimentary tract in the terminal ileum and colon.
- Ulcerative colitis in contrast, is generally considered to be restricted to the colon and the rectum.
- the various regions of the gastrointestinal tract in which these inflammatory conditions may exhibit symptoms include: the bowel or intestine, including: the small intestine (which has three parts: the duodenum, the jejunum, and the ileum); the large intestine (which has three parts: the cecum, the colon, which includes the ascending colon, transverse colon, descending colon and sigmoid flexure; and the rectum); and, the anus.
- a “site specific immunotherapy” is an immunomodulatory treatment that is effective to therapeutically or prophylactically alter an aspect of the immune state, or immune system physiology, at an anatomical site or sites, such as an organ or tissue.
- an SSI may be adapted to ameliorate an immune dysregulation, or to treat a condition characterized by an immune dysregulation.
- a “cancer” or “neoplasm” is any unwanted growth of cells serving no physiological function.
- a cancer cell has been released from its normal cell division control, i.e., a cell whose growth is not regulated by the ordinary biochemical and physical influences in the cellular environment.
- cancer is a general term for diseases characterized by abnormal uncontrolled cell growth.
- a cancer cell proliferates to form clonal cells that are malignant.
- the lump or cell mass, “neoplasm” or “tumour,” is generally capable of invading and destroying surrounding normal tissues.
- malignancy is meant as an abnormal growth of any cell type or tissue that has a deleterious effect in the organism having the abnormal growth.
- malignancy or “cancer” includes cell growths that are technically benign but which carry the risk of becoming malignant. Cancer cells may spread from their original site to other parts of the body through the lymphatic system or blood stream in a process known as “metastasis.” Many cancers are refractory to treatment and prove fatal. Examples of cancers or neoplasms include, without limitation, transformed and immortalized cells, tumours, carcinomas, in various organs and tissues as described herein or known to those of skill in the art.
- carcinomas which are the predominant cancers and are cancers of epithelial cells or cells covering the external or internal surfaces of organs, glands, or other body structures (for e.g., skin, uterus, lung, breast, prostate, stomach, bowel), and which tend to metastasize; carcinomas, which are derived from connective or supportive tissue (for e.g., bone, cartilage, tendons, ligaments, fat, muscle); and hematologic tumours, which are derived from bone marrow and lymphatic tissue.
- connective or supportive tissue for e.g., bone, cartilage, tendons, ligaments, fat, muscle
- hematologic tumours which are derived from bone marrow and lymphatic tissue.
- Carcinomas may be adenocarcinomas (which generally develop in organs or glands capable of secretion, such as breast, lung, colon, prostate or bladder) or may be squamous cell carcinomas (which originate in the squamous epithelium and generally develop in most areas of the body).
- adenocarcinomas which generally develop in organs or glands capable of secretion, such as breast, lung, colon, prostate or bladder
- squamous cell carcinomas which originate in the squamous epithelium and generally develop in most areas of the body.
- Sarcomas may be osteosarcomas or osteogenic sarcomas (bone), chondrosarcomas (cartilage), leiomyosarcomas (smooth muscle), rhabdomyosarcomas (skeletal muscle), mesothelial sarcomas or mesotheliomas (membranous lining of body cavities), fibrosarcomas (fibrous tissue), angiosarcomas or hemangioendotheliomas (blood vessels), liposarcomas (adipose tissue), gliomas or astrocytomas (neurogenic connective tissue found in the brain), myxosarcomas (primitive embryonic connective tissue), or mesenchymous or mixed mesodermal tumours (mixed connective tissue types).
- Hematologic tumours may be myelomas, which originate in the plasma cells of bone marrow; leukemias which may be “liquid cancers” and are cancers of the bone marrow and may be myelogenous or granulocytic leukemia (myeloid and granulocytic white blood cells), lymphatic, lymphocytic, or lymphoblastic leukemias (lymphoid and lymphocytic blood cells) or polycythemia vera or erythremia (various blood cell products, but with red cells predominating); or lymphomas, which may be solid tumours and which develop in the glands or nodes of the lymphatic system, and which may be Hodgkin or Non-Hodgkin lymphomas.
- mixed type cancers such as adenosquamous carcinomas, mixed mesodermal tumours, carcinosarcomas, or teratocarcinomas also exist.
- lung cancers are generally small cell lung cancers or non-small cell lung cancers, which may be squamous cell carcinoma, adenocarcinoma, or large cell carcinoma; skin cancers are generally basal cell cancers, squamous cell cancers, or melanomas. Lymphomas may arise in the lymph nodes associated with the head, neck and chest, as well as in the abdominal lymph nodes or in the axillary or inguinal lymph nodes.
- Identification and classification of types and stages of cancers may be performed by using for example information provided by the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, which is an authoritative source of information on cancer incidence and survival in the United States and is recognized around the world.
- SEER Program currently collects and publishes cancer incidence and survival data from 14 population-based cancer registries and three supplemental registries covering approximately 26 percent of the US population.
- the program routinely collects data on patient demographics, primary tumour site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status, and is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.
- the incidence and survival data of the SEER Program may be used to access standard survival for a particular cancer site and stage.
- specific criteria may be selected from the database, including date of diagnosis and exact stage (for example, in the case of the lung cancer example herein, the years were selected to match the time-frame of the retrospective review, and stage 3B and 4 lung cancer were selected; and in the case of the colon cancer example herein, the years were also selected to match the time-frame of the retrospective review, and the stage 4 colon cancer was selected).
- Cancers may also be named based on the organ in which they originate i.e., the “primary site,” for example, cancer of the breast, brain, lung, liver, skin, prostate, testicle, bladder, colon and rectum, cervix, uterus, etc. This naming persists even if the cancer metastasizes to another part of the body that is different from the primary site.
- treatment is directed to the site of the cancer, not type of cancer, so that a cancer of any type that is symptomatic or etiologically located in the lung, for example, would be treated on the basis of this localization in the lung.
- PRR ligands may for example be available commercially, for example in widely available preparations of attenuated or killed recombinant bacteria, which may for example be ligands for TLR2, TLR4 and TLR5.
- Compositions of pathogen-associated molecular patterns may include PAMPS that are recognized by PRRs, including: Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-1-like receptors (RLRs), C-type lectin receptors (CLRs) including Dectin-1, cytosolic dsDNA sensors (CDSs) and NLRs involved in the formation of inflammasomes.
- Toll-like receptor 2 (TLR2) is involved in the recognition of a wide array of microbial molecules representing broad groups of species including Gram-positive and Gram-negative bacteria, as well as mycoplasma and yeast. TLR2 recognizes cell-wall components such as peptidoglycan, lipoteichoic acid and lipoprotein from Gram-positive bacteria, lipoarabinomannan from mycobacteria, and zymosan from the yeast cell wall. Toll-like receptor 3 (TLR3) recognizes double-stranded RNA (dsRNA).
- dsRNA double-stranded RNA
- LPS Bacterial lipopolysaccharide
- TLR4 Toll-like receptor 4
- LBP LPS-binding protein
- CD14 CD14
- MD-2 myeloid differentiation protein 2
- LPS generally consists of a polysaccharide region that is anchored in the outer bacterial membrane by a carbohydrate lipid moiety: lipid A, which is largely responsible for the immunostimulatory activity of LPS.
- lipid A contains six fatty acyl groups, as for example may be found in pathogenic bacteria that are strains of Escherichia coli or Salmonella spp.
- Toll-like receptor 5 (TLR5) recognizes flagellin from both Gram-positive and Gram-negative bacteria.
- Toll-like receptor 7 (TLR7) and TLR8 recognize single stranded RNAs and small synthetic molecules such as imidazoquinolines and nucleoside analogs.
- Toll-like receptor 9 (TLR9) recognizes specific unmethylated CpG motifs prevalent in microbial but not vertebrate genomic DNA.
- NLRs are a family of at least 22 cytoplasmic innate immune sensors, including NOD1 (CARD4) and NOD2 (CARD15) which are intracellular pattern-recognition receptors involved in the recognition of peptidoglycan (PGN). These receptors detect specific motifs within PGN.
- NOD1 senses the diaminopimelatic acid (DAP)-containing muropeptide (specifically d-Glu-meso-DAP dipeptide “iE-DAP” dipeptide) which is found primarily in PGN of Gram-negative bacteria, as well as certain Gram-positive bacteria.
- NOD2 recognizes the muramyl dipeptide (MDP) structure found in almost all bacterial PGN.
- RIG-1-Like receptors particularly RIG-1 and MDA-5, detect viral RNA species.
- CLR ligands include Dectin-1 and Mincle (macrophage-inducible C-type lectin) agonists.
- Dectin-1 is a specific receptor for ⁇ -glucans, which are glucose polymers found in the cell walls of fungi.
- Mincle is a multi-tasking danger signal receptor that recognizes a wide variety of ligands such as damaged cells, fungal components, yeast components and components of mycobacteria.
- Cytosolic DNA Sensors bind intracellular DNA from pathogens, and there are multiple CDSs which may display contextual preferences for the recognition of particular DNAs.
- Cyclic dinucleotides and xanthenone derivatives, such as DMXAA, bind to and activate STING (STimulator of INterferon Genes).
- the inflammasome is a multi-protein complex involved in the production of mature IL-1 ⁇ , specifically through cleavage of pro-IL-1 ⁇ and pro-IL-18 into active and secretable forms. Inflammasomes may be segregated into NLRP1, NLRP3, NLRC4 and AIM2 subtypes, which are activated by a wide variety of microbial molecules, danger signals and crystalline substances.
- PRR Ligand TLR2 Microbial cell wall components/preparations Pam2C- Aca-Benzyl-Murabutide (Pam2C- conjugated murabutide) TLR3 Polyadenylic-polyuridylic acid, Polyinosine-polycytidylic acid TLR4 Lipopolysaccharide, Monophosphoryl Lipid A TLR5 Flagellin TLR7/8 Single-stranded RNAs, Nucleoside analogs, Imidazoquinolines/Thiazoquinolines TLR9 unmethylated CpG DNA motifs NOD1 iE-DAP, Acylated iE-DAP, D-gamma- Glu-mDAP, L-Ala-gamma-D-Glu- mDAP NOD2 MDP (MurNAc-L-Ala-D-isoGln, muramyl dipeptide), N-glycolylated muramyldi
- PRR Ligands RIG-I PPP-ssRNA (PPP-ssRNA, ssRNA with a 5′- triphosphate group), RNA with base pairing and polyl:C MDA5 Long dsRNA LGP2 dsRNA DDX41 B-form DNA and CDNs (cyclic dinucleotides) DHX9 DNA, RNA, CpG-A oligodeoxynucleotids and CpG-B ODNs DDX3 Viral RNA DHX36 DNA, RNA, CpG-A oligodeoxynucleotids and CpG-B oligodeoxynucleotids DDX1-DDX21- RNA and polyl:C DDX36 DDX60 ssRNA, dsRNA and ds
- PRR agonists derived from a selected microbial pathogen For example, peptidoglycan (PGN) may be obtained from a bacteria or bacterial strain that is pathogenic in a selected target tissue or organ, for use as a NOD1/NOD2 agonist.
- PPN peptidoglycan
- cell wall components may be obtained from a bacteria or bacterial strain that is pathogenic in a selected target tissue or organ, for use as a TLR32 agonist.
- DNA including double stranded DNA, particularly repetitive double stranded DNA
- a microbial pathogen such as a bacteria or bacterial strain that is pathogenic in a selected target tissue or organ, for use as a DAI, LRRFIP1, RIG1, TLR9, AIM2 or cytosolic DNA sensor (CDS) agonist.
- Beta-glucan peptides may be obtained from fungi or yeast that are pathogenic in a selected target tissue or organ, for use as a Dectin-1 agonists.
- Cyclic dinucleotides may be obtained from a microbial pathogen that is pathogenic in a selected target tissue or organ, for use as a STING agonist.
- compositions that have a distinct PRR agonist signature, which connotes a repertoire of PRR agonists that are together collected in a therapeutic vehicle, so that the selected collection of PRR agonists is distinct.
- a “therapeutic vehicle” in this context is a formulation that aggregates and retains the PRR agonists, for example in a pharmaceutically acceptable particle or vesicle, such as a recombinant microbe.
- the PRR agonist signature may be different from a reference PRR agonist signature, for example different from the collection of PRR agonists that would be present on a microbe that is not pathogenic in the target tissue.
- the PRR signature may also be distinct in the sense that it is different than a native PRR agonist signature of the microbial mammalian pathogen, for example altered by way of the recombinant expression of genes that alter what would otherwise be the wildtype PRR agonist signature of the pathogen.
- the levels or kinds of PRR agonist may be directly measured, or may be measured for example by determining the activation or inhibition of a signalling pathway in a cell consequent to PRR agonist/receptor binding.
- nucleic acid sequences of the invention may be recombinant sequences.
- the term “recombinant” means that something has been recombined, so that when made in reference to a nucleic acid construct the term refers to a molecule that is comprised of nucleic acid sequences that are joined together or produced by means of molecular biological techniques.
- Nucleic acid “constructs” are accordingly recombinant nucleic acids, which have been generally been made by aggregating interoperable component sequencers.
- the term “recombinant” when made in reference to a protein or a polypeptide refers to a protein or polypeptide molecule which is expressed using a recombinant nucleic acid construct created by means of molecular biological techniques.
- Recombinant nucleic acid constructs may include a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Referring to a nucleic acid construct as “recombinant” therefore indicates that the nucleic acid molecule has been manipulated using genetic engineering, i.e. by human intervention (so that it is anthropogenic). Recombinant nucleic acid constructs may for example be introduced into a host cell by transformation.
- Such recombinant nucleic acid constructs may include sequences derived from the same host cell species or from different host cell species, which have been isolated and reintroduced into cells of the host species. Recombinant nucleic acid construct sequences may become integrated into a host cell genome, either as a result of the original transformation of the host cells, or as the result of subsequent recombination and/or repair events.
- Recombinant constructs of the invention may include a variety of functional molecular or genomic components, as required for example to mediate gene expression or suppression in a transformed plant.
- DNA regulatory sequences such as promoters, enhancers, polyadenylation signals, terminators, and protein degradation signals that regulate gene expression, as well as epigenetic regulatory signals for example involving methylation or acetylation of histones (e.g. histone methyltransferase or acetyltransferase), leading to conformational changes in the transcriptional landscape and gene expression differences.
- promoter means a sequence sufficient to direct transcription of a gene when the promoter is operably linked to the gene.
- the promoter is accordingly the portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription.
- Promoter sequences are commonly, but not universally, located in the 5′ non-coding regions of a gene.
- a promoter and a gene are “operably linked” when such sequences are functionally connected so as to permit gene expression mediated by the promoter.
- the term “operably linked” accordingly indicates that DNA segments are arranged so that they function in concert for their intended purposes, such as initiating transcription in the promoter to proceed through the coding segment of a gene to a terminator portion of the gene.
- Gene expression may occur in some instances when appropriate molecules (such as transcriptional activator proteins) are bound to the promoter. Expression is the process of conversion of the information of a coding sequence of a gene into mRNA by transcription and subsequently into polypeptide (protein) by translation, as a result of which the protein is said to be expressed.
- a gene or nucleic acid is “expressible” if it is capable of expression under appropriate conditions in a particular host cell.
- nucleic acid or polynucleotide refers to a component that is removed from its original environment (for example, its natural environment if it is naturally occurring).
- An isolated nucleic acid or polypeptide may contain less than about 50%, less than about 75%, less than about 90%, less than about 99.9% or less than any integer value between 50 and 99.9% of the cellular or biological components with which it was originally associated.
- a polynucleotide amplified using PCR so that it is sufficiently distinguishable (on a gel from example) from the rest of the cellular components is, for example, thereby “isolated”.
- the polynucleotides of the invention may be “substantially pure,” i.e., having the high degree of isolation as achieved using a purification technique.
- endogenous refers to a molecule such as a nucleic acid that is naturally found in and/or produced by a given organism or cell.
- An “endogenous” molecule may also be referred to as a “native” molecule.
- exogenous refers to a molecule, such as a nucleic acid, that is not normally or naturally found in and/or produced by a given organism or cell in nature.
- heterologous refers to molecules or portions of molecules, such as DNA sequences, that are artificially introduced into a particular host cell, for example by transformation.
- Heterologous DNA sequences may for example be introduced into a host cell by transformation.
- Such heterologous molecules may include sequences derived from the host cell.
- Heterologous DNA sequences may become integrated into the host cell genome, either as a result of the original transformation of the host cells, or as the result of subsequent recombination events.
- nucleic acid or amino acid sequences that are homologous to other sequences.
- an amino acid or nucleic acid sequence is “homologous” to another sequence if the two sequences are substantially identical and the functional activity of the sequences is conserved (as used herein, sequence conservation or identity does not infer evolutionary relatedness).
- Nucleic acid sequences may also be homologous if they encode substantially identical amino acid sequences, even if the nucleic acid sequences are not themselves substantially identical, for example as a result of the degeneracy of the genetic code.
- substantially homology or “substantial identity” is meant, in the alternative, a homology of greater than 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% up to 100% sequence identity.
- Homology may refer to nucleic acid or amino acid sequences as the context dictates. In alternative embodiments, sequence identity may for example be at least 75%, at least 90% or at least 95%.
- Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math 2: 482, the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444, and the computerized implementations of these algorithms (such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, Wis., U.S.A.). Sequence identity may also be determined using the BLAST algorithm, described in Altschul et al. (1990), J. Mol. Biol.
- HSPs high scoring sequence pairs
- T some positive-valued threshold score
- Initial neighborhood word hits act as seeds for initiating searches to find longer HSPs.
- the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased.
- Extension of the word hits in each direction is halted when the following parameters are met: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
- nucleotide or amino acid sequences are considered substantially identical if the smallest sum probability in a comparison of the test sequences is less than about 1, less than about 0.1, less than about 0.01, or less than about 0.001.
- an alternative indication that two amino acid sequences are substantially identical is that one peptide is specifically immunologically reactive with antibodies that are also specifically immunoreactive against the other peptide.
- Antibodies are specifically immunoreactive to a peptide if the antibodies bind preferentially to the peptide and do not bind in a significant amount to other proteins present in the sample, so that the preferential binding of the antibody to the peptide is detectable in an immunoassay and distinguishable from non-specific binding to other peptides.
- immunoassay formats such as solid-phase ELISA immunoassays for selecting monoclonal antibodies specifically immunoreactive with a protein (see Harlow and Lane (1988) Antibodies, A Laboratory Manual , Cold Spring Harbor Publications, New York).
- Hybridization to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.2 ⁇ SSC/0.1% SDS at 42° C. (see Ausubel, et al. (eds), 1989 , Current Protocols in Molecular Biology , Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3).
- hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M NaHPO 4 , 7% SDS, 1 mM EDTA at 65° C., and washing in 0.1 ⁇ SSC/0.1% SDS at 68° C. (see Ausubel, et al. (eds), 1989, supra).
- Hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993 , Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes , Part I, Chapter 2 “Overview of principles of hybridization and the strategy of nucleic acid probe assays”, Elsevier, N.Y.).
- stringent conditions are selected to be about 5° C. lower than the thermal melting point for the specific sequence at a defined ionic strength and pH.
- the term “a polynucleotide that hybridizes under stringent (low, intermediate) conditions” is intended to encompass both single and double-stranded polynucleotides although only one strand will hybridize to the complementary strand of another polynucleotide. Washing in the specified solutions may be conducted for a range of times from several minutes to several days and those skilled in the art will readily select appropriate wash times to discriminate between different levels of homology in bound sequences.
- substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing.
- non-conserved amino acid substitutions refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution causes an appreciable loss or gain of function of the peptide, to obtain a polypeptide that is not biologically equivalent.
- conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophilicity value (e.g., within a value of plus or minus 2.0), where the following hydrophilicity values are assigned to amino acid residues (as detailed in U.S. Pat. No.
- Non-conserved amino acid substitutions may be made were the hydrophilicity value of the residues is significantly different, e.g. differing by more than 2.0.
- conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydropathic index (e.g., within a value of plus or minus 2.0).
- each amino acid residue may be assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics, as follows: lie (+4.5); Val (+4.2); Leu (+3.8); Phe (+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8); Gly ( ⁇ 0.4); Thr ( ⁇ 0.7); Ser ( ⁇ 0.8); Trp ( ⁇ 0.9); Tyr ( ⁇ 1.3); Pro ( ⁇ 1.6); His ( ⁇ 3.2); Glu ( ⁇ 3.5); Gln ( ⁇ 3.5); Asp ( ⁇ 3.5); Asn ( ⁇ 3.5); Lys ( ⁇ 3.9); and Arg ( ⁇ 4.5).
- Non-conserved amino acid substitutions may be made were the hydropathic index of the residues is significantly different, e.g. differing by more than 2.0.
- conserved amino acid substitutions may be made where an amino acid residue is substituted for another in the same class, where the amino acids are divided into non-polar, acidic, basic and neutral classes, as follows: non-polar: Ala, Val, Leu, lie, Phe, Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral: Gly, Ser, Thr, Cys, Asn, Gin, Tyr.
- Non-conserved amino acid substitutions may be made were the residues do not fall into the same class, for example substitution of a basic amino acid for a neutral or non-polar amino acid.
- microorganisms such as bacteria, which exist in symbiotic or commensal relationships with the host animal.
- Microbes that are generally harmless such as Escherichia coli , can cause infection in healthy subjects, with results ranging from mild infection to death. Whether or not a microorganism is pathogenic (i.e., causes infection) depends on factors such as: the route of entry and access to specific host cells, tissues, or organs; the intrinsic virulence of the microorganism; the amount of the microorganism present at the site of potential infection; or the health of the host animal.
- microorganisms that are normally harmless can become pathogenic given favorable conditions for infection, and even the most virulent microorganism generally requires specific circumstances to cause infection.
- microbial species that are members of the normal flora can be pathogens when they move beyond their normal ecological role in the endogenous flora.
- endogenous species can cause infection outside of their ecological niche in regions of anatomical proximity, for example by contiguous spread. When this occurs, these normally harmless endogenous bacteria are pathogenic.
- Specific microbial species are known to cause infections in specific cells, tissues, or organs in otherwise healthy subjects.
- Examples of bacteria and viruses that commonly cause infections in specific organs and tissues of the body are listed below; and these examples are not limiting in the sense that a skilled person would be able to recognize and identify infectious or pathogenic bacteria that cause infections, or commonly cause infections, in various organs and tissues in otherwise healthy organisms (and recognize the relative frequency of infection with each bacterial species) based on the knowledge in the field as represented, for example, by the following publications: Manual of Clinical Microbiology 8th Edition, Patrick Murray, Ed., 2003, ASM Press American Society for Microbiology, Washington D.C., USA; Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 5th Edition, G. L. Mandell, J. E. Bennett, R. Dolin, Eds., 2000, Churchill Livingstone, Philadelphia, Pa., USA, all of which are incorporated by reference herein.
- Infections of the skin are commonly caused by the following bacterial species: Staphylococcus aureus , Beta hemolytic streptococci group A, B, C or G, Corynebacterium diptheriae, Corynebacterium ulcerans , or Pseudomonas aeruginosa ; or viral pathogens: rubeola, rubella, varicella-zoster, echoviruses, coxsackieviruses, adenovirus, vaccinia, herpes simplex, or parvo B19.
- Infections of the soft tissue are commonly caused by the following bacterial species: Streptococcus pyogenes, Staphylococcus aureus, Clostridium perfringens , or other Clostridium spp.; or viral pathogens: influenza, or coxsackieviruses.
- Infections of the breast are commonly caused by the following bacterial species: Staphylococcus aureus , or Streptococcus pyogenes.
- Infections of the lymph nodes of the head and neck are commonly caused by the following bacterial species: Staphylococcus aureus , or Streptococcus pyogenes ; or viral pathogens: Epstein-Barr, cytomegalovirus, adenovirus, measles, rubella, herpes simplex, coxsackieviruses, or varicella-zoster.
- Infections of the lymph nodes of the arm/axillae are commonly caused by the following bacterial species: Staphylococcus aureus , or Streptococcus pyogenes ; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, adenovirus, or varicella-zoster.
- Infections of the lymph nodes of the mediastinum are commonly caused by the following bacterial species: viridans streptococci, Peptococcus spp., Peptostreptococcus spp., Bacteroides spp., Fusobacterium spp., or Mycobacterium tuberculosis ; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, varicella-zoster, or adenovirus.
- Infections of the pulmonary hilar lymph nodes are commonly caused by the following bacterial species: Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae, Haemophilus influenza, Chlamydophila pneumoniae, Bordetella pertussis or Mycobacterium tuberculosis ; or viral pathogens: influenza, adenovirus, rhinovirus, coronavirus, parainfluenza, respiratory syncytial virus, human metapneumovirus, or coxsackievirus.
- Infections of the intra-abdominal lymph nodes are commonly caused by the following bacterial species: Yersinia enterocolitica, Yersinia pseudotuberculosis, Salmonella spp., Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus , or Mycobacterium tuberculosis ; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, varicella-zoster, adenovirus, influenza, or coxsackieviruses.
- Infections of the lymph nodes of the leg/inguinal region are commonly caused by the following bacterial species: Staphylococcus aureus , or Streptococcus pyogenes ; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, or herpes simplex.
- Infections of the blood are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes , coagulase-negative staphylococci, Enterococcus spp., Escherichia coli, Klebsiella spp., Enterobacter spp., Proteus spp., Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus pneumoniae , or group B streptococci; or viral pathogens: rubeola, rubella, varicella-zoster, echoviruses, coxsackieviruses, adenovirus, Epstein-Barr, herpes simplex, or cytomegalovirus.
- Infections of the bone are commonly caused by the following bacterial species: Staphylococcus aureus , coagulase-negative staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae , other streptococci spp., Escherichia coli, Pseudomonas spp., Enterobacter spp., Proteus spp., or Serratia spp.; or viral pathogens: parvovirus B19, rubella, or hepatitis B.
- Infections of the joint are commonly caused by the following bacterial species: Staphylococcus aureus , coagulase-negative staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae , other streptococci spp., Escherichia coli, Pseudomonas spp., Enterobacter spp., Proteus spp., Serratia spp., Neisseria gonorrhea, salmonella species, Mycobacterium tuberculosis, Hemophilus influenza ; or viral pathogens: parvovirus B19, rubella, hepatitis B; or fungal pathogen: Scedosporium prolificans
- Infections of the meninges are commonly caused by the following bacterial species: Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus agalactiae , or Listeria monocytogenes ; or viral pathogens: echoviruses, coxsackieviruses, other enteroviruses, or mumps.
- Infections of the brain are commonly caused by the following bacterial species: Streptococcus spp. (including S. anginosus, S. constellatus, S. intermedius ), Staphylococcus aureus, Bacteroides spp., Prevotella spp., Proteus spp., Escherichia coli, Klebsiella spp., Pseudomonas spp., Enterobacter spp., or Borrelia burgdorferi ; or viral pathogens: coxsackieviruses, echoviruses, poliovirus, other enteroviruses, mumps, herpes simplex, varicella-zoster, flaviviruses, or bunyaviruses.
- Infections of the spinal cord are commonly caused by the following bacterial species: Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus agalactiae, Listeria monocytogenes , or Borrelia burgdorferi ; or viral pathogens: coxsackieviruses, echoviruses, poliovirus, other enteroviruses, mumps, herpes simplex, varicella-zoster, flaviviruses, or bunyaviruses.
- Infections of the eye/orbit are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus miller, Escherichia coli, Bacillus cereus, Chlamydia trachomatis, Haemophilus influenza, Pseudomonas spp., Klebsiella spp., or Treponema pallidum ; or viral pathogens: adenoviruses, herpes simplex, varicella-zoster, or cytomegalovirus.
- Infections of the salivary glands are commonly caused by the following bacterial species: Staphylococcus aureus, viridans streptococci (e.g., Streptococcus salivarius, Streptococcus sanguis, Streptococcus mutans ), Peptostreptococcus spp., or Bacteroides spp., or other oral anaerobes; or viral pathogens: mumps, influenza, enteroviruses, or rabies.
- Staphylococcus aureus viridans streptococci (e.g., Streptococcus salivarius, Streptococcus sanguis, Streptococcus mutans ), Peptostreptococcus spp., or Bacteroides spp., or other oral anaerobes
- viral pathogens mumps, influenza, enteroviruses, or rabies.
- Infections of the mouth are commonly caused by the following bacterial species: Prevotella melaninogenicus , anaerobic streptococci, viridans streptococci, Actinomyces spp., Peptostreptococcus spp., or Bacteroides spp., or other oral anaerobes; or viral pathogens: herpes simplex, coxsackieviruses, or Epstein-Barr.
- Infections of the tonsils are commonly caused by the following bacterial species: Streptococcus pyogenes , or Group C or G B-hemolytic streptococci; or viral pathogens: rhinoviruses, influenza, coronavirus, adenovirus, parainfluenza, respiratory syncytial virus, or herpes simplex.
- Infections of the sinuses are commonly caused by the following bacterial species: Streptococcus pneumoniae, Haemophilus influenza, Moraxella catarrhalis, a -streptococci, anaerobic bacteria (e.g., Prevotella spp.), or Staphylococcus aureus ; or viral pathogens: rhinoviruses, influenza, adenovirus, or parainfluenza.
- Infections of the nasopharynx are commonly caused by the following bacterial species: Streptococcus pyogenes , or Group C or G B-hemolytic streptococci; or viral pathogens: rhinoviruses, influenza, coronavirus, adenovirus, parainfluenza, respiratory syncytial virus, or herpes simplex.
- Infections of the thyroid are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes , or Streptococcus pneumoniae ; or viral pathogens: mumps, or influenza.
- Infections of the larynx are commonly caused by the following bacterial species: Mycoplasma pneumoniae, Chlamydophila pneumoniae , or Streptococcus pyogenes ; or viral pathogens: rhinovirus, influenza, parainfluenza, adenovirus, corona virus, or human metapneumovirus.
- Infections of the trachea are commonly caused by the following bacterial species: Mycoplasma pneumoniae ; or viral pathogens: parainfluenza, influenza, respiratory syncytial virus, or adenovirus.
- Infections of the bronchi are commonly caused by the following bacterial species: Mycoplasma pneumoniae, Chlamydophila pneumoniae, Bordetella pertussis, Streptococcus pneumoniae , or Haemophilus influenzae ; or viral pathogens: influenza, adenovirus, rhinovirus, coronavirus, parainfluenza, respiratory syncytial virus, human metapneumovirus, or coxsackievirus.
- Infections of the lung are commonly caused by the following bacterial species: Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae , or Haemophilus influenza; or viral pathogens: influenza, adenovirus, respiratory syncytial virus, or parainfluenza.
- Infections of the pleura are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Bacteroides fragilis, Prevotella spp., Fusobacterium nucleatum, peptostreptococcus spp., or Mycobacterium tuberculosis ; or viral pathogens: influenza, adenovirus, respiratory syncytial virus, or parainfluenza.
- Infections of the mediastinum are commonly caused by the following bacterial species: viridans streptococci, Peptococcus spp., Peptostreptococcus spp., Bacteroides spp., Fusobacterium spp., or Mycobacterium tuberculosis ; or viral pathogens: measles, rubella, Epstein-Barr, or cytomegalovirus.
- Infections of the heart are commonly caused by the following bacterial species: Streptococcus spp. (including S. mitior, S. bovis, S. sanguis, S. mutans, S. anginosus ), Enterococcus spp., Staphylococcus spp., Corynebacterium diptheriae, Clostridium perfringens, Neisseria meningitidis , or Salmonella spp.; or viral pathogens: enteroviruses, coxsackieviruses, echoviruses, poliovirus, adenovirus, mumps, rubeola, or influenza.
- Streptococcus spp. including S. mitior, S. bovis, S. sanguis, S. mutans, S. anginosus
- Enterococcus spp. Staphylococcus spp.
- Corynebacterium diptheriae Clostridium perfring
- Infections of the esophagus are commonly caused by the following bacterial species: Actinomyces spp., Mycobacterium avium, Mycobacterium tuberculosis , or Streptococcus spp.; or viral pathogens: cytomegalovirus, herpes simplex, or varicella-zoster.
- Infections of the stomach are commonly caused by the following bacterial species: Streptococcus pyogenes or Helicobacter pylori ; or viral pathogens: cytomegalovirus, herpes simplex, Epstein-Barr, rotaviruses, noroviruses, or adenoviruses.
- Infections of the small bowel are commonly caused by the following bacterial species: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica , or Shigella flexneri ; or viral pathogens: adenoviruses, astroviruses, caliciviruses, noroviruses, rotaviruses, or cytomegalovirus.
- Infections of the colon/rectum are commonly caused by the following bacterial species: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica , or Shigella flexneri ; or viral pathogens: adenoviruses, astroviruses, caliciviruses, noroviruses, rotaviruses, or cytomegalovirus.
- Infections of the anus are commonly caused by the following bacterial species: Streptococcus pyogenes, Bacteroides spp., Fusobacterium spp., anaerobic streptococci, Clostridium spp., Escherichia coli, Enterobacter spp., Pseudomonas aeruginosa , or Treponema pallidum ; or viral pathogens: herpes simplex.
- Infections of the perineum are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterococcus spp., Bacteroides spp., Fusobacterium spp., Clostridium spp., Pseudomonas aeruginosa , anaerobic streptococci, Clostridium spp., or Enterobacter spp.; or viral pathogens: herpes simplex.
- Infections of the liver are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Streptococcus ( anginosus group), Enterococcus , spp. other viridans streptococci, or Bacteroides spp.; or viral pathogens: hepatitis A, Epstein-Barr, herpes simplex, mumps, rubella, rubeola, varicella-zoster, coxsackieviruses, or adenovirus.
- Infections of the gallbladder are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterobacter spp., enterococci, Bacteroides spp., Fusobacterium spp., Clostridium spp., Salmonella enteriditis, Yersinia enterocolitica , or Shigella flexneri.
- Infections of the biliary tract are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterobacter spp., enterococci, Bacteroides spp., Fusobacterium spp., Clostridium spp., Salmonella enteriditis, Yersinia enterocolitica , or Shigella flexneri ; or viral pathogens: hepatitis A, Epstein-Barr, herpes simplex, mumps, rubella, rubeola, varicella-zoster, cocsackieviruses, or adenovirus.
- Infections of the pancreas are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterococcus spp., Pseudomonas spp., Staphylococcal spp., Mycoplasma spp., Salmonella typhi , Leptospirosis spp., or Legionella spp.; or viral pathogens: mumps, coxsackievirus, hepatitis B, cytomegalovirus, herpes simplex 2, or varicella-zoster.
- Infections of the spleen are commonly caused by the following bacterial species: Streptococcus spp., Staphylococcus spp., Salmonella spp., Pseudomonas spp., Escherichia coli , or Enterococcus spp.; or viral pathogens: Epstein-Barr, cytomegalovirus, adenovirus, measles, rubella, coxsackieviruses, or varicella-zoster.
- Infections of the adrenal gland are commonly caused by the following bacterial species: Streptococcus spp., Staphylococcus spp., Salmonella spp., Pseudomonas spp., Escherichia coli , or Enterococcus spp.; or viral pathogens: varicella-zoster.
- Infections of the kidney are commonly caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgatus, Providentia spp., Morganella spp., Enterococcus faecalis , or Pseudomonas aeruginosa ; or viral pathogens: BK virus, or mumps.
- Infections of the ureter are commonly caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgatus, Providentia spp., Morganella spp., or Enterococcus spp.
- Infections of the bladder are commonly caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgatus, Providentia spp., Morganella spp., Enterococcus faecalis , or Corynebacterium jekeum ; or viral pathogens: adenovirus, or cytomegalovirus.
- Infections of the peritoneum are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella spp., Proteus spp., enterococci, Bacteroides fragilis, Prevotella melaninogenica, Peptococcus spp., Peptostreptococcus spp., Fusobacterium spp., or Clostridium spp.
- Infections of the retroperitoneal area are commonly caused by the following bacterial species: Escherichia coli , or Staphylococcus aureus.
- Infections of the prostate are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterobacter spp., Proteus mirabilis , enterococci spp., Pseudomonas spp., Corynebacterium spp., or Neisseria gonorrhoeae ; or viral pathogens: herpes simplex.
- Infections of the testicle are commonly caused by the following bacterial species: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus spp., Streptococcus spp., or Salmonella enteriditis ; or viral pathogens: mumps, coxsackievirus, or lymphocytic choriomeningitis virus.
- Infections of the penis are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Neisseria gonorrhoeae , or Treponema pallidum ; or viral pathogens: herpes simplex.
- Infections of the ovary/adnexae are commonly caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis, Gardenerella vaginalis, Prevotella spp., Bacteroides spp., Peptococcus spp. Streptococcus spp., or Escherichia coli.
- Infections of the uterus are commonly caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis, Gardenerella vaginalis, Prevotella spp., Bacteroides spp., Peptococcus spp., Streptococcus spp., or Escherichia coli.
- Infections of the cervix are commonly caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis , or Treponema pallidum ; or viral pathogens: herpes simplex.
- Infections of the vagina are commonly caused by the following bacterial species: Gardenerella vaginalis, Prevotella spp., Bacteroides spp., peptococci spp., Escherichia coli, Neisseria gonorrhoeae, Chlamydia Trachomatis , or Treponema pallidum ; or viral pathogens: herpes simplex.
- Infections of the vulva are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes , or Treponema pallidum ; or viral pathogens: herpes simplex.
- Bacterial species are classified operationally as collections of similar strains (which generally refers to groups of presumed common ancestry with identifiable physiological but usually not morphological distinctions, and which may be identified using serological techniques against bacterial surface antigens).
- each bacterial species e.g., Streptococcus pneumoniae
- serotypes 1, 3, 4, 7, 8, and 12 are most frequently responsible for pneumococcal disease in humans.
- ETEC extraintestinal pathogenic E. coli
- EHEC enterohemorrhagic E. coli
- STEC Shiga toxin-producing E. coli
- EAEC enteroaggregative E. coli
- EIEC enteroinvasive E. coli
- DAEC diffuse adhering E. coli
- ExPEC strains Even among the sub-category of ExPEC strains, specific virulence factors (e.g., production of type-1 fimbriae) enable certain strains to be more capable of causing infection of the bladder, while other virulence factors (e.g., production of P fimbriae) enable other strains to be more capable of causing infection in the kidneys.
- an ExPEC strain(s) that is more likely to cause infection in the bladder may be chosen for a formulation to target immune dysregulation in the bladder cancer
- an ExPEC strain(s) that is more likely to cause infection in the kidney may be chosen for a formulation to target immune dysregulation in the kidney cancer.
- ETEC ETEC
- EPEC EHEC
- STEC EAEC
- EIEC EIEC
- DAEC strains of E. coli may be chosen for a formulation to treat immune dysregulation in the colon.
- influenza viruses there may be numerous subtypes of specific viruses.
- influenza A is more likely to be associated with viral lung infection
- influenza B is more likely to be associated with myositis (i.e., muscle infection).
- each of these three types of influenza virus have numerous subtypes, which also may differ in epidemiology, host range and clinical characteristics.
- microbiota associated with some pathological tissue states, for example microbiota of specific tumours.
- microbiota of specific tumours for example, Fusobacterium and Providencia have been associated with colorectal cancer.
- compositions of the invention include immunogens of pathogenic microbial species (bacterial, viral or fungal) that are pathogenic in a specific tissue or organ, in which the immunogens are provided in the form of an artificial repertoire of mammalian PRR agonists that recapitulate a distinct portion of the PRR agonist signature of the microbial mammalian pathogen that is pathogenic in the target tissue.
- the portion of the PRR agonist signature is distinct in the sense that it is both: different from a reference PRR agonist signature of a microbe that is not pathogenic in the target tissue; and, different than the native PRR agonist signature of the microbial mammalian pathogen.
- This distinct artificial repertoire of mammalian PRR agonists are formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in the target tissue in the mammalian host.
- compositions of the invention may be provided alone or in combination with other compounds (for example, nucleic acid molecules, small molecules, peptides, or peptide analogues), in the presence of a liposome, an adjuvant, or any pharmaceutically acceptable carrier, in a form suitable for administration to mammals, for example, humans (a “therapeutic vehicle”).
- pharmaceutically acceptable carrier or “excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- the carrier can be suitable for any appropriate form of administration, including subcutaneous, intradermal, intravenous, parenteral, intraperitoneal, intramuscular, sublingual, inhalational, intratumoural or oral administration.
- Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound (i.e., the specific bacteria, bacterial antigens, or compositions thereof of the invention), use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- VLPs virus-like particles
- NP nanoparticle
- VLPs virus-like particles
- NPs membrane envelopes
- VLPs lack genetic material.
- Production of VLPs may for example be by expression of viral proteins in mammalian, avian, insect, plant, yeast, or bacterial cells.
- fully synthetic VLPs may be produced.
- Alternative nanoparticle formulations emulsions, liposomes alginates, chitosan, and polylactide-coglycolide (PLGA) NPs.
- NP/TLR ligand preparations that may be adapted for use to induce immune responses are ligands for TLR2 (Pam(3)Cys), TLR9 (Poly I:C), TLR4 (3-O-desacyl-4 0-monophosphoryl lipid A (MPL)), TLR7 (9-benzyl-8-hydroxyadenine), TLR7/8 (resiquimod, R848), and TLR9 (CpG DNA).
- adjuvants may be used to potentiate a desired immune response (see Levast et al., 2014, Vaccines, 2, 297-322).
- PRR ligands may be combined with more traditional and existing therapies.
- these may include chemotherapy, radiation therapy, surgery, etc., or with a therapy that stimulates the immune system, reduces inflammation or otherwise benefits the subject, such as nutrients, vitamins and supplements.
- vitamin A, vitamin D, vitamin E, vitamin C, vitamin B complex, selenium, zinc, co-enzyme Q10, beta carotene, fish oil, curcumin, green tea, bromelain, resveratrol, ground flaxseed, garlic, lycopene, milk thistle, melatonin, other antioxidants, cimetidine, indomethacin, or COX-2 Inhibitors e.g., CelebrexTM [celecoxib] or VioxxTM [rofecoxib]
- COX-2 Inhibitors e.g., CelebrexTM [celecoxib] or VioxxTM [rofecoxib]
- CelebrexTM [celecoxib] or VioxxTM [rofecoxib] may be also be administered to the subject.
- Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the compounds to subjects.
- Alternative routes of administration may be employed, for example, parenteral, intravenous, intradermal, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intrathecal, intracisternal, intraperitoneal, intranasal, inhalational, aerosol, topical, intratumoural, sublingual or oral administration.
- Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; for intranasal formulations, in the form of powders, nasal drops, or aerosols; and for sublingual formulations, in the form of drops, aerosols or tablets.
- Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
- Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
- parenteral delivery systems for include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
- Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
- the pathogenic bacterial species are administered to an individual in an amount effective to stop or slow progression or metastasis of the cancer, or to increase survival of the subject (relative to, for example, prognoses derived from the SEER database) depending on the disorder.
- compositions or formulations may be packaged in a variety of ways depending upon the method used for administering the drug.
- an article of manufacture or package may include a container having deposited therein the pharmaceutical formulation in an appropriate form.
- Suitable containers may for example include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and vials.
- the container may have a sterile access port, for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle.
- the package or container may also include a tamper-proof or multi-use mechanism adapted to control access to the contents of the package or the container, for example a multi dose vial adapter matched to a vial contained in the package.
- the container or package may include a label, for example a label that describes the contents of the container, for example a drug label identifying the pharmaceutical composition therein and/or specifying modes or routes of administration.
- the label may also include appropriate warnings, for example specifying storage conditions for the container or package, or setting out contraindications or adverse effects of a mode of treatment.
- Articles of manufacture may accordingly take the form of a “kit” comprising pharmaceutical compositions or accessories adapted to facilitate use of pharmaceutical compositions.
- Kits may include a label or package insert, where the term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. Kits may further include accessories associated with use of the pharmaceutical composition, including buffers, diluents, filters, needles, and syringes. Kits may also be adapted for the delivery of selected dosage forms of a pharmaceutical composition, for example including a number of unit dosages. Such kits can include a memory aid or mechanism, in the form of a physical or written indication of the intended timing of a treatment schedule in which the dosages are to be used.
- a “companion diagnostic” may be associated with a pharmaceutical treatment or composition.
- Companion diagnostics are assays that facilitate the associated treatment, by providing diagnostic or prognostic information, typically in the form of a diagnostic test to determine the applicability of a treatment to a specific patient.
- Point-of-care companion diagnostics may for example involve providing diagnostic compositions and/or articles of manufacture in conjunction with providing a pharmaceutical formulation, for example as part of a kit.
- companion diagnostics may be separately provided, as assays to monitor the therapy of subjects or to predict the therapeutic efficacy of an intended treatment.
- a companion diagnostic may for example take the form of a medical device, such as an imaging tool, or a process carried out by such a device, for example for conducting assays in vitro, which provides information that is relevant for the safe and effective use of a corresponding drug or biological product.
- Companion diagnostics may be used with therapies disclosed herein so as to provide diagnostic or prognostic information about therapeutic efficacy or evidence of undesirable side effects or risks.
- the use of a companion diagnostic with a particular therapeutic may be stipulated in instructions, for example on the labeling of a diagnostic device and/or the labeling of the corresponding therapeutic product.
- Types of companion diagnostic tests may for example include: screening and detection, in form of tests that screen for genetic patterns, such as genetic SSI response markers; prognosis and theranostics, such as assays for biochemical SSI response markers that help to predict the future course of a disease, or indicate a patient's response to a therapy; monitoring, for example to evaluate the effectiveness and appropriate dosing of a prescribed therapy; or, recurrence, involving tests that analyze the patient's risk for a recurrence of the disease.
- genetic patterns such as genetic SSI response markers
- prognosis and theranostics such as assays for biochemical SSI response markers that help to predict the future course of a disease, or indicate a patient's response to a therapy
- monitoring for example to evaluate the effectiveness and appropriate dosing of a prescribed therapy
- recurrence involving tests that analyze the patient's risk for a recurrence of the disease.
- an “effective amount” of a composition according to the invention includes a therapeutically effective amount or a prophylactically effective amount.
- a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduction or elimination of the immune dysregulation.
- a therapeutically effective amount of a composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response.
- a therapeutically effective amount may also be one in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects.
- a “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as amelioration of immune dysregulation.
- a prophylactic dose is used in subjects prior to or at an earlier stage of cancer, so that a prophylactically effective amount may be less than a therapeutically effective amount.
- the timing and dose of treatments may be adjusted over time (e.g., timing may be daily, every other day, weekly, monthly) according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
- the compositions may be administered every second day.
- An initial dose of approximately 0.05 ml may be administered subcutaneously, followed by increases from 0.01-0.02 ml every second day until an adequate skin reaction is achieved at the injection site (for example, a 1 inch to 2 inch diameter delayed reaction of visible redness at the injection site). Once this adequate immune reaction is achieved, this dosing is continued as a maintenance dose.
- the maintenance dose may be adjusted from time to time to achieve the desired visible skin reaction (inflammation) at the injection site. Dosing may be for a dosage duration, for example of at least 1 week, 2 weeks, 2 months, 6 months, 1, 2, 3, 4, or 5 years or longer.
- Oral dosages may for example range from 4 times per day, daily or weekly. Dosing may be for a dosage duration, for example of at least 1 week, 2 weeks, 2 months, 6 months, 1, 2, 3, 4, or 5 years or longer.
- the invention may include compositions administered sublingually or by inhalation, or administered to one or more epithelial tissues (i.e., skin by intradermal or subcutaneous injection; lung epithelium by inhalation; gastrointestinal mucosa by oral ingestion; mouth mucosa by sublingual administration) simultaneously or sequentially. Accordingly, in some embodiments the compositions of the invention are administered so as to provoke an immune response in an epithelial tissue.
- one or more epithelial routes of administration may be combined with one or more additional routes of administration, such as intratumoural, intramuscular or intravenous administration.
- an immunogenically effective amount of a composition of the invention can be provided, alone or in combination with other compounds, for example with an immunological adjuvant.
- the composition may for example include compounds linked with a carrier molecule, such as bovine serum albumin or keyhole limpet hemocyanin to enhance immunogenicity.
- An immunogenic composition is a composition that includes materials that elicit a desired immune response.
- An immunogenic composition may select, activate or expand, without limitation: memory B, T cells, neutrophils, monocytes or macrophages of the immune system.
- An antigenic composition comprising killed recombinant bacteria for administration by injection may be made as follows.
- the bacteria may be grown in suitable media, and washed with physiological salt solution.
- the bacteria may then be centrifuged, resuspended in saline solution, and killed with heat.
- the suspensions may be standardized by direct microscopic count, mixed in required amounts, and stored in appropriate containers, which may be tested for safety, shelf life, and sterility in an approved manner.
- a killed bacterial vaccine suitable for administration to humans may include 0.4% phenol preservative and/or 0.9% sodium chloride.
- the bacterial vaccine may also include trace amounts of brain heart infusion (beef), peptones, yeast extract, agar, sheep blood, dextrose, sodium phosphate and/or other media components.
- medicaments may be administered at an administration site in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least one week.
- the medicament may be administered intradermally or subcutaneously.
- the medicament may be administered in a dose so that each dose is effective to cause a visible localized inflammatory immune response at the administration site.
- the medicament may be administered so that visible localized inflammation at the administration site occurs within 1 to 48 hours.
- a visible localized inflammatory immune response may not always be present in all circumstances despite an immune response being initiated.
- the mounting of an immune response can be monitored. For example, the profile (and relative change in characterization) of immune cells from a subject undergoing an immune reaction can be compared with those from a subject that is not undergoing an immune reaction.
- a method of monitoring efficacy of a treatment regime in an individual being treated for an immune dysfunction in a specific organ or tissue involves measuring a characteristic of an immune response in a past-treatment immune sample obtained from the specific organ or tissue after the individual has been subject to the treatment regime for a period of time.
- PRR agonists derived from bacteria that are members of the endogenous flora of a particular region of the GIT may be used to formulate immunogenic compositions of the invention.
- the rows of Table 3 list a number of bacterial species, together with the biological regions in which each species may form a part of the endogenous flora.
- Abiotrophia spp. are typically members of the endogenous flora of the mouth.
- Endogenous microbial flora such as bacteria
- Endogenous microbial flora have access to tissues for pathogenesis either through contiguous spread or bacteremic spread. Under favorable conditions, endogenous organisms can become pathogenic and invade locally and spread by contiguous spread to adjacent tissues and organs.
- Endogenous bacterial flora of the skin, mouth and colon are species that are understood to also be amenable to bacteremic spread. Bacteria that are members of a particular endogenous flora domain may therefore cause infection in tissues or organs to which these bacteria may spread.
- one aspect of the invention involves the use of PRR agonists derived from endogenous microbial pathogens to treat an immune dysregulation having symptoms localized to a region of the GIT in which the endogenous bacteria may spread to cause infection.
- the columns of Table 2 list domains for endogenous flora.
- the rows of Table 4 list regions of the GIT within which immune dysregulation may be symptomatic or etiologically located.
- PRR agonists derived from endogenous microbial pathogens to formulate immunogenic compositions for treating an immune dysregulation symptomatic or etiologically located in the region of the GIT to which the pathogen may spread to cause an infection.
- an immune dysregulation that is symptomatic in the region listed in the first column of Table 2 may be treated with immunogenic compositions comprising an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial mammalian pathogen that is a member of the endogenous flora of one or more of the endogenous flora domains listed in the first row of Table 2 and indicated with an X or a check mark in the appropriate row.
- an immune dysregulation manifest in a particular region of the GIT set out in column 1 of Table 2 may be treated with antigenic compositions comprising an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial mammalian pathogen that is one of the corresponding bacterial species of Table 1, so that the column headings in Table 2 are in effect replaced with the bacterial species of Table 1.
- PRR agonists may be derived from exogenous bacterial pathogens.
- PRR agonists derived from the organisms listed in Table 5 may be used in an artificial repertoire of PRR agonists to treat an immune dysregulation that is symptomatic in the region of the GIT listed with the relevant organism in Table 5.
- PRR agonists derived from both endogenous and exogenous microbial species may be used in combination.
- PRR agonists for use in the invention may be derived from viral pathogens.
- Table 6 provides an exemplary list of viral pathogens together with the tissue and organ sites for which each viral species is reportedly a pathogen. Accordingly, one aspect of the invention involves utilizing immunogenic compositions of PRR agonists derived from the named viruses to treat an immune dysregulation that is symptomatic in the region of the GIT that is identified adjacent to the name of the virus in Table 6.
- the pathogen from which PRR agonists are derived for use in immunogenic compositions of the invention may be one that is a common cause of acute infection in the region of the GIT in which the immune dysregulation to be treated is symptomatic.
- Table 7 identifies bacterial and viral pathogens of this kind, together with the region of the GIT in which they commonly cause infection. Accordingly, in selected embodiments, an immune dysregulation that is symptomatic in a region of the GIT identified in the first column of Table 7 may be treated with an immunogenic composition that comprises an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of the PRR agonist signature of a pathogenic organism listed in the second column of Table 7.
- compositions of the invention may accordingly include PRR agonists of various protozoa, including for example: Giardia lamblia, Cryptosporidium parvum, Cryptosporidium hominus, Isospora belli, Sarcocystis species, Coccidian like bodies ( Cyclospora species), Enterocytozoon bieneusi, Entamoeba histolytica, Entamoeba dispar, Entamoeba coli, Entamoeba hartmanni, Endolimax nana, Iodamoeba bütschlii, Dientameoba fragilis, Blastocystis hominus, Cyclospora cayetanensis, Microsporidia, Trypanosoma cruzi, Chidomastix mesnili, Pentatrichomonas hominis, Balantidium coli .
- PRR agonists of various protozoa including for example: Giardia lamblia, Cryptosporidium parv
- compositions of the invention may include antigenic components of various helminths, including for example: Cestodes (tapeworms), Taenia saginata, Taenia solium, Diphyllobothrium species, Hymenolepis nana, Hymenolepis diminuta, Dipylidium caninum , Nematodes (round worms), Ascaris lumbricoides, Strongyloides stercoralis, Necator americanus, Ancylostoma duodenale, Ancylostoma caninum, Tichuris trichiura, Capillaria philippinensis, Trichostrongylus species, Trichinella species, Necator americanus, Anisakis and related species, Angiostrongylus costaricensis, Enterobius vermicularis , Trematodes (flukes), Fasciolopsis buski, Heterophyes species, Echinostoma species, Clonorchis sinensis,
- the invention may involve the treatment of an immune dysregulation with formulations of an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial pathogen that is an: Acidaminococcus fermentans; Acinetobacter spp.; Actinobaculum spp.; Actinomyces spp.; Aeromonas spp.; Anaerorhabdus furcosus; Anaerococcus hydrogenalis; Anaerococcus lactolyticus; Anaerococcus prevotii; Atopobium spp.; Bacillus spp.; Bacteroides caccae; Bacteroides distasonis; Bacteroides eggerthii; Bacteroides fragilis; Bacteroides merdae; Bacteroides ovatus; Bacteroides splanchnicus; Bacteroides thetaiotaomicron; Bactero
- the invention may involve the treatment of an immune dysregulation with formulations of an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial mammalian pathogen that is a common small and larger bowel pathogens, for example: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica, Shigella flexneri ; adenoviruses, astroviruses, caliciviruses, noroviruses, rotaviruses, and cytomegalovirus.
- an immune dysregulation with formulations of an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial mammalian pathogen that is a
- the invention involves diagnostic steps to assess a patient's previous exposure to an organism.
- the diagnostic steps may include taking a medical history of exposure to selected pathogens, and/or evaluating a patient's immune response to a selected pathogen.
- a serology test may be conducted to detect antibodies to selected pathogens in a patient's sera.
- antigenic determinants of a selected pathogen may be chosen for use in an immunogenic composition on a selected patient based on a diagnostic indication that the patient has had one or more prior exposure(s) to the pathogen, for example by virtue of the presence of antibodies to antigenic determinants of that pathogen in the patient's sera.
- the invention involves diagnostic steps to assess a patient's immunological response to treatment with a selected immunogenic composition.
- the diagnostic steps may include evaluating a patient's immune response to the immunological determinants of that immunogenic composition, for example using a serological test to detect antibodies to those immunogenic determinants.
- a treatment with a selected immunogenic composition may be continued if the evaluation indicates that there is an active immunological response to the immunogenic determinants of that composition, and the treatment may be discontinued, and an alternative treatment with a different immunogenic composition may be initiated, if the evaluation indicates that there is not a sufficiently active immunological response to the immunogenic determinants of the immunogenic composition.
- the immunomodulatory properties of formulations of the invention can be employed for use in the treatment of a variety of diseases characterized by pathological immune dysregulation, for example using PRR agonists derived from endogenous pathogens or exogenous pathogens that are pathogenic in the tissue or organ within which the immune dysregulation is symptomatic or manifest, including bacterial, viral and fungal pathogens.
- PRR agonists derived from endogenous pathogens or exogenous pathogens that are pathogenic in the tissue or organ within which the immune dysregulation is symptomatic or manifest, including bacterial, viral and fungal pathogens.
- Table 8 lists diseases characterized by immune dysregulation, which may be treated in accordance with alternative aspects of the invention.
- arthritis is a chronic inflammatory disease.
- arthritis is understood to be a description of inflammation of one or more joints.
- arthritic symptoms include (but are not limited to) the following: Ankylosing spondylitis, Behcet's disease, Ehlers-Danlos Syndrome, Familial Mediterranean fever, Fibromyalgia, Fifth disease, Giant cell arteritis, Gout, Haemochromatosis, Henoch-Schönleinpurpura, Hyperimmunoglobulinemia D with recurrent fever, Inflammatory bowel disease arthritis (including Crohn's Disease and Ulcerative Colitis), Juvenile rheumatoid arthritis, Juvenile spondyloarthropathy, Lyme disease, Marfan syndrome, Osteoarthritis, Pseudo-gout, Psoriatic arthritis, Reactive Arthritis (Reiter's syndrome), Rheumatoid arthritis
- Patients may advantageously be screened for disorders of innate immunity, such as genetic disorders, for example by primary sequence analysis or by analysis of epigenetic changes.
- disorders of innate immunity such as genetic disorders, for example by primary sequence analysis or by analysis of epigenetic changes.
- a variety of genetic disorders have for example been identified that are associated with gene products involved in innate immunity (see Mogensen T., 2009, Clinical Microbiology Reviews, Vol. 22, No. 2, p. 240-273), such as TLR genes (TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9), signalling protein genes (MyD88, Mal, IRAK1, IRAK4, NEMO, I ⁇ B ⁇ , IRF5), NLR genes (NOD2, NALP1, NALP3) and others (CD14, UNC93B).
- TLR genes TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9
- signalling protein genes MyD88, Mal, IRAK1, IRAK4, NEMO, I ⁇ B ⁇ , IRF
- Patients identified as having a Medelian primary immunodeficiency associated with impaired TLR signaling or NF- ⁇ B activation may for example not benefit from some embodiments, or may require an approach adapted to their condition.
- Patients having polymorphisms in genes encoding components of innate signalling pathways may also be identified prior to treatment with an SSI, for example having mutations in the gene encoding TIR-domain-containing adaptor-inducing beta interferon (TRIF).
- TIR-domain-containing adaptor-inducing beta interferon TIR-domain-containing adaptor-inducing beta interferon
- embodiments of the invention may accordingly be adapted to avoid the inhibitory effect of such strategies on the triggered innate response.
- Select embodiments provide recombinant microorganisms that lack virulence factors that impede TLR signalling, such as recombinant E. coli that lack TIR domain-containing proteins (Cirl, C. et al., 2008, Nat. Med. 14:399-406).
- Gram negative bacterial formulation may advantageously comprise an LPS that is recognized by a TLR, such as TLR4, rather than a form of LPS that is not recognized by a TLR (Homef, M. W. et al., 2002, Nat. Immunol. 3:1033-1040).
- bacterial formulations may advantageously include a class of flagellin that activates a TLR, such as TLR5, rather than one that does not (Andersen-Nissen, E. et al., 2005, Proc. Natl. Acad. Sci. USA 102-9247-9252).
- peptidases that proteolytically degrade important components of the triggered innate response such as the amastigote-specific cysteine peptidases of Leishmania mexicana that proteolytically degrade I ⁇ B and NF- ⁇ B (Cameron, P. et al., 2004, J. Immunol. 173:3297-3304).
- these undesirable components may be removed from a formulation by an appropriate step of manufacturing, for example to wash or fractionate a microbial preparation so as to remove a component.
- Patients may be genotyped, for example by identifying polymorphisms in PRR genes (see WO 2009003905).
- Genes associated with inflammation and immune related diseases and disorders may for example be the subject of screening, such as:
- AIDS Keratin-1 (IL-1a)
- IL-2a Combined immunodeficiency, (IL2RG, SCIDX1, SCIDX, IMD4)
- HIV-1 CCL5, SCYA5, D17S136E, TCP228), HIV susceptibility or infection (IL10, CSIF, CMKBR2, CCR2, CMKBR5, CCCKR5 (CCR5)
- Immunodeficiencies CD3E, CD3G, AICDA, AID, HIGM2, TNFRSF5, CD40, UNG, DGU, HIGM4, TNFSF5, CD40LG, HIGM1, IGM, FOXP3, IPEX, AIID, XPID, PIDX, TNFRSF14B, TACI); Inflammation (IL-10, IL-1 (IL-1a)
- genes involved in selected signalling pathways may for example be screened, identifying for example patients that are more or less susceptible to an SSI treatment, such as: GM-CSF Signaling (LYN; ELK1; MAPK1; PTPN11; AKT2; PIK3CA; CAMK2A; STAT5B; PIK3CB; PIK3C3; GNB2L1; BCL2L1; MAPK3; ETS1; KRAS; RUNX1; PIM1; PIK3C2A; RAF1; MAP2K2; AKT1; JAK2; PIK3R1; STAT3; MAP2K1; CCND1; AKT3; STAT1); IL-10 Signaling (TRAF6; CCR1; ELK1; IKBKB; SP1; FOS; NFKB2; MAP3K14; MAPK8; MAPK13; RELA; MAPK14; TNF; IKBKG; RELB; MAP3K7
- patients may for example be genotyped for SNPs located in the non-coding regions of the genome that are linked to inflammatory disorders, such as SNP's identified through publicly available GWAS datasets, for example SNPs in genomic regions linked to sequences which serve a regulatory role in immune-function-related gene expression.
- the invention excludes steps that involve medical or surgical treatment. Similarly, in some embodiments, the invention disclaims naturally occurring embodiments, so that aspects of the invention relate only to anthropogenic compositions. Further, in select aspects of the invention, previously known products, process of making products, or methods of using products are hereby disclaimed.
- TIR domain-containing proteins A family of virulence factors in Escherichia coli and Brucella melitensis , named TIR domain-containing proteins, impede TLR signalling through direct binding to MyD88, thus suppressing innate immunity and increasing bacterial virulence. Aspects of the invention accordingly provide recombinant bacteria that lack expression of TIR domain-containing proteins, or other virulence factors that interfere with an innate host immune response to the pathogen.
- compositions may be prepared from recombinant S. aureus strains.
- strains of sequence type ST-291 having the following alleles, or homologous sequences being at least 99% identical thereto: arcc-3, aroe-37, glpf-19, gmk-2, pta-20, tpi-26, and yqil-32 (Larsen et al., 2012, O. J. Clin. Micobiol 50(4): 1355-1361).
- Strains may totally lack resistance genes to the following classes of antibiotic: aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide.
- strains may have one or more resistance genes, such as the blaZ beta-lactam resistance gene (accession AP004832).
- strains may or may not include one or more virulence factor genes (Cosentino et al., 2013, PLoS ONE 8(10):e77302), having for example at least 90%, 95%, 99% or 100% identity to selected database sequences (identified by accession number in the following tables). [Recite strains lacking leukotoxins, particularly targeting the innate immune system]
- Recombinant strains may include one or more plasmids (Carattoli et al., 2014, Antimicrobial Agents and Chemotherapy 58(7): 3895-3903), for example having 90%, 95%, 99% or 100% identity to plasmid rep5 (accession NC005011) or plasmid rep16 (accession CP002115.1).
- compositions may be prepared from recombinant Klebsiella strains, such as K. pneumoniae or K. variicola (formerly identified as K. pneumoniae ).
- Klebsiella strains such as K. pneumoniae or K. variicola (formerly identified as K. pneumoniae ).
- Strains may totally lack resistance genes to the following classes of antibiotic: aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide.
- strains may have one or more resistance genes, such as the blaLEN24 beta-lactam resistance gene (accession AM850914).
- strains may or may not include one or more virulence factors identified in the following table (see Leticia et al., 2014, BMC Biology 12:41).
- compositions may be prepared from recombinant E. coli strains specifically adapted for therapy of prostate immune dysfunction.
- Strains may totally lack resistance genes to the following classes of antibiotic: aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide.
- strains may or may not include one or more virulence factor genes, having for example at least 90%, 95%, 99% or 100% identity to selected database sequences (identified by accession number in the following tables). The strain may also lack stx holotoxin virulence factors.
- E. coli - Virulence factors Virulence Accession factor Protein function number iroN Enterobactin siderophore CP000243 receptor protein sfaS S-fimbriae minor subunit CP000243 senB Plasmid-encoded enterotoxin CP000038 iss Increased serum survival CU928160 gad Glutamate decarboxylase CP002167 cnf1 Cytotoxic necrotizing factor CP002167 ccl Cloacin DQ298019
- the serotype of the E. coli strain may for example be O18ac:H7, for example representing the presence of H type serotype gene fliC (accession AF228492, and O type serotype genes wzx (accession GU299793), and wzy (accession GU299793).
- Recombinant strains may include one or more plasmids, for example having 90%, 95%, 99% or 100% identity to plasmid IncFIB (accession AP001918) and/or plasmid IncFII(29) (accession CP003035), and/or plasmid CoIRNAI (accession DQ298019) and/or plasmid Col156 (accession NC009781).
- the recombinant E. coli may for example be, or be derived from an E. coli strain having at least 80%, 90% or 95% sequence identity to E. coli UT189 (see Chen et al., 2006, Proc Natl Acad Sci USA 103:5977-82).
- compositions may be prepared from recombinant E. coli strains specifically adapted for therapy of colon immune dysfunction.
- Strains may totally lack resistance genes to the following classes of antibiotic: aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide.
- antibiotics aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide.
- strains may have one or more resistance genes, such as the strB or strA aminoglycoside resistance genes (accession numbers M96392 or AF321551), and/or sul1 sulphonamide resistance gene (accession AY224185), and/or sul2 sulphonamide resistance gene (accession GQ421466), and/or dfrA5 trimethoprim resistance (accession X12868).
- strains may or may not include one or more virulence factor genes, having for example at least 90%, 95%, 99% or 100% identity to selected database sequences (identified by accession number in the following tables). The strain may also have a gene that is at least 95% or 99% or 100% identical to the stx holotoxin virulence factor gene stx1 (accession M19437).
- E. coli - Virulence factors Virulence Accession factor Protein function number Gad Glutamate decarboxylase CP001671 lha Adherence protein AE005174 Gad Glutamate decarboxylase CP001671 senB Plasmid-encoded enterotoxin CP000038 sigA Shigella IgA-like protease CP000038 homologue stx1B Shiga toxin 1, subunit B, AM230663 variant a stx1A Shiga toxin 1, subunit A, EF079675 variant a astA EAST-1 heat-stable toxin AB042002
- the serotype of the E. coli strain may for example be O117:H7, for example representing the presence of H type serotype gene fliC (accession AF228492, and O type serotype genes wzx (accession EU694096).
- Recombinant strains may include one or more plasmids, as set out in the following table.
- the recombinant E. coli may for example be, or be derived from an E. coli strain having at least 80%, 90% or 95% sequence identity to E. coli SE15 or any O117:H7 serotype E. coli.
- TLR agonists are a TLR2/6 agonist, diacylated lipoprotein (InVivogen Pam2CSK4) and a TLR4 agonist (LPS, Sigma L1519).
- the microbial antigen was a recombinant outer membrane protein A (ompA) from Klebsiella pneumoniae (CUSABIO CSB-EP340587KBG). These components were formulated together in a liposomal vehicle, and administered in a murine model of SSI therapy in accordance with the treatment timeline illustrated in FIG. 1 . As illustrated in FIG.
- TLR-only liposomes did not have the same degree of activity as the TLR+Ag liposome constructs, illustrating that the engagement of alternative immunogenic pathways can augment an SSI effect. It is important to note in the context of this data that the antigenic component of these minimal formulations was recombinantly expressed in E. coli , with a purity given by the manufacturer of >90% (SDS-PAGE) with the attendant characteristic that the antigen preparations included additional bacterial components, including additional PRR agonists, that act as additional innate immunogens.
- KPN SSI Klebsiella SSI
- SSIs can work in a MyD88-independent manner, at least in part, indicating that alternative PRR signalling pathways, beyond what are generally considered classic TLR signalling, are involved in the SSI mediated innate immune responses.
- NOD-like receptor NLRP3 is up-regulated in cultured cells treated with KPN SSI and ECO SSI.
- SSIs may mediate classical TLR signalling via an adaptor other than MyD88 downstream of TLR, such as TRIF.
- an adaptor other than MyD88 downstream of TLR such as TRIF.
- SSI therapies can engage the MyD88 signalling pathway. In combination, these results are evidence of the robust and diverse PRR signalling pathways that may be engaged by SSI therapies.
- This Example illustrates that in some embodiments, pre-exposure of an organism to a microbial pathogen potentiates subsequent SSI efficacy.
- This Example illustrates Klebsiella -mediated anti-cancer efficacy in metastatic-like B16 melanoma using heat-killed Klebsiella pneumoniae SSI.
- Subcutaneous injection of KPN SSI significantly reduced tumour burden.
- subcutaneous treatment with heat-killed E. coli (ECO SSI) or Staph. aureus (SAU SSI) did not have a therapeutic effect in the lung tumour model.
- ECO SSI heat-killed E. coli
- SAU SSI Staph. aureus
- mice were exposed to live K. pneumoniae via intratracheal infection prior to subcutaneous injections with KPN SSI. Pre-exposure to K.
- This Example illustrates site specificity of a S. aureus SSI in a murine skin cancer model.
- This Example involved the use of a concentrated S. aureus SSI (10 ⁇ QBSAU which is designated “QBSAUR” herein), as well as a Klebsiella sp. SSI, an E. coli SSI and placebo, in a B16 skin tumour model in which ⁇ 100,000 B16 melanoma cells were injected into the right flank of C57BL/6 mice in a volume of 100 ul on Day 0.
- SSI treatment started on Day ⁇ 10 and continued till Day +12. Tumour volumes were monitored starting on Day 7, and the endpoint reached at Day 14.
- the tumour volume results of FIGS. 5-10 illustrate dramatically the site specificity of the S. aureus SSI formulation.
- This Example illustrates the effect of combining an SSI (such as Klebsiella spp. SSI, abbreviated as “KPN SSI”) with a model cancer antigen (in this case OVA, or hen egg ovalbumin) expressed by transformed cancer cells, in this case in a B16 melanoma animal model.
- OVA does not naturally occur in mammals or bacteria, and is immunogenic in C57Bl/6 mice, with known CD4- and CD8-associated epitopes.
- B16 cells have been transfected to express cytoplasmic OVA protein, leading to presentation of the OVA epitopes in the tumour's MHC, thereby allowing OVA-specific T cell recognition of the melanoma.
- OT1 cells transgenic CD8 cells that specifically recognize SIINFEKL through the T cell receptor
- the data generated provide evidence of enhanced efficacy of the model cancer antigen admixed with an SSI.
- decreased tumour nodule counts were found in conjunction with treatment using a Klebsiella spp. SSI+OVA, compared to PBS+OVA (assessed photographically and by quantitative PCR for Tyrp1, a melanoma-specific gene). Consistent with this, KPN SSI+OVA increased the proportion of OVA-specific CD8 T cells in the lungs.
- expression of genes associated with effective anti-tumour immunity was increased by KPN SSI+OVA vs. PBS+OVA.
- the same study showed survival data in lung cancer models, in which Klebsiella sp. SSI+OVA showed extended survival compared with control; and an E. coli SSI+OVA showed much improved survival.
- mice were treated with Klebsiella sp. SSI, then challenged with B16 melanoma (IV). 5 days later, mice received an adoptive transfer of TCR transgenic cells (Pmel T cells) specific for a natural cancer antigen in melanoma. Mice were also treated with FTY-720 (fingolimod), to prevent T cell egress from lymph nodes and allow recovery of cells from the draining lymph node of a tumour.
- SSI enhanced the proportion of T cells in the draining lymph node that were activated (i.e., antigen-exposed). This provides evidence that an SSI may be adapted to augment the processing and presentation of immunogenic cancer antigens, including self antigens and exogenously-administered cancer antigens.
- fractions may for example be prepared from: bacterial outer membrane (for example from Gram negative spp.); bacterial inner membrane; the pellet of a gradient centrifugation (for example from a sucrose gradient); chromosomal DNA; a capsular glycoprotein fraction; or, a peptidoglycan fraction, such as peptidoglycan ghosts.
- engineered or recombinant organisms may be used in SSIs, in which genes involved in pathways relevant to particular cellular fractions have been modified, in particular genes involved in determining the composition of the foregoing fractions.
- bacteria may for example be grown and heat-inactivated.
- Cell fractions may for example be resuspended in sterile saline+0.4% phenol.
- Inner membranes may for example be collected using the 2-step sucrose density gradient, as for example described in Methods in Enzymology, Vol 125:309-328, 1986.
- the bacterial pellet obtained after cultivation of 250 mls of cells may be resuspended in 20% sucrose, 10 mM Tris-HCl pH 8.0 and 50 ug/ml DNase 1. Cells may be incubated at 23° C. for 10 min.
- Cells may then be placed on ice and lysed two times through a French pressure cell at 15,000 psi; unbroken cells may be removed by centrifugation at 5,000 ⁇ g for 10 min at 4° C.
- Supernatants may be layered onto a 2-step sucrose gradient (60% and 70%) and centrifuged in a SW28 swinging bucket rotor at 23,000 rpm for 18 hours at a temperature of 4° C.
- the inner membranes may be collected at the junction between the 20% and 60% sucrose.
- Sucrose may be diluted to below 20% with sterile distilled water and the membranes may be pelleted in an ultracentrifuge at 41,000 rpm at 4° C. for 1 hour.
- the inner membranes may be washed once with sterile water, and then resuspended in sterile saline+0.4% phenol.
- Crude outer membrane preparations may also be collected from the junction between the 60% and 70% sucrose gradient steps.
- Chromosomal DNA for example for Klebsiella pneumoniae , may be prepared using a Qiagen Blood and Tissue midi kit. Cells from 15 or 40 mls of broth culture from each strain may be harvested. The manufacture's protocol for purification of total DNA may then be followed.
- KPN Klebsiella pneumoniae
- OM 1 ⁇ outer membrane
- both 1 ⁇ and 0.01 ⁇ KPN outer membrane fractions (i) were efficacious in the B16 melanoma model in the lung, in a dose-dependent manner, with the 1 ⁇ fraction having comparable efficacy to the whole killed cell formulation, as were the 1 ⁇ and 4 ⁇ DNA fractions (ii), while the inner membrane fraction showed a dose dependent trend that lacked strong statistical significance (iii).
- Rae-1 expression was elevated by the 1 ⁇ outer membrane fraction in a dose dependent effect.
- FIG. 47C illustrates elevated neutrophil and monocyte blood counts after 4 injections of SSI or placebo, in blood collected 2 days prior to tumour implant.
- the KPN fractions illustrate site specific preferential lung activity compared to E. coli fractions in the B16 lung cancer model.
- whole QBKPN was efficacious in reducing lung tumour burden.
- a whole killed E. coli formulation (QBECO) was not as efficacious as QBKPN.
- QBKPN fractions (OM or DNA alone) were efficacious.
- OM+DNA When combined (OM+DNA), QBKPN fractions were approximately as efficacious as whole QBKPN.
- QBECO fractions (OM, DNA, or OM+DNA) did not show the same efficacy as QBKPN fractions. Together, this illustrates site specificity associated with QBKPN fractions, particularly combined DNA (4 ⁇ ) and OM (1 ⁇ ) fraction.
- This Example illustrates embodiments in which an SSI is co-formulated with or co-administered with additional therapeutic components.
- One class of additional therapeutic components comprises molecules or compositions for activating or recruiting innate immune cells, and these include:
- An additional class of therapeutic components for co-formulation or co-administration comprise molecules or compositions that relieve immunosuppression:
- An additional class of therapeutic components for co-formulation or co-administration comprise molecules or compositions that prevent oxidative damage and improve immune function under stress:
- An additional class of therapeutic components for co-formulation or co-administration comprise co-stimulatory molecules for innate cytotoxic lymphocytes (for example for anticancer treatments):
- This Example illustrates results from a mouse spontaneous colitis model (Muc2 knockout “KO” mice) that mimics the underlying immune system defect and chronic bacterial infection associated with Crohn's disease and ulcerative colitis.
- IBD patients typically display structural and/or functional defects in their normally protective colonic mucosal barriers.
- the mucus barrier is largely dependent on the release of goblet cell-derived mucin (Muc2) which prevents microbes and luminal antigens from contacting the epithelial surface in the gastrointestinal tract.
- Muc2 KO mice are healthy just after weaning (1 month old), as they age, they develop progressive diarrhea and sporadic rectal prolapse.
- Muc2 KO mice Histological analysis of colonic tissue shows crypt hyperplasia, crypt abscesses, inflammatory cell infiltration and submucosal edema. Accordingly, the Muc2 KO mice have a defective gastrointestinal mucosal barrier and after time spontaneously develop colitis, resembling ulcerative colitis in humans. In this model, young (2 month old) Muc2 KO mice have less severe colitis, and older (3 month old) Muc2 KO mice have more severe colitis.
- FIGS. 14A, 14B and 14C illustrate that an E. coli SSI (QBECO) decreases pro-inflammatory markers in the colon (using qPCR gene expression data).
- FIG. 14D illustrates the site specific activity of QBECO in increasing IL-18 gene expression in the colon, compared to QBKPN.
- the IFN-gamma expression data in particular illustrates how SSI efficacy can be affected by the stage of colitis (comparing expression data in old vs young mice).
- IL17A data relating to a cytokine that is produced by activated T-cells (a marker of IBD inflammation), illustrates a significant decrease in this marker of inflammation after E. coli SSI treatment.
- QBECO treatment substantially improved all components of the histopathology score, including infiltration, integrity, hyperplasia, and edema.
- this Example illustrates that an SSI, such as QBECO, may be used to significantly decrease disease severity in IBD model, including so as to substantially dampen adaptive immune system over-response.
- QBECO was also shown to have a positive impact on the gastrointestinal microbiome. Alterations in bacterial species in the intestinal microbiome can either be detrimental (‘unhealthy’ bacteria) or therapeutic (‘healthy’ bacteria) in IBD patients (and mouse models). Some bacteria promote a healthy immune environment and can improve symptoms (for example, Lactobacillus species), whereas others (for example, ⁇ -proteobacteria) can have detrimental effects in IBD.
- QBECO SSI improved dysbiosis in the colon of Muc2 mice, increasing the relative proportion of Lactobacillus (healthy bacterial species) and decreasing the relative proportion of gamma-proteobacteria (unhealthy bacterial species).
- FIG. 15C QBECO SSI also reduced all aspects of the histological inflammation/damage score (infiltration, integrity, hyperplasia and edema) in the colon of MUC2 spontaneous colitis mice.
- QBECO treatment significantly improved the overall histological score and reduced T cell infiltration in the colonic tissues. Furthermore, a reduction in pro-inflammatory mediators in the colon (IL-17A) and serum (KC) was observed. QBECO treatment did not impact regulatory T cell marker (FoxP3) and anti-inflammatory growth factor (TGF- ⁇ ) expressions in affected tissues.
- SSI treated mice demonstrated reduced levels of the antimicrobial lectins RegIII- ⁇ and RegIII- ⁇ . The changes in antimicrobial lectins brought on by QBECO allowed for a modulation of the gut microbiome causing a reduction in gamma-proteobacteria and a significant increase in lactobacilli.
- KPN SSI SSI-SSI
- FIG. 16 KPN SSI decreases total BAL cell count in asthmatic mice.
- FIG. 17 KPN SSI decreases eosinophil and lymphocyte counts in the BAL: A) Eosinophils, B) Lymphocytes.
- FIG. 18 KPN SSI decreases TH2 cytokines in the BAL supernatant: A) IL-4, B) IL-5.
- Example 12 Systemic Distribution of SSI Administered SubQ
- This example illustrates systemic distribution of a KPN SSI administered subcutaneously in a murine model; using cyanine dye (Cy5.5) labeled whole killed KPN cells and optical in-vivo dorsal and ventral whole-body imaging.
- imaging at 1 hr, 3 hr, 6 hr, 24 hr and 47 hr revealed systemic distribution with the highest concentrations of the SSI at the injection site.
- the SSI was cleared from circulation within approximately 24 hours.
- Example 13 Surgical Wound Treatment
- a topical formulation of an SSI is formulated for administration to wounds, for example surgical wounds, partial-thickness burns, lacerations, chronic wounds, or vascular ulcers.
- the topical SSI formulation may for example include PPR agonists derived from microbes that are skin pathogens, formulated in an ointment or gel.
- This example involved use of a whole killed E. coli SSI preparation, administered every second day by subcutaneous injection.
- the dose was individualized to the patient by adjusting the dose so that each dose was effective to cause a visible localized inflammatory immune response at the administration site (a 1 inch to 2 inch diameter delayed reaction of visible redness at the injection site).
- aspects of the invention involve use of an SSI over an extended duration period, with dosage intervals and dosage duration adapted to provide an increased therapeutic benefit over the entire dosage duration, such as a progressive reduction of CDAI score in Crohn's patients over a duration period of at last 16 weeks.
- This example illustrates therapeutic efficacy of an SSI (KPN SSI) in a murine House Dust Mite (HDM)-induced asthma model, explifying the underlying mechanistic basis for the use of SSIs in treating asthmatic inflammation.
- KPN SSI SSI
- HDM House Dust Mite
- BALB/c mice were exposed intranasally to HDM for two weeks. Mice were treated subcutaneously with either KPN SSI or placebo for one week prior to HDM exposure and throughout the two week exposure period. 24 hours after the last exposure, lungs were analysed for inflammatory cell infiltrate, gene expression, cytokine levels, goblet cell metaplasia, and serum was analysed for allergen-specific serum IgE levels.
- mice Female mice (BALB/c) age 6-8 weeks old were purchased from Jackson Laboratory (Bar Harbor, Me.). 10 mice per group were used. Mice were housed in environmentally controlled specific pathogen free conditions with a 12:12 hour light/dark cycle for the duration of the study.
- mice were exposed to saline (35 ⁇ L) or house dust mite (HDM, Dermatophagoides pteronyssimus , Greer Laboratories, Lenoir, N.C.), intranasally, 25 ⁇ g in 35 ⁇ L of saline, under isoflurane anesthesia. HDM or saline nasal exposure was done for 5 consecutive days in week 1 and 4 consecutive days in week 2 (experimental days: 1-5; 8-11, FIG. 1 ). Mice were euthanized 24 hours after the last exposure.
- HDM house dust mite
- KPN SSI was derived from Klebsiella originally isolated from a patient infection, with whole heat killed cells suspended in physiological saline containing 0.4% phenol as a preservative for a final OD 600 of 5.0. Placebo was physiological saline containing 0.4% phenol.
- KB or placebo was prophylactically given on day ⁇ 7, ⁇ 5, ⁇ 3 of the experiment, and treatment was continued on experimental days 1, 3, 5, 8, 10. 30 ⁇ L of placebo or KB was injected subcutaneously at alternative sites access skin in lower right and left quadrant of the abdomen and upper right and left quadrant of the chest.
- BAL cell differential counts were performed by examining cytospins according to cell morphology and Wright-Giemsa staining. A total of 100 cells per mouse were differentiated by a blinded observer.
- HDM was coated onto 96-well plates (2.5 ug/well) and incubated overnight at 4° C. After blocking with 5% FBS in PBS, undiluted serum was added and incubated overnight at 4° C. After washing, biotin anti-mouse IgE (BD Bioscience—San Jose, Calif., USA) was added and incubated at 37° C. for one hour. Streptavidin-HRP/TMB substrate was used to visualize levels and absorbance was recorded at 450 nm.
- cytokine/chemokine/growth factor biomarkers were quantified simultaneously using a Milliplex Mouse Cytokine/Chemokine kit (Millipore, St. Charles, Mo., USA) according to the manufacture's protocol.
- the multiplex was performed by using the Bio-PlexTM 200 system (Bio-Rad Laboratories, Inc., Hercules, Calif., USA).
- the 31-plex consisted of eotaxin, G-CSF, GM-CSF, IFN ⁇ , IL-1 ⁇ , IL-1 ⁇ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, KC, LIF, MCP-1, M-CSF, MIG, MIP-1 ⁇ , MIP-1 ⁇ , MIP-2, RANTES, TNF ⁇ , and VEGF.
- the assay sensitivities of these markers range from 0.1-33.3 pg/mL.
- IL-13 levels in the multiplex were mainly below detection, IL-13 protein levels were measured in the BAL fluid by an ELISA (eBioscience San Diego, Calif., USA).
- Lungs were dissected and inflated with 5 mL of 10% formalin. Tissues were embedded with paraffin and sectioned at 3 ⁇ m. Sections were stained with Periodic acid-Schiff to quantify mucus-containing goblet cells. Stained sections were scanned at 60 ⁇ magnification using an Aperio Slidescanner (Vista, Calif.), version 11.1.2.760. Positively stained pixels were identified by colour segmentation in a cross-sectional manner in the lung airway using Aperio Image Scope software to express the number of strong positive pixels (Periodic acid-Schiff) normalized to basement membrane length ( ⁇ M).
- FIG. 20 is a graph illustrating HDM specific IgE responses following saline or HDM exposure, treated with either Placebo or QBKPN. *P ⁇ 0.05 between HDM treated mice and their appropriate control (HDM Placebo vs Saline Placebo and HDM QBKPN vs Saline QBKPN).
- FIG. 23 is a series of graphs illustrating Th1 and Th2 lung gene expression following HDM exposure and QBPKN treatment: A) Th-1-mediated response IFN- ⁇ cytokine gene expression, B) Th-2-mediated response IL-4 cytokine gene expression, and C) IL-13 cytokine gene expression (data are means ⁇ SD of 10 mice per group; *P ⁇ 0.05 between HDM treated mice and their appropriate control).
- FIG. 24 is a series of bar graphs illustrating the effects of HDM exposure and QBKPN treatment on Th1- and Th2-mediated BAL fluid cytokine levels: A) IFN- ⁇ cytokine level; B) IL-2 cytokine level; C) TNF- ⁇ cytokine level; D) IL-4 cytokine level; E) IL-5 cytokine level; F) IL-13 cytokine level (data are means ⁇ SD of 10 mice per group; *P ⁇ 0.05 between HDM treated mice and their appropriate control).
- FIG. 25 is a graph illustrating a principal component analysis (PCA) of BAL cytokines showing partial normalization of overall cytokine profile.
- PCA principal component analysis
- the top 5 cytokines that determined PC1 were LIF (Lekemia Inhibitory Factor; 8.2%), IL-5 (8.2%), Eotaxin (8.1%), IL-4 (7.5%) and CXCL10 (7.3%).
- Completing the principle component analysis with an additional asthma markers (IL-13) measured by ELISA provided similar clustering with the top 5 cytokines that determined PC1 were IL-5 (7.3%), eotaxin (7.2%), LIF (Leukemia Inhibitory Factor; 7.2%), IL-4 (6.8%) and IL-13 (6.7%).
- FIG. 26 is a bar graph illustrating airway goblet cell quantification following HDM exposure and QBPKN treatment. Goblet cell quantification expressed as number of strong positive pixels/basement membrane length. Data are means ⁇ SD of 10 mice per group. P ⁇ 0.05 between HDM treated mice and their appropriate control. #P ⁇ 0.05 between HDM QBKPN treated mice and HDM Placebo treated mice.
- asthma QBKPN SSI decreases the BAL total cells, neutrophils, lymphocytes, macrophages and eosinophils; decreases mediators of eosinophilia including serum IL-5 and BAL eotaxin; decreases Th2 cytokines in the BAL (IL-4 and IL-5); and, reduces goblet cell hyperplasia.
- this Example illustrated that HDM exposed mice developed classical symptoms of experimental allergic asthma including goblet cell hyperplasia, elevated allergen-specific serum IgE, airway eosinophilia, and a concomitant increase in T H 2 cytokines including IL-4, IL-13 and IL-5.
- An aspect of the invention accordingly provides a treatment, such as subcutaneous treatment, with microbial biologics, such as compositions derived from bacterial lung pathogens, as a treatment for allergic airway disease, for example so as to attenuate an allergen-induced T H 2-skewed airway inflammatory response, and/or an associated goblet cell metaplasia.
- microbial biologics such as compositions derived from bacterial lung pathogens
- an SSI treatment with a biologic is capable of simultaneously targeting two of the key molecular components that promote airway eosinophilia, in a process that is independent of the regulation of allergen specific IgE.
- a KPN SSI may be administered in a dosage and for a time that is efficacious at attenuating HDM-induced T H 2 skewed allergic airway inflammation, and/or airway eosinophilia, and/or mucus content in goblet cells, and this may for example be independent of modulating allergen-specific IgE levels.
- mice are pre-treated (with placebo or KPN SSI) every other day 3 times (Monday, Wednesday and Friday of week 1). Mice are then exposed to smoke over days 8-25 (air or cigarette smoke exposure was done for 5 consecutive week days for the first 2 weeks and for 4 consecutive week days in week 3 (with no treatment or exposure on weekends) with continued treatment (placebo or KPN SSI) every other week day (Monday, Wednesday and Friday). On day 26, mice were euthanized 24 hours after the last air/cigarette smoke exposure and samples are collected.
- Cigarettes were placed into smoking machine and lit with a lighter and vacuum in the fume hood. The 20 cc syringes in the smoking machine were filled with smoke, automatic valve was turned followed by smoke injection into the nose only exposure chambers. Each smoking puff cycle took 1.5 minutes. Each mouse smoked 3 cigarettes per day for a total of 45 minutes of exposure. Control air exposure mice were restrained for a similar duration without exposure to smoke. Animals were monitored throughout the smoke exposure procedure and for 30 minutes post smoke exposure.
- the heat-killed Klebsiella strain (originating from a patient infection) was administered as follows. KPN SSI or placebo vehicle (physiological saline containing 0.4% phenol) was prophylactically administered 3 ⁇ every other day, and the regimen continued therapeutically throughout the period of smoke administration. Subcutaneous injections of 30 ⁇ L placebo or KPN SSI were administered into the lower right abdomen, the lower left abdomen, the upper right chest, and the upper left chest, rotating clockwise for each injection.
- Cytospins were performed and evaluated based on morphology and Wright-Giemsa staining. BAL cell differentials were then counted using the prepared cytospin slide with 100 cells per mouse counted in a blinded fashion.
- Immune mediator profiling of BAL and serum samples was performed as follows. Soluble mediator analysis in BAL and serum was performed using a 31 cytokine/chemokine/growth factor multiplex kit according to the manufacture's protocol (Eve Technologies Corp, Calgary, AB, Canada) using the Bio-PlexTM 200 system (Bio-Rad Laboratories, Inc., Hercules, Calif., USA).
- the 31-plex assay included the following mediators: Eotaxin, G-CSF, GM-CSF, IFN ⁇ , IL-1 ⁇ , IL-1 ⁇ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10 (CXCL10), KC (CXCL1), LIF, MCP-1 (CCL2), M-CSF, MIG (CXCL9), MIP-1 ⁇ (CCL3), MIP-1 ⁇ (CCL4), MIP-2 (CXCL2), RANTES (CCL5), TNF ⁇ , and VEGF.
- the assay sensitivities of these markers range from 0.1-33.3 pg/mL.
- Flow cytometric analysis of blood Ly6CHI monocytes/macrophages and neutrophils was performed as follows. Blood was collected in EDTA coated tubes (BD Microtainer) to prevent clotting and stored on ice prior to staining. Blood was stained with CD11b-FITC, Ly6G-PE, CD11c-PerCPCy5.5 and Ly6C-APC before red blood cell lysis (BD lysis buffer). Flow cytometry was run on a FACSCalibur (BD Bioscience). Analysis was completed on a FlowJo V10.1. Neutrophils were defined as Ly6G + CD11b + cells. Ly6CHI monocytes/macrophage were defined as Ly6C HI Ly6G ⁇ CD11b + cells.
- Body weight and clinical scores were used to monitor the overall health of mice exposed to filtered air or cigarette smoke in the presence or absence KPN.
- Body weight was normalized to the starting weight of each animal. No changes in body weight were recorded in air-exposed group treated with placebo or KPN (p>0.05). However, cigarette smoking exposed mice had a prominent loss in body weight (p ⁇ 0.05) and KPN treatment did not reverse this detrimental effect (p>0.05). No observed changes for clinical scores were observed for any groups.
- FIG. 27A is a bar graph illustrating BAL cell differential, showing that QBKPN decreases the total BAL cell count after smoke exposure through reduction in lymphocyte and macrophage populations.
- cigarette smoke exposure induced an elevation in total cell number in the BAL that was not attenuated with KPN intervention ( FIG. 27B (a), p ⁇ 0.05).
- the cigarette smoke exposure induced increase in BAL total cells was attributed to lymphocytes, macrophages, and neutrophils ( FIG. 27B (b)-(d), p ⁇ 0.05) but not eosinophils (p>0.05, data not shown).
- KPN intervention attenuated the increase in lymphocytes and macrophages in the cigarette smoke exposure group (p ⁇ 0.05), although macrophages remained elevated relative to air+KPN ( FIG. 27B (b)-(c). PN intervention had no impact on cigarette smoke induced increases in neutrophils ( FIG. 27B (d)).
- IL-17 was elevated with cigarette smoke exposure in 4 of 10 samples at values close to the level of detection of this mediator (0.64 pg/ml).
- KPN intervention attenuated cigarette smoke-induced increases in IFN ⁇ , CXCL9, CXCL10, CCL5, IL-6, G-CSF, and IL-17 ( FIG. 28A ), all mediators that are associated with a TH1 skewed inflammatory response.
- KPN SSI intervention had no impact on air-exposed animals for any mediator measured.
- the serum immune mediator protein expression profile was minimally impacted by cigarette smoke exposure but is augmented by KPN intervention, as evidenced by the same multiplex assay of 31 mediators applied to the serum from the four experimental groups.
- Cigarette smoke exposure induced an increase in only VEGF, which had elevated levels relative to air exposed control ( FIG. 28B (a), p ⁇ 0.05).
- the KPN SSI intervention did not reverse the cigarette smoke exposure-induced elevation in serum VEGF.
- KPN intervention in air exposed animals decreased only 1 mediator, IL12p40, relative to air+placebo, while the levels of IL-1 ⁇ , CCL2, CXCL9, and CXCL10 ( FIG. 28B (b)-(d) p ⁇ 0.05) were increased.
- FIG. 28D includes three bar graphs for select lung gene expression profiles, illustrating that QBKPN decreases the expression of three important inflammatory cytokine genes (IL-6, IL-1beta, and IL-17A) in the lung tissue after smoke exposure.
- IL-6 important inflammatory cytokine genes
- IL-17A important inflammatory cytokine genes
- FIG. 29 illustrates select BAL cytokine expression profiles, with six bar graphs illustrating that QBKPN caused a significant decrease in G-CSF, IL-6 and IP-10 in the COPD model, and a downwards trend in IL-4, KC, MIG, TNFalpha.
- FIG. 30 illustrates serum cytokine expression profiles, identifying a number of markers for SSI efficacy, particularly elevated serum levels of IP-10, MIG and RANTES. These serum markers may accordingly be used as a biomarker for SSI efficacy, for example to identify responders or non-responders to a particular SSI, or as a marker of efficacious dosing in a dose adjustment protocol.
- This Example illustrates that a QBKPN SSI decreased a number of markers of an inflammatory environment in a COPD model, in particular: decreased BAL total cells, lymphocytes and macrophages; decreased gene expression of cytokines that are usually elevated in COPD including IL-6, IL-1beta and IL-17A; and decreased levels of cytokines of importance in the BAL in COPD including IL-6, IP-10 and G-CSF. More particularly, these results demonstrate that KPN treatment attenuated cigarette smoke-induced TH1-skewed lung inflammation and BAL cellularity.
- KPN SSI induced a systemic immune response that included immune mediator production, and mobilization of monocytes and neutrophils, which was mirrored in the local lung environment with an increase in Ly6C HI monocytes/macrophages and neutrophils.
- This Example therefore indicates that interventions with microbial components that enhance certain aspects of an immune response, rather than generally suppressing the immune responses, may be used to alter the course of cigarette smoke exposure related COPD pathogenesis.
- COPD has many underlying pathways with other inflammatory diseases, including asthma and inflammatory bowel disease (IBD).
- IBD and COPD share common observations including an altered microbiome, immune dysfunction, altered epithelial cell function, and chronic inflammation. There is also significant overlap between asthma and IBD including altered respiratory microbiome and immune dysfunction.
- SSIs inflammatory bowel disease
- KPN treatment induced a systemic immune activation with increases in Ly6C HI monocytes/macrophages and neutrophils.
- This Example accordingly indicates that KPN SSI actively stimulates aspects of an immune response that may be adapted to lead to mobilization and recruitment of TH1-skewed immune cells systemically, but a reduction locally in the BAL.
- this Example indicates that KPN SSI administration increased pro-inflammatory cytokines (e.g. IL-1 ⁇ ) and blood inflammatory monocytes (defined as Ly6C HI ) and neutrophils, similar to the response seen with an acute infection.
- pro-inflammatory cytokines e.g. IL-1 ⁇
- Ly6C HI blood inflammatory monocytes
- neutrophils similar to the response seen with an acute infection.
- cytokines e.g. IL-1 ⁇
- Ly6C HI blood inflammatory monocytes
- neutrophils neutrophils
- CD25 is expressed on activated T cells, activated B cells, T regs and resting memory T cells (cells involved in adaptive immunity).
- this example illustrates QBKPN SSI efficacy in reducing lung nodules in the absence of CD25 positive cells, as shown in FIG. 32 .
- FIG. 33A shows the C t (cycle threshold) values associated with a KPN SSI formulation (QBKPN), and progressive dilutions of the KPN SSI (10 ⁇ , 100 ⁇ and 1000 ⁇ ), on day 5 following B16 challenge.
- C t values accordingly indicate the number of PCR cycles required for the fluorescent signal to cross the threshold (i.e. to exceed background level).
- Delta C t values took into account of C t values of a housekeeping gene, and the levels are accordingly inversely proportional to the amount of target nucleic acid in the sample.
- FIG. 33C is a bar graph illustrating that a variety of dosing regimes provide a therapeutic effect, with intervals between injections varying from 1 to 7 days all providing a therapeutic effect.
- FIG. 34 illustrated that the proportion of cells that express Rae-1 was inversely correlated with tumour burden, evidencing the fact that SSIs increase target tissue Rae-1 expression in a dose-dependent manner.
- the increased Rae-1 signal would facilitate immune stimulation through NKG2D (see below) receptors on innate lymphoid cells, such as NK cells, leading to increased cancer cell killing and the reduced tumour burden evidenced in this example.
- NKG2D see below
- NKG2D natural-killer group 2, member D
- the therapeutic efficacy of QBKPN in the B16 lung metastasis model is abrogated.
- QBECO conferred a greater survival advantage than did either QBKPN or 10 ⁇ concentrated QBSAU (QBSAUR), as illustrated in FIG. 37 .
- QBKPN demonstrated site specificity in the lung by elevating Rae-1 expression and the recruitment of monocytes and neutrophils in animals having both skin and lung tumours.
- 10 ⁇ QBSAU demonstrated site-specific efficacy by reducing skin tumour in these animals.
- a KPN SSI (QBKPN) was administered either IV or SQ in a B16 lung metastasis model.
- B16 cells were administered IV to seed tumours.
- KPN SSI was administered (IV or SQ).
- the endpoint was reached and tumour counts measured.
- both routes of administration provide therapeutic benefit.
- FIG. 42 is a schematic illustration of the study design, based on efficacy of QBKPN in a treatment versus prophylactic regimen in the B16 lung cancer model. As illustrated in FIG. 43 , while the prophylactic regimen provided earlier therapeutic benefit, by day 17 the treatment regimen shows a very strong trend of efficacy.
- This example illustrates aspects of how quickly SSI therapies have detectable therapeutic effects involving myeloid cell populations, providing examples of therapeutic biomarkers.
- neutrophils increase at all time points for QBKPN and QBECO SSIs, with significant increases seen even within 3 hours post injection.
- Ly6C HI Ly6G + CD11b + cells Ly6C monocytes
- the cellular immune response provoked by an SSI therapy may accordingly be characterized by a rapid onset, within hours, followed by a resolution within days.
- This pattern of cellular response supports a dosing schedule with repeated administrations at an interval that is measured in days, for example one administration every 1, 2, 3, 4, 5, 6, or 7 days.
- NCI-H358 cells a human lung cell line
- CFSE carboxyfluorescein succinimidyl ester
- QBKPN increases NCI-H358 cancer cell death at high doses (1/20, 1/200 dilution) in this 24 hour killing assay.
- KPN SSI increases ⁇ T cell mediated killing of the NCI-H358 cancer cells at similar doses (1/20 dilution, 1/200 dilution) in the 24 hour killing assay, as illustrated in FIG. 49 .
- the KPN SSI potentiated the effect of zoledronate in inducing ⁇ T cell mediated cancer cell lysis, at 1/200 and 1/2000 dilutions, as shown in FIG. 50 .
- SSIs can be administered directly to cancerous tissues, for example at the site of surgical resection of a cancer.
- an SSI such as QBSAU
- QBSAU may be applied topically to a melanoma in the skin or to the site of a surgical excision of a skin melanoma.
- This example illustrates the involvement of the NKG2D receptor in mediating a therapeutic response to an SSI.
- MC-38 cells a murine adenocarcinoma cell line derived from a primary mouse colon carcinoma.
- the tumour cells were injected intraperitoneally in order to allow the tumour cells to seed the gut, creating a MC-38 cell colon cancer model.
- QBECO treatment was compared to placebo in wildtype mice (C57BL/6 mice) and NKG2D knockout mice (on a C57BL/6 background). Wildtype and NKG2D mice were treated with either QBECO or placebo (10 per group) for 10 days every second day before MC-38 injection. Treatment was continued throughout the survival study every second day.
- this study confirmed the therapeutic efficacy of QBECO in the MC-38 colon cancer model, showing in the wildtype mice a statistically significant increase in survival with QBECO treatment compared to placebo treatment.
- NKG2D expression is correlated with QBECO efficacy, as there was no statistical difference in survival between NKG2D knockout mice treated with either QBECO or placebo.
- Immunophenotyping confirmed that the NKG2D knockout mice had reduced levels of NKG2D positive cells.
- QBECO caused a decrease in NKG2D at each time point within the wildtype mice (illustrating the use of NKG2D expression as a biomarker for SSI efficacy).
- Immunophenotyping also showed a characteristic increase in neutrophils by day ⁇ 9 and monocytes by day ⁇ 1 in both wildtype and NKG2D KO mice treated with QBECO compared to placebo. There was also an increase in PDL1+ after QBECO treatment, with QBECO causing an increase in PDL1+ cells in the blood throughout the experiment, with significance in wildtype mice at day ⁇ 9 and ⁇ 1, and a similar by attenuated pattern in NKG2D knockout mice.
- This example illustrates the use of an SSI to treat neutropenia in a mouse model.
- Neutrophil populations were assessed in spleen (in mouse, representative of circulation) and lungs in response to SSI treatment (QBKPN) and neutrophil-depleting (anti-Ly6G) monoclonal antibody, as illustrated in the treatment schema in FIG. 53 .
- SSI treatment was performed every two days from Day ⁇ 10 to Day +10.
- SSI (QBKPN) was injected SC in alternating sites at a dose of 0.03 ml of an OD5.0 solution.
- anti-Ly6G treatment was performed every three days from Day ⁇ 1 to Day +11.
- the proportions of neutrophils in lungs ( FIG. 55A , showing % of live CD45+CD11b+ cells) and spleen ( FIG. 56A ) were calculated from primary cytometry data. Numbers of neutrophils (CD45+CD11b+Ly6G+Ly6C+ cells) in the lungs ( FIG. 55B ) and spleen ( FIG. 56B ) were calculated by multiplying the proportion of cells by the total cellularity.
- QBKPN treatment significantly increased the proportion ( FIG. 55A and FIG. 56A ) of neutrophils.
- an SSI may accordingly be given so as to restore neutrophil counts.
- SSI therapies of this kind In addition to treating neutropenia, in the context of treating an underlying disease, the selection of a targeted SSI, with a PRR agonist signature that recapitulates a distinct portion of a PRR agonist signature of a microbial pathogen that is pathogenic in the target tissue, results in site specific restoration of innate immune function in the target tissue. This may for example involve an anti-cancer immune response, or an anti-inflammatory immune response mediated by the SSI (in addition to the effect of treating the neutropenia).
- Chemotherapy commonly produces myelosuppression, of which the most clinically relevant component is neutropenia occurring between 2-10 days post-chemotherapy.
- the clinical implications of this are serious, interfering with the ability to maintain a chemotherapeutic dose and schedule, and giving rise to the risk of neutropenic sepsis.
- an SSI may be given to patients undergoing a myelosuppressive chemotherapy as a prophylaxis or treatment for neutropenia, for example being administered every other day between cycles of chemotherapy.
- Example 25 PD1 and PDL1 Markers in Patients
- This Example provides clinical data illustrating the efficacy of an SSI acting to down-regulate PD1 and PDL1 expression in neoplastic disease. This also illustrates the use of PD1 and PDL1 as markers of SSI efficacy, augmenting the NKG2D mouse model data in Example 23. This is significant, given the understanding that PD1 (expressed on T-cells) and it's ligand PD-L1 play a role in preventing T-cell activation and mediating pathological immunosuppression.
- the 2 neoplastic patients presented with elevated PDL1 and PD1 expression compared to the pre-neoplastic patients. This is shown in the bar graph of FIG. 57 as a percentage of the distinct cell populations, and in FIG. 58 as the relative number of cells having the denoted characteristics.
- the neoplastic patients (01-001 and 01-002) express higher levels of PD1 and PDL1, ad have a lower level of M4 macrophages than the pre-neoplastic patients.
- FIGS. 59A-59B illustrate the reduction of PD-L1 expression in Patient 01-001 (panel A) and Patient 01-002 (panel B), at: week 1, day 4 (W1D4); week 1, day 5 (W1D5); week 2 (W2); week 4 (W4), week 12 (W12) and week 16 (W16); during the course of SSI treatment every other day.
- FIGS. 60A-60B illustrate the reduction in PD-1 expression in these patients at these time points.
- 61A-61B illustrate the increase in the proportion of M1 macrophages in these patients at these time points.
- PDL1 expression decreases on CD45+ cells (all white blood cells)
- PD1 expression decreases in CD3+ cells (lymphocytes)
- M1 macrophages increase in the blood (CD45 + CD14 + HLA-DR + CD86 + ).
- SSI treatment was discontinued at week 12 (W12), and the assays indicated that the relative M2 macrophage populations (CD14+CD163+) generally decreased until the cessation of treatment, and then rebounded.
- This Example illustrates the relationship between SSI dosage, tumour load, and expression of granzyme A, granzyme B, and perforin in B16 melanoma mouse lung models, providing evidence that eficatious SSI therapy elevates granzyme and perforin levels while reducing tumour load.
- mice were intravenously injected with B16 melanoma cells to provide a mouse lung cancer model.
- SSIs were administered prophylactically ten days prior to tumour inoculation at every second day.
- Mice were continually injected with SSIs every two days until they were euthanized at fourteen days post-tumour injection. The right lung post-caval lobe was removed and stored in RNAlater®.
- the entire mouse right lung post-caval lobe was homogenized in lysis buffer by a small bead mill (Qiagen, Cat No. 85600). All of the homogenate was extracted for RNA using the PureLink® RNA Mini Kit (ThermoFisher Scientific, Cat No. 12183018A). A NanodropTM spectrophotometer was used to quantify the RNA concentrations and purity. One microgram of RNA was reverse transcribed into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad, Cat no. 170-8891). For quantitative PCR, fifty nanograms of cDNA were loaded into each well of the reaction plate.
- the wells contained TaqMan® Fast Advanced Master Mix (ThermoFisher Scientific, Cat No. 4444554), and TaqMan® Gene Expression Assays probes.
- Samples were quantified for granzyme A (ThermoFisher Scientific, Mm01304452_m1), granzyme B (ThermoFisher Scientific, Mm00442837_m1), perforin (ThermoFisher Scientific, Mm00812512_m1), tyrosinase (ThermoFisher Scientific, Mm00495817_m1), and GAPDH (ThermoFisher Scientific, Mm99999915_g1) as the housekeeping gene.
- Two technical replicates were plated for the genes of interest (GOI), and in singlicate for the housekeeping gene.
- the ddC t method was used to calculate gene expression fold changes.
- Technical replicates for the GOI were averaged, and biological replicates were tested for outliers using the ROUT method on GraphPad Prism 7.00 at 95% confidence.
- the technical outliers for GzmB: 1/500x-3 and Prf1: 1/500x-3 were removed from further analyses.
- the dC t value was calculated by subtracting C t ,GOI by C t ,GAPDH.
- the ddC t values were calculated by subtracting dC t of the sample by average dC t of the placebo group.
- Fold change was calculated by taking the negative exponent of ddC t with base two (2-ddC t ).
- the average fold change of each treatment group was analyzed for significance using a one-way Tukey's multiple comparison ANOVA test at 95% confidence.
- FIGS. 62A-62B illustrate the results of the foregoing assays, showing RT-qPCR fold changes in (A) GzmA, GzmB, Prf1, and (B) Tyr in lungs of B16 inoculated mice euthanized on day 14 with differing QBKPN doses.
- Taqman® Gene Expression Assays were performed on 50 ng of cDNA isolated from the right lung post-caval lobe of mice. Values are normalized to GAPDH, and relative to the gene expression of the placebo group, which were mice injected with saline. Data points are mean+/ ⁇ SD.
- SSIs may be formulated and administered in a dosage regime that is effective in a target organ or tissue to mediate increased expression of one or more granzyme or perforin, such as of granzyme A, granzyme B, and perforin.
- Example 27 Distinct SSIs Agonize Distinct PRRs
- This data in this Example was obtained from assays of QBKPN and QBECO PRR activation in cell lines that have a single PRR.
- the cell lines used were HEK293 cells lines that express a single human Toll-Like Receptor (TLR2, 3, 4, 5, 7, 8 and 9), NOD-Like Receptor (NOD1 and NOD2), C-Type Lectin (Dectin 1a, Dectin 1b, and Mincle) or RIG-1-like receptor (RIG-1 and MDA5).
- TLR 2 and TLR4 Two TLRs were highly activated by both QBECO and QBKPN (TLR 2 and TLR4).
- One TLR was highly activated by just QBKPN (TLR5).
- 1 PRR was moderately activated by bother QBECO and QBKPN (NOD2).
- 4 were moderately activated by only QBECO (TLR3, TLR7, TLR8, TLR9) while 2 were moderately activated by only QBKPN (Dectin 1a, Dectin 1b).
- NOD1 Mincle, RIG-1 and MDA5 were not activated by either QBECO or QBKPN.
- TLR2 and TLR4 are localized on the plasma membrane and primarily recognize lipoprotein and LPS respectively.
- TLR5 is a plasma membrane receptor that responds to Flagellin.
- TLR3 was only slightly activated by QBECO (and not by QBKPN).
- TLR3 is primarily a dsRNA receptor for viral RNA.
- TLR7 and 8 which are located in the endolysosome and also recognize RNA (bacterial and viral) were activated by only QBECO.
- TLR9 which recognized CpG-DNA and is located in the endolysosome was also activated by only QBECO.
- HEK cells are not known to highly uptake bacteria in endolysosomes.
- NLR Nod-Like Receptors
- NOD1 was not activated by either QBECO or QBKPN, but NOD2, which recognizes muramyl dipeptide (MDP) was activated by both QBECO and QBKPN.
- MDP muramyl dipeptide
- the other cytoplasmic receptors, RIG-1 and MDA5 which recognize short dsRNA and long dsRNA respectively, were not activated.
- the C-type lectin receptors (CLR) are located in the plasma membrane and primarily recognize carbohydrates. Mincle was not increased by either QBKPN or QBECO. Dectin 1a and Dectin 1b are primarily fungi receptors for beta-Glucans but can also see bacteria carbohydrates.
- This Example illustrates that viral SSIs induce immune changes are similar to bacterial SSIs, as evidenced by immune correlates in the blood after 7 days of Viral SSI treatment compared to QBKPN SSI treatment.
- Mice were treated with Placebo, QBKPN, or three viral SSI models: Rabies Vaccine, Feline Rhinotracheitis-Calici-Panleukopenia Vaccine and Canine Influenza Vaccine. 30 ⁇ L of the treatments were injected subcutaneously every second day. The endpoint was 24 hours after the 4th SSI injection (day 7). At endpoint, blood was collected and stained for flow cytometry to determine the numbers of neutrophils and Ly6C HI monocytes in the blood as a percentage of CD45 + cells.
- Rabies vaccine killed rabies virus
- Fel-O-Vac Feline Rhinotracheitis-Calici-Panleukopenia virus
- Nobivac Canine Influence H3H8 virus
- SSIs potentiate an immune response when used in combination with cancer antigens.
- the lung-targeted SSI QBKPN mediated a reduction in tumour burden, and when used in combination therapy with a melanoma-associated antigen (gp100) further reduced tumour burden.
- gp100 melanoma-associated antigen
- This effect was specific to the use of the cancer antigen, as evidenced by the fact that an irrelevant (immunogenic but non tumour-associated) antigen did not impact tumour burden.
- the SSI cancer antigen combination therapy was effective both as co-formulated compositions and as separate injections of SSI and antigen. This evidences the use of an SSI as a adjuvant to drive immune responses to immunogenic cancer antigens.
- mice On days ⁇ 10, ⁇ 6, and ⁇ 4, some mice were also treated with indicated antigens and/or adjuvants, either co-mixed with SSI or s.c. in a distal site (nape).
- Peptide vaccines consisted of the melanoma-specific antigen gp100 25-33 (KVPRNQDWL, 100 ⁇ g/mouse) or the immunogenic control antigen from OVA (OVA 257-264 , SIINFEKL, 100 ⁇ g/mouse).
- Adjuvant consisted of commercial CpG (ODN 1585 VacciGrade, 30 ⁇ g/mouse s.c).
- mice were challenged with B16 melanoma (3 ⁇ 10 5 cells/mouse, i.v.).
- mice were sacrificed, surface metastases enumerated, and spleens and blood collected.
- Splenocytes were pooled among each group.
- Splenocytes (1 ⁇ 10 6 cells/well) were cultured with gp100 25-33 , OVA 257-264 , or control peptide (influenza NP366-374) (all peptides at 10 ⁇ g/ml) for 5 days, then supernatants assessed for IFN- ⁇ (by specific ELISA) as a readout of immunogenicity.
- Blood was collected into heparin-containing tubes, then centrifuged to remove cells.
- QBKPN treatment of K. pneumoniae -pre-exposed mice significantly (p ⁇ 0.0001) reduced metastatic-like B16 melanoma in the lungs.
- Administration of cancer antigen (gp100) without adjuvant had no significant effect, in keeping with the relative paucity of response to non-adjuvanted vaccines in murine systems.
- Combination of QBKPN SSI with gp100 (tumour-associated antigen) significantly (p ⁇ 0.05) enhanced anti-tumour efficacy, compared with QBKPN alone.
- This Example illustrates enhanced efficacy of a microbial SSI augmented with an additional PRR agonist, in this case a STING agonist.
- These formulations constitute a class of artificial PRR agonist repertoires in which a microbial PRR agonist repertoire is augmented with one or more additional heterologous PRR agonists.
- mice were infected with K. pneumoniae (2.5 ⁇ 10 5 cells/mouse) by oropharyngeal instillation after being anaesthetized with isofluorane, then rested. Within 5-7 days, all mice were fully recovered from K. pneumonia challenge. Starting on day ⁇ 10, some mice were S.C. injected with QBKPN SSI; mice were injected every other day from Day ⁇ 10 to day +12.
- mice were challenged with B16 melanoma by tail-vein (I.V.) injection of single cell suspensions of tumour cells (2.0 ⁇ 10 5 cells/mouse).
- I.V. tail-vein
- Serum was collected into heparin-containing tubes, then centrifuged to remove cells.
- the combination of SSI and STING agonist further increased cytokine levels, even though STING agonist treatment had not occurred for 18 days. Cytokine levels following combination treatment were statistically greater than single agent treatment. There was a significant inverse correlation between tumour burden and plasma IFN- ⁇ levels. In sum, this data illustrate effective combination therapy using a STING agonist and an SSI.
- This Example provides a genetic analysis of subjects with IBD undergoing treated with an SSI therapy, illustrating the use of genetic markers associated with IBD to identify patient populations amenable to SSI treatments.
- this Example there were 48 subjects with IBD and approximately 2.4 million single nucleotide polymorphisms (SNPs) which were the subject of analyses following genotyping on the Infinium Omni2.5-8 bead chip.
- SNPs single nucleotide polymorphisms
- the end-points used for these genetic analyses were varied and encompassed both clinical response and also the use of object markers of disease activity.
- standard quality control measures including call frequency, minor allele frequency, and Hardy-Weinberg equilibrium test
- 113 known IBD loci were represented on the chip and passed quality control.
- CD Crohn's disease
- UC ulcerative colitis
- an aspect of the present invention involves the provision of companion diagnostic genetic testing assays in association with an SSI therapy. SNPs and genetic loci that may be used in such assays are set out below.
- Tables 23A and 236 which identifies the relevant allele for each SNP and the odds ratio reflecting the association of that allele with SSI response.
- Table 23A odds ratios greater than 1 indicate that the designated allele is positively associated with response to SSI therapy
- odds ratios less 1 indicate that alternative allele is positively associated with response to SSI therapy
- the allele set out in the Table is negatively associated with response to SSI therapy.
- Table 23B the odds ratios that are negative in Table 23A have been converted to positive odds ratios for the alternative allele, so that all odds ratios are greater than one and the Response Allele is the allele associated with response to SSI therapy.
- IBD associated SNPs are spacially associated with genes (Liu et al., Nature Genetics. 47.9 (September 2015): p 979), so that alternative markers, such as SNPs, associated with these genes may also serve as markers of SSI efficacy, as set out in Table 25:
- IBD associated SNPs are spacially associated with genes (Jostins, et al., Nature. 2012; 491: 119-124), so that alternative markers, such as SNPs, associated with these genes may also serve as markers of SSI efficacy, as set out in Table 26:
- IBD associated SNPs are spacially associated with genes (Jostins, eta, Nature. 2012; 491: 119-124), so that alternative markers, such as SNPs, associated with these genes may also serve as markers of SSI efficacy, as set out in Table 27a:
- r-squared a measure of the degree to which alternative genetic markers provide similar diagnostic or prognostic information.
- the value of r 2 ranges between 0 and 1 (1 when two markers provide identical information, and 0 when they are in perfect equilibrium).
- markers with r 2 >0.8 may be considered to be in high linkage disequilibrium, so that they may provide similar diagnostic or prognostic information.
- an aspect of the assays described herein involves the use of makers that are in linkage disequilibrium with the markers identified above, having for example r 2 >0.7, r 2 >0.8, r 2 >0.9 or r 2 >0.95.
- markers that provide related information may be characterized by physical proximity in the genome, for example being within 1 Mbp of each other, for example within 50 Kb, 60 Kb, 70 Kb, 80 Kb, 90 Kb, 100 Kb, 200 Kb, 300 Kb, 400 Kb or 500 Kb of each other.
- a “genetic SSI response marker” means a genetic biomarker, the presence of which is correlated with the probability of response to a treatment with an SSI.
- Exemplary genetic SSI response markers are disclosed in this Example, evidencing a correlation with response to an SSI in IBD patients.
- Genetic SSI response markers may be detected by a wide range of genomic assays, and may also be detected by assays that interrogate the transcription or translation products of a genome, for example protein isoforms associated with a particular genomic allele.
- biochemical SSI response markers are disclosed herein that provide a biochemical indication of response to an SSI therapy, these for example include temporal or special changes in cellular populations or in the abundance or concentration of biologically relevant molecules.
- Biochemical and genetic SSI response markers may be used as diagnostic or prognostic indicators in the context of an SSI treatment, for example for IBD in general, or for specific forms of IBD such as Crohn's Disease and ulcerative colitis.
- Exemplary genetic SSI response markers are set out in Table 27b, as well as Tables 23 to 26.
- This Example provides an analysis of the PRR receptors that are the targets for alternative SSIs.
- PRRs stimulated by select SSIs including QBKPN, QBECO and QBSAU. Where a PRR is “Optional”, this indicates that some embodiments may be designed to include agonists for the specificed PRR.
- Pattern Recognition Receptor Major Agonists QBECO QBKPN QBSAU TLRs (Toll-Like Receptors) TLR1 Triacyl lipoprotein/peptidoglycan Yes Yes Yes Yes Yes Yes Yes Yes TLR2 Glycolipds, Lipoprotein, Yes Yes Yes Yes lipopeptides, lipoteichoic acid, others TLR3 dsRNA (viral) No No No No TLR4 Lipopolysaccharide (LPS), heat Yes Yes No shock proteins, others TLR5 Flagellin, Profilin Yes No No TLR6 Diacyl lipoprotein Yes Yes Yes Yes TLR7 ssRNA No No No TLR9 CpG-DNA Yes Yes Yes Yes TLR10 Unclear Optional Optional Optional CLR (C-Type Lec
- PNAS Macrophage ⁇ - or ⁇ -N-acetylgalactosamine Optional Optional Optional galactose-type (GalNAc, Tn) residues of N- lectin (MGL) and O-glycans carried by glycoproteins and/or glycosphingolipids (PMID 15802303) DC-SIGN (CD- High-mannose-containing Optional Optional Optional 209) glycoproteins Langerin (CD207) Similar to CD-209 Optional Optional Optional Mannose Binding Mannose and N- Optional Optional Optional Optional Lectin (MBL) acetylucosamine Myeloid DAP12- Unclear, dengue viral particles Optional Optional Optional associating lectin (PMC3204838) (MDL-1/CLEC5A) Dectin1/CLEC7A B glucans on fungi, Optional Optional Optional mycobacteria DNGR1/CLEC9A Actin filaments (no microbial Optional
- NLRC4 Flagellin, components of the Optional Optional Optional type three secretion system, others NLRC6 Unclear Optional Optional Optional NLRX1 (NOD5) Unclear Optional Optional NALP1-14 Pathway unclear (Anthrax and Optional Optional Optional muramyldipeptide for NALP1) NAIP Unclear Optional Optional Optional CIITA (NLRA) Unclear (does not directly bind Optional Optional Optional DNA) RLR (Rig-1 Like Receptors) RIG-1 dsRNA (viral), maybe bacterial Optional Optional Optional Optional MDA5 dsRNA (viral) Optional Optional Optional Optional LGP2 dsRNA (viral) Optional Optional Optional Optional Others DAI (DNA- DNA Optional Optional Optional dependent activator of IRFs) (PMID 20098460) AIM2 (PMID dsDNA Optional Optional Optional 20098460) Caspase 11 LPS Optional Optional Optional (P
- SSI therapies are provided that target a select subset of PRRs, using microbial PRR agonists derived from microbial pathogens of a target tissue.
- an immunogenic composition is provided that comprises microbial agonists for at least a select number of distinct PRRs, for use so as to illicit an innate response in a target tissue, wherein the PRR agonists are microbial components from a single species of microbe that is selectively pathogenic in the target tissue.
- the number of distinct PRRs targeted by the agonists may for example be a number from 5 to 25, or at least a number within that range of integers, for example at least 5, 6, etc.
- the distinct PRRs may for example be selected from the PRRs set out in Tables 28, 29 and/or 30.
- This Example provides an indication of cytokine markers indicative of various facets of SSI therapies.
- This data reflects the analysis of 42 cytokines/chemokines from a cohort of Crohn's Disease patients undergoing SSI therapy with QBECO, at baseline, week 4, week 8, week 16, and week 24, of a randomized placebo-controlled trial involving 68 patients.
- QBECO exposure increased IL-18 and IP-10 at both the 8 week and 16 week time points.
- VEGF-A Vascular endothelial growth factor A
- GCSF granulocyte colony stimulating factor
- IFN ⁇ granulocyte colony stimulating factor
- IL-17A granulocyte colony stimulating factor
- IL-7 transforming growth factor- ⁇
- Eotaxin 1 was a predictive biomarker for remission in response to QBECO treatment.
- baseline serum levels of Eotaxin-1 C-C chemokine 11
- patients who had higher levels at baseline being less likely to go into clinical into clinical remission by week 8 with QBECO treatment ( FIG. 76 ).
- patients with higher baseline IL-10 and IL-12p40 were also less likely to have a clinical response to QBECO treatment by week 8 ( FIG. 76 ).
- TNF ⁇ inhibitors such as RemicadeTM or HumeraTM
- Stratifying the mean baseline serum levels of the immune factors that associated with clinical outcome by previous TNF ⁇ inhibitor exposure provides evidence to support this.
- CDAI Crohn's Disease Activity Index
- Anti-TNF ⁇ na ⁇ ve patients include, for example, patients who have not been treated with the immunosuppressive drugs Remicade®, Humira®, Cimzia® and Simponi®. In patients previously been treated with TNF ⁇ inhibitors who completed 16 weeks of SSI treatment, 40% were in remission, indicating that this more challenging patient group may respond to QB
- a composite prediction model was built including both the baseline biomarker measures (i.e. the 42 immune factors including cytokines, chemokines and growth factors) and baseline clinical and demographic characteristics.
- the variables available for the latter included enrollment year, age at randomization, age at diagnosis, time from diagnosis to randomization, sex, race (Caucasian or not), site (Vancouver or not), prior anti-TNF ⁇ therapy, baseline Crohn's Disease Activity Index (CDAI) score, baseline fecal calprotectin levels, and baseline C-reactive protein levels.
- the baseline biomarker measures i.e. the 42 immune factors including cytokines, chemokines and growth factors
- the variables available for the latter included enrollment year, age at randomization, age at diagnosis, time from diagnosis to randomization, sex, race (Caucasian or not), site (Vancouver or not), prior anti-TNF ⁇ therapy, baseline Crohn's Disease Activity Index (CDAI) score, baseline fecal calprotectin levels, and baseline C-
- the composite model generated from this data achieved this level of predictive value with the inclusion of the following variables: sex, prior TNF ⁇ therapy, and baseline levels of Eotaxin-1, GRO ⁇ (also called CXCL1—a neutrophil chemokine), IL-10, PDGF AA and RANTES (also called CCL5—a chemokine for activated T cells, eosinophils, basophils).
- Eotaxin-1 also called CXCL1—a neutrophil chemokine
- IL-10 also called CXCL1—a neutrophil chemokine
- PDGF AA a chemokine for activated T cells
- eosinophils basophils
- a predictive model may also be developed using Eotaxin, GRO ⁇ , IL10, PDGF AA, RANTES, Sex and prior aTNF ⁇ , predicting response with high confidence.
- QBECO SSI therapy provokes a biological response by increasing certain cytokines (IL-18 and IP-10) over time.
- cytokines IL-18 and IP-10
- Treatment protocols such as dosing, may accordingly be adjusted to achieve this result.
- TGFa may for example be used as a marker of mucosal healing.
- Eotaxin 1 levels may be used as an indicator of patients more amenable to SSI treatment.
- This biomarker analysis illustrates the formulation of a viable predictive composite model that can provide personalized treatment for Crohn's disease.
- This biomarker analysis maybe useful alone, or in combination with the genetic analysis exemplified herein, which showed significant stratification between responders and non-responders based on a derivation of a gene score.
- This Example illustrates results from a mouse model of chemically induced colitis, used to assess the efficacy of QBECO SSI therapy.
- Mice were given dextran sodium sulfate (DSS) in drinking water to induce colitis that mimics human ulcerative colitis.
- DSS dextran sodium sulfate
- one cohort of mice was exposed to DSS for 7 days, a second cohort was exposed to DSS for 7 days followed by 3 days of water.
- Mice were given SSI injections every other day during a 10 day period prior to DSS exposure. The SSI injections continued every other day during DSS exposure.
- the results, as illustrated, indicate that SSI treatment with QBECO ameliorates disease severity by limiting weight loss ( FIG. 77 ), lowering disease severity ( FIG.
- FIG. 80 The pharmacodynamics of QBECO SSI treatment in this model are illustrated by the blood neutrophil ( FIG. 80 ) and blood cytokine ( FIG. 81 ) levels in disease-free mice treated with QBECO or placebo, with the pharmacokinetics of QBKPN ( FIG. 82 ) used to model the pharmacokinetics of SSIs in general, including QBECO (QBKPN SSI was fluorescently labelled and subcutaneously injected into disease-free mice, mice were bled at different timepoints over 48 hours).
- QBECO QBKPN SSI was fluorescently labelled and subcutaneously injected into disease-free mice, mice were bled at different timepoints over 48 hours).
- This Example illustrates results from a mouse cancer model, showing a tissue-specific biomarker response to SSI therapy.
- gene expression in the lung tissues evidences tissue-specific SSI responses for CXCL10 (IP-10), CCL2 (MCP-1) and CCR2.
- mice were treated every second day for 10 days with Placebo, QBKPN or QBECO before B16F10 tumour implantation into the lungs via tail vein injection. Treatment continued every second day after tumour inoculation. Mice were euthanized on day 5 (A, C, E) or day 17 (B, D, F).
- CXCL10 (IP-10), CCL2 (MCP-1) and/or CCR2 may be used as biochemical SSI response markers, for example in biopsy tissue sample assays.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
Abstract
The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/096,120 filed Oct. 24, 2018, now issued as U.S. Pat. No. 11,226,340, which application is a U.S. National Stage Application of PCT Application No. PCT/CA2017/050513 filed Apr. 26, 2017, which application, pursuant to 35 U.S.C. § 119(e), claims priority to the filing dates of U.S. Provisional Application No. 62/327,953 filed Apr. 26, 2016, U.S. Provisional Application No. 62/385,798 filed Sep. 9, 2016, U.S. Provisional Application No. 62/395,783 filed Sep. 16, 2016, U.S. Provisional Application No. 62/421,511 filed Nov. 14, 2016, U.S. Provisional Application No. 62/442,759 filed Jan. 5, 2017, U.S. Provisional Application No. 62/457,618 filed Feb. 10, 2017, and U.S. Provisional Application No. 62/472,394 filed Mar. 16, 2017, which applications are incorporated herein by reference in its entirety.
- Innovations are disclosed in the field of medical and veterinary science, relating to preparations that contain immunogens, such as microbial components. The preparations are formulated for medical purposes, and methods of using the preparations in therapy are provided.
- There is growing recognition that immunological dysregulation, an imbalance between immune response and immune tolerance, is not only a primary factor in allergic and autoimmune disease, it also has an underlying mechanistic role in a wide variety of pathologies, including cancer (see Mills et al., 2016, Cancer Res; 76(3); 1-4), metabolic disease (obesity, diabetes), degenerative disease (Alzheimer's, Parkinson's, Amyotrophic Lateral Sclerosis, osteoporosis), respiratory and cardiovascular disease (see Immune Rebalancing, 1st Edition: The Future of Immunosuppression, 2016, Boraschi and Penton-Rol Eds, Academic Press).
- In vertebrates, an important aspect of immunological regulation involves the concerted activity of the innate immune system and the adaptive immune system. This concerted activity involves metabolic, enzymatic and molecular genetic changes within immune cells, orchestrating an elaborate system of cellular, cytokine and chemokine communication pathways mediating the coordinated activity of the disparate components of these complementary systems (see Iwasaki & Madzhitov, 2015, Nature Immunology 16:343-353; WO0209748; WO03051305; Turner et al., 2014, BBA-Molecular Cell Research 1843:11 2563-2582). An aspect of this coordinated activity underlies the recognition that ligands of the pattern recognition receptors (PRRs) of the innate immune system may be used as vaccine adjuvants to improve an adaptive immune response (see Maisonneuve et al., 2014, PNAS 111(34), 12294-9; WO2007035368).
- Immunological memory, involving the recognition of specific antigens by B and T cell receptors, is a long recognized and central feature of the adaptive immune system, and the basis for vaccine efficacy (see Nature Immunology, Focus on immunological memory: June 2011,
Volume 12No 6 pp 461-575). Innate immune memory is a more recently recognized and less well understood characteristic of the immune system (see Netea et al., 2015, Nature Immunology 16, 675-679; and Bordon, 2014, Nature Reviews Immunology 14, 713). - A wide variety of innate and adaptive immune cells are understood to be resident in non-lymphoid tissues, with diverse roles in tissue homeostasis (see Nature Immunology, Focus on tissue-resident leukocytes, October 2013,
Volume 14No 10 pp 977-1100). The complexities of this homeostasis are evident in the observation that even the ontogeny of tissue resident immune cells may in some cases be distinct from the ontogeny of similar immune cells that are not tissue resident (Italiani and Boraschi, Frontiers in Immunology, October 2014,Vol 5, article 514). - Immunomodulatory or immunogenic compositions are provided that constitute an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists. The PRR agonist repertoire is selected so that it in effect recapitulates a distinct portion of a PRR agonist signature of a microbial pathogen, and more specifically a pathogen that is pathogenic in a selected target tissue. The PRR agonist signature is distinct in the sense that it is different from PRR agonist signatures of microbes that are not pathogenic in the target tissue, and it is also distinct in the sense that it is different from the native PRR agonist signature of the wild-type pathogen. This distinct artificial repertoire of PRR agonists may then be formulated so that the PRR agonists are presented together in a therapeutic vehicle, for example so that the PRR agonist repertoire may be presented in combination. The therapeutic vehicle may for example be a recombinant microbe, a cellular fraction of a microbial cell, a microparticle or a liposome. The composition may for example comprise microbial agonists for at least a minimum number of distinct mammalian PRRs, for example at least 5, as described in more detail herein. The vehicle may then be delivered, for example systemically, so that the PRR agonist repertoire is presented to an innate immune cell resident in the target tissue in a host, such as a mammalian host. The therapeutic vehicle may for example aggregate the artificial repertoire of PRR agonists, so that the proximity of the plurality of PRR agonists is maintained during systemic distribution in a host. Compositions of this kind may be used to treat a wide variety of diseases characterized by immune dysregulation, including neoplastic diseases and auto-immune diseases.
- Aspects of the innovation involve the use of an immunogenic composition in methods of treating an immune dysregulation in a target tissue in a mammalian host, wherein the composition comprises the foregoing artificial repertoire of mammalian PRR. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation following administration to a mammalian host. Composition may for example include components of the microbial mammalian pathogen that are agonists for a select number of distinct mammalian PRRs, as discussed in more detail below, for example at least 5. Compositions may for example be adapted for use so as to modulate an innate immune response in the target tissue. The therapeutic vehicle may for example include a recombinant microbe, a cellular fraction of the recombinant microbe, a cellular fraction of a microbial cell, a microparticle or a liposome, each comprising components of the microbial mammalian pathogen that provide the PRR agonists that together make up the artificial repertoire of PRR agonists. A recombinant microbe may for example include a recombinant gene encoding a component of at least one of the PRR agonists. In select aspects, the therapeutic vehicle may for example include a whole killed or attenuated cell of the recombinant microbe. Alternatively, the cellular fraction of the microbial mammalian pathogen may be used, for example, a bacterial outer membrane fraction; a bacterial inner membrane fraction; a pellet from a gradient centrifugation of microbial cell components; or chromosomal DNA. The therapeutic vehicle may for example be formulated for use for delivering the PRR agonists to the target tissue.
- In select embodiments, the PRRs and the corresponding PRR agonists may for example be selected from the group consisting of:
-
PRR PRR Agonist TLR2 Microbial cell wall components/preparations, Pam2C- Aca-Benzyl-Murabutide (Pam2C- conjugated murabutide) TLR3 Polyadenylic-polyuridylic acid, Polyinosine-polycytidylic acid TLR4 Lipopolysaccharide, Monophosphoryl Lipid A TLR5 Flagellin TLR7/8 Single-stranded RNAs, Nucleoside analogs, Imidazoquinolines/Thiazoquinolines TLR9 unmethylated CpG DNA motifs NOD1 iE-DAP, Acylated iE-DAP, D-gamma- Glu-mDAP, L-Ala-gamma-D-Glu-mDAP NOD2 MDP (MurNAc-L-Ala-D-isoGln, muramyl dipeptide), N-glycolylated muramyldipeptide, N-Acetyl-muramyl- L-Alanyl-D-Glutamin-n-butyl-ester, MurNAc-Ala-D-isoGln-Lys, N- Acetylmuramyl-L-Alanyl-D- Isoglutamine (L-D isoform), 6-O- stearoyl-N-Acetyl-muramyl-L-alanyl-D- isoglutamine, Pam2C-Aca-Benzyl- Murabutide, TLR2/NOD2 Pam2C-conjugated murabutide NOD1/NOD2 PGN, Pam2C-conjugated murabutide RIG1/MDA5 5′ triphosphate double stranded RNA (18-20mer), polyriboinosinic:polyribocytidylic acid DAI, LRRFIP1, AIM2, dsDNA, poly(dA-dT)•poly(dT-dA) RIG1 Dectin-1 Beta-glucan peptide, fungal cell wall preparations Mincle damaged microbial cells, fungus, yeast and mycobacteria, Trehalose-6,6- dibehenate, trehalose-6,6-dimycolate STING Cyclic dinucleotides (c-di-nucleotides), xanthenone derivatives, 3′3′-cGAMP, 2′3′-cGAMP, 2′2′-cGAMP, 2′2′-cGAMP, c-di-AMP (cyclic di-adenylate monophosphate), c-di-GMP, c-di-IMP, c-di-UMP, c-di-AMP RIG-I PPP-ssRNA (PPP-ssRNA, ssRNA with a 5′-triphosphate group), RNA with base pairing and polyl:C MDA5 Long dsRNA LGP2 dsRNA DDX41 B-form DNA and CDNs (cyclic dinucleotides) DHX9 DNA, RNA, CpG-A oligodeoxynucleotids and CpG-B ODNs DDX3 Viral RNA DHX36 DNA, RNA, CpG-A oligodeoxynucleotids and CpG-B oligodeoxynucleotids DDX1-DDX21-DDX36 RNA and polyl:C DDX60 ssRNA, dsRNA and dsDNA KU70 DNA cGAS DNA STING CDNs (c-di-GMP and c-di-AMP) NOD2 ssRNA NLRP3 ssRNA, dsRNA, bacterial mRNA and oxidized mitochondrial DNA AIM2 DNA IFI16 dsDNA LRRFIP1 B-form DNA, Z-form DNA and dsRNA DAI DNA IFIT1, 2, 3 and 5 PPP-ssRNA - The therapeutic vehicle may for example include additional therapeutic moieties, such as one or more of: GMCSF, vitamin D, NOHA, alph1 antitrypsin, glutathione, an isoprenoid, or α-galactosylceramide. In alternative embodiments, the therapeutic vehicle further comprises an antigen, such as a cancer antigen. Alternatively, the therapeutic vehicle may further include a heterologous PRR agonist, such as a PRR agonist that is not a component of the microbial mammalian pathogen.
- The subject of treatment, such as a mammalian host or human patient, may for example be suffering from a disease or condition characterized by the immune dysregulation in the target tissue, such as a cancer or an inflammatory disorder.
- The composition may be adapted for use in an amount effective to modulate a biomarker, for example one or more of PD1, PDL1, IP-10, MIG, RANTES, neutrophils, Ly6C monocytes, and NKG2D. In select embodiments, the composition may for example be adapted for use in an amount effective to down-regulate PD1 and/or PDL1 expression in cells present in the target tissue. The composition may accordingly be adapted for use so as to modulate an adaptive immune response in the host, for example as a concomitant of modulating an innate immune response.
- The therapeutic vehicle is for administration at an administration site that is not the target tissue, and the site may for example be the skin, subcutaneous tissue, the respiratory tract. Administration may be enteric, or non-enteric. The therapeutic vehicle may be formulated for systemic distribution of the PRR agonists following administration at a localized administration site. The therapeutic vehicle may be administered in a plurality of doses over a dosage duration, and the dosage duration may for example be at least two weeks, or any of other wide range of dosage regimens disclosed herein or known in the art.
- In select embodiments, human patient treated in accordance with the invention may for example be immunosuppressed or immunocompromised, or may be geriatric or pediatric patients.
- The therapeutic uses recited herein are reflected in corresponding methods of treatment, and vice versa.
-
FIG. 1 is a schematic timeline of a site specific immunotherapy (SSI) in accordance with one aspect of the invention, illustrating intra-tracheal (IT) instillation of a K. pneumoniae (KPN) whole killed cell SSI at day −31, and subcutaneous (SQ) injections of SSI or saline (placebo) every other day starting on day −10, with intravenous (IV) Lewis lung carcinoma (LLC) administration onday 0, followed by sacrifice (sac) onday 18. -
FIG. 2 is a graph illustrating therapeutic efficacy of alternative SSI formulations in a murine cancer model. -
FIG. 3 is a schematic timeline illustrating a murine pre-infection model of SSI-mediated anti-tumour efficacy. -
FIG. 4 is a graph illustrating anti-cancer efficacy of an SSI after pre-infection in a murine Lewis lung carcinoma (LLC) cancer model. -
FIG. 5 is a line graph illustrating tumour volume over time for alternative SSI therapies in a murine B16 skin cancer model. 10×QBSAU and 1×QBSAU are denoted as QBSAUR and QBSAU, respectively, herein. -
FIG. 6 is a bar graph illustrating tumour volume atday 7 for alternative SSI therapies in a murine B16 skin cancer model. -
FIG. 7 is a bar graph illustrating tumour volume atday 8 for alternative SSI therapies in a murine B16 skin cancer model. -
FIG. 8 is a bar graph illustrating tumour volume atday 10 for alternative SSI therapies in a murine B16 skin cancer model. -
FIG. 9 is a bar graph illustrating tumour volume atday 12 for alternative SSI therapies in a murine B16 skin cancer model. -
FIG. 10 is a bar graph illustrating tumour volume atday 14 for alternative SSI therapies in a murine B16 skin cancer model. -
FIG. 11 is a schematic illustration, top panel, showing an SSI administration schedule, and a bar graph, bottom panel, illustrating therapeutic efficacy of an SSI in a murine cancer model. -
FIG. 12 is a chart illustrating the efficacy of various SSI co-formulations in a murine cancer model. -
FIG. 13 is an alternative bar graph representation of the efficacy of various SSI co-formulations in a murine cancer model. -
FIG. 14 is a series of graphs illustrating efficacy of SSI treatment in alternative model animals in the colitis model: a logarithmic Y axis scale illustrating relative levels of IFN-gamma (A) and IL-17A expression (B), and cumulative data for IL-17A expression (C), as well as site-specific evidence of QBECO efficacy in increasing IL-18 gene expression in colon tissue, compared to QBKPN (D). -
FIG. 15 is a series of graphs illustrating efficacy of SSI treatment in alternative model animals in the colitis model: microbiome (A and B) and histology (C). -
FIG. 16 is a bar graph illustrating efficacy of an SSI in a murine asthma/allergy model. -
FIG. 17 includes two bar graphs illustrating efficacy of an SSI in a murine asthma/allergy model, showing counts of A) Eosinophils, B) Lymphocytes. -
FIG. 18 includes two bar graphs illustrating efficacy of an SSI in a murine asthma/allergy model, showing A) IL-4 and B) IL-5 concentrations. -
FIG. 19 is a bar graph illustrating results of ex-vivo imaging of Cy5.5 labelled KPN SSI (QBKPN) measured in organs (heart, lungs and spleen) 24 hours after a third SQ SSI injection. -
FIG. 20 is a bar graph illustrating house dust mite (HDM)-specific IgE responses following saline or HDM exposure, treated with either Placebo or QBKPN. -
FIG. 21 is a series of bar graphs (A-E) illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly BAL cell counts and differentials in Saline or HDM exposed mice treated with Placebo or QBKPN SSI. -
FIG. 22 includes two bar graphs illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly serum (A) and BAL (B) mediators that are linked to eosinophilia. -
FIG. 23 is a series of bar graphs illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly Th1 (A) and Th2 (B and C) lung gene expression following HDM exposure and QBPKN treatment. -
FIG. 24 is a series of bar graphs illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly the effects of HDM exposure and QBKPN treatment on Th1- (A-C) and Th2- (D-F) mediated BAL fluid cytokine levels. -
FIG. 25 is a graph illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly a principal component analysis (PCA) of BAL cytokines showing partial normalization of overall cytokine profile. -
FIG. 26 is a bar graph illustrating aspects of an anti-inflammatory SSI treatment for asthma from an animal model, particularly illustrating airway goblet cell quantification following HDM exposure and QBPKN treatment. -
FIG. 27A is a bar graph illustrating aspects of an anti-inflammatory SSI treatment for COPD from an animal model, particularly BAL cell differential.FIG. 27B reflects this data, illustrating that a KPN SSI intervention attenuated cigarette smoke exposure induced increases in lung macrophages and lymphocytes but not total cells or neutrophils.FIG. 27B illustrates BAL cell counts and differentials following placebo and KPN SSI treatment in filtered air or cigarette smoke-exposed groups: (a) BAL total cells, (b) lymphocytes, (c), macrophages (d), and neutrophils. *p<0.05 comparing to the groups relative control; #p<0.05 comparing KB group to relative placebo control. Data are means±SD of 9-10 mice per group. -
FIGS. 28A-28D :FIG. 28A illustrates data showing that a KPN SSI intervention attenuated cigarette smoke exposure induced increases Th1-skewed lung inflammatory responses, as follows. BAL supernatant fluid analysis following placebo and KB treatment in filtered air or cigarette smoke-exposed groups. (a) IFNγ, (b) CXCL9, (c) CXCL10, (d) CCL5, (e) IL-6, (f) G-CSF, (g) CXCL1, (h) IL-17. *p<0.05 comparing to the groups relative control; #p<0.05 comparing KPN SSI group to relative placebo control. Data are means±SD of 10 mice per group.FIG. 28B provides data illustrating that KPN SSI intervention differentially modulates cigarette smoke exposure induced changes in serum immune mediators, as follows. Serum analysis following placebo and KPN treatment in filtered air or cigarette smoke-exposed groups: (a) VEGF, (b) IL-1β, (c) CCL2, (d) CXCL9, (e) CXCL10 and (f) CCL5. *p<0.05 comparing to the groups relative control; #p<0.05 comparing KB group to relative placebo control. Data are means±SD of 9-10 mice per group.FIG. 28C provides data illustrating that KPN SSI intervention increased blood and lung Ly6CHI monocytes and neutrophils, as follows. Flow cytometric analysis of blood (a-b) and lung (c-d) Ly6CHI monocytes and neutrophils following placebo and KB treatment in filtered air or cigarette smoke-exposed groups. *p<0.05 comparing to the groups relative control. #p<0.05 comparing KB group to relative placebo control. Data are means±SD of 10 mice per group.FIG. 28D is series of bar graphs (A-C) illustrating aspects of an anti-inflammatory SSI treatment for COPD from an animal model, particularly select lung gene expression profiles. -
FIG. 29 is a series of bar graphs (A-G) illustrating aspects of an anti-inflammatory SSI treatment for COPD from an animal model, particularly select BAL cytokine expression profiles. -
FIG. 30 is a series of bar graphs (A-C) illustrating aspects of an anti-inflammatory SSI treatment for COPD from an animal model, particularly serum cytokine expression profiles. -
FIG. 31 is a bar graph illustrating reduced tumour burden in a B16 melanoma model of metastases to the lung using a Klebsiella variicola SSI. -
FIG. 32 is a bar graph illustrating QBKPN SSI efficacy in reducing lung nodules in the absence of CD25 positive cells. -
FIG. 33 includes three bar graphs:FIG. 33A is a bar graph illustrating delta Ct (cycle threshold) values associated with a KPN SSI formulation (QBKPN) administered in a B16 melanoma model of metastases to the lung, with progressive dilutions of the KPN SSI (10×, 100× and 1000×). Delta Ct values are inversely proportional to the amount of target nucleic acid in the sample. As illustrated, tumour burden increased with increasing dilution of the SSI.FIG. 33B is a bar graph illustrating a similar dose-dependent effect of the KPN SSI as measured by the number of B16 tumour nodules in the lung.FIG. 33C is a bar graph illustrating that a variety of dosing regimes provide a therapeutic effect, with intervals between injections varying from 1 to 7 days all providing a therapeutic effect. -
FIG. 34 includes two bar graphs illustrating that the proportion of cells that express Rae-1 was inversely correlated with tumour burden in a B16 melanoma model of metastases to the lung (A) and this is dependent on NKG2D expression (B). -
FIG. 35 is a bar graph illustrating that a QBKPN SSI provided a markedly stronger effect in reducing tumour nodules in the lung in a Lewis lung carcinoma (LLC)-RFP model. -
FIG. 36 is a bar graph illustrating a concomitant reduction in the number of LLC-RFP cells in the lungs atday 15 after inoculation with LLC. -
FIG. 37 is a line graph showing that a QBECO SSI conferred a greater survival advantage than did either QBKPN or QBSAU in an MC38 colon cancer model. -
FIG. 38 is a bar graph illustrating that mice treated with a QBKPN SSI, but not 10×QBSAU, exhibited elevated lung-specific Rae-1 expression in a skin and lung tumour model. -
FIG. 39 is a bar graph illustrating decreased PD-1 expression in the lung of QBKPN-treated mice as compared to placebo-treated mice in the skin and lung tumour model. -
FIG. 40 is a bar graph illustrating that treating mice with 10×QBSAU, but not QBKPN, led to a decrease in the skin tumour burden as compared to placebo control in the B16 skin and lung tumour model. -
FIG. 41 is a bar graph illustrating that both intravenous (IV) SSI and subcutaneous (SQ) SSI treatments provide therapeutic benefit in a B16 lung metastasis model. -
FIG. 42 is a schematic time line illustrating the study design for an example based on efficacy of QBKPN in a treatment and prophylaxis of cancer in a B16 lung cancer model. -
FIG. 43 includes 4 bar graphs illustrating efficacy of QBKPN in a treatment and prophylaxis of cancer in a B16 lung cancer model. -
FIG. 44 is a bar graph illustrating aspects of the efficacy of QBKPN in a treatment and prophylaxis of cancer in a B16 lung cancer model. -
FIG. 45 is a bar graph illustrating aspects of how quickly SSI therapies have detectable therapeutic effects involving myeloid cell populations, particularly neutrophils. -
FIG. 46 is a bar graph illustrating aspects of how quickly SSI therapies have detectable therapeutic effects involving myeloid cell populations, particularly Ly6C monocytes. -
FIGS. 47A and 47D are a series of graphs illustrating efficacy of alternative cellular fractions in a B16 melanoma model in the lung, including dose-dependent and site-specific efficacy.FIG. 47A includes three bar graphs illustrating that both 1× and 0.01×KPN outer membrane fractions (i) were efficacious, in a dose-dependent manner, with the 1× fraction having comparable efficacy to the whole killed cell formulation, as were the 1× and 4×DNA fractions (ii), while the inner membrane fraction showed a dose dependent trend that lacked strong statistical significance (iii).FIG. 47B is a bar graph illustrating results following 10 injections of outer membrane SSI, showing that Rae-1 expression was elevated by the outer membrane fraction in a dose dependent manner.FIG. 47C includes two bar graphs illustrating OM dose-dependent elevated neutrophil and monocyte blood counts after 4 injections of QBKPN SSI, placebo, or various concentrations of OM fraction (0.01×, 1×, 10× or 20×) in blood collected 2 days prior to tumour implant.FIG. 47D is a column scatter graph plot illustrating the site-specific efficacy of KPN fractions compared to E. coli fractions in the B16 lung cancer model. -
FIG. 48 is a bar graph illustrating that a QBKPN SSI increases NCI-H358 cancer cell death at high doses (1/20, 1/200 dilution) in a 24-hour killing assay. -
FIG. 49 is a bar graph illustrating that a KPN SSI increases γδ T cell mediated killing of NCI-H358 cancer cells at alternative doses (1/20 dilution, 1/200 dilution) in a 24 hour cell killing assay. -
FIG. 50 is a bar graph illustrating that a KPN SSI (QBKPN) potentiated the effect of zoledronate in inducing γδ T cell mediated cancer cell lysis, at 1/200 and 1/2000 dilutions in a 24 hour cell killing assay. -
FIG. 51 is a line graph illustrating the therapeutic efficacy of a QBECO SSI in a MC-38 colon cancer model. -
FIG. 52 is a line graph illustrating that NKG2D expression is correlated with QBECO efficacy in a MC-38 colon cancer model using NKG2D knockout mice. -
FIG. 53 is a schematic representation of a treatment schema in a model neutropenia system. -
FIG. 54 is a series of 4 graphs that depict the results of flow cytometry in the neutropenia model, illustrating counts of particular cell populations from lung samples, gated on live, CD45+CD11b+ cells. -
FIG. 55 includes two column scatter graph plots illustrating the proportion (A) and number (B) of neutrophils in lung samples in the neutropenia model. -
FIG. 56 includes two plots illustrating the proportion (A) and number (B) of neutrophils in spleen samples in the neutropenia model. -
FIG. 57 is a bar graph illustrating the proportion of cells having the denoted characteristics in blood samples from lung cancer patients segregated into a neoplastic patient population and a pre-neoplastic patient population, showing elevated PDL1 and PD1 expression in the neoplastic patient population compared to the pre-neoplastic patients. -
FIG. 58 is a bar graph illustrating the relative number of cells having the denoted characteristics in blood samples from lung cancer patients segregated into a neoplastic patient population and a pre-neoplastic patient population, showing elevated PDL1 and PD1 expression in the neoplastic patient population compared to the pre-neoplastic patients. -
FIGS. 59A and 59B include two bar graphs illustrating the SSI mediated reduction of PD-L1 expression in neoplastic lung cancer in two patients, Patient 01-001 (FIG. 59A ) and Patient 01-002 (FIG. 59B ), at:week 1, day 4 (W1D4);week 1, day 5 (W1D5); week 2 (W2); week 4 (W4), week 12 (W12) and week 16 (W16) -
FIGS. 60A and 60B include two bar graphs illustrating the SSI mediated reduction in PD-1 expression in two neoplastic lung cancer patients, Patient 01-001 (FIG. 60A ) and Patient 01-002 (FIG. 60B ). -
FIGS. 61A and 61B include two bar graphs illustrating the increase in the proportion of M1 macrophages in two neoplastic lung cancer patients, Patient 01-001 (FIG. 61A ) and Patient 01-002 (FIG. 61B ). -
FIGS. 62A and 62B include two bar graphs, showing RT-qPCR fold changes in (FIG. 62A ) GzmA, GzmB, Prf1, and (FIG. 62B ) Tyr in lungs of B16 inoculated mice with differing QBKPN doses. Data points are mean+/−SD. Significance was calculated using a one-way Tukey's multiple comparison ANOVA test. **p<0.01, p<0.001 and ****p<0.0001. -
FIG. 63 includes three bar graphs illustrating the activation of pattern recognition receptors in HEK cells after QBECO or QBKPN stimulation, showing respectively: A) Toll-like receptor (TLR) activation as measured by NK-κB activation; B) NOD2 and C-type lectin receptors (CTL) as measured by NK-κB activation; and, C) RLR (Rig-1-like receptors) as measured by IRF3 activation. -
FIG. 64 is a PRR repertoire fingerprint bar graph, in which a PRR fingerprint was constructed for QBECO and QBKPN SSIs from the 1/10 dilution data, after subtracted the negative control data. Bars, in order, represent TLR2, 3, 4, 5, 7, 8, 9, NOD1, NOD2,Dectin 1a,Dectin 1b and Mincle. RIG-1 and MDA5 are not shown. The positive control is specific for each PRR (ie LPS for TLR4). -
FIG. 65 is a PRR fingerprint radar graph, in which a PRR fingerprint was constructed for QBECO and QBKPN SSIs from the 1/10 dilution data, after subtracted the negative control data, and plotted on a radar graph. -
FIG. 66 is a bar graph illustrating neutrophil levels in the blood atday 7 after treatment with Placebo, QBKPN or Rabies Vaccine. Neutrophil levels were measured by flow cytometry and were assessed as the percentage of neutrophils (Ly6G+) of total CD45+ cells. N=4-5 mice per group. * is P<0.05 compared to placebo as assessed by Student's t-test. Average±standard deviation shown. QBKPN is a bacterial SSI derived from Klebsiella. Rabies is the Imrab 3TF Rabies Vaccine which contains killed rabies virus. -
FIG. 67 is a bar graph illustrating Ly6CHI monocyte levels in the blood atday 7 after treatment with Placebo, QBKPN or Rabies Vaccine. Ly6CHI monocyte levels were measured by flow cytometry and were assessed as the percentage of Ly6CHI monocyte (Ly6CHILy6G−) of total CD45+ cells. N=4-5 mice per group. * is P<0.05 compared to placebo as assessed by Student's t-test. Average±standard deviation shown. QBKPN is a bacterial SSI derived from Klebsiella. Rabies is the Imrab 3TF Rabies Vaccine which contains killed rabies virus. Fel-O-Vac is Feline Rhinotracheitis-Calici-Panleukopenia Vaccine which contains the three killed viruses. Nobivac is Canine Influenza H3H8 which contains killed influenza H3H8. -
FIG. 68 is a column scatter plot illustrating cancer antigen potentiation using QBKPN to potentiate the effect of the melanoma-associated antigen gp100. The anti-tumour efficacy of QBKPN SSI in combination with gp100 is compared to the irrelevant control antigen OVA (SIINFEKL), including OVA adjuvanted with CpG. -
FIG. 69 is a column scatter plot illustrating surface metastatic-like tumour nodules in mice challenged with B16 melanoma, evidencing enhanced efficacy of the microbial SSI QBKPN augmented with an additional PRR agonist, theSTING agonist 2′2′-cGMAP. -
FIG. 70 is a column scatter plot illustrating treatment-induced IFN-γ levels in plasma in mice challenged with B16 melanoma, evidencing enhanced IFN-γ levels when the microbial SSI QBKPN is augmented with a STING agonist. -
FIG. 71A is a violin plot representing the log distribution of risk scores, comparing last recorded response for all CD subjects using risk scores based on 112 IBD SNPs (P-value: 2.430E-05). -
FIG. 71B is a violin plot representing the log distribution of risk scores, comparing last recorded response for all CD subjects using risk scores based on 3 IBD SNPs (P-value: 1.385E-04). -
FIG. 72 is a violin plot representing the log distribution of risk scores, comparing last recorded response for all UC subjects using risk scores based on 84 IBD SNPs (P-value: 1.255E-02). -
FIG. 73 is a violin plot representing the log distribution of risk scores, comparing last recorded response for all CD and UC subjects using risk scores based on 112 IBD SNPs (P-value: 8.184E-07). -
FIG. 74 is a graph illustrating the change in serum IL-18 levels in patients treated with QBECO vs. Placebo. -
FIG. 75 is a set of 4 graphs illustrating serum immune cytokine changes with QBECO treatment that associated with clinical response. -
FIG. 76 is a set of 3 graphs illustrating baseline levels of Eotaxin-1, IL-10 and IL-12p40 by patient response to QBECO. -
FIG. 77 is a graph illustrating the change in body weight over time in a murine DSS colitis model. -
FIG. 78 is a graph illustrating change in disease activity index over time in a murine DSS colitis model. -
FIG. 79 is a graph illustrating change in the FITC-dextran assay over time in a murine DSS colitis model. -
FIG. 80 is a graph illustrating blood neutrophil levels in disease free mice, over time, with or without an initial QBECO SSI treatment (mean+/−SEM, n=10 mice per group). -
FIG. 81 is a collection of three graphs illustrating blood cytokine levels in disease free mice, over time, with or without an initial QBECO SSI treatment (mean+/−SEM, n=10 mice per group). -
FIG. 82 is a graph illustrating the pharmacokinetics of QBKPN, in which QBKPN SSI was fluorescently labelled and subcutaneously injected into disease-free mice. Mice were bled at different timepoints over 48 hours and the blood cell count was quantified. -
FIG. 83 : includes 6 bar graphs, illustrating gene expression in the lung tissues for CXCL10 (IP-10), CCL2 (MCP-1) and CCR2. Mice were treated every second day for 10 days with Placebo, QBKPN or QBECO before B16F10 tumour implantation into the lungs via tail vein injection. Treatment continued every second day after tumour inoculation. Mice were euthanized on day 5 (A, C, E) or day 17 (B, D, F). - In the following detailed description, various examples are set out of particular embodiments, together with experimental procedures that may be used to implement a wide variety of modifications and variations in the practice of the present invention. For clarity, a variety of technical terms are used herein in accordance with what is understood to be the commonly understood meaning, as reflected in definitions set out below.
- An “immunogen” refers to a molecule, or a composition comprising the molecule, that is capable of eliciting an immune response by an organism's immune system. An “antigen” refers to a molecule that is capable of binding to the product of an immune response.
- “Pathogenic” agents are agents, such as microbes, such as bacteria or viruses, which are known to cause infection in a host in nature, and in this sense, “pathogenic” is used in the context of the present invention to mean “naturally pathogenic”. Although a wide variety of microbes may be capable of causing infection under artificial conditions, such as artificial inoculations of a microbe into a tissue, the range of microbes that naturally cause infection is necessarily limited, and well established by medical practice.
- An “infection” is the state or condition in which the body or a part of it is invaded by a pathogenic agent (e.g., a microbe, such as a bacterium) which, under favorable conditions, multiplies and produces effects that are injurious (Taber's Cyclopedic Medical Dictionary, 14th Ed., C. L. Thomas, Ed., F. A. Davis Company, PA, USA). An infection may not always be apparent clinically and may result in only localized cellular injury. Infections may remain subclinical, and temporary if the body's defensive mechanisms are effective. Infections may spread locally to become clinically apparent as an acute, a subacute, or a chronic clinical infection or disease state. A local infection may also become systemic when the pathogenic agent gains access to the lymphatic or vascular. Infection is usually accompanied by inflammation, but inflammation may occur without infection.
- “Inflammation” is the characteristic tissue reaction to injury (marked by swelling, redness, heat, and pain), and includes the successive changes that occur in living tissue when it is injured. Infection and inflammation are different conditions, although one may arise from the other (Taber's Cyclopedic Medical Dictionary, supra). Accordingly, inflammation may occur without infection and infection may occur without inflammation (although inflammation typically results from infection by pathogenic bacteria or viruses). Inflammation is characterized by the following symptoms: redness (rubor), heat (calor), swelling (tumour), pain (dolor). Localized visible inflammation on the skin may be apparent from a combination of these symptoms, particularly redness at a site of administration.
- Various subjects may be treated or assayed or sampled in accordance with alternative aspects of the invention. As used herein, a “subject” is an animal, for e.g., a vertebrate or a mammal. Accordingly, a subject may be a patient, e.g., a human, suffering from an immune dysregulation. A subject may also be an experimental animal, e.g., an animal model of an immune dysregulation. In some embodiments, the terms “subject” and “patient” may be used interchangeably, and may include a human, a non-human mammal, a non-human primate, a rat, mouse, or dog. A healthy subject may be a human who is not suffering from a disease, such as a cancer or immune dysfunction, or suspected of having the disease, or who is not suffering from a chronic disorder or condition. A “healthy subject” may also be a subject who is not immunocompromised. By immunocompromised is meant any condition in which the immune system functions in an abnormal or incomplete manner. Immunocompromisation may be due to disease, certain medications, or conditions present at birth. Immunocompromised subjects may be found more frequently among infants, the elderly, and individuals undergoing extensive drug or radiation therapy.
- A “sample” from a subject may include any relevant biological material, including for example a cell, tissue or bodily fluid sample taken from a patient. For example, a sample may conveniently include samples of skin, cheek, blood, stool, hair or urine. Sample nucleic acids for use in diagnostic and prognostic methods can for example be obtained from a selected cell type or tissue of a subject. For example, a subject's bodily fluid (e.g. blood) can be obtained by known techniques. Alternatively, nucleic acid tests can be performed on dry samples (e.g., hair or skin).
- The term “polymorphism” refers to a location within a biological sequence, such as a genomic sequence, which varies within a population. Polymorphisms are comprised of different “alleles”. The term “genotype” refers to the specific alleles in a genome, for example in a cell, tissue sample or an individual. The location of a polymorphism may be identified by its position, for example within the genome or within a sequence such as a protein that is reflective of a genomic locus. This may for example be provided in the form of a characterization of the different amino acids or bases that are found at a designated location. For diploid genomes, the genotype is typically comprised of at least two alleles, which may be the same (homozygous) or different (heterozygous). Individual polymorphisms are typically assigned unique identifiers in the art (such as “Reference SNP”, “refSNP” or “rs#”), for example in the Single Nucleotide Polymorphism Database (dbSNP) of Nucleotide Sequence Variation available on the NCBI website.
- Characterization of polymorphisms, alleles or a genotype may be performed by any of very wide variety of methods. These methods may for example variously involve hybridization, labeling, cloning, sequencing and/or amplification of nucleic acids, such as genomic DNA, for example using PCR, LCR, xMAP, invader assays, mass spectrometry, pyrosequencing, selective oligonucleotide hybridization, selective amplification, selective primer extension or probes. In this context, the term “probes” includes naturally occurring or recombinant single- or double-stranded nucleic acids or chemically synthesized nucleic acids. A probe can for example be a polynucleotide of a length suitable for selective hybridization to a nucleic acid containing a polymorphic region. Labeled probes also can be used in conjunction with amplification of a polymorphism. DNA microarray technologies, sometimes referred to as DNA chips or gene chips, may for example be used for genomic characterization, for example to characterize point mutations, single nucleotide polymorphisms (SNPs), and/or short tandem repeats (STRs). For example, several probes capable of hybridizing specifically to an allelic variant may be attached to a solid phase support by a variety of processes, including lithography. Additional methods include laser capture microdissection (LCM), comparative genomic hybridization (CGH) and chromatin immunoprecipitation (ChiP). Allele specific hybridization may for example make use of probes overlapping the polymorphic site and having about 5, or alternatively 10, or alternatively 20, or alternatively 25, or alternatively 30 nucleotides around the polymorphic region. Alternatively, the presence of the specific allele in DNA from a subject can in some case be characterized by restriction enzyme analysis. Similarly, protection from cleavage agents (such as a nuclease, hydroxylamine or osmium tetroxide) can be used to detect mismatched bases in RNA/RNA DNA/DNA, or RNA/DNA heteroduplexes, using technique that may be described as “mismatch cleavage” assays. Alterations in electrophoretic mobility may be used to characterize allelic variants, for example to detect single strand conformation polymorphisms.
- Many of the methods described herein may be performed using kits, for example comprising at least one probe or primer nucleic acid, or one of more of the compositions described herein and instructions for use of the kit. Kits can for example comprise at least one probe or primer which is capable of specifically hybridizing to a polymorphic region or adjacent to the polymorphic region, so that the oligonucleotides are “specific for” the polymorphic region. Kits may also comprise at least one reagent necessary to perform a particular assay. Kits can also include positive controls, negative controls, sequencing markers, or antibodies, for example for determining a subject's genotype or biological marker profile.
- An “immune response” includes, but is not limited to, one or more of the following responses in a mammal: induction or activation of antibodies, neutrophils, monocytes, macrophages (including both M1-like macrophages and M2-like macrophages as described herein), B cells, or T cells (including helper T cells, natural killer cells, cytotoxic T cells, gamma-delta (γδ) T cells), such as induction or activation by one or more immunogens in an immunogenic composition, following administration of the composition. An immune response to a composition thus generally includes the development in the host animal of a cellular and/or antibody-mediated response to the composition. In some embodiments, the immune response is such that it will also result in slowing or stopping the progression of an immune dysregulation, or a disease characterized by immune dysregulation. An immune response may accordingly include one or both of a cellular immune response and/or a humoral immune response, and may be an adaptive response or an innate immune response.
- “Immune dysregulation” is an inappropriately regulated immune response, such as an inappropriately restrained or inappropriately robust immune response. The immune dysregulation may for example be in the context of an autoimmune, inflammatory, or degenerative disease (such as rheumatoid arthritis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, neurodegenerative disease, or allergies) or a neoplastic disease, such as a cancer, or a host defense against pathogens. Inflammatory bowel disease (IBD) is a name frequently given to a group of inflammatory conditions of the colon and small intestine, generally characterized by similar symptoms of immune dysregulation and indeterminate etiology. Major sub-types of IBD are recognized clinically as Crohn's disease and ulcerative colitis. In addition to Crohn's disease and ulcerative colitis, IBD may also include conditions recognized as any one of the following: collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behget's syndrome or indeterminate colitis. The difference between these conditions relate primarily to the location and nature of the inflammatory changes in the gastrointestinal tract (GIT). Crohn's disease, for example, is generally recognized as potentially affecting any part of the gastrointestinal tract, from mouth to anus, with a majority of the cases marked by relapsing and remitting granulomatous inflammation of the alimentary tract in the terminal ileum and colon. Ulcerative colitis, in contrast, is generally considered to be restricted to the colon and the rectum. The various regions of the gastrointestinal tract in which these inflammatory conditions may exhibit symptoms include: the bowel or intestine, including: the small intestine (which has three parts: the duodenum, the jejunum, and the ileum); the large intestine (which has three parts: the cecum, the colon, which includes the ascending colon, transverse colon, descending colon and sigmoid flexure; and the rectum); and, the anus.
- A “site specific immunotherapy” (SSI) is an immunomodulatory treatment that is effective to therapeutically or prophylactically alter an aspect of the immune state, or immune system physiology, at an anatomical site or sites, such as an organ or tissue. In some instances, for example, an SSI may be adapted to ameliorate an immune dysregulation, or to treat a condition characterized by an immune dysregulation.
- A “cancer” or “neoplasm” is any unwanted growth of cells serving no physiological function. In general, a cancer cell has been released from its normal cell division control, i.e., a cell whose growth is not regulated by the ordinary biochemical and physical influences in the cellular environment. Thus, “cancer” is a general term for diseases characterized by abnormal uncontrolled cell growth. In most cases, a cancer cell proliferates to form clonal cells that are malignant. The lump or cell mass, “neoplasm” or “tumour,” is generally capable of invading and destroying surrounding normal tissues. By “malignancy”, as used herein, is meant as an abnormal growth of any cell type or tissue that has a deleterious effect in the organism having the abnormal growth. The term “malignancy” or “cancer” includes cell growths that are technically benign but which carry the risk of becoming malignant. Cancer cells may spread from their original site to other parts of the body through the lymphatic system or blood stream in a process known as “metastasis.” Many cancers are refractory to treatment and prove fatal. Examples of cancers or neoplasms include, without limitation, transformed and immortalized cells, tumours, carcinomas, in various organs and tissues as described herein or known to those of skill in the art.
- Most cancers fall within three broad histological classifications: carcinomas, which are the predominant cancers and are cancers of epithelial cells or cells covering the external or internal surfaces of organs, glands, or other body structures (for e.g., skin, uterus, lung, breast, prostate, stomach, bowel), and which tend to metastasize; carcinomas, which are derived from connective or supportive tissue (for e.g., bone, cartilage, tendons, ligaments, fat, muscle); and hematologic tumours, which are derived from bone marrow and lymphatic tissue. Carcinomas may be adenocarcinomas (which generally develop in organs or glands capable of secretion, such as breast, lung, colon, prostate or bladder) or may be squamous cell carcinomas (which originate in the squamous epithelium and generally develop in most areas of the body). Sarcomas may be osteosarcomas or osteogenic sarcomas (bone), chondrosarcomas (cartilage), leiomyosarcomas (smooth muscle), rhabdomyosarcomas (skeletal muscle), mesothelial sarcomas or mesotheliomas (membranous lining of body cavities), fibrosarcomas (fibrous tissue), angiosarcomas or hemangioendotheliomas (blood vessels), liposarcomas (adipose tissue), gliomas or astrocytomas (neurogenic connective tissue found in the brain), myxosarcomas (primitive embryonic connective tissue), or mesenchymous or mixed mesodermal tumours (mixed connective tissue types). Hematologic tumours may be myelomas, which originate in the plasma cells of bone marrow; leukemias which may be “liquid cancers” and are cancers of the bone marrow and may be myelogenous or granulocytic leukemia (myeloid and granulocytic white blood cells), lymphatic, lymphocytic, or lymphoblastic leukemias (lymphoid and lymphocytic blood cells) or polycythemia vera or erythremia (various blood cell products, but with red cells predominating); or lymphomas, which may be solid tumours and which develop in the glands or nodes of the lymphatic system, and which may be Hodgkin or Non-Hodgkin lymphomas. In addition, mixed type cancers, such as adenosquamous carcinomas, mixed mesodermal tumours, carcinosarcomas, or teratocarcinomas also exist.
- Cancers named based on primary site may be correlated with histological classifications. For example, lung cancers are generally small cell lung cancers or non-small cell lung cancers, which may be squamous cell carcinoma, adenocarcinoma, or large cell carcinoma; skin cancers are generally basal cell cancers, squamous cell cancers, or melanomas. Lymphomas may arise in the lymph nodes associated with the head, neck and chest, as well as in the abdominal lymph nodes or in the axillary or inguinal lymph nodes. Identification and classification of types and stages of cancers may be performed by using for example information provided by the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, which is an authoritative source of information on cancer incidence and survival in the United States and is recognized around the world. The SEER Program currently collects and publishes cancer incidence and survival data from 14 population-based cancer registries and three supplemental registries covering approximately 26 percent of the US population. The program routinely collects data on patient demographics, primary tumour site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status, and is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage. Information on more than 3 million in situ and invasive cancer cases is included in the SEER database, and approximately 170,000 new cases are added each year within the SEER coverage areas. The incidence and survival data of the SEER Program may be used to access standard survival for a particular cancer site and stage. For example, to ensure an optimal comparison group, specific criteria may be selected from the database, including date of diagnosis and exact stage (for example, in the case of the lung cancer example herein, the years were selected to match the time-frame of the retrospective review, and
stage 3B and 4 lung cancer were selected; and in the case of the colon cancer example herein, the years were also selected to match the time-frame of the retrospective review, and thestage 4 colon cancer was selected). - Cancers may also be named based on the organ in which they originate i.e., the “primary site,” for example, cancer of the breast, brain, lung, liver, skin, prostate, testicle, bladder, colon and rectum, cervix, uterus, etc. This naming persists even if the cancer metastasizes to another part of the body that is different from the primary site. With the present invention, treatment is directed to the site of the cancer, not type of cancer, so that a cancer of any type that is symptomatic or etiologically located in the lung, for example, would be treated on the basis of this localization in the lung.
- Aspects of the invention relate to the use of PRR ligands. PRR ligands may for example be available commercially, for example in widely available preparations of attenuated or killed recombinant bacteria, which may for example be ligands for TLR2, TLR4 and TLR5. Compositions of pathogen-associated molecular patterns (PAMPs) may include PAMPS that are recognized by PRRs, including: Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-1-like receptors (RLRs), C-type lectin receptors (CLRs) including Dectin-1, cytosolic dsDNA sensors (CDSs) and NLRs involved in the formation of inflammasomes.
- Toll-like receptor 2 (TLR2) is involved in the recognition of a wide array of microbial molecules representing broad groups of species including Gram-positive and Gram-negative bacteria, as well as mycoplasma and yeast. TLR2 recognizes cell-wall components such as peptidoglycan, lipoteichoic acid and lipoprotein from Gram-positive bacteria, lipoarabinomannan from mycobacteria, and zymosan from the yeast cell wall. Toll-like receptor 3 (TLR3) recognizes double-stranded RNA (dsRNA). Bacterial lipopolysaccharide (LPS) is recognized by Toll-like receptor 4 (TLR4) which interacts with at least three different extracellular proteins: LPS-binding protein (LBP), CD14 and, myeloid differentiation protein 2 (MD-2), to induce a signaling cascade leading to the activation of NF-κB and the production of proinflammatory cytokines. LPS generally consists of a polysaccharide region that is anchored in the outer bacterial membrane by a carbohydrate lipid moiety: lipid A, which is largely responsible for the immunostimulatory activity of LPS. Particularly active forms of lipid A contain six fatty acyl groups, as for example may be found in pathogenic bacteria that are strains of Escherichia coli or Salmonella spp. Toll-like receptor 5 (TLR5) recognizes flagellin from both Gram-positive and Gram-negative bacteria. Toll-like receptor 7 (TLR7) and TLR8 recognize single stranded RNAs and small synthetic molecules such as imidazoquinolines and nucleoside analogs. Toll-like receptor 9 (TLR9) recognizes specific unmethylated CpG motifs prevalent in microbial but not vertebrate genomic DNA.
- NLRs are a family of at least 22 cytoplasmic innate immune sensors, including NOD1 (CARD4) and NOD2 (CARD15) which are intracellular pattern-recognition receptors involved in the recognition of peptidoglycan (PGN). These receptors detect specific motifs within PGN. NOD1 senses the diaminopimelatic acid (DAP)-containing muropeptide (specifically d-Glu-meso-DAP dipeptide “iE-DAP” dipeptide) which is found primarily in PGN of Gram-negative bacteria, as well as certain Gram-positive bacteria. NOD2 recognizes the muramyl dipeptide (MDP) structure found in almost all bacterial PGN.
- The RIG-1-Like receptors (RLRs), particularly RIG-1 and MDA-5, detect viral RNA species.
- CLR ligands include Dectin-1 and Mincle (macrophage-inducible C-type lectin) agonists. Dectin-1 is a specific receptor for β-glucans, which are glucose polymers found in the cell walls of fungi. Mincle is a multi-tasking danger signal receptor that recognizes a wide variety of ligands such as damaged cells, fungal components, yeast components and components of mycobacteria.
- Cytosolic DNA Sensors (CDS) bind intracellular DNA from pathogens, and there are multiple CDSs which may display contextual preferences for the recognition of particular DNAs.
- Cyclic dinucleotides (CDNs) and xanthenone derivatives, such as DMXAA, bind to and activate STING (STimulator of INterferon Genes).
- The inflammasome is a multi-protein complex involved in the production of mature IL-1β, specifically through cleavage of pro-IL-1β and pro-IL-18 into active and secretable forms. Inflammasomes may be segregated into NLRP1, NLRP3, NLRC4 and AIM2 subtypes, which are activated by a wide variety of microbial molecules, danger signals and crystalline substances.
-
TABLE 1 PRR Receptors and their Ligands PRR Ligand TLR2 Microbial cell wall components/preparations, Pam2C- Aca-Benzyl-Murabutide (Pam2C- conjugated murabutide) TLR3 Polyadenylic-polyuridylic acid, Polyinosine-polycytidylic acid TLR4 Lipopolysaccharide, Monophosphoryl Lipid A TLR5 Flagellin TLR7/8 Single-stranded RNAs, Nucleoside analogs, Imidazoquinolines/Thiazoquinolines TLR9 unmethylated CpG DNA motifs NOD1 iE-DAP, Acylated iE-DAP, D-gamma- Glu-mDAP, L-Ala-gamma-D-Glu- mDAP NOD2 MDP (MurNAc-L-Ala-D-isoGln, muramyl dipeptide), N-glycolylated muramyldipeptide, N-Acetyl-muramyl- L- Alanyl-D-Glutamin-n-butyl-ester, MurNAc-Ala-D-isoGln-Lys, N- Acetylmuramyl-L-Alanyl-D- Isoglutamine (L-D isoform), 6-O- stearoyl-N-Acetyl-muramyl-L-alanyl-D- isoglutamine, Pam2C-Aca-Benzyl- Murabutide, TLR2/NOD2 Pam2C-conjugated murabutide NOD1/NOD2 PGN, Pam2C-conjugated murabutide RIG1/ MDA5 5′ triphosphate double stranded RNA (18-20mer), polyriboinosinic:polyribocytidylic acid DAI, LRRFIP1, AIM2, RIG1 dsDNA, poly(dA-dT)•poly(dT-dA) Dectin-1 Beta-glucan peptide, fungal cell wall preparations Mincle damaged microbial cells, fungus, yeast and mycobacteria, Trehalose- 6,6-dibehenate, trehalose-6,6- dimycolate STING Cyclic dinucleotides (c-di-nucleotides), xanthenone derivatives, 3′3′-cGAMP, 2′3′-cGAMP, 2′2′-cGAMP, 2′2′- cGAMP, c-di-AMP (cyclic di-adenylate monophosphate), c-di-GMP, c-di-IMP, c-di-UMP, c-di-AMP -
TABLE 2 Cytosolic nucleic acid-sensing PRRs and their Ligands (Broz & Monack, 2013, Nature Reviews Immunology 13, 551-565).PRR Ligands RIG-I PPP-ssRNA (PPP-ssRNA, ssRNA with a 5′- triphosphate group), RNA with base pairing and polyl:C MDA5 Long dsRNA LGP2 dsRNA DDX41 B-form DNA and CDNs (cyclic dinucleotides) DHX9 DNA, RNA, CpG-A oligodeoxynucleotids and CpG-B ODNs DDX3 Viral RNA DHX36 DNA, RNA, CpG-A oligodeoxynucleotids and CpG-B oligodeoxynucleotids DDX1-DDX21- RNA and polyl:C DDX36 DDX60 ssRNA, dsRNA and dsDNA KU70 DNA cGAS DNA STING CDNs (c-di-GMP and c-di-AMP) NOD2 ssRNA NLRP3 ssRNA, dsRNA, bacterial mRNA and oxidized mitochondrial DNA AIM2 DNA IFI16 dsDNA LRRFIP1 B-form DNA, Z-form DNA and dsRNA DAI DNA IFIT1, 2, 3 and 5 PPP-ssRNA - Aspects of the invention accordingly involve using PRR agonists derived from a selected microbial pathogen. For example, peptidoglycan (PGN) may be obtained from a bacteria or bacterial strain that is pathogenic in a selected target tissue or organ, for use as a NOD1/NOD2 agonist. Similarly, cell wall components may be obtained from a bacteria or bacterial strain that is pathogenic in a selected target tissue or organ, for use as a TLR32 agonist. Similarly, DNA, including double stranded DNA, particularly repetitive double stranded DNA, may be obtained from a microbial pathogen, such as a bacteria or bacterial strain that is pathogenic in a selected target tissue or organ, for use as a DAI, LRRFIP1, RIG1, TLR9, AIM2 or cytosolic DNA sensor (CDS) agonist. Beta-glucan peptides may be obtained from fungi or yeast that are pathogenic in a selected target tissue or organ, for use as a Dectin-1 agonists. Cyclic dinucleotides may be obtained from a microbial pathogen that is pathogenic in a selected target tissue or organ, for use as a STING agonist.
- Aspects of the invention involve compositions that have a distinct PRR agonist signature, which connotes a repertoire of PRR agonists that are together collected in a therapeutic vehicle, so that the selected collection of PRR agonists is distinct. A “therapeutic vehicle” in this context is a formulation that aggregates and retains the PRR agonists, for example in a pharmaceutically acceptable particle or vesicle, such as a recombinant microbe. For example, the PRR agonist signature may be different from a reference PRR agonist signature, for example different from the collection of PRR agonists that would be present on a microbe that is not pathogenic in the target tissue. The PRR signature may also be distinct in the sense that it is different than a native PRR agonist signature of the microbial mammalian pathogen, for example altered by way of the recombinant expression of genes that alter what would otherwise be the wildtype PRR agonist signature of the pathogen. For purposes of determining the distinctiveness of a PRR agonist signature, the levels or kinds of PRR agonist may be directly measured, or may be measured for example by determining the activation or inhibition of a signalling pathway in a cell consequent to PRR agonist/receptor binding.
- Various genes and nucleic acid sequences of the invention may be recombinant sequences. The term “recombinant” means that something has been recombined, so that when made in reference to a nucleic acid construct the term refers to a molecule that is comprised of nucleic acid sequences that are joined together or produced by means of molecular biological techniques. Nucleic acid “constructs” are accordingly recombinant nucleic acids, which have been generally been made by aggregating interoperable component sequencers. The term “recombinant” when made in reference to a protein or a polypeptide refers to a protein or polypeptide molecule which is expressed using a recombinant nucleic acid construct created by means of molecular biological techniques. The term “recombinant” when made in reference to the genetic composition or an organism or cell refers to new combinations of alleles that did not occur in the parental genomes. Recombinant nucleic acid constructs may include a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Referring to a nucleic acid construct as “recombinant” therefore indicates that the nucleic acid molecule has been manipulated using genetic engineering, i.e. by human intervention (so that it is anthropogenic). Recombinant nucleic acid constructs may for example be introduced into a host cell by transformation. Such recombinant nucleic acid constructs may include sequences derived from the same host cell species or from different host cell species, which have been isolated and reintroduced into cells of the host species. Recombinant nucleic acid construct sequences may become integrated into a host cell genome, either as a result of the original transformation of the host cells, or as the result of subsequent recombination and/or repair events.
- Recombinant constructs of the invention may include a variety of functional molecular or genomic components, as required for example to mediate gene expression or suppression in a transformed plant. In this context, “DNA regulatory sequences,” “control elements,” and “regulatory elements,” refer to transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, and protein degradation signals that regulate gene expression, as well as epigenetic regulatory signals for example involving methylation or acetylation of histones (e.g. histone methyltransferase or acetyltransferase), leading to conformational changes in the transcriptional landscape and gene expression differences. In the context of the present disclosure, “promoter” means a sequence sufficient to direct transcription of a gene when the promoter is operably linked to the gene. The promoter is accordingly the portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not universally, located in the 5′ non-coding regions of a gene. A promoter and a gene are “operably linked” when such sequences are functionally connected so as to permit gene expression mediated by the promoter. The term “operably linked” accordingly indicates that DNA segments are arranged so that they function in concert for their intended purposes, such as initiating transcription in the promoter to proceed through the coding segment of a gene to a terminator portion of the gene. Gene expression may occur in some instances when appropriate molecules (such as transcriptional activator proteins) are bound to the promoter. Expression is the process of conversion of the information of a coding sequence of a gene into mRNA by transcription and subsequently into polypeptide (protein) by translation, as a result of which the protein is said to be expressed. As the term is used herein, a gene or nucleic acid is “expressible” if it is capable of expression under appropriate conditions in a particular host cell.
- An “isolated” nucleic acid or polynucleotide as used herein refers to a component that is removed from its original environment (for example, its natural environment if it is naturally occurring). An isolated nucleic acid or polypeptide may contain less than about 50%, less than about 75%, less than about 90%, less than about 99.9% or less than any integer value between 50 and 99.9% of the cellular or biological components with which it was originally associated. A polynucleotide amplified using PCR so that it is sufficiently distinguishable (on a gel from example) from the rest of the cellular components is, for example, thereby “isolated”. The polynucleotides of the invention may be “substantially pure,” i.e., having the high degree of isolation as achieved using a purification technique.
- In the context of biological molecules “endogenous” refers to a molecule such as a nucleic acid that is naturally found in and/or produced by a given organism or cell. An “endogenous” molecule may also be referred to as a “native” molecule. Conversely, in the context of biological molecules “exogenous” refers to a molecule, such as a nucleic acid, that is not normally or naturally found in and/or produced by a given organism or cell in nature.
- As used herein to describe nucleic acid or amino acid sequences, the term “heterologous” refers to molecules or portions of molecules, such as DNA sequences, that are artificially introduced into a particular host cell, for example by transformation. Heterologous DNA sequences may for example be introduced into a host cell by transformation. Such heterologous molecules may include sequences derived from the host cell. Heterologous DNA sequences may become integrated into the host cell genome, either as a result of the original transformation of the host cells, or as the result of subsequent recombination events.
- Various aspects of the present disclosure encompass nucleic acid or amino acid sequences that are homologous to other sequences. As the term is used herein, an amino acid or nucleic acid sequence is “homologous” to another sequence if the two sequences are substantially identical and the functional activity of the sequences is conserved (as used herein, sequence conservation or identity does not infer evolutionary relatedness). Nucleic acid sequences may also be homologous if they encode substantially identical amino acid sequences, even if the nucleic acid sequences are not themselves substantially identical, for example as a result of the degeneracy of the genetic code.
- With reference to biological sequences “substantial homology” or “substantial identity” is meant, in the alternative, a homology of greater than 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% up to 100% sequence identity. Homology may refer to nucleic acid or amino acid sequences as the context dictates. In alternative embodiments, sequence identity may for example be at least 75%, at least 90% or at least 95%. Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math 2: 482, the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444, and the computerized implementations of these algorithms (such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, Wis., U.S.A.). Sequence identity may also be determined using the BLAST algorithm, described in Altschul et al. (1990), J. Mol. Biol. 215:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (NCBI) at their Internet site. The BLAST algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold. Initial neighborhood word hits act as seeds for initiating searches to find longer HSPs. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction is halted when the following parameters are met: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program may use as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands. One measure of the statistical similarity between two sequences using the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. In alternative embodiments, nucleotide or amino acid sequences are considered substantially identical if the smallest sum probability in a comparison of the test sequences is less than about 1, less than about 0.1, less than about 0.01, or less than about 0.001.
- An alternative indication that two amino acid sequences are substantially identical is that one peptide is specifically immunologically reactive with antibodies that are also specifically immunoreactive against the other peptide. Antibodies are specifically immunoreactive to a peptide if the antibodies bind preferentially to the peptide and do not bind in a significant amount to other proteins present in the sample, so that the preferential binding of the antibody to the peptide is detectable in an immunoassay and distinguishable from non-specific binding to other peptides. Specific immunoreactivity of antibodies to peptides may be assessed using a variety of immunoassay formats, such as solid-phase ELISA immunoassays for selecting monoclonal antibodies specifically immunoreactive with a protein (see Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York).
- An alternative indication that two nucleic acid sequences are substantially identical is that the two sequences hybridize to each other under moderately stringent, or stringent, conditions. Hybridization to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.2×SSC/0.1% SDS at 42° C. (see Ausubel, et al. (eds), 1989, Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3). Alternatively, hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M NaHPO4, 7% SDS, 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C. (see Ausubel, et al. (eds), 1989, supra). Hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes, Part I,
Chapter 2 “Overview of principles of hybridization and the strategy of nucleic acid probe assays”, Elsevier, N.Y.). Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point for the specific sequence at a defined ionic strength and pH. The term “a polynucleotide that hybridizes under stringent (low, intermediate) conditions” is intended to encompass both single and double-stranded polynucleotides although only one strand will hybridize to the complementary strand of another polynucleotide. Washing in the specified solutions may be conducted for a range of times from several minutes to several days and those skilled in the art will readily select appropriate wash times to discriminate between different levels of homology in bound sequences. - It is well known in the art that some modifications and changes can be made in the structure of a polypeptide without substantially altering the biological function of that peptide, to obtain a biologically equivalent polypeptide. As used herein, the term “conserved amino acid substitutions” refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution can be made without any appreciable loss or gain of function, to obtain a biologically equivalent polypeptide. In making such changes, substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing. Conversely, as used herein, the term “non-conserved amino acid substitutions” refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution causes an appreciable loss or gain of function of the peptide, to obtain a polypeptide that is not biologically equivalent.
- In some embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophilicity value (e.g., within a value of plus or minus 2.0), where the following hydrophilicity values are assigned to amino acid residues (as detailed in U.S. Pat. No. 4,554,101): Arg (+3.0); Lys (+3.0); Asp (+3.0); Glu (+3.0); Ser (+0.3); Asn (+0.2); Gln (+0.2); Gly (0); Pro (−0.5); Thr (−0.4); Ala (−0.5); His (−0.5); Cys (−1.0); Met (−1.3); Val (−1.5); Leu (−1.8); Ile (−1.8); Tyr (−2.3); Phe (−2.5); and Trp (−3.4). Non-conserved amino acid substitutions may be made were the hydrophilicity value of the residues is significantly different, e.g. differing by more than 2.0.
- In alternative embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydropathic index (e.g., within a value of plus or minus 2.0). In such embodiments, each amino acid residue may be assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics, as follows: lie (+4.5); Val (+4.2); Leu (+3.8); Phe (+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8); Gly (−0.4); Thr (−0.7); Ser (−0.8); Trp (−0.9); Tyr (−1.3); Pro (−1.6); His (−3.2); Glu (−3.5); Gln (−3.5); Asp (−3.5); Asn (−3.5); Lys (−3.9); and Arg (−4.5). Non-conserved amino acid substitutions may be made were the hydropathic index of the residues is significantly different, e.g. differing by more than 2.0.
- In alternative embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another in the same class, where the amino acids are divided into non-polar, acidic, basic and neutral classes, as follows: non-polar: Ala, Val, Leu, lie, Phe, Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral: Gly, Ser, Thr, Cys, Asn, Gin, Tyr. Non-conserved amino acid substitutions may be made were the residues do not fall into the same class, for example substitution of a basic amino acid for a neutral or non-polar amino acid.
- Most animals are colonized to some degree by microorganisms, such as bacteria, which exist in symbiotic or commensal relationships with the host animal.
- Thus, many species of normally harmless bacteria are found in healthy animals, and are usually localized to the surface of specific organs and tissues. Often, these microbial communities aid in the normal functioning of the body, as members of what is termed the microbiome. Microbes that are generally harmless, such as Escherichia coli, can cause infection in healthy subjects, with results ranging from mild infection to death. Whether or not a microorganism is pathogenic (i.e., causes infection) depends on factors such as: the route of entry and access to specific host cells, tissues, or organs; the intrinsic virulence of the microorganism; the amount of the microorganism present at the site of potential infection; or the health of the host animal. Thus, microorganisms that are normally harmless can become pathogenic given favorable conditions for infection, and even the most virulent microorganism generally requires specific circumstances to cause infection. Accordingly, microbial species that are members of the normal flora can be pathogens when they move beyond their normal ecological role in the endogenous flora. For example, endogenous species can cause infection outside of their ecological niche in regions of anatomical proximity, for example by contiguous spread. When this occurs, these normally harmless endogenous bacteria are pathogenic.
- Specific microbial species are known to cause infections in specific cells, tissues, or organs in otherwise healthy subjects. Examples of bacteria and viruses that commonly cause infections in specific organs and tissues of the body are listed below; and these examples are not limiting in the sense that a skilled person would be able to recognize and identify infectious or pathogenic bacteria that cause infections, or commonly cause infections, in various organs and tissues in otherwise healthy organisms (and recognize the relative frequency of infection with each bacterial species) based on the knowledge in the field as represented, for example, by the following publications: Manual of Clinical Microbiology 8th Edition, Patrick Murray, Ed., 2003, ASM Press American Society for Microbiology, Washington D.C., USA; Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 5th Edition, G. L. Mandell, J. E. Bennett, R. Dolin, Eds., 2000, Churchill Livingstone, Philadelphia, Pa., USA, all of which are incorporated by reference herein.
- Infections of the skin are commonly caused by the following bacterial species: Staphylococcus aureus, Beta hemolytic streptococci group A, B, C or G, Corynebacterium diptheriae, Corynebacterium ulcerans, or Pseudomonas aeruginosa; or viral pathogens: rubeola, rubella, varicella-zoster, echoviruses, coxsackieviruses, adenovirus, vaccinia, herpes simplex, or parvo B19.
- Infections of the soft tissue (e.g., fat and muscle) are commonly caused by the following bacterial species: Streptococcus pyogenes, Staphylococcus aureus, Clostridium perfringens, or other Clostridium spp.; or viral pathogens: influenza, or coxsackieviruses.
- Infections of the breast are commonly caused by the following bacterial species: Staphylococcus aureus, or Streptococcus pyogenes.
- Infections of the lymph nodes of the head and neck are commonly caused by the following bacterial species: Staphylococcus aureus, or Streptococcus pyogenes; or viral pathogens: Epstein-Barr, cytomegalovirus, adenovirus, measles, rubella, herpes simplex, coxsackieviruses, or varicella-zoster.
- Infections of the lymph nodes of the arm/axillae are commonly caused by the following bacterial species: Staphylococcus aureus, or Streptococcus pyogenes; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, adenovirus, or varicella-zoster.
- Infections of the lymph nodes of the mediastinum are commonly caused by the following bacterial species: viridans streptococci, Peptococcus spp., Peptostreptococcus spp., Bacteroides spp., Fusobacterium spp., or Mycobacterium tuberculosis; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, varicella-zoster, or adenovirus.
- Infections of the pulmonary hilar lymph nodes are commonly caused by the following bacterial species: Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae, Haemophilus influenza, Chlamydophila pneumoniae, Bordetella pertussis or Mycobacterium tuberculosis; or viral pathogens: influenza, adenovirus, rhinovirus, coronavirus, parainfluenza, respiratory syncytial virus, human metapneumovirus, or coxsackievirus.
- Infections of the intra-abdominal lymph nodes are commonly caused by the following bacterial species: Yersinia enterocolitica, Yersinia pseudotuberculosis, Salmonella spp., Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus, or Mycobacterium tuberculosis; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, varicella-zoster, adenovirus, influenza, or coxsackieviruses.
- Infections of the lymph nodes of the leg/inguinal region are commonly caused by the following bacterial species: Staphylococcus aureus, or Streptococcus pyogenes; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, or herpes simplex.
- Infections of the blood (i.e., septicemia) are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, coagulase-negative staphylococci, Enterococcus spp., Escherichia coli, Klebsiella spp., Enterobacter spp., Proteus spp., Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus pneumoniae, or group B streptococci; or viral pathogens: rubeola, rubella, varicella-zoster, echoviruses, coxsackieviruses, adenovirus, Epstein-Barr, herpes simplex, or cytomegalovirus.
- Infections of the bone are commonly caused by the following bacterial species: Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, other streptococci spp., Escherichia coli, Pseudomonas spp., Enterobacter spp., Proteus spp., or Serratia spp.; or viral pathogens: parvovirus B19, rubella, or hepatitis B.
- Infections of the joint are commonly caused by the following bacterial species: Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, other streptococci spp., Escherichia coli, Pseudomonas spp., Enterobacter spp., Proteus spp., Serratia spp., Neisseria gonorrhea, salmonella species, Mycobacterium tuberculosis, Hemophilus influenza; or viral pathogens: parvovirus B19, rubella, hepatitis B; or fungal pathogen: Scedosporium prolificans
- Infections of the meninges are commonly caused by the following bacterial species: Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus agalactiae, or Listeria monocytogenes; or viral pathogens: echoviruses, coxsackieviruses, other enteroviruses, or mumps.
- Infections of the brain are commonly caused by the following bacterial species: Streptococcus spp. (including S. anginosus, S. constellatus, S. intermedius), Staphylococcus aureus, Bacteroides spp., Prevotella spp., Proteus spp., Escherichia coli, Klebsiella spp., Pseudomonas spp., Enterobacter spp., or Borrelia burgdorferi; or viral pathogens: coxsackieviruses, echoviruses, poliovirus, other enteroviruses, mumps, herpes simplex, varicella-zoster, flaviviruses, or bunyaviruses.
- Infections of the spinal cord are commonly caused by the following bacterial species: Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus agalactiae, Listeria monocytogenes, or Borrelia burgdorferi; or viral pathogens: coxsackieviruses, echoviruses, poliovirus, other enteroviruses, mumps, herpes simplex, varicella-zoster, flaviviruses, or bunyaviruses.
- Infections of the eye/orbit are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus miller, Escherichia coli, Bacillus cereus, Chlamydia trachomatis, Haemophilus influenza, Pseudomonas spp., Klebsiella spp., or Treponema pallidum; or viral pathogens: adenoviruses, herpes simplex, varicella-zoster, or cytomegalovirus.
- Infections of the salivary glands are commonly caused by the following bacterial species: Staphylococcus aureus, viridans streptococci (e.g., Streptococcus salivarius, Streptococcus sanguis, Streptococcus mutans), Peptostreptococcus spp., or Bacteroides spp., or other oral anaerobes; or viral pathogens: mumps, influenza, enteroviruses, or rabies.
- Infections of the mouth are commonly caused by the following bacterial species: Prevotella melaninogenicus, anaerobic streptococci, viridans streptococci, Actinomyces spp., Peptostreptococcus spp., or Bacteroides spp., or other oral anaerobes; or viral pathogens: herpes simplex, coxsackieviruses, or Epstein-Barr.
- Infections of the tonsils are commonly caused by the following bacterial species: Streptococcus pyogenes, or Group C or G B-hemolytic streptococci; or viral pathogens: rhinoviruses, influenza, coronavirus, adenovirus, parainfluenza, respiratory syncytial virus, or herpes simplex.
- Infections of the sinuses are commonly caused by the following bacterial species: Streptococcus pneumoniae, Haemophilus influenza, Moraxella catarrhalis, a-streptococci, anaerobic bacteria (e.g., Prevotella spp.), or Staphylococcus aureus; or viral pathogens: rhinoviruses, influenza, adenovirus, or parainfluenza.
- Infections of the nasopharynx are commonly caused by the following bacterial species: Streptococcus pyogenes, or Group C or G B-hemolytic streptococci; or viral pathogens: rhinoviruses, influenza, coronavirus, adenovirus, parainfluenza, respiratory syncytial virus, or herpes simplex.
- Infections of the thyroid are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus pneumoniae; or viral pathogens: mumps, or influenza.
- Infections of the larynx are commonly caused by the following bacterial species: Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Streptococcus pyogenes; or viral pathogens: rhinovirus, influenza, parainfluenza, adenovirus, corona virus, or human metapneumovirus.
- Infections of the trachea are commonly caused by the following bacterial species: Mycoplasma pneumoniae; or viral pathogens: parainfluenza, influenza, respiratory syncytial virus, or adenovirus.
- Infections of the bronchi are commonly caused by the following bacterial species: Mycoplasma pneumoniae, Chlamydophila pneumoniae, Bordetella pertussis, Streptococcus pneumoniae, or Haemophilus influenzae; or viral pathogens: influenza, adenovirus, rhinovirus, coronavirus, parainfluenza, respiratory syncytial virus, human metapneumovirus, or coxsackievirus.
- Infections of the lung are commonly caused by the following bacterial species: Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae, or Haemophilus influenza; or viral pathogens: influenza, adenovirus, respiratory syncytial virus, or parainfluenza.
- Infections of the pleura are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Bacteroides fragilis, Prevotella spp., Fusobacterium nucleatum, peptostreptococcus spp., or Mycobacterium tuberculosis; or viral pathogens: influenza, adenovirus, respiratory syncytial virus, or parainfluenza.
- Infections of the mediastinum are commonly caused by the following bacterial species: viridans streptococci, Peptococcus spp., Peptostreptococcus spp., Bacteroides spp., Fusobacterium spp., or Mycobacterium tuberculosis; or viral pathogens: measles, rubella, Epstein-Barr, or cytomegalovirus.
- Infections of the heart are commonly caused by the following bacterial species: Streptococcus spp. (including S. mitior, S. bovis, S. sanguis, S. mutans, S. anginosus), Enterococcus spp., Staphylococcus spp., Corynebacterium diptheriae, Clostridium perfringens, Neisseria meningitidis, or Salmonella spp.; or viral pathogens: enteroviruses, coxsackieviruses, echoviruses, poliovirus, adenovirus, mumps, rubeola, or influenza.
- Infections of the esophagus are commonly caused by the following bacterial species: Actinomyces spp., Mycobacterium avium, Mycobacterium tuberculosis, or Streptococcus spp.; or viral pathogens: cytomegalovirus, herpes simplex, or varicella-zoster.
- Infections of the stomach are commonly caused by the following bacterial species: Streptococcus pyogenes or Helicobacter pylori; or viral pathogens: cytomegalovirus, herpes simplex, Epstein-Barr, rotaviruses, noroviruses, or adenoviruses.
- Infections of the small bowel are commonly caused by the following bacterial species: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica, or Shigella flexneri; or viral pathogens: adenoviruses, astroviruses, caliciviruses, noroviruses, rotaviruses, or cytomegalovirus.
- Infections of the colon/rectum are commonly caused by the following bacterial species: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica, or Shigella flexneri; or viral pathogens: adenoviruses, astroviruses, caliciviruses, noroviruses, rotaviruses, or cytomegalovirus.
- Infections of the anus are commonly caused by the following bacterial species: Streptococcus pyogenes, Bacteroides spp., Fusobacterium spp., anaerobic streptococci, Clostridium spp., Escherichia coli, Enterobacter spp., Pseudomonas aeruginosa, or Treponema pallidum; or viral pathogens: herpes simplex.
- Infections of the perineum are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterococcus spp., Bacteroides spp., Fusobacterium spp., Clostridium spp., Pseudomonas aeruginosa, anaerobic streptococci, Clostridium spp., or Enterobacter spp.; or viral pathogens: herpes simplex.
- Infections of the liver are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Streptococcus (anginosus group), Enterococcus, spp. other viridans streptococci, or Bacteroides spp.; or viral pathogens: hepatitis A, Epstein-Barr, herpes simplex, mumps, rubella, rubeola, varicella-zoster, coxsackieviruses, or adenovirus.
- Infections of the gallbladder are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterobacter spp., enterococci, Bacteroides spp., Fusobacterium spp., Clostridium spp., Salmonella enteriditis, Yersinia enterocolitica, or Shigella flexneri.
- Infections of the biliary tract are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterobacter spp., enterococci, Bacteroides spp., Fusobacterium spp., Clostridium spp., Salmonella enteriditis, Yersinia enterocolitica, or Shigella flexneri; or viral pathogens: hepatitis A, Epstein-Barr, herpes simplex, mumps, rubella, rubeola, varicella-zoster, cocsackieviruses, or adenovirus.
- Infections of the pancreas are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterococcus spp., Pseudomonas spp., Staphylococcal spp., Mycoplasma spp., Salmonella typhi, Leptospirosis spp., or Legionella spp.; or viral pathogens: mumps, coxsackievirus, hepatitis B, cytomegalovirus,
herpes simplex 2, or varicella-zoster. - Infections of the spleen are commonly caused by the following bacterial species: Streptococcus spp., Staphylococcus spp., Salmonella spp., Pseudomonas spp., Escherichia coli, or Enterococcus spp.; or viral pathogens: Epstein-Barr, cytomegalovirus, adenovirus, measles, rubella, coxsackieviruses, or varicella-zoster.
- Infections of the adrenal gland are commonly caused by the following bacterial species: Streptococcus spp., Staphylococcus spp., Salmonella spp., Pseudomonas spp., Escherichia coli, or Enterococcus spp.; or viral pathogens: varicella-zoster.
- Infections of the kidney are commonly caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgatus, Providentia spp., Morganella spp., Enterococcus faecalis, or Pseudomonas aeruginosa; or viral pathogens: BK virus, or mumps.
- Infections of the ureter are commonly caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgatus, Providentia spp., Morganella spp., or Enterococcus spp.
- Infections of the bladder are commonly caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgatus, Providentia spp., Morganella spp., Enterococcus faecalis, or Corynebacterium jekeum; or viral pathogens: adenovirus, or cytomegalovirus.
- Infections of the peritoneum are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella spp., Proteus spp., enterococci, Bacteroides fragilis, Prevotella melaninogenica, Peptococcus spp., Peptostreptococcus spp., Fusobacterium spp., or Clostridium spp.
- Infections of the retroperitoneal area are commonly caused by the following bacterial species: Escherichia coli, or Staphylococcus aureus.
- Infections of the prostate are commonly caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterobacter spp., Proteus mirabilis, enterococci spp., Pseudomonas spp., Corynebacterium spp., or Neisseria gonorrhoeae; or viral pathogens: herpes simplex.
- Infections of the testicle are commonly caused by the following bacterial species: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus spp., Streptococcus spp., or Salmonella enteriditis; or viral pathogens: mumps, coxsackievirus, or lymphocytic choriomeningitis virus.
- Infections of the penis are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Neisseria gonorrhoeae, or Treponema pallidum; or viral pathogens: herpes simplex.
- Infections of the ovary/adnexae are commonly caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis, Gardenerella vaginalis, Prevotella spp., Bacteroides spp., Peptococcus spp. Streptococcus spp., or Escherichia coli.
- Infections of the uterus are commonly caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis, Gardenerella vaginalis, Prevotella spp., Bacteroides spp., Peptococcus spp., Streptococcus spp., or Escherichia coli.
- Infections of the cervix are commonly caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis, or Treponema pallidum; or viral pathogens: herpes simplex.
- Infections of the vagina are commonly caused by the following bacterial species: Gardenerella vaginalis, Prevotella spp., Bacteroides spp., peptococci spp., Escherichia coli, Neisseria gonorrhoeae, Chlamydia Trachomatis, or Treponema pallidum; or viral pathogens: herpes simplex.
- Infections of the vulva are commonly caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, or Treponema pallidum; or viral pathogens: herpes simplex.
- Bacterial species are classified operationally as collections of similar strains (which generally refers to groups of presumed common ancestry with identifiable physiological but usually not morphological distinctions, and which may be identified using serological techniques against bacterial surface antigens). Thus, each bacterial species (e.g., Streptococcus pneumoniae) has numerous strains (or serotypes), which may differ in their ability to cause infection or differ in their ability to cause infection in a particular organ/site. For example, although there are at least 90 serotypes of Streptococcus pneumoniae, serotypes 1, 3, 4, 7, 8, and 12 are most frequently responsible for pneumococcal disease in humans.
- Certain strains of Escherichia coli, referred to as extraintestinal pathogenic E. coli(ExPEC), are more likely to cause urinary tract infection or other extraintestinal infections such as neonatal meningitis, whereas other strains, including enterotoxigenic E. coli(ETEC), enteropathogenic E. coli(EPEC), enterohemorrhagic E. coli(EHEC), Shiga toxin-producing E. coli(STEC), enteroaggregative E. coli(EAEC), enteroinvasive E. coli(EIEC) and diffuse adhering E. coli(DAEC) are more likely to cause gastrointestinal infection/diarrhea. Even among the sub-category of ExPEC strains, specific virulence factors (e.g., production of type-1 fimbriae) enable certain strains to be more capable of causing infection of the bladder, while other virulence factors (e.g., production of P fimbriae) enable other strains to be more capable of causing infection in the kidneys. In accordance with the present invention, an ExPEC strain(s) that is more likely to cause infection in the bladder may be chosen for a formulation to target immune dysregulation in the bladder cancer, whereas an ExPEC strain(s) that is more likely to cause infection in the kidney may be chosen for a formulation to target immune dysregulation in the kidney cancer. Likewise, one or more of an ETEC, EPEC, EHEC, STEC, EAEC, EIEC or DAEC strains of E. coli(i.e., strains that cause colon infection), may be chosen for a formulation to treat immune dysregulation in the colon.
- Similarly, there may be numerous subtypes of specific viruses. For example, there are three types of influenza viruses, influenza A, influenza B and influenza C, which differ in epidemiology, host range and clinical characteristics. For example, influenza A is more likely to be associated with viral lung infection, whereas influenza B is more likely to be associated with myositis (i.e., muscle infection). Furthermore, each of these three types of influenza virus have numerous subtypes, which also may differ in epidemiology, host range and clinical characteristics. In accordance with the present invention, one may choose an influenza A subtype most commonly associated with lung infection to target immune dysregulation in the lung, whereas one may choose an influenza B strain most commonly associated with myositis to treat immune dysregulation in the muscle/soft tissues.
- There are specific microbiota associated with some pathological tissue states, for example microbiota of specific tumours. For example, Fusobacterium and Providencia have been associated with colorectal cancer.
- The compositions of the invention include immunogens of pathogenic microbial species (bacterial, viral or fungal) that are pathogenic in a specific tissue or organ, in which the immunogens are provided in the form of an artificial repertoire of mammalian PRR agonists that recapitulate a distinct portion of the PRR agonist signature of the microbial mammalian pathogen that is pathogenic in the target tissue. In select embodiments, the portion of the PRR agonist signature is distinct in the sense that it is both: different from a reference PRR agonist signature of a microbe that is not pathogenic in the target tissue; and, different than the native PRR agonist signature of the microbial mammalian pathogen. This distinct artificial repertoire of mammalian PRR agonists are formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in the target tissue in the mammalian host.
- Compositions of the invention may be provided alone or in combination with other compounds (for example, nucleic acid molecules, small molecules, peptides, or peptide analogues), in the presence of a liposome, an adjuvant, or any pharmaceutically acceptable carrier, in a form suitable for administration to mammals, for example, humans (a “therapeutic vehicle”). As used herein “pharmaceutically acceptable carrier” or “excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The carrier can be suitable for any appropriate form of administration, including subcutaneous, intradermal, intravenous, parenteral, intraperitoneal, intramuscular, sublingual, inhalational, intratumoural or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound (i.e., the specific bacteria, bacterial antigens, or compositions thereof of the invention), use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- Aspects of the invention involve the use of nanoparticle (NP) formulations. For example, virus-like particles (VLPs) are in essence empty viral particles with an intact protein hull and, in some embodiments, membrane envelopes. In general, VLPs lack genetic material. Production of VLPs may for example be by expression of viral proteins in mammalian, avian, insect, plant, yeast, or bacterial cells. Alternatively, fully synthetic VLPs may be produced. Alternative nanoparticle formulations emulsions, liposomes alginates, chitosan, and polylactide-coglycolide (PLGA) NPs. Examples of NP/TLR ligand preparations that may be adapted for use to induce immune responses are ligands for TLR2 (Pam(3)Cys), TLR9 (Poly I:C), TLR4 (3-O-desacyl-4 0-monophosphoryl lipid A (MPL)), TLR7 (9-benzyl-8-hydroxyadenine), TLR7/8 (resiquimod, R848), and TLR9 (CpG DNA).
- In addition to selected co-formulations, a wide variety of adjuvants may be used to potentiate a desired immune response (see Levast et al., 2014, Vaccines, 2, 297-322).
- Treatment with PRR ligands according to the invention may be combined with more traditional and existing therapies. For cancer, for example, these may include chemotherapy, radiation therapy, surgery, etc., or with a therapy that stimulates the immune system, reduces inflammation or otherwise benefits the subject, such as nutrients, vitamins and supplements. For example, vitamin A, vitamin D, vitamin E, vitamin C, vitamin B complex, selenium, zinc, co-enzyme Q10, beta carotene, fish oil, curcumin, green tea, bromelain, resveratrol, ground flaxseed, garlic, lycopene, milk thistle, melatonin, other antioxidants, cimetidine, indomethacin, or COX-2 Inhibitors (e.g., Celebrex™ [celecoxib] or Vioxx™ [rofecoxib]) may be also be administered to the subject.
- Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the compounds to subjects. Alternative routes of administration may be employed, for example, parenteral, intravenous, intradermal, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intrathecal, intracisternal, intraperitoneal, intranasal, inhalational, aerosol, topical, intratumoural, sublingual or oral administration. Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; for intranasal formulations, in the form of powders, nasal drops, or aerosols; and for sublingual formulations, in the form of drops, aerosols or tablets.
- Methods well known in the art for making formulations are found in, for example, “Remington's Pharmaceutical Sciences” (20th edition), ed. A. Gennaro, 2000, Mack Publishing Company, Easton, Pa. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel. For therapeutic or prophylactic compositions, the pathogenic bacterial species are administered to an individual in an amount effective to stop or slow progression or metastasis of the cancer, or to increase survival of the subject (relative to, for example, prognoses derived from the SEER database) depending on the disorder.
- Pharmaceutical compositions or formulations may be packaged in a variety of ways depending upon the method used for administering the drug. For example, an article of manufacture or package may include a container having deposited therein the pharmaceutical formulation in an appropriate form. Suitable containers may for example include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and vials. The container may have a sterile access port, for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle. The package or container may also include a tamper-proof or multi-use mechanism adapted to control access to the contents of the package or the container, for example a multi dose vial adapter matched to a vial contained in the package. The container or package may include a label, for example a label that describes the contents of the container, for example a drug label identifying the pharmaceutical composition therein and/or specifying modes or routes of administration. The label may also include appropriate warnings, for example specifying storage conditions for the container or package, or setting out contraindications or adverse effects of a mode of treatment. Articles of manufacture may accordingly take the form of a “kit” comprising pharmaceutical compositions or accessories adapted to facilitate use of pharmaceutical compositions. Kits may include a label or package insert, where the term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. Kits may further include accessories associated with use of the pharmaceutical composition, including buffers, diluents, filters, needles, and syringes. Kits may also be adapted for the delivery of selected dosage forms of a pharmaceutical composition, for example including a number of unit dosages. Such kits can include a memory aid or mechanism, in the form of a physical or written indication of the intended timing of a treatment schedule in which the dosages are to be used.
- A “companion diagnostic” may be associated with a pharmaceutical treatment or composition. Companion diagnostics are assays that facilitate the associated treatment, by providing diagnostic or prognostic information, typically in the form of a diagnostic test to determine the applicability of a treatment to a specific patient. Point-of-care companion diagnostics may for example involve providing diagnostic compositions and/or articles of manufacture in conjunction with providing a pharmaceutical formulation, for example as part of a kit. Alternatively, companion diagnostics may be separately provided, as assays to monitor the therapy of subjects or to predict the therapeutic efficacy of an intended treatment. A companion diagnostic may for example take the form of a medical device, such as an imaging tool, or a process carried out by such a device, for example for conducting assays in vitro, which provides information that is relevant for the safe and effective use of a corresponding drug or biological product. Companion diagnostics may be used with therapies disclosed herein so as to provide diagnostic or prognostic information about therapeutic efficacy or evidence of undesirable side effects or risks. The use of a companion diagnostic with a particular therapeutic may be stipulated in instructions, for example on the labeling of a diagnostic device and/or the labeling of the corresponding therapeutic product. Types of companion diagnostic tests may for example include: screening and detection, in form of tests that screen for genetic patterns, such as genetic SSI response markers; prognosis and theranostics, such as assays for biochemical SSI response markers that help to predict the future course of a disease, or indicate a patient's response to a therapy; monitoring, for example to evaluate the effectiveness and appropriate dosing of a prescribed therapy; or, recurrence, involving tests that analyze the patient's risk for a recurrence of the disease.
- An “effective amount” of a composition according to the invention includes a therapeutically effective amount or a prophylactically effective amount. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduction or elimination of the immune dysregulation. A therapeutically effective amount of a composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount may also be one in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as amelioration of immune dysregulation. Typically, a prophylactic dose is used in subjects prior to or at an earlier stage of cancer, so that a prophylactically effective amount may be less than a therapeutically effective amount.
- For any particular subject, the timing and dose of treatments may be adjusted over time (e.g., timing may be daily, every other day, weekly, monthly) according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. For example, in the context of subcutaneous or intradermal administration, the compositions may be administered every second day. An initial dose of approximately 0.05 ml may be administered subcutaneously, followed by increases from 0.01-0.02 ml every second day until an adequate skin reaction is achieved at the injection site (for example, a 1 inch to 2 inch diameter delayed reaction of visible redness at the injection site). Once this adequate immune reaction is achieved, this dosing is continued as a maintenance dose. The maintenance dose may be adjusted from time to time to achieve the desired visible skin reaction (inflammation) at the injection site. Dosing may be for a dosage duration, for example of at least 1 week, 2 weeks, 2 months, 6 months, 1, 2, 3, 4, or 5 years or longer.
- Oral dosages may for example range from 4 times per day, daily or weekly. Dosing may be for a dosage duration, for example of at least 1 week, 2 weeks, 2 months, 6 months, 1, 2, 3, 4, or 5 years or longer. In some embodiments, the invention may include compositions administered sublingually or by inhalation, or administered to one or more epithelial tissues (i.e., skin by intradermal or subcutaneous injection; lung epithelium by inhalation; gastrointestinal mucosa by oral ingestion; mouth mucosa by sublingual administration) simultaneously or sequentially. Accordingly, in some embodiments the compositions of the invention are administered so as to provoke an immune response in an epithelial tissue. In some embodiments, one or more epithelial routes of administration may be combined with one or more additional routes of administration, such as intratumoural, intramuscular or intravenous administration.
- In the case of immunogenic formulations, an immunogenically effective amount of a composition of the invention can be provided, alone or in combination with other compounds, for example with an immunological adjuvant. The composition may for example include compounds linked with a carrier molecule, such as bovine serum albumin or keyhole limpet hemocyanin to enhance immunogenicity. An immunogenic composition is a composition that includes materials that elicit a desired immune response. An immunogenic composition may select, activate or expand, without limitation: memory B, T cells, neutrophils, monocytes or macrophages of the immune system.
- An antigenic composition comprising killed recombinant bacteria for administration by injection may be made as follows. The bacteria may be grown in suitable media, and washed with physiological salt solution. The bacteria may then be centrifuged, resuspended in saline solution, and killed with heat. The suspensions may be standardized by direct microscopic count, mixed in required amounts, and stored in appropriate containers, which may be tested for safety, shelf life, and sterility in an approved manner. In addition to the pathogenic bacterial species and/or antigens thereof, a killed bacterial vaccine suitable for administration to humans may include 0.4% phenol preservative and/or 0.9% sodium chloride. The bacterial vaccine may also include trace amounts of brain heart infusion (beef), peptones, yeast extract, agar, sheep blood, dextrose, sodium phosphate and/or other media components.
- In select embodiments, medicaments may be administered at an administration site in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least one week. Optionally, the medicament may be administered intradermally or subcutaneously. Optionally, the medicament may be administered in a dose so that each dose is effective to cause a visible localized inflammatory immune response at the administration site. Optionally, the medicament may be administered so that visible localized inflammation at the administration site occurs within 1 to 48 hours. However, a visible localized inflammatory immune response may not always be present in all circumstances despite an immune response being initiated. There are other methods by which the mounting of an immune response can be monitored. For example, the profile (and relative change in characterization) of immune cells from a subject undergoing an immune reaction can be compared with those from a subject that is not undergoing an immune reaction.
- In another aspect, a method of monitoring efficacy of a treatment regime in an individual being treated for an immune dysfunction in a specific organ or tissue is provided. The method involves measuring a characteristic of an immune response in a past-treatment immune sample obtained from the specific organ or tissue after the individual has been subject to the treatment regime for a period of time.
- In some embodiments, PRR agonists derived from bacteria that are members of the endogenous flora of a particular region of the GIT may be used to formulate immunogenic compositions of the invention. The rows of Table 3 list a number of bacterial species, together with the biological regions in which each species may form a part of the endogenous flora. For example, Abiotrophia spp. are typically members of the endogenous flora of the mouth.
-
TABLE 3 Human Bacterial Normal Flora (Endogenous Bacterial Human Pathogens) Duodenum/ Bacterial species Mouth Stomach Jejunum Ileum Colon CFU/mL 10{circumflex over ( )}5 10{circumflex over ( )}2 10{circumflex over ( )}5 10{circumflex over ( )}8 10{circumflex over ( )}11 Abiotrophia spp + Acholeplasma + laidlawii Acidaminococcus + + + + fermentans Acinetobacter + + + + spp. Actinobacillus + spp. Actinobaculum + + + + spp. Actinomyces + + + + spp. Aeromonas spp. + + + Anaerorhabdus + + furcosus Anaerococcus + + hydrogenalis Anaerococcus + + lactolyticus Anaerococcus + + prevotii Atopobium spp. + + + + Bacillus spp. + + Bacteroides + + caccae Bacteroides + + distasonis Bacteroides + + eggerthii Bacteroides + + fragilis Bacteroides + + merdae Bacteroides + + ovatus Bacteroides + + splanchnicus Bacteroides + + thetaiotaomicron Bacteroides + + vulgatus Bifidobacterium + + + adolescentis Bifidobacterium + + + bifidum Bifidobacterium + + + breve Bifidobacterium + + + catenulatum Bifidobacterium + + + + dentium Bifidobacterium + + + longum Bilophila + + + + wadsworthia Burkholderia + + + cepacia Butyrivibrio + + + fibrisolvens Campylobacter + + + concisus Campylobacter + + + curvus Campylobacter + + + gracilis Campylobacter + + + jejuni Campylobacter + + + rectus Campylobacter + + + + showae Campylobacter + sputorum Capnocytophaga + granulosum Capnocytophaga + gingivalis Campylobacter + haemolytica Capnocytophaga + + + + ochracea Capnocytophaga + sputigena Cardiobacterium + hominis Cedecea spp + Centipeda + periodontii Citrobacter + + + freundii Citrobacter + + + koseri Clostridium spp. + + + Corynebacterium + accolens Corynebacterium + afermentans Desulfomonas + + + pigra Dysgonomonas + + + spp. Eikenella + + + + corrodens Enterobacter + + + aerogenes Enterobacter + + + cloacae Enterobacter + + + gergoviae Enterobacter + + + sakazakii Enterobacter + + + taylorae Enterococcus + + + spp. Escherichia coli + + + Escherichia + + + fergusonii Escherichia + + + hermannii Escherichia + + + vulneris Eubacterium spp. + + + + Ewingella + americana Finegoldia + + + magnus Fusobacterium + alocis Fusobacterium + + + gonidiaformans Fusobacterium + + + mortiferum Fusobacterium + + + naviforme Fusobacterium + + + + necrophorum Fusobacterium + + nucleatum Fusobacterium + sulci Fusobacterium + + + russii Fusobacterium + + + varium Gardnerella + + + vaginalis Gemella + haemolysans Gemella + + + + morbillorum Globicatella spp. + + Granulicatella + spp. Haemophilus + spp. Hafnia alvei + + + Helcococcus kunzii Helicobacter spp. + + + Kingella spp. + Klebsiella spp. + + + + Lactobacillus + + + + + acidophilus Lactobacillus + breve Lactobacillus + casei Lactobacillus + + + + + fermentum Lactobacillus + + + + reuteri Lactobacillus + + + + + salivarius Leclercia + + + adecarboxylata Leminorella spp. + + + Leptotrichia + buccalis Megasphaera + + + elsdenii Micrococcus + luteus Micrococcus + lylae Micromonas + micros Mitsuokella + + + multiacidus Mobiluncus + + + curisii Mobiluncus + + + mulieris Moellerella + + + wisconsensis Moraxella + catarrhalis other Moraxella + spp. Morganella + + + morganii Mycoplasma + buccale Mycoplasma + fermentans Mycoplasma + hominis Mycoplasma + lipophilum Mycoplasma + orale Mycoplasma + pneumoniae Mycoplasma + salivarium Pantoea + + + agglomerans Pasteurella + multocida Pediococcus + + spp. Peptoniphilus + + + asaccharolyticus Peptostreptococcus + + + + anaerobus Peptostreptococcus + + + productus Porphyromonas + + + + asaccharolytica Porphyromonas + + catoniae Porphyromonas + + endodontalis Porphyromonas + + gingivalis Prevotella + + buccae Prevotella + + buccalis Prevotella + + corporis Prevotella + + dentalis Prevotella + + denticola Prevotella + + enoeca Prevotella + + heparinolytica Prevotella + + intermedia Prevotella + + loescheii Prevotella + + melaninogenica Prevotella + + nigrescens Prevotella oralis + + Prevotella oris + + Prevotella + + oulorum Prevotella + + tannerae Prevotella + + veroralis Prevotella + + zoogleoformans Propionibacterium + propionicum Proteus mirabilis + + Proteus penneri + + Proteus vulgaris + + Providencia + + rettgeri Providencia + + + stuartii Pseudomonas + + + aeruginosa Retortamonas + + + intestinalis Rothia + dentocariosa Rothia + mucilaginosa Ruminococcus + + + productus Selenomonas + spp. Serratia + + liquefaciens Serratia + + marcescens Serratia odorifera + + Staphylococcus + aureus Staphylococcus + epidermidis Streptococcus + + + agalactiae Streptococcus + + + + anginosus Streptococcus + + + bovis Streptococcus + + + + constellatus Streptococcus + criceti Streptococcus + crista Streptococcus + equisimilis Streptococcus + gordonii Streptococcus + + + intermedius Streptococcus + + mitis Streptococcus + mutans Streptococcus + oralis Streptococcus + parasanguis Streptococcus + + pyogenes Streptococcus + + salivarius Streptococcus + + sanguis Streptococcus + sobrinus Streptococcus + vestibularis Group C + G + + Streptococci Succinivibrio + + + dextrinosolvens Sutterella spp. + + + Suttonella + indologenes Tissierella + + + praeacuta Treponema + denticola Treponema + maltophilum Treponema + socranskii Treponema + vincentii Ureaplasma + urealyticum Veillonella spp. + + + + - Endogenous microbial flora, such as bacteria, have access to tissues for pathogenesis either through contiguous spread or bacteremic spread. Under favorable conditions, endogenous organisms can become pathogenic and invade locally and spread by contiguous spread to adjacent tissues and organs. Endogenous bacterial flora of the skin, mouth and colon are species that are understood to also be amenable to bacteremic spread. Bacteria that are members of a particular endogenous flora domain may therefore cause infection in tissues or organs to which these bacteria may spread. Accordingly, one aspect of the invention involves the use of PRR agonists derived from endogenous microbial pathogens to treat an immune dysregulation having symptoms localized to a region of the GIT in which the endogenous bacteria may spread to cause infection. The columns of Table 2 list domains for endogenous flora. The rows of Table 4 list regions of the GIT within which immune dysregulation may be symptomatic or etiologically located. Accordingly, one aspect of the invention involves the use of PRR agonists derived from endogenous microbial pathogens to formulate immunogenic compositions for treating an immune dysregulation symptomatic or etiologically located in the region of the GIT to which the pathogen may spread to cause an infection. Accordingly, in alternative embodiments, an immune dysregulation that is symptomatic in the region listed in the first column of Table 2 may be treated with immunogenic compositions comprising an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial mammalian pathogen that is a member of the endogenous flora of one or more of the endogenous flora domains listed in the first row of Table 2 and indicated with an X or a check mark in the appropriate row.
-
TABLE 4 Tissue/Organ Pathogenicity of Endogenous Flora organ site Duo-denum/ Tissue Mouth Stomach Jejunum Ileum Colon Oral x Tonsil x Nasopharynx/Sinus x Esophagus x Stomach x Small bowel x x Colon/Rectum x Anus x - In accordance with the combined information in Tables 1 and 2, an immune dysregulation manifest in a particular region of the GIT set out in
column 1 of Table 2 may be treated with antigenic compositions comprising an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial mammalian pathogen that is one of the corresponding bacterial species of Table 1, so that the column headings in Table 2 are in effect replaced with the bacterial species of Table 1. - In some embodiments, PRR agonists may be derived from exogenous bacterial pathogens. For example, PRR agonists derived from the organisms listed in Table 5 may be used in an artificial repertoire of PRR agonists to treat an immune dysregulation that is symptomatic in the region of the GIT listed with the relevant organism in Table 5. In some embodiments, PRR agonists derived from both endogenous and exogenous microbial species may be used in combination.
-
TABLE 5 Exogenous Bacterial Human Pathogens, and their Sites of Infection in the GIT. Bacterial Species Region of the GIT Aerobacter spp. small bowel, colon, Bacillus anthracis oral, small bowel, colon, hematological Bacillus cereus colon, other Bacillus spp. colon, stomach, small bowel Brucella spp. small bowel, colon Campylobacter coli small bowel, colon Campylobacter colon jejuni Campylobacter small bowel, colon sputorum Clostridium small bowel, colon, stomach bifermentans Clostridium colon, small bowel botulinum Clostridium difficile colon Clostridium indolis small bowel, colon, stomach, Clostridium small bowel, colon, stomach mangenolii Clostridium small bowel, colon, stomach perfringens Clostridium sordellii small bowel, colon, stomach Clostridium small bowel, colon, stomach sporogenes Clostridium small bowel, colon, stomach subterminale Edwarsiella tarda small bowel, colon Francisella small bowel tularensis Helicobacter pylori stomach Leptospirosis spp. oral Listeria small bowel, colon monocytogenes Mycobacterium colon, small bowel bovis Mycobacterium small bowel, colon tuberculosis Pediococcus spp. colon Plesiomonas small bowel, colon shigelloides Rickettsia small bowel rickettsiae Salmonella spp. stomach, small bowel, colon Shigella boydii colon Shigella colon dysenteriae Shigella flexneri colon Shigella sonnei colon other Spirillum spp. colon Streptococcus small bowel zooepidemicus Treponema oral, anus pallidum Tropheryma small bowel, colon whipplei Vibrio cholerae colon, small bowel Vibrio fluvialis small bowel, colon Vibrio furnissii small bowel, colon Vibrio hollisae small bowel, colon Vibrio colon, small bowel parahaemolyticus Yersinia small bowel, colon enterocolitica Yersinia small bowel, colon pseudotuberculosis - In some embodiments, PRR agonists for use in the invention may be derived from viral pathogens. Table 6 provides an exemplary list of viral pathogens together with the tissue and organ sites for which each viral species is reportedly a pathogen. Accordingly, one aspect of the invention involves utilizing immunogenic compositions of PRR agonists derived from the named viruses to treat an immune dysregulation that is symptomatic in the region of the GIT that is identified adjacent to the name of the virus in Table 6.
-
TABLE 6 Viral Human Pathogens and Their Sites of Infection Virus Region of the GIT Herpes Simplex rectum, anus virus (1 and 2) Cytomegalovirus small bowel, colon/rectum Epstein-Barr virus oral Adenovirus oral, small bowel, colon Human anus, oral papillomavirus Orthoreoviruses small bowel, colon, oral Coltiviruses oral Rotaviruses small bowel, colon Alphaviruses small bowel, colon, Coronaviruses oral, small bowel, colon Toroviruses small bowel, colon Parainfluenza oral viruses Respiratory syncytial oral virus Human oral, small bowel, colon metapneumovirus Vesicular stomatitis oral, small bowel, colon virus Rabies virus oral Influenza virus oral Hantaviruses oral Machupo virus small bowel, colon Junin virus small bowel, colon Poliovirus small bowel, colon Coxsackieviruses small bowel, colon Echoviruses oral, small bowel, colon Hepatitis A virus small bowel, colon Rhinoviruses oral Noroviruses and small bowel, colon other Caliciviruses Astroviruses small bowel, colon Picobirnaviruses small bowel, colon Hepatitis E virus small bowel, colon - In some embodiments, the pathogen from which PRR agonists are derived for use in immunogenic compositions of the invention may be one that is a common cause of acute infection in the region of the GIT in which the immune dysregulation to be treated is symptomatic. Table 7 identifies bacterial and viral pathogens of this kind, together with the region of the GIT in which they commonly cause infection. Accordingly, in selected embodiments, an immune dysregulation that is symptomatic in a region of the GIT identified in the first column of Table 7 may be treated with an immunogenic composition that comprises an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of the PRR agonist signature of a pathogenic organism listed in the second column of Table 7.
-
TABLE 7 Common causes of acute infection (bacteria and viruses) for selected regions of the GIT Selected regions of the GIT Common Bacterial or Viral Pathogens Oral Prevotella melaninogenicus, anaerobic streptococci, viridans streptococci, Actinomyces spp., Peptostreptococcus spp., Bacteroides spp., and other oral anaerobes herpes simplex, coxsackieviruses, Epstein-Barr Stomach Streptococcus pyogenes, Helicobacter pylori cytomegalovirus, herpes simplex, Epstein-Barr, rotaviruses, noroviruses, adenoviruses Small Escherichia coli, Clostridium difficile, Bacteroides fragilis, bowel Bacteroides vulgatus, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica, Shigella flexneri adenoviruses, astroviruses, caliciviruses, noroviruses, rotaviruses, cytomegalovirus Colon/ Escherichia coli, Clostridium difficile, Bacteroides fragilis, Rectum Bacteroides vulgatus, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica, Shigella flexneri adenoviruses, astroviruses, caliciviruses, noroviruses, rotaviruses, cytomegalovirus Anus Streptococcus pyogenes, Bacteroides spp., Fusobacterium spp., anaerobic streptococci, Clostridium spp., E. coli, Enterobacter spp., Pseudomonas aeruginosa, Treponema pallidum herpes simplex - Humans are hosts to a wide range of gastrointestinal parasites, including various protozoa and helminths, which for purposes of the present invention constitute pathogens of the GIT (Schafer, T. W., Skopic, A. Parasites of the small intestine. Curr Gastroenterol Reports 2006; 8:312-20; Jernigan, J., Guerrant, R. L., Pearson, R. D. Parasitic infections of the small intestine. Gut 1994; 35:289-93; Sleisenger & Fordtran's Gastrointestinal and liver disease. 8th ed. 2006; Garcia, L. S. Diagnostic medical parasitology. 5th ed. 2007). Compositions of the invention may accordingly include PRR agonists of various protozoa, including for example: Giardia lamblia, Cryptosporidium parvum, Cryptosporidium hominus, Isospora belli, Sarcocystis species, Coccidian like bodies (Cyclospora species), Enterocytozoon bieneusi, Entamoeba histolytica, Entamoeba dispar, Entamoeba coli, Entamoeba hartmanni, Endolimax nana, Iodamoeba bütschlii, Dientameoba fragilis, Blastocystis hominus, Cyclospora cayetanensis, Microsporidia, Trypanosoma cruzi, Chidomastix mesnili, Pentatrichomonas hominis, Balantidium coli. Similarly, compositions of the invention may include antigenic components of various helminths, including for example: Cestodes (tapeworms), Taenia saginata, Taenia solium, Diphyllobothrium species, Hymenolepis nana, Hymenolepis diminuta, Dipylidium caninum, Nematodes (round worms), Ascaris lumbricoides, Strongyloides stercoralis, Necator americanus, Ancylostoma duodenale, Ancylostoma caninum, Tichuris trichiura, Capillaria philippinensis, Trichostrongylus species, Trichinella species, Necator americanus, Anisakis and related species, Angiostrongylus costaricensis, Enterobius vermicularis, Trematodes (flukes), Fasciolopsis buski, Heterophyes species, Echinostoma species, Clonorchis sinensis, Opisthorchis species, Fasciola species, Metagonimus yokogawi, Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma intercalatum, Echinostoma species and Paragonimus species.
- In accordance with the foregoing, in various aspects, the invention may involve the treatment of an immune dysregulation with formulations of an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial pathogen that is an: Acidaminococcus fermentans; Acinetobacter spp.; Actinobaculum spp.; Actinomyces spp.; Aeromonas spp.; Anaerorhabdus furcosus; Anaerococcus hydrogenalis; Anaerococcus lactolyticus; Anaerococcus prevotii; Atopobium spp.; Bacillus spp.; Bacteroides caccae; Bacteroides distasonis; Bacteroides eggerthii; Bacteroides fragilis; Bacteroides merdae; Bacteroides ovatus; Bacteroides splanchnicus; Bacteroides thetaiotaomicron; Bacteroides vulgatus; Bifidobacterium adolescentis; Bifidobacterium bifidum; Bifidobacterium breve; Bifidobacterium catenulatum; Bifidobacterium dentium; Bifidobacterium longum; Bilophila wadsworthia; Burkholderia cepacia; Butyrivibrio fibrisolvens; Campylobacter concisus; Campylobacter curvus; Campylobacter gracilis; Campylobacter jejuni; Campylobacter rectus; Campylobacter showae; Capnocytophaga ochracea; Cedecea spp; Citrobacter freundii; Citrobacter koseri; Clostridium spp.; Desulfomonas pigra; Dysgonomonas spp.; Eikenella corrodens; Enterobacter aerogenes; Enterobacter cloacae; Enterobacter gergoviae; Enterobacter sakazakii; Enterobacter taylorae; Enterococcus spp.; Escherichia coli; Escherichia fergusonii; Escherichia hermannii; Escherichia vulneris; Eubacterium spp.; Finegoldia magnus; Fusobacterium gonidiaformans; Fusobacterium mortiferum; Fusobacterium naviforme; Fusobacterium necrophorum; Fusobacterium nucleatum; Fusobacterium russii; Fusobacterium varium; Gardnerella vaginalis; Gemella morbillorum; Globicatella spp.; Hafnia alvei; Helicobacter spp.; Klebsiella spp.; Lactobacillus acidophilus; Lactobacillus fermentum; Lactobacillus reuteri; Lactobacillus salivarius; Leclercia adecarboxylata; Leminorella spp.; Megasphaera elsdenii; Mitsuokella multiacidus; Mobiluncus curisii; Mobiluncus mulieris; Moellerella wisconsensis; Morganella morganii; Pantoea agglomerans; Pediococcus spp.; Peptoniphilus asaccharolyticus; Peptostreptococcus anaerobus; Peptostreptococcus productus; Porphyromonas asaccharolytica; Proteus mirabilis; Proteus penneri; Proteus vulgaris; Providencia rettgeri; Providencia stuartii; Pseudomonas aeruginosa; Retortamonas intestinalis; Ruminococcus productus; Serratia liquefaciens; Serratia marcescens; Serratia odorifera; Streptococcus agalactiae; Streptococcus anginosus; Streptococcus bovis; Streptococcus constellatus; Streptococcus intermedius; Group C+G Streptococci; Succinivibrio dextrinosolvens; Sutterella spp.; Tissierella praeacuta; Veillonella spp.; Aerobacter spp.; Bacillus anthracis; Bacillus cereus; other Bacillus spp.; Borrelia recurrentis; Brucella spp.; Campylobacter coli; Campylobacter fetus; Campylobacter jejuni; Campylobacter sputorum; Clostridium bifermentans; Clostridium botulinum; Clostridium difficile; Clostridium indolis; Clostridium mangenolii; Clostridium perfringens; Clostridium sordellii; Clostridium sporogenes; Clostridium subterminale; Edwarsiella tarda; Francisella tularensis; Listeria monocytogenes; Mycobacterium bovis; Mycobacterium tuberculosis; Pediococcus spp.; Plesiomonas shigelloides; Rickettsia rickettsiae; Salmonella spp.; Shigella boydii; Shigella dysenteriae; Shigella flexneri; Shigella sonnei; other Spirillum spp.; Streptococcus zooepidemicus; Tropheryma whipplei; Vibrio cholerae; Vibrio fluvialis; Vibrio fumissii; Vibrio hollisae; Vibrio parahaemolyticus; Yersinia enterocolitica; Yersinia pseudotuberculosis; Herpes Simplex virus (1 and 2); Cytomegalovirus; Adenovirus; Orthoreoviruses; Rotaviruses; Alphaviruses; Coronaviruses; Toroviruses; Human metapneumovirus; Vesicular stomatitis virus; Machupo virus; Junin virus; Poliovirus; Coxsackieviruses; Echoviruses; Hepatitis A virus; Noroviruses and other Caliciviruses; Astroviruses; Picobimaviruses; or Hepatitis E virus.
- In alternative aspects, the invention may involve the treatment of an immune dysregulation with formulations of an artificial repertoire of mammalian PRR agonists that recapitulates a distinct portion of a PRR agonist signature of a microbial mammalian pathogen that is a common small and larger bowel pathogens, for example: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica, Shigella flexneri; adenoviruses, astroviruses, caliciviruses, noroviruses, rotaviruses, and cytomegalovirus.
- In selected embodiments, the invention involves diagnostic steps to assess a patient's previous exposure to an organism. For example, the diagnostic steps may include taking a medical history of exposure to selected pathogens, and/or evaluating a patient's immune response to a selected pathogen. For example, a serology test may be conducted to detect antibodies to selected pathogens in a patient's sera. In connection with this aspect of the invention, antigenic determinants of a selected pathogen may be chosen for use in an immunogenic composition on a selected patient based on a diagnostic indication that the patient has had one or more prior exposure(s) to the pathogen, for example by virtue of the presence of antibodies to antigenic determinants of that pathogen in the patient's sera.
- In further selected embodiments, the invention involves diagnostic steps to assess a patient's immunological response to treatment with a selected immunogenic composition. For example, the diagnostic steps may include evaluating a patient's immune response to the immunological determinants of that immunogenic composition, for example using a serological test to detect antibodies to those immunogenic determinants. In connection with this aspect of the invention, a treatment with a selected immunogenic composition may be continued if the evaluation indicates that there is an active immunological response to the immunogenic determinants of that composition, and the treatment may be discontinued, and an alternative treatment with a different immunogenic composition may be initiated, if the evaluation indicates that there is not a sufficiently active immunological response to the immunogenic determinants of the immunogenic composition.
- The immunomodulatory properties of formulations of the invention can be employed for use in the treatment of a variety of diseases characterized by pathological immune dysregulation, for example using PRR agonists derived from endogenous pathogens or exogenous pathogens that are pathogenic in the tissue or organ within which the immune dysregulation is symptomatic or manifest, including bacterial, viral and fungal pathogens. Table 8 lists diseases characterized by immune dysregulation, which may be treated in accordance with alternative aspects of the invention.
-
TABLE 8 List of Diseases of Immune Dysregulation. Acne vulgaris Acute disseminated encephalomyelitis Acute hemorrhagicleukoencephalitis Addison's Disease Agammaglobulinemia Allergies Alopecia areata Alzheimer's Amyotrophic Lateral Sclerosis Anaemia, autoimmune hemolytic Anaemia, pernicious Ankylosing spondylitis Anti-GBM/TBM Nephritis Antiphospholipid syndrome Antisynthetase syndrome Arteritis, temporal (also known as “giant cell arteritis”) Arthritis, juvenile Arthritis, psoriatic Arthritis, reactive (Reiter's syndrome, rea) Arthritis, rheumatoid Asthma Atherosclerosis Atopic allergy Atopic dermatitis Autoimmune enteropathy Autoimmune aplastic anemia Balo disease/Balo concentric sclerosis Bartter syndrome Bechets Syndrome Berger's disease Bickerstaff's encephalitis Blau syndrome Bronchitis, chronic Bullous pemphigoid Bursitis Cardiomyopathy, autoimmune Castleman's disease Celiac disease Chronic fatigue syndrome Chronic inflammatory demyelinating polyneuropathy Chronic recurrent multifocal osteomyelitis Churg-Strauss syndrome Cicatricialpemphigoid Cirrhosis, primary biliary Cogan syndrome Cold agglutinin disease Colitis Complement component 2 deficiency Connective tissue disease, mixed Connective tissue disease, undifferentiated COPD (chronic obstructive lung disease) Cranial arteritis CREST syndrome Cryoglobulinemia Cushing's Syndrome Cutaneous leukocytoclasticangiitis Cystitis, interstitial Dacryadenitis Dego's disease Dercum's disease Dermatitis Dermatitis herpetiformis Dermatitis, autoimmune progesterone Dermatomyositis Diabetes Diabetes insipidus, nephrogenic Diabetes mellitus type 1Diffuse cutaneous systemic sclerosis Discoid lupus erythematosus Diverticulitis Dressier's syndrome Dysmenorrhea (menstrual cramps/pain) Eczema Eczema Endometriosis Enthesitis-related arthritis Eosinophilic fasciitis Eosinophilic gastroenteritis Epidermolysisbullosaacquisita Erythema nodosum Essential mixed cryoglobulinemia Evan's syndrome Fibrodysplasiaossificansprogressiva Fibromyalgia Fibrosingaveolitis Fungal infections (tinea pedis, onchomycosis, etc.) Gastritis, atrophic Gastritis, atrophic Gastrointestinal pemphigoid Giant cell arteritis Glomerulonephritis Glomerulonephritis Goodpasture's syndrome Gout, acute Gout, arthritic Graves' disease Guillain-Barré syndrome (GBS) Haemolytic anaemia Hashimoto's encephalitis Hashimoto's thyroiditis Hemolyticanemia, autoimmune Henoch-Schonleinpurpura Hepatitis, autoimmune Hepatitis, viral Herpes gestationis Hypogammaglobulinemia Idiopathic Inflammatory Demyelinating Diseases Idiopathic pulmonary fibrosis Iga nephropathy Ileus (bowel obstruction) Inclusion body myositis Inflammatory bowel disease, Crohn's disease Inflammatory bowel disease, ulcerative colitis Inflammatory demyelinating polyneuopathy Inner ear disease, autoimmune Interstitial cystitis Irritable bowel syndrome (IBS) Juvenile idiopathic arthritis Juvenile rheumatoid arthritis Kawasaki's Disease Kidney stones Lambert-Eaton myasthenic syndrome Leukocytoclasticvasculitis Lichen planus Lichen sclerosus Linear iga disease (LAD) Lou Gehrig's disease (Also Amyotrophic lateral sclerosis) Lupoid hepatitis Lupus Lupus erythematous Lymphoproliferative syndrome, autoimmune Majeed syndrome Ménière's disease Meningitis Metabolic Syndrome Microscopic polyangiitis Miller-Fisher syndrome Morphea Mucha-Habermann disease Multiple sclerosis Myasthenia gravis Myositis Myositis, inclusion body Nephritis Nephrotic syndrome Neuromyelitisoptica (Also Devic's Disease) Neuromyotonia Occular cicatricial pemphigoid Ocular inflammation (acute and chronic non-bacterial inflammation of the anterior part of the eyes) Opsoclonus myoclonus syndrome Ord thyroiditis Osteoarthritis Osteoporosis Paget's disease of bone Palindromic rheumatism Pancreatitis, autoimmune PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcus) Paraneoplastic cerebellar degeneration Parkinsonism Paroxysmal nocturnal hemoglobinuria (PNH) Parry Romberg syndrome Pars planitis Parsonnage-Turner syndrome Pelvic inflammatory disease Pemphigus Pemphigus vulgaris Pericarditis, non-rheumatic Peripheral neuropathy, autoimmune Perivenous encephalomyelitis POEMS syndrome Polyarteritisnodosa Polychondritis, relapsing Polycystic ovary syndrome (PCOS) Polyendocrine syndrome, autoimmune Polymyalgia rheumatica Polymyalgia rheumatica Polymyositis Primary sclerosing cholangitis Progressive inflammatory neuropathy Prostatitis, chronic Pseudogout Psoriasis Psoriasis Pure red cell aplasia Pyodermagangrenosum Rasmussen's encephalitis Raynaud phenomenon Reiter's syndrome Restless leg syndrome Retinopathy of prematurity Retroperitoneal fibrosis Rheumatoid fever Rhinitis, allergic Sarcoidosis Schmidt syndrome Schnitzler syndrome Scleritis Scleroderma Sclerosis, systemic Sjögren's syndrome Spondyloarthropathy Still's disease Subacute bacterial endocarditis (SBE) Susac's syndrome Sweet's syndrome Sydenham chorea Sympathetic ophthalmia Takayasu's arteritis Temporomandibular joint disorder (TMJD or TMD), or TMJ syndrome Thrombocytopenic purpura, autoimmune Thrombocytopenic purpura, idiopathic Tolosa-Hunt syndrome Toxic Shock Syndrome Transplant rejection Transverse myelitis Undifferentiated spondyloarthropathy Urticaria Uveitis, autoimmune Valvular disease, non -rheumatic Vasculitis Vitiligo Wegener's granulomatosis - As provided in the Table above, arthritis is a chronic inflammatory disease. In particular, arthritis is understood to be a description of inflammation of one or more joints. There are many types of arthritis, or conditions that have arthritic symptoms, which include (but are not limited to) the following: Ankylosing spondylitis, Behcet's disease, Ehlers-Danlos Syndrome, Familial Mediterranean fever, Fibromyalgia, Fifth disease, Giant cell arteritis, Gout, Haemochromatosis, Henoch-Schönleinpurpura, Hyperimmunoglobulinemia D with recurrent fever, Inflammatory bowel disease arthritis (including Crohn's Disease and Ulcerative Colitis), Juvenile rheumatoid arthritis, Juvenile spondyloarthropathy, Lyme disease, Marfan syndrome, Osteoarthritis, Pseudo-gout, Psoriatic arthritis, Reactive Arthritis (Reiter's syndrome), Rheumatoid arthritis, Sarcoidosis, Scleroderma, SEA syndrome (seronegativity, enthesopathy, arthropathy), Sjogren's syndrome, Still's disease, Systemic lupus erythematosus (SLE), TNF receptor associated periodic syndrome, and Wegener's granulomatosis (and other vasculitis syndromes).
- Patients may advantageously be screened for disorders of innate immunity, such as genetic disorders, for example by primary sequence analysis or by analysis of epigenetic changes. A variety of genetic disorders have for example been identified that are associated with gene products involved in innate immunity (see Mogensen T., 2009, Clinical Microbiology Reviews, Vol. 22, No. 2, p. 240-273), such as TLR genes (TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9), signalling protein genes (MyD88, Mal, IRAK1, IRAK4, NEMO, IκBα, IRF5), NLR genes (NOD2, NALP1, NALP3) and others (CD14, UNC93B). Patients identified as having a Medelian primary immunodeficiency associated with impaired TLR signaling or NF-κB activation may for example not benefit from some embodiments, or may require an approach adapted to their condition. Patients having polymorphisms in genes encoding components of innate signalling pathways may also be identified prior to treatment with an SSI, for example having mutations in the gene encoding TIR-domain-containing adaptor-inducing beta interferon (TRIF).
- There are a variety of microbial strategies for evading the innate immune system (Mogensen T., 2009, Clinical Microbiology Reviews, Vol. 22, No. 2, p. 240-273), and embodiments of the invention may accordingly be adapted to avoid the inhibitory effect of such strategies on the triggered innate response. Select embodiments provide recombinant microorganisms that lack virulence factors that impede TLR signalling, such as recombinant E. coli that lack TIR domain-containing proteins (Cirl, C. et al., 2008, Nat. Med. 14:399-406). Gram negative bacterial formulation may advantageously comprise an LPS that is recognized by a TLR, such as TLR4, rather than a form of LPS that is not recognized by a TLR (Homef, M. W. et al., 2002, Nat. Immunol. 3:1033-1040). Similarly, bacterial formulations may advantageously include a class of flagellin that activates a TLR, such as TLR5, rather than one that does not (Andersen-Nissen, E. et al., 2005, Proc. Natl. Acad. Sci. USA 102-9247-9252). In some embodiments, it may be advantageous to exclude peptidases that proteolytically degrade important components of the triggered innate response, such as the amastigote-specific cysteine peptidases of Leishmania mexicana that proteolytically degrade IκB and NF-κB (Cameron, P. et al., 2004, J. Immunol. 173:3297-3304). In alternative embodiments, these undesirable components may be removed from a formulation by an appropriate step of manufacturing, for example to wash or fractionate a microbial preparation so as to remove a component.
- Patients may be genotyped, for example by identifying polymorphisms in PRR genes (see WO 2009003905). Genes associated with inflammation and immune related diseases and disorders may for example be the subject of screening, such as:
- AIDS (KIR3DL1, NKAT3, NKB1, AMB11, KIR3DS1, IFNgamma, CXCL12, SDF1); Autoimmune lymphoproliferative syndrome (TNFRSF6, APT1, FAS, CD95, ALPS1A); Combined immunodeficiency, (IL2RG, SCIDX1, SCIDX, IMD4); HIV-1 (CCL5, SCYA5, D17S136E, TCP228), HIV susceptibility or infection (IL10, CSIF, CMKBR2, CCR2, CMKBR5, CCCKR5 (CCR5)); Immunodeficiencies (CD3E, CD3G, AICDA, AID, HIGM2, TNFRSF5, CD40, UNG, DGU, HIGM4, TNFSF5, CD40LG, HIGM1, IGM, FOXP3, IPEX, AIID, XPID, PIDX, TNFRSF14B, TACI); Inflammation (IL-10, IL-1 (IL-1a, IL-1b), IL-13, IL-17 (IL-17a (CTLA8), IL-17b, IL-17c, IL-17d, IL-17f), 11-23, Cx3cr1, ptpn22, TNFa, NOD2/CARD15 for IBD, IL-6, IL-12 (IL-12a, IL-12b), CTLA4, Cx3cl1); Severe combined immunodeficiencies (SCIDs)(JAK3, JAKL, DCLRE1C, ARTEMIS, SCIDA, RAG1, RAG2, ADA, PTPRC, CD45, LCA, IL7R, CD3D, T3D, IL2RG, SCIDX1, SCIDX, IMD4). Alternatively, genes involved in selected signalling pathways may for example be screened, identifying for example patients that are more or less susceptible to an SSI treatment, such as: GM-CSF Signaling (LYN; ELK1; MAPK1; PTPN11; AKT2; PIK3CA; CAMK2A; STAT5B; PIK3CB; PIK3C3; GNB2L1; BCL2L1; MAPK3; ETS1; KRAS; RUNX1; PIM1; PIK3C2A; RAF1; MAP2K2; AKT1; JAK2; PIK3R1; STAT3; MAP2K1; CCND1; AKT3; STAT1); IL-10 Signaling (TRAF6; CCR1; ELK1; IKBKB; SP1; FOS; NFKB2; MAP3K14; MAPK8; MAPK13; RELA; MAPK14; TNF; IKBKG; RELB; MAP3K7; JAK1; CHUK; STAT3; NFKB1; JUN; IL1R1; IL6); Toll-like Receptor Signaling (IRAK1; EIF2AK2; MYD88; TRAF6; PPARA; ELK1; IKBKB; FOS; NFKB2; MAP3K14; MAPK8; MAPK13; RELA; TLR4; MAPK14; IKBKG; RELB; MAP3K7; CHUK; NFKB1; TLR2; JUN).
- In addition, patients may for example be genotyped for SNPs located in the non-coding regions of the genome that are linked to inflammatory disorders, such as SNP's identified through publicly available GWAS datasets, for example SNPs in genomic regions linked to sequences which serve a regulatory role in immune-function-related gene expression.
- Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range, and inclusive of all numbers and fractions subsumed within the respective ranges. The word “comprising” is used herein as an open-ended term, substantially equivalent to the phrase “including, but not limited to”, and the word “comprises” has a corresponding meaning. Terms such as “consisting essentially of” and “consists essentially of” allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention. As used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a thing” includes more than one such thing. Citation of references herein is not an admission that such references are prior art to the present invention. Any priority document(s) and all publications, including but not limited to patents and patent applications, cited in this specification are incorporated herein by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein and as though fully set forth herein. The invention includes all embodiments and variations substantially as hereinbefore described and with reference to the examples and drawings. Nothing herein is intended as a promise of any specific utility for all embodiments.
- The term “about” or “approximately” as used herein when referring to a measurable value such as a parameter, an amount, a temporal duration, and the like, is meant to encompass variations of +/−20% or less, preferably +/−10% or less, more preferably +/−5% or less, and still more preferably +/−1% or less of and from the specified value, insofar such variations are appropriate to perform in the disclosed invention. It is to be understood that the value to which the modifier “about” or “approximately” refers is itself also specifically, and preferably, disclosed.
- All references cited in the present specification are hereby incorporated by reference in their entirety. In particular, the teachings of all references herein specifically referred to are incorporated by reference, along with all documents cited in documents that are cited herein.
- Standard reference works setting forth the general principles of recombinant DNA technology include Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; Current Protocols in Molecular Biology, ed. Ausubel et al., Greene Publishing and Wiley-Interscience, New York, 1992 (with periodic updates) (“Ausubel et al. 1992”); the series Methods in Enzymology (Academic Press, Inc.); Innis et al., PCR Protocols: A Guide to Methods and Applications, Academic Press: San Diego, 1990; PCR 2: A Practical Approach (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995); Harlow and Lane, eds. (1988) Antibodies, a Laboratory Manual; and Animal Cell Culture (R. I. Freshney, ed. (1987). General principles of microbiology are set forth, for example, in Davis, B. D. et al., Microbiology, 3rd edition, Harper & Row, publishers, Philadelphia, Pa. (1980).
- Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention, and form different embodiments, as would be understood by those in the art. For example, in the appended claims, any of the claimed embodiments can be used in any combination.
- In this description of the invention, reference is made to the accompanying drawings that form a part hereof, and in which are shown by way of illustration only of specific embodiments in which the invention may be practiced. It is to be understood that other embodiments may be utilized and structural or logical changes may be made without departing from the scope of the present invention. The description, therefore, is not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims.
- Preferred statements (features) and embodiments may be combined with any other features or embodiments unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features or statements indicated as being preferred or advantageous.
- In some embodiments, the invention excludes steps that involve medical or surgical treatment. Similarly, in some embodiments, the invention disclaims naturally occurring embodiments, so that aspects of the invention relate only to anthropogenic compositions. Further, in select aspects of the invention, previously known products, process of making products, or methods of using products are hereby disclaimed.
-
-
- SSI Site Specific Immunomodulator
- MC-38 Murine Colon Adenocarcinoma cell line
- PD1
Programmed cell death 1 - OD Optical density
- IP Intraperitoneal
- SC Subcutaneous
- SOP Standard operating protocol
- RPM Revolutions per minute
- EDTA Ethylenediaminetetraacetic acid
- ANOVA Analysis of variance
-
Ly6G Lymphocyte antigen 6 complex, locus G -
Ly6C Lymphocyte antigen 6 complex, locus C - CD45 Cluster of differentiation 45
- SD Standard deviation
- NA No value; not applicable; not present
- Rael
Ribonucleic acid export 1 - CD3 Cluster of
differentiation 3 - CD11b Cluster of differentiation molecule 11B
- KO knockout
- PBS Phosphate Buffered Saline
- NKG2D
Natural killer group 2, member D - g Gram
- μM micrometre
- μL Microliter
- hr Hours
- min Minute
- QBECO Escherichia coli whole killed cell SSI
- QBKPN Klebsiella pneumoniae phylogroup III (also known as K. variicola) whole killed cell SSI
- QBSAU Staphylococcus aureus whole killed cell SSI
- A family of virulence factors in Escherichia coli and Brucella melitensis, named TIR domain-containing proteins, impede TLR signalling through direct binding to MyD88, thus suppressing innate immunity and increasing bacterial virulence. Aspects of the invention accordingly provide recombinant bacteria that lack expression of TIR domain-containing proteins, or other virulence factors that interfere with an innate host immune response to the pathogen.
- Staphylococcus aureus
- In select embodiments, compositions may be prepared from recombinant S. aureus strains. For example, strains of sequence type ST-291, having the following alleles, or homologous sequences being at least 99% identical thereto: arcc-3, aroe-37, glpf-19, gmk-2, pta-20, tpi-26, and yqil-32 (Larsen et al., 2012, O. J. Clin. Micobiol 50(4): 1355-1361). Strains may totally lack resistance genes to the following classes of antibiotic: aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide. Alternatively, strains may have one or more resistance genes, such as the blaZ beta-lactam resistance gene (accession AP004832). Similarly, strains may or may not include one or more virulence factor genes (Cosentino et al., 2013, PLoS ONE 8(10):e77302), having for example at least 90%, 95%, 99% or 100% identity to selected database sequences (identified by accession number in the following tables). [Recite strains lacking leukotoxins, particularly targeting the innate immune system]
-
TABLE 9 S. aureus - Adherence Virulence Factors Virulence Accession factor Protein function number eap extracellular adherence protein CP002110.1 fnbB fibronectin-binding protein B AM990992.1 fnbB fibronectin-binding protein B AM990992.1 icaA intercellular adhesion protein A CP003808.1 atl bifunctional autolysin Atl AM990992.1 eap extracellular adherence protein CP002114.2 icaB intercellular adhesion protein B AM990992.1 vwb von Willebrand factor-binding CP002643.1 protein spa spa immunoglobulin G binding BA000033.2 protein A spa spa immunoglobulin G binding AM990992.1 protein A vwb von Willebrand factor-binding AM990992.1 protein vwb von Willebrand factor-binding AM990992.1 protein icaC intercellular adhesion protein C CP003808.1 ebpS cell surface elastin binding CP001996.1 protein clfA fibrinogen-binding protein A, AM990992.1 clumping factor icaR intercellular adhesion regulator AJ938182.1 sdrC Ser-Asp rich fibrinogen-binding CP001996.1 protein C spa spa immunoglobulin G binding CP002110.1 protein A efb extracelular fibrinogen-binding CP003045.1 protein fib fibrinogen-binding protein CP003045.1 sdrH Ser-Asp rich fibrinogen-binding CP003194.1 portein H -
TABLE 10 S. aureus - Toxin Virulence Factors Virulence Accession factor Protein function number SEntA putative enterotoxin type A CP003194.1 hlgA gamma-hemolysin chain II CP002110.1 precursor hlgC gamma-hemolysin component BX571856.1 C hlgB gamma-hemolysin component HE681097.1 B precursor lukE leukotoxin LukE AJ938182.1 hlgB gamma-hemolysin component FR821779.1 B precursor eta exfoliative toxin A AM990992.1 SExo exotoxin CP003045.1 SExo exotoxin CP003045.1 SExo exotoxin CP003045.1 hla alpha-hemolysin precursor AM990992.1 SExo exotoxin CP003045.1 hlb beta-hemolysin CP003166.1 lukF-PV LukF-PV BX571856.1 set16 exotoxin homolog BA000033.2 SExo exotoxin CP003045.1 SExo exotoxin CP003045.1 SExo exotoxin CP003045.1 set1 superantigen-like protein BX571856.1 set5 superantigen- like protein 5CP003045.1 set4 superantigen-like protein AM990992.1 hld delta-hemolysin HE681097.1 set26 exotoxin homolog BA000033.2 -
TABLE 11 S. aureus - Exoenzyme Virulence Factors Virulence Accession factor Protein function number geh glycerol ester hydrolase HE681097.1 hysA hyaluronate lyase BA000018.3 nuc thermonuclease BA000018.3 sspA serine V8 protease FR821779.1 sspB cysteine protease BX571856.1 sspC cysteine protease CP003808.1 nuc thermonuclease CP003808.1 splA serine protease splA CP003194.1 splC serine protease splC BX571856.1 splB serine protease splB CP002110.1 sak staphylokinase CP000253.1 scn complement inhibitor SCIN CP002120.1 splE serine protease splE BX571856.1 splF serine protease splF CP002110.1 geh glycerol ester hydrolase AM990992.1 sspB cysteine protease CP002110.1 hysA hyaluronate lyase AM990992.1 -
TABLE 12 S. aureus - Host Immune Evasion Virulence Factors Virulence Accession factor Protein function number capP capsular polysaccharide CP001996.1 synthesis enzyme capP capO capsular polysaccharide CP003808.1 synthesis enzyme capO capN capsular polysaccharide FR821779.1 synthesis enzyme capN capM capsular polysaccharide CP003808.1 synthesis enzyme capM cap5L capsular polysaccharide CP002120.1 biosynthesis protein cap5L cap5K capsular polysaccharide CP003045.1 biosynthesis protein cap5K cap5I capsular polysaccharide AM990992.1 biosynthesis protein cap5I cap5H capsular polysaccharide AM990992.1 biosynthesis protein cap5H capG capsular polysaccharide CP003808.1 synthesis enzyme capG capF capsular polysaccharide CP003808.1 synthesis enzyme capF capE capsular polysaccharide CP003808.1 synthesis enzyme capE capD polysaccharide biosynthesis CP003808.1 protein capD cap5C capsular polysaccharide CP001844.2 biosynthesis protein cap5C capB capsular polysaccharide HE681097.1 biosynthesis protein capB cap8A truncated capsular BA000033.2 polysaccharide synthesis enzyme cap5A isb IgG-binding protein SBI BX571856.1 capD polysaccharide biosynthesis AP009351.1 protein capD capC capsular polysaccharide AM990992.1 synthesis protein capC cap1B capsular polysaccharide CP002120.1 biosynthesis protein cap1B cap1A capsular polysaccharide CP002110.1 biosynthesis protein cap1A cap5M capsular polysaccharide AJ938182.1 biosynthesis protein cap5M -
TABLE 13 S. aureus - Secretion system Virulence Factors Virulence Accession factor Protein function number esxB virulence factor EsxB family FR821777.2 protein esaC EsaC protein within ESAT-6 CP000730.1 gene cluster essC type VII secretion protein EssC BA000018.3 esaC EsaC protein within ESAT-6 CP003166.1 gene cluster essB putative secretion system CP003808.1 component EssB esaB Putative secretion accessory CP001844.2 protein EsaB/YukD essA protein secretion system EssA CP001844.2 esaA type VII secretion protein EsaA CP001844.2 esxA ESAT-6/WXG100 family CP002120.1 secreted protein EsxA/YukE - Recombinant strains may include one or more plasmids (Carattoli et al., 2014, Antimicrobial Agents and Chemotherapy 58(7): 3895-3903), for example having 90%, 95%, 99% or 100% identity to plasmid rep5 (accession NC005011) or plasmid rep16 (accession CP002115.1).
- In select embodiments, compositions may be prepared from recombinant Klebsiella strains, such as K. pneumoniae or K. variicola (formerly identified as K. pneumoniae). For example, strains of a sequence type having the following alleles, or homologous sequences being at least 99% identical thereto: gapa16, infb24, mdh30, pgi40, phoe92, rpob17, tonb67. Strains may totally lack resistance genes to the following classes of antibiotic: aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide. Alternatively, strains may have one or more resistance genes, such as the blaLEN24 beta-lactam resistance gene (accession AM850914). Similarly, strains may or may not include one or more virulence factors identified in the following table (see Leticia et al., 2014, BMC Biology 12:41).
-
TABLE 14 KPN Virulence Factors Virulence-factor Function rmpA Regulator of capsule expression Aerobactin Siderophore Enterobactin Siderophore Yersiniabactin Siderophore Colibactin Genotoxin T4SS (virB) Conjugative machinery/protein secretion T2SS Protein secretion T6SS Protein secretion Pld-family Lipid metabolism Sel1 lipoproteins Unknown cOMP Putative cytotoxin Igg-like Binding to extra cellular matrix compounds SEFIR-domain Potentially hijack IL17R signaling pathways Bcl Binding to hydrophobic ligands/putative regulation of homeostasis and immunity
Escherichia coli. (Prostate) - In select embodiments, compositions may be prepared from recombinant E. coli strains specifically adapted for therapy of prostate immune dysfunction. For example, strains of a sequence type having the following alleles, or homologous sequences being at least 99% identical thereto: adk-37, fumc-38, gyrb-19, icd-37, mdh-151, pura-11, reca-26 (sequence type 1231). Strains may totally lack resistance genes to the following classes of antibiotic: aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide. Similarly, strains may or may not include one or more virulence factor genes, having for example at least 90%, 95%, 99% or 100% identity to selected database sequences (identified by accession number in the following tables). The strain may also lack stx holotoxin virulence factors.
-
TABLE 15 E. coli - Virulence factors Virulence Accession factor Protein function number iroN Enterobactin siderophore CP000243 receptor protein sfaS S-fimbriae minor subunit CP000243 senB Plasmid-encoded enterotoxin CP000038 iss Increased serum survival CU928160 gad Glutamate decarboxylase CP002167 cnf1 Cytotoxic necrotizing factor CP002167 ccl Cloacin DQ298019 - The serotype of the E. coli strain may for example be O18ac:H7, for example representing the presence of H type serotype gene fliC (accession AF228492, and O type serotype genes wzx (accession GU299793), and wzy (accession GU299793).
- Recombinant strains may include one or more plasmids, for example having 90%, 95%, 99% or 100% identity to plasmid IncFIB (accession AP001918) and/or plasmid IncFII(29) (accession CP003035), and/or plasmid CoIRNAI (accession DQ298019) and/or plasmid Col156 (accession NC009781).
- The recombinant E. coli may for example be, or be derived from an E. coli strain having at least 80%, 90% or 95% sequence identity to E. coli UT189 (see Chen et al., 2006, Proc Natl Acad Sci USA 103:5977-82).
- Escherichia coli. (Colon)
- In select embodiments, compositions may be prepared from recombinant E. coli strains specifically adapted for therapy of colon immune dysfunction. For example, strains of a sequence type having the following alleles, or homologous sequences being at least 99% identical thereto: adk-76, fumc-43, gyrb-9, icd-36, mdh-404, pura-14, reca-10 (sequence type ST-5292). Strains may totally lack resistance genes to the following classes of antibiotic: aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin, fusidic acid, MLS—macrolide, lincosamide and streptogramin B, nitroimidazole, oxazolidinone, phenicol, rifampicin, sulphonamide, tetracycline, trimethoprim, and glycopeptide. Alternatively, strains may have one or more resistance genes, such as the strB or strA aminoglycoside resistance genes (accession numbers M96392 or AF321551), and/or sul1 sulphonamide resistance gene (accession AY224185), and/or sul2 sulphonamide resistance gene (accession GQ421466), and/or dfrA5 trimethoprim resistance (accession X12868). Similarly, strains may or may not include one or more virulence factor genes, having for example at least 90%, 95%, 99% or 100% identity to selected database sequences (identified by accession number in the following tables). The strain may also have a gene that is at least 95% or 99% or 100% identical to the stx holotoxin virulence factor gene stx1 (accession M19437).
-
TABLE 16 E. coli - Virulence factors Virulence Accession factor Protein function number Gad Glutamate decarboxylase CP001671 lha Adherence protein AE005174 Gad Glutamate decarboxylase CP001671 senB Plasmid-encoded enterotoxin CP000038 sigA Shigella IgA-like protease CP000038 homologue stx1B Shiga toxin 1, subunit B, AM230663 variant a stx1A Shiga toxin 1, subunit A, EF079675 variant a astA EAST-1 heat-stable toxin AB042002 - The serotype of the E. coli strain may for example be O117:H7, for example representing the presence of H type serotype gene fliC (accession AF228492, and O type serotype genes wzx (accession EU694096).
- Recombinant strains may include one or more plasmids, as set out in the following table.
-
TABLE 17 E. coli plasmids Accession Plasmid Note number IncFII(pRSB107) pRSB107 AJ851089 IncB/O/K/Z CU928147 Col(BS512) NC_010656 IncFIB(AP001918) AP001918 IncB/O/K/Z GU256641 Col156 NC_009781 IncFII AY458016 - The recombinant E. coli(colon) may for example be, or be derived from an E. coli strain having at least 80%, 90% or 95% sequence identity to E. coli SE15 or any O117:H7 serotype E. coli.
- This Example illustrates modest efficacy in a minimal SSI formulation comprising TLR agonists and a microbial antigen. In this Example, the TLR agonists are a TLR2/6 agonist, diacylated lipoprotein (InVivogen Pam2CSK4) and a TLR4 agonist (LPS, Sigma L1519). The microbial antigen was a recombinant outer membrane protein A (ompA) from Klebsiella pneumoniae (CUSABIO CSB-EP340587KBG). These components were formulated together in a liposomal vehicle, and administered in a murine model of SSI therapy in accordance with the treatment timeline illustrated in
FIG. 1 . As illustrated inFIG. 2 , TLR-only liposomes did not have the same degree of activity as the TLR+Ag liposome constructs, illustrating that the engagement of alternative immunogenic pathways can augment an SSI effect. It is important to note in the context of this data that the antigenic component of these minimal formulations was recombinantly expressed in E. coli, with a purity given by the manufacturer of >90% (SDS-PAGE) with the attendant characteristic that the antigen preparations included additional bacterial components, including additional PRR agonists, that act as additional innate immunogens. - Pathogen recognition and inflammatory signalling in innate immune defenses involves a number of pathways, including MyD88 dependent and MyD88 independent pathways (Mogensen, 2009, Clinical Microbiology Reviews, 22(2): 240). In this Example, using a B16 melanoma model in a commercial strain of MyD88−/− mice, it was observed that B16 tumour burden is enhanced in MyD88 mice, relative to B6 mice (genetically matched except for the MyD88 knockout). This is consistent with literature reports to the effect that MyD88 knockouts are inherently less able to control disease. In the model of SSI therapy, with a Klebsiella SSI (“KPN SSI”), a significantly reduced tumour burden was observed following treatment with KPN SSI in both WT B6 and MyD88-knockout mice. This is evidence that SSIs can work in a MyD88-independent manner, at least in part, indicating that alternative PRR signalling pathways, beyond what are generally considered classic TLR signalling, are involved in the SSI mediated innate immune responses. This is consistent with another exemplary observation, that the NOD-like receptor NLRP3 is up-regulated in cultured cells treated with KPN SSI and ECO SSI. Alternatively, in some embodiments, SSIs may mediate classical TLR signalling via an adaptor other than MyD88 downstream of TLR, such as TRIF. Furthermore, in additional studies it has been shown that SSI therapies can engage the MyD88 signalling pathway. In combination, these results are evidence of the robust and diverse PRR signalling pathways that may be engaged by SSI therapies.
- This Example illustrates that in some embodiments, pre-exposure of an organism to a microbial pathogen potentiates subsequent SSI efficacy.
- In an animal model of SSI therapy, treated in accordance with the treatment timeline illustrated in
FIG. 3 , pre-infection with Klebsiella pneumoniae potentiated KPN SSI efficacy using a distinct strain of Klebsiella sp., whereas pre-infection with S. pneumoniae failed to induce KPN SSI efficacy (in models of cancer in the lungs). The result, as illustrated inFIG. 4 , indicates that an SSI response may require or benefit from pre-exposure of an organism to at least closely-related pathogens. This is consistent with another observation, of KPN SSI activity in mice from colonies that test negative for K. pneumoniae, but may carry K. oxytoca, a strain that's commonly found in research animal colonies, indicating that in some cases pre-exposure to K. oxytoca is adequate to induce responsiveness to KPN SSI. Differences in pre-exposure in mice from Jackson Labs (JAX) compared to mice from Taconic (TAC) are evident inFIG. 4 , which illustrates that even without pre-infection, S. pneumoniae (SPN) did not elicit the same therapeutic efficacy that QBKPN did in mice sourced from JAX. In mice sourced from TAC, pre-infection was needed for QBKPN to show efficacy. - This Example illustrates Klebsiella-mediated anti-cancer efficacy in metastatic-like B16 melanoma using heat-killed Klebsiella pneumoniae SSI. Subcutaneous injection of KPN SSI significantly reduced tumour burden. Furthermore, subcutaneous treatment with heat-killed E. coli(ECO SSI) or Staph. aureus (SAU SSI) did not have a therapeutic effect in the lung tumour model. This illustrates that subcutaneous immune induction using a lung-specific pathogen activates a lung-specific antitumour response. To illustrate the effects of pre-exposure to K. pneumoniae, mice were exposed to live K. pneumoniae via intratracheal infection prior to subcutaneous injections with KPN SSI. Pre-exposure to K. pneumoniae significantly enhanced KPN SSI-induced anti-tumour immunity and control of metastatic-like B16 melanoma in the lungs. The anti-tumour efficacy in exposed mice correlated with an influx of monocytes and neutrophils, but did not correlate with an influx of T cells into the lungs. Collectively, these data illustrate that pre-exposure to K. pneumoniae may, in some embodiments, induce tissue-specific immunologic memory, for example an innate immunological memory, that mediates tumour cytolysis.
- This Example illustrates site specificity of a S. aureus SSI in a murine skin cancer model. This Example involved the use of a concentrated S. aureus SSI (10×QBSAU which is designated “QBSAUR” herein), as well as a Klebsiella sp. SSI, an E. coli SSI and placebo, in a B16 skin tumour model in which ˜100,000 B16 melanoma cells were injected into the right flank of C57BL/6 mice in a volume of 100 ul on
Day 0. SSI treatment started on Day −10 and continued till Day +12. Tumour volumes were monitored starting onDay 7, and the endpoint reached atDay 14. The tumour volume results ofFIGS. 5-10 illustrate dramatically the site specificity of the S. aureus SSI formulation. - This Example illustrates the effect of combining an SSI (such as Klebsiella spp. SSI, abbreviated as “KPN SSI”) with a model cancer antigen (in this case OVA, or hen egg ovalbumin) expressed by transformed cancer cells, in this case in a B16 melanoma animal model. OVA does not naturally occur in mammals or bacteria, and is immunogenic in C57Bl/6 mice, with known CD4- and CD8-associated epitopes. In this Example, B16 cells have been transfected to express cytoplasmic OVA protein, leading to presentation of the OVA epitopes in the tumour's MHC, thereby allowing OVA-specific T cell recognition of the melanoma. In some studies, whole protein was used; evidencing host immune system processing of the protein into relevant antigens. In other studies, purified OVA antigen (SIINFELK, a class I-restricted, CD8-specific antigen) was used. Some studies also used OT1 cells (transgenic CD8 cells that specifically recognize SIINFEKL through the T cell receptor) as a readout system.
- The data generated provide evidence of enhanced efficacy of the model cancer antigen admixed with an SSI. In one result, decreased tumour nodule counts were found in conjunction with treatment using a Klebsiella spp. SSI+OVA, compared to PBS+OVA (assessed photographically and by quantitative PCR for Tyrp1, a melanoma-specific gene). Consistent with this, KPN SSI+OVA increased the proportion of OVA-specific CD8 T cells in the lungs. Similarly, expression of genes associated with effective anti-tumour immunity (granzyme B and IFN-gamma) was increased by KPN SSI+OVA vs. PBS+OVA. The same study showed survival data in lung cancer models, in which Klebsiella sp. SSI+OVA showed extended survival compared with control; and an E. coli SSI+OVA showed much improved survival.
- In an alternative study, it was observed that SSI induced or enhanced the process of epitope spreading (see
FIG. 11 ; and for background see Vanderlugt & Miller, 2002,Nature Reviews Immunology 2, 85-95). In this study, mice were treated with Klebsiella sp. SSI, then challenged with B16 melanoma (IV). 5 days later, mice received an adoptive transfer of TCR transgenic cells (Pmel T cells) specific for a natural cancer antigen in melanoma. Mice were also treated with FTY-720 (fingolimod), to prevent T cell egress from lymph nodes and allow recovery of cells from the draining lymph node of a tumour. The activation status of the recovered pmel T cells was assessed, and it was found that SSI enhanced the proportion of T cells in the draining lymph node that were activated (i.e., antigen-exposed). This provides evidence that an SSI may be adapted to augment the processing and presentation of immunogenic cancer antigens, including self antigens and exogenously-administered cancer antigens. - This Example relates to the fractionation of microbial preparations for the purpose of formulating alternative SSIs. In alternative embodiments, fractions may for example be prepared from: bacterial outer membrane (for example from Gram negative spp.); bacterial inner membrane; the pellet of a gradient centrifugation (for example from a sucrose gradient); chromosomal DNA; a capsular glycoprotein fraction; or, a peptidoglycan fraction, such as peptidoglycan ghosts. In alternative embodiments, engineered or recombinant organisms may be used in SSIs, in which genes involved in pathways relevant to particular cellular fractions have been modified, in particular genes involved in determining the composition of the foregoing fractions.
- For cell fraction preparations, bacteria may for example be grown and heat-inactivated. Cell fractions may for example be resuspended in sterile saline+0.4% phenol. Inner membranes may for example be collected using the 2-step sucrose density gradient, as for example described in Methods in Enzymology, Vol 125:309-328, 1986. The bacterial pellet obtained after cultivation of 250 mls of cells may be resuspended in 20% sucrose, 10 mM Tris-HCl pH 8.0 and 50 ug/
ml DNase 1. Cells may be incubated at 23° C. for 10 min. Cells may then be placed on ice and lysed two times through a French pressure cell at 15,000 psi; unbroken cells may be removed by centrifugation at 5,000×g for 10 min at 4° C. Supernatants may be layered onto a 2-step sucrose gradient (60% and 70%) and centrifuged in a SW28 swinging bucket rotor at 23,000 rpm for 18 hours at a temperature of 4° C. The inner membranes may be collected at the junction between the 20% and 60% sucrose. Sucrose may be diluted to below 20% with sterile distilled water and the membranes may be pelleted in an ultracentrifuge at 41,000 rpm at 4° C. for 1 hour. The inner membranes may be washed once with sterile water, and then resuspended in sterile saline+0.4% phenol. Crude outer membrane preparations may also be collected from the junction between the 60% and 70% sucrose gradient steps. - Chromosomal DNA, for example for Klebsiella pneumoniae, may be prepared using a Qiagen Blood and Tissue midi kit. Cells from 15 or 40 mls of broth culture from each strain may be harvested. The manufacture's protocol for purification of total DNA may then be followed.
- The efficacy of a component formulation was demonstrated with a Klebsiella pneumoniae (KPN) outer membrane fraction in the B16 lung cancer model, in which SSIs were injected every other day beginning 10 days before tumour cell inoculation by intravenous injection. Three SSIs were compared, whole killed cell KPN (QBKPN), a 1× outer membrane (OM) fraction (having an outer membrane concentration that approximated the outer membrane concentration of the whole cell formulation) and a 0.01× dilution of the outer membrane fraction. As illustrated in
FIG. 47A , both 1× and 0.01×KPN outer membrane fractions (i) were efficacious in the B16 melanoma model in the lung, in a dose-dependent manner, with the 1× fraction having comparable efficacy to the whole killed cell formulation, as were the 1× and 4×DNA fractions (ii), while the inner membrane fraction showed a dose dependent trend that lacked strong statistical significance (iii). - As illustrated in
FIG. 47B , following 10 injections of outer membrane SSI, Rae-1 expression was elevated by the 1× outer membrane fraction in a dose dependent effect. - Of note, higher concentrations of the membrane fraction caused pathology in animals prior to inoculation with tumour cells. In particular, 10× and 20× outer membrane fractions elicited strong toxicity in mice as evidenced by highly elevated innate cell (monocyte and neutrophil) recruitment to the blood with attendant deteriorating health conditions (e.g. dramatic weight loss, gait, hunched posture, eye conditions). Similarly, in some embodiments, concentrated whole cell preparations did not elicit toxicity.
FIG. 47C illustrates elevated neutrophil and monocyte blood counts after 4 injections of SSI or placebo, in blood collected 2 days prior to tumour implant. - As illustrated in
FIG. 470 , the KPN fractions illustrate site specific preferential lung activity compared to E. coli fractions in the B16 lung cancer model. In particular, compared to placebo control, whole QBKPN was efficacious in reducing lung tumour burden. A whole killed E. coli formulation (QBECO) was not as efficacious as QBKPN. QBKPN fractions (OM or DNA alone) were efficacious. When combined (OM+DNA), QBKPN fractions were approximately as efficacious as whole QBKPN. QBECO fractions (OM, DNA, or OM+DNA) did not show the same efficacy as QBKPN fractions. Together, this illustrates site specificity associated with QBKPN fractions, particularly combined DNA (4×) and OM (1×) fraction. - This Example illustrates embodiments in which an SSI is co-formulated with or co-administered with additional therapeutic components.
- One class of additional therapeutic components comprises molecules or compositions for activating or recruiting innate immune cells, and these include:
-
- GMCSF (particularly for cancer), for example in an amount that synergistically recruits and promotes the production of neutrophils and potentiates the SSI-induced innate immune response.
- Vitamin D (for inflammatory disease, such as IBD, and cancer), for example in an amount that is effective to differentiate and activate monocytes and play a role in regulating innate immune function. In alternative embodiments, the vitamin D used in conjunction with SSIs may for example be one or more of vitamin D3, D2 or calcitriol (1,25-dihydroxycholecalciferol). In some embodiments, vitamin D3 and/or D2 may for example be given locally at a dosage that is effective to provide a locally effective amount of calcitriol at the site of SSI and vitamin D administration. For example, vitamin D precursors (D3 and/or D2) may be administered in an amount that is locally effective once it is converted into the calcitriol active form by local monocytes and/or macrophages (expressing CYP27B1) at the site of administration. In alternative embodiments, calcitriol may be administered in dose that is locally effective at the site of SSI administration, and this may for example be dose that is less than the dose required for other systemic effects.
- An additional class of therapeutic components for co-formulation or co-administration comprise molecules or compositions that relieve immunosuppression:
-
- NOHA (N(omega)-hydroxy-nor-L-arginine), an Arginase inhibitor—Arginase degrades arginine needed for immune activation. NOHA may for example be used in an amount effective to relieve immune suppression by making available free arginine.
- Alpha1 antitrypsin—for example in an amount effective to relieve immune suppression mediated by neutrophils secreting proteases.
- An additional class of therapeutic components for co-formulation or co-administration comprise molecules or compositions that prevent oxidative damage and improve immune function under stress:
-
- Glutathione and other antioxidants, particularly for fibrotic diseases (such as IBD).
- An additional class of therapeutic components for co-formulation or co-administration comprise co-stimulatory molecules for innate cytotoxic lymphocytes (for example for anticancer treatments):
-
- Phospho-antigens (isoprenoid molecules, such as isopentenyl pyrophosphate)—recognized by human peripheral blood Vγ9Vδ2 T cells which play a central role in anticancer responses, for example in amounts effective for activating and differentiating monocytes working in concert with NK cells to target both solid and liquid cancers. In exemplary embodiments, it has been found that SSIs in co-formulation or co-administration with zoledronate increase markers of activation, for example CD25 and CD69, on human peripheral blood Vγ9Vδ2 T cells.
- Glycolipid molecules recognized by Type I NKT cells (such as synthetic α-galactosylceramide)
- As set out in Table 18, and
FIGS. 12 and 13 , in an in vivo demonstration of SSI co-formulations that improve anti-cancer effects using the LLC model, co-formulations with GMCSF and Vitamin D (D3) show the best performance, followed by NOHA (arginase inhibitor) and alpha1-antitrypsin. -
TABLE 18 Co-Formulations - comparing the mean differences in tumour count vs placebo Mean Dunnett's multiple comparisons test Diff. 95% CI of diff. Placebo vs. QBKPN 26.44 8.035 to 44.85 ** Placebo vs. QBKPN + Glutathione 27.41 8.998 to 45.82 ** Placebo vs. QBKPN + alpha-1-antitrypsin 29.33 10.92 to 47.74 *** Placebo vs. QBKPN + NOHA 30.31 11.90 to 48.72 *** (arginase inhibitor) Placebo vs. QBKPN + Vitamin D 33.50 15.09 to 51.91 **** Placebo vs. QBKPN + GM-CSF 34.73 16.32 to 53.14 **** - This Example illustrates results from a mouse spontaneous colitis model (Muc2 knockout “KO” mice) that mimics the underlying immune system defect and chronic bacterial infection associated with Crohn's disease and ulcerative colitis. IBD patients typically display structural and/or functional defects in their normally protective colonic mucosal barriers. The mucus barrier is largely dependent on the release of goblet cell-derived mucin (Muc2) which prevents microbes and luminal antigens from contacting the epithelial surface in the gastrointestinal tract. Muc2 KO mice are healthy just after weaning (1 month old), as they age, they develop progressive diarrhea and sporadic rectal prolapse. Histological analysis of colonic tissue shows crypt hyperplasia, crypt abscesses, inflammatory cell infiltration and submucosal edema. Accordingly, the Muc2 KO mice have a defective gastrointestinal mucosal barrier and after time spontaneously develop colitis, resembling ulcerative colitis in humans. In this model, young (2 month old) Muc2 KO mice have less severe colitis, and older (3 month old) Muc2 KO mice have more severe colitis.
- Results from this animal model, as shown in
FIGS. 14A, 14B and 14C illustrate that an E. coli SSI (QBECO) decreases pro-inflammatory markers in the colon (using qPCR gene expression data).FIG. 14D illustrates the site specific activity of QBECO in increasing IL-18 gene expression in the colon, compared to QBKPN. The IFN-gamma expression data in particular illustrates how SSI efficacy can be affected by the stage of colitis (comparing expression data in old vs young mice). IL17A data, relating to a cytokine that is produced by activated T-cells (a marker of IBD inflammation), illustrates a significant decrease in this marker of inflammation after E. coli SSI treatment. Accordingly, QBECO treatment substantially improved all components of the histopathology score, including infiltration, integrity, hyperplasia, and edema. The infiltration of T lymphocytes in the colonic tissue, a hallmark of IBD in patients and mouse models, was markedly decreased with QBECO treatment. Accordingly, this Example illustrates that an SSI, such as QBECO, may be used to significantly decrease disease severity in IBD model, including so as to substantially dampen adaptive immune system over-response. - QBECO was also shown to have a positive impact on the gastrointestinal microbiome. Alterations in bacterial species in the intestinal microbiome can either be detrimental (‘unhealthy’ bacteria) or therapeutic (‘healthy’ bacteria) in IBD patients (and mouse models). Some bacteria promote a healthy immune environment and can improve symptoms (for example, Lactobacillus species), whereas others (for example, γ-proteobacteria) can have detrimental effects in IBD. We analyzed the intestinal microbiome before and after QBECO SSI treatment. As illustrated in
FIGS. 15A and 15B , QBECO SSI improved dysbiosis in the colon of Muc2 mice, increasing the relative proportion of Lactobacillus (healthy bacterial species) and decreasing the relative proportion of gamma-proteobacteria (unhealthy bacterial species). As illustrated inFIG. 15C , QBECO SSI also reduced all aspects of the histological inflammation/damage score (infiltration, integrity, hyperplasia and edema) in the colon of MUC2 spontaneous colitis mice. These results illustrate that an SSI treatment using a formulation derived from a GI pathogen, such as QBECO, has a therapeutic effect on the gastrointestinal microbiome. Accordingly, aspects of the invention involve the use of an SSI, such as an E. coli derived SSI, for treating dysbiosis in IBD. - To summarize, QBECO treatment significantly improved the overall histological score and reduced T cell infiltration in the colonic tissues. Furthermore, a reduction in pro-inflammatory mediators in the colon (IL-17A) and serum (KC) was observed. QBECO treatment did not impact regulatory T cell marker (FoxP3) and anti-inflammatory growth factor (TGF-β) expressions in affected tissues. In addition, SSI treated mice demonstrated reduced levels of the antimicrobial lectins RegIII-μ and RegIII-γ. The changes in antimicrobial lectins brought on by QBECO allowed for a modulation of the gut microbiome causing a reduction in gamma-proteobacteria and a significant increase in lactobacilli.
- This Example provides animal model data illustrating the efficacy of an SSI therapy, KPN SSI, in treating asthma/allergy. As shown in
FIG. 16 , KPN SSI decreases total BAL cell count in asthmatic mice. As shown inFIG. 17 , KPN SSI decreases eosinophil and lymphocyte counts in the BAL: A) Eosinophils, B) Lymphocytes. As shown inFIG. 18 , KPN SSI decreases TH2 cytokines in the BAL supernatant: A) IL-4, B) IL-5. - This example illustrates systemic distribution of a KPN SSI administered subcutaneously in a murine model; using cyanine dye (Cy5.5) labeled whole killed KPN cells and optical in-vivo dorsal and ventral whole-body imaging. After a first injection, imaging (at 1 hr, 3 hr, 6 hr, 24 hr and 47 hr) revealed systemic distribution with the highest concentrations of the SSI at the injection site. Following the first injection, the SSI was cleared from circulation within approximately 24 hours. Subsequent injections took place at alternative injection sites, and imaging (at 1 hr, 3 hr, 6 hr and 24 hr) revealed systemic distribution with highest concentrations seen at the new sites of injection and, surprisingly, at previous sites of injection. This provides an illustration of preferential SSI delivery/retention at sites of inflammation following systemic dispersal of locally administered formulations. Microscopic evaluation of blood samples confirmed that the Cy5.5 fluorescence detected in the blood was not free dye. As illustrated in
FIG. 19 , the distribution of SSI in organs after 24 hours showed a preferential accumulation of KPN SSI in the lungs, compared to the heart and the spleen. - In this Example, a topical formulation of an SSI is formulated for administration to wounds, for example surgical wounds, partial-thickness burns, lacerations, chronic wounds, or vascular ulcers. The topical SSI formulation may for example include PPR agonists derived from microbes that are skin pathogens, formulated in an ointment or gel.
- This Example illustrates that efficacious treatment for Crohn's disease may be carried out over an extended period of periodic dosing of an SSI. In particular, in a
phase 1/2, randomized, placebo-controlled, double-blinded clinical trial involving adults with moderate to severe Crohn's disease, the Crohn's Disease Activity Index (CDAI, Best et al., 1976, Gastroenterology 70 (3): 439-444) declined on average by significantly more onweek 16 of treatment compared toweek 8. More specifically, byweek 8, the average reduction in CDAI score in SSI treated patients was approximately 80 points; byweek 16, the average reduction in CDAI score was approx 120 points. This illustrates continued clinical improvement through 16 weeks of SSI treatment. - This example involved use of a whole killed E. coli SSI preparation, administered every second day by subcutaneous injection. The dose was individualized to the patient by adjusting the dose so that each dose was effective to cause a visible localized inflammatory immune response at the administration site (a 1 inch to 2 inch diameter delayed reaction of visible redness at the injection site).
- Accordingly, aspects of the invention involve use of an SSI over an extended duration period, with dosage intervals and dosage duration adapted to provide an increased therapeutic benefit over the entire dosage duration, such as a progressive reduction of CDAI score in Crohn's patients over a duration period of at last 16 weeks.
- This example illustrates therapeutic efficacy of an SSI (KPN SSI) in a murine House Dust Mite (HDM)-induced asthma model, explifying the underlying mechanistic basis for the use of SSIs in treating asthmatic inflammation. In this Example, BALB/c mice were exposed intranasally to HDM for two weeks. Mice were treated subcutaneously with either KPN SSI or placebo for one week prior to HDM exposure and throughout the two week exposure period. 24 hours after the last exposure, lungs were analysed for inflammatory cell infiltrate, gene expression, cytokine levels, goblet cell metaplasia, and serum was analysed for allergen-specific serum IgE levels.
- Female mice (BALB/c) age 6-8 weeks old were purchased from Jackson Laboratory (Bar Harbor, Me.). 10 mice per group were used. Mice were housed in environmentally controlled specific pathogen free conditions with a 12:12 hour light/dark cycle for the duration of the study.
- Mice were exposed to saline (35 μL) or house dust mite (HDM, Dermatophagoides pteronyssimus, Greer Laboratories, Lenoir, N.C.), intranasally, 25 μg in 35 μL of saline, under isoflurane anesthesia. HDM or saline nasal exposure was done for 5 consecutive days in
week FIG. 1 ). Mice were euthanized 24 hours after the last exposure. - KPN SSI was derived from Klebsiella originally isolated from a patient infection, with whole heat killed cells suspended in physiological saline containing 0.4% phenol as a preservative for a final OD600 of 5.0. Placebo was physiological saline containing 0.4% phenol. KB or placebo was prophylactically given on day −7, −5, −3 of the experiment, and treatment was continued on
experimental days - BAL cell differential counts were performed by examining cytospins according to cell morphology and Wright-Giemsa staining. A total of 100 cells per mouse were differentiated by a blinded observer.
- HDM was coated onto 96-well plates (2.5 ug/well) and incubated overnight at 4° C. After blocking with 5% FBS in PBS, undiluted serum was added and incubated overnight at 4° C. After washing, biotin anti-mouse IgE (BD Bioscience—San Jose, Calif., USA) was added and incubated at 37° C. for one hour. Streptavidin-HRP/TMB substrate was used to visualize levels and absorbance was recorded at 450 nm.
- Right lung tissue was lysed by homogenizing with a TissueLyser LT (Qiagen—Toronto, Ontario, Canada) and RNA isolation performed using a PureLink RNA Mini Kit (Life Technologies—Carlsbad, Calif., USA). iScript cDNA Synthesis Kit-170-8891 was used for cDNA synthesis (Biorad). Gene expression was done by quantitative RT-PCR on a StepOnePLus RT-PCR machine (Applied Biosystems—Foster City, Calif., USA) using TaqMan Fast Advanced Master Mix (Applied Biosystems) with Taqman probes for IL-4 (Mn00445259_m1), IL-13 (Mn00434204_m1) and IFN-γ (Mn01168134_m1).
- 31 cytokine/chemokine/growth factor biomarkers were quantified simultaneously using a Milliplex Mouse Cytokine/Chemokine kit (Millipore, St. Charles, Mo., USA) according to the manufacture's protocol. The multiplex was performed by using the
Bio-Plex™ 200 system (Bio-Rad Laboratories, Inc., Hercules, Calif., USA). The 31-plex consisted of eotaxin, G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, KC, LIF, MCP-1, M-CSF, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNFα, and VEGF. The assay sensitivities of these markers range from 0.1-33.3 pg/mL. As IL-13 levels in the multiplex were mainly below detection, IL-13 protein levels were measured in the BAL fluid by an ELISA (eBioscience San Diego, Calif., USA). - Lungs were dissected and inflated with 5 mL of 10% formalin. Tissues were embedded with paraffin and sectioned at 3 μm. Sections were stained with Periodic acid-Schiff to quantify mucus-containing goblet cells. Stained sections were scanned at 60× magnification using an Aperio Slidescanner (Vista, Calif.), version 11.1.2.760. Positively stained pixels were identified by colour segmentation in a cross-sectional manner in the lung airway using Aperio Image Scope software to express the number of strong positive pixels (Periodic acid-Schiff) normalized to basement membrane length (μM).
- Data were analysed using GraphPad Prism and are expressed as mean±SD. Multi-group comparisons were made by one-way ANOVA followed by Sidak post-hoc test. Four experimental group combinations were compared; Saline-placebo vs. Saline-Klebsiella, Saline-placebo vs. HDM-placebo, Saline-Klebsiella vs. HDM-Klebsiella, HDM-placebo vs. HDM-Klebsiella. For the purpose of statistical analysis, any value that was below the lowest value of the standard was recorded as half the lowest value of the standard. Principal component analysis (PCA) was performed for the BAL multiplex data, with and without the IL-13 ELISA. PCA was completed in R (version 3.2.4) using the prcomp command. (R Core Team (2016) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).
-
FIG. 20 is a graph illustrating HDM specific IgE responses following saline or HDM exposure, treated with either Placebo or QBKPN. *P<0.05 between HDM treated mice and their appropriate control (HDM Placebo vs Saline Placebo and HDM QBKPN vs Saline QBKPN). -
FIG. 21 is a series of graphs illustrating BAL cell counts and differentials in Saline or HDM exposed mice treated with Placebo or QBKPN: A) BAL total cells; B) BAL neutrophils; C) BAL lymphocytes; D) BAL macrophages; Panel (E); BAL eosinophils. Data are means±SEM of 10 mice per group (*=p<0.05). Data are means±SD of 10 mice per group. *P<0.05 between HDM treated mice and their appropriate control. #P<0.05 between HDM QBKPN treated mice and HDM Placebo treated mice. -
FIG. 22 includes two graphs illustrating BAL and serum mediators that are linked to eosinophilia: Serum IL-5 (A) and BAL eotaxin (B). Data are means±SD of 10 mice per group (*=p<0.05) between HDM treated mice and their appropriate control. #P<0.05 between HDM QBKPN treated mice and HDM Placebo treated mice. -
FIG. 23 is a series of graphs illustrating Th1 and Th2 lung gene expression following HDM exposure and QBPKN treatment: A) Th-1-mediated response IFN-γ cytokine gene expression, B) Th-2-mediated response IL-4 cytokine gene expression, and C) IL-13 cytokine gene expression (data are means±SD of 10 mice per group; *P<0.05 between HDM treated mice and their appropriate control). -
FIG. 24 is a series of bar graphs illustrating the effects of HDM exposure and QBKPN treatment on Th1- and Th2-mediated BAL fluid cytokine levels: A) IFN-γ cytokine level; B) IL-2 cytokine level; C) TNF-α cytokine level; D) IL-4 cytokine level; E) IL-5 cytokine level; F) IL-13 cytokine level (data are means±SD of 10 mice per group; *P<0.05 between HDM treated mice and their appropriate control). -
FIG. 25 is a graph illustrating a principal component analysis (PCA) of BAL cytokines showing partial normalization of overall cytokine profile. This exemplifies overall BAL cytokine profile changes between groups, using a principle component analysis (PCA) based on all multiplex data. The different experimental groups clustered separately based on the 1st principle component (PC1). Within the placebo treated mice, saline-exposed mice clustered separately from HDM exposed mice. KB treatment minimized the separation of HDM exposed mice from saline controls. Within the saline control group, KB and placebo treated mice were similar—as shown by their clustering together. As PC1 appeared to best differentiate the mice into different groups, the cytokines that had the greatest contribution to PC1 were identified. The top 5 cytokines that determined PC1 were LIF (Lekemia Inhibitory Factor; 8.2%), IL-5 (8.2%), Eotaxin (8.1%), IL-4 (7.5%) and CXCL10 (7.3%). Completing the principle component analysis with an additional asthma markers (IL-13) measured by ELISA provided similar clustering with the top 5 cytokines that determined PC1 were IL-5 (7.3%), eotaxin (7.2%), LIF (Leukemia Inhibitory Factor; 7.2%), IL-4 (6.8%) and IL-13 (6.7%). -
FIG. 26 is a bar graph illustrating airway goblet cell quantification following HDM exposure and QBPKN treatment. Goblet cell quantification expressed as number of strong positive pixels/basement membrane length. Data are means±SD of 10 mice per group. P<0.05 between HDM treated mice and their appropriate control. #P<0.05 between HDM QBKPN treated mice and HDM Placebo treated mice. -
TABLE 19 BAL cytokine changes Statistical Statistical Statistical Statistical significance significance significanceSaline + significanceSaline + HDM + Saline + Placebo vs. Placebo vs. Placebo vs. QBKPN vs. Saline + HDM + HDM + HDM + Analyte QBKPN Placebo QBKPN QBKPN G-CSF ns ns ns ns GM-CSF ns ns ns ns IFNg ns ns ns ns IL-1a ns ** ns ns IL-1b ns ns ns ns IL-2 ns ns ns ns IL-3 ns ns ns ns IL-4 ns **** ** ns IL-5 ns **** *** ** IL-6 ns ns ns ns IL-7 ns ns ns ns IL-9 ns * ns ns IL-10 ns ** ns ns IL-12p40 ns ns ns ns IL-12p70 ns ns ns ns IL-13 ns ns ns ns IL-15 ns ns ns ns IL-17 ns ns ns ns IP-10 ns **** * * KC ns ns ns ns LIX - CXCL5 ns ns ns ns MCP-1 - CCL2 ns ns ns ns M-CSF ns ns ns ns MIG - CXCL9 ns **** * ns MIP-1a-CCL3 ns ns ns ns MIP-1b - CCL4 ns ns ns ns RANTES - CCL5 ns ns * ns TNFa ns ns ns ns VEGF ns * ns ns MIP-2 - CXCL2 ns ns ns ns -
TABLE 20 SERUM Cytokine Levels Statistical Statistical Statistical Statistical significance significance significanceSaline + significanceSaline + HDM + Saline + Placebo vs. Placebo vs. Placebo vs. QBKPN vs. Saline + HDM + HDM + HDM + Analyte QBKPN Placebo QBKPN QBKPN G-CSF ns ** *** **** GM-CSF ns ns ns ns IFNg ns ns ns ns IL-1a ns ns ns ns IL-1b ns ns ns ns IL-2 ns ns ns ns IL-3 ns ns ns ns IL-4 ns ns ns ns IL-5 ns **** ** ns IL-6 **** ns * ** IL-7 ns ns ns ns IL-9 ** ns ns ns IL-10 ns ns ns ns IL-12p40 ns ns ns ns IL-12p70 ns ns ns ns IL-13 ns ns ns ns IL-15 ns ns ns ns IL-17 * ns ns ns IP-10 * ns ** ns KC ns ns ns ns LIX - CXCL5 ns ns ns ns MCP-1 - CCL2 ns ns ns ns M-CSF ns ns ns ns MIG - CXCL9 ns ns ns ns MIP-1a - CCL3 ns ns ns ns MIP-1b - CCL4 ns ns ns ns RANTES - CCL5 ns ns ns ns TNFa ns ns ns ns VEGF ns ns ns ns MIP-2 - CXCL2 ns ns ns * - As this example illustrates, in asthma QBKPN SSI: decreases the BAL total cells, neutrophils, lymphocytes, macrophages and eosinophils; decreases mediators of eosinophilia including serum IL-5 and BAL eotaxin; decreases Th2 cytokines in the BAL (IL-4 and IL-5); and, reduces goblet cell hyperplasia. In particular, in summary, this Example illustrated that HDM exposed mice developed classical symptoms of experimental allergic asthma including goblet cell hyperplasia, elevated allergen-specific serum IgE, airway eosinophilia, and a concomitant increase in
T H2 cytokines including IL-4, IL-13 and IL-5. Treatment with KPN SSI attenuated HDM-mediated airway eosinophilia, total BAL cell numbers, bronchoalveolar lavage (BAL)T H2 cytokine production, and goblet cell metaplasia. This Example demonstrates that treatment with KPN SSI attenuated HDM-induced TH2-skewed airway inflammatory responses and the associated goblet cell metaplasia. An aspect of the invention accordingly provides a treatment, such as subcutaneous treatment, with microbial biologics, such as compositions derived from bacterial lung pathogens, as a treatment for allergic airway disease, for example so as to attenuate an allergen-induced TH2-skewed airway inflammatory response, and/or an associated goblet cell metaplasia. These results accordingly indicate that an SSI treatment with a biologic is capable of simultaneously targeting two of the key molecular components that promote airway eosinophilia, in a process that is independent of the regulation of allergen specific IgE. In particular, a KPN SSI may be administered in a dosage and for a time that is efficacious at attenuating HDM-inducedT H2 skewed allergic airway inflammation, and/or airway eosinophilia, and/or mucus content in goblet cells, and this may for example be independent of modulating allergen-specific IgE levels. - This example illustrates anti-inflammatory efficacy in a murine model of COPD, a short term (3 week) smoking model. In this model, mice are pre-treated (with placebo or KPN SSI) every
other day 3 times (Monday, Wednesday and Friday of week 1). Mice are then exposed to smoke over days 8-25 (air or cigarette smoke exposure was done for 5 consecutive week days for the first 2 weeks and for 4 consecutive week days in week 3 (with no treatment or exposure on weekends) with continued treatment (placebo or KPN SSI) every other week day (Monday, Wednesday and Friday). Onday 26, mice were euthanized 24 hours after the last air/cigarette smoke exposure and samples are collected. - Briefly, cigarette smoke exposure (Kentucky Research Grade Cigarettes) was done by placing mice into plexiglass nose only exposure chambers, ensuring the nose extends from main chamber. Cigarettes were placed into smoking machine and lit with a lighter and vacuum in the fume hood. The 20 cc syringes in the smoking machine were filled with smoke, automatic valve was turned followed by smoke injection into the nose only exposure chambers. Each smoking puff cycle took 1.5 minutes. Each mouse smoked 3 cigarettes per day for a total of 45 minutes of exposure. Control air exposure mice were restrained for a similar duration without exposure to smoke. Animals were monitored throughout the smoke exposure procedure and for 30 minutes post smoke exposure.
- The heat-killed Klebsiella strain (originating from a patient infection) was administered as follows. KPN SSI or placebo vehicle (physiological saline containing 0.4% phenol) was prophylactically administered 3× every other day, and the regimen continued therapeutically throughout the period of smoke administration. Subcutaneous injections of 30 μL placebo or KPN SSI were administered into the lower right abdomen, the lower left abdomen, the upper right chest, and the upper left chest, rotating clockwise for each injection.
- Cytospins were performed and evaluated based on morphology and Wright-Giemsa staining. BAL cell differentials were then counted using the prepared cytospin slide with 100 cells per mouse counted in a blinded fashion.
- Immune mediator profiling of BAL and serum samples was performed as follows. Soluble mediator analysis in BAL and serum was performed using a 31 cytokine/chemokine/growth factor multiplex kit according to the manufacture's protocol (Eve Technologies Corp, Calgary, AB, Canada) using the
Bio-Plex™ 200 system (Bio-Rad Laboratories, Inc., Hercules, Calif., USA). The 31-plex assay included the following mediators: Eotaxin, G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10 (CXCL10), KC (CXCL1), LIF, MCP-1 (CCL2), M-CSF, MIG (CXCL9), MIP-1α (CCL3), MIP-1β (CCL4), MIP-2 (CXCL2), RANTES (CCL5), TNFα, and VEGF. The assay sensitivities of these markers range from 0.1-33.3 pg/mL. - Flow cytometric analysis of blood Ly6CHI monocytes/macrophages and neutrophils was performed as follows. Blood was collected in EDTA coated tubes (BD Microtainer) to prevent clotting and stored on ice prior to staining. Blood was stained with CD11b-FITC, Ly6G-PE, CD11c-PerCPCy5.5 and Ly6C-APC before red blood cell lysis (BD lysis buffer). Flow cytometry was run on a FACSCalibur (BD Bioscience). Analysis was completed on a FlowJo V10.1. Neutrophils were defined as Ly6G+CD11b+ cells. Ly6CHI monocytes/macrophage were defined as Ly6CHILy6G−CD11b+ cells.
- Data Analysis was performed as follows.
GraphPad Prism 6 Software (GraphPad Software, San Diego, Calif.) was used to perform statistical analysis of the results. Data are expressed as mean±SD. One-way ANOVA analysis followed by multiple comparisons using a Sidak post-hoc test was performed on the selected group comparisons. Four experimental group combinations were compared; air-placebo vs. air-KB, air-placebo vs. cigarette smoke-placebo, air-KB vs. cigarette smoke-KB, cigarette smoke-placebo vs. cigarette smoke-KB. - Body weight and clinical scores (e.g. hunched posture, interaction with other animals, activity levels) were used to monitor the overall health of mice exposed to filtered air or cigarette smoke in the presence or absence KPN. Body weight was normalized to the starting weight of each animal. No changes in body weight were recorded in air-exposed group treated with placebo or KPN (p>0.05). However, cigarette smoking exposed mice had a prominent loss in body weight (p<0.05) and KPN treatment did not reverse this detrimental effect (p>0.05). No observed changes for clinical scores were observed for any groups.
- Total BAL cell counts and cellular differentials were analysed to assess airway lung inflammation.
FIG. 27A is a bar graph illustrating BAL cell differential, showing that QBKPN decreases the total BAL cell count after smoke exposure through reduction in lymphocyte and macrophage populations. In placebo treated animals, cigarette smoke exposure induced an elevation in total cell number in the BAL that was not attenuated with KPN intervention (FIG. 27B (a), p<0.05). The cigarette smoke exposure induced increase in BAL total cells was attributed to lymphocytes, macrophages, and neutrophils (FIG. 27B (b)-(d), p<0.05) but not eosinophils (p>0.05, data not shown). KPN intervention attenuated the increase in lymphocytes and macrophages in the cigarette smoke exposure group (p<0.05), although macrophages remained elevated relative to air+KPN (FIG. 27B (b)-(c). PN intervention had no impact on cigarette smoke induced increases in neutrophils (FIG. 27B (d)). - Previous reports have indicated that mouse cigarette smoke exposure models result in a TH1 skewed inflammatory response. This Example illustrates that KPN SSI intervention attenuated cigarette smoke exposure-induced TH1-skewed lung inflammatory responses, as evidenced by multiplex analysis of 31 cytokines, chemokines, and growth factors that included TH1 and non-TH1 mediators. Cigarette smoke exposure induced 15 of 31 (46.7%) mediators measured in BAL fluid that included IFNγ, CXCL9, CXCL10, CCL5, IL-6, IL-17, G-CSF, CXCL1, LIF, CCL2, CCL3, CCL4, TNFα, eotaxin, and VEGF (p<0.05). IL-17 was elevated with cigarette smoke exposure in 4 of 10 samples at values close to the level of detection of this mediator (0.64 pg/ml). KPN intervention attenuated cigarette smoke-induced increases in IFNγ, CXCL9, CXCL10, CCL5, IL-6, G-CSF, and IL-17 (
FIG. 28A ), all mediators that are associated with a TH1 skewed inflammatory response. KPN SSI intervention had no impact on air-exposed animals for any mediator measured. - The serum immune mediator protein expression profile was minimally impacted by cigarette smoke exposure but is augmented by KPN intervention, as evidenced by the same multiplex assay of 31 mediators applied to the serum from the four experimental groups. Cigarette smoke exposure induced an increase in only VEGF, which had elevated levels relative to air exposed control (
FIG. 28B (a), p<0.05). The KPN SSI intervention did not reverse the cigarette smoke exposure-induced elevation in serum VEGF. KPN intervention in air exposed animals decreased only 1 mediator, IL12p40, relative to air+placebo, while the levels of IL-1β, CCL2, CXCL9, and CXCL10 (FIG. 28B (b)-(d) p<0.05) were increased. In the smoke exposed mice, KPN intervention increased the levels of CXCL9, CXCL10, and CCL5 relative to the cigarette smoke+placebo group. Collectively these serum data illustrate that the SSI intervention induced a systemic impact independent of cigarette smoke exposure that may administered so as to be efficacious for the local suppression of cigarette smoke-induced lung inflammation. - To illustrate a systemic cellular immune response in this COPD model, flow cytometry was used to assess the levels of Ly6CHI monocytes/macrophages, an inflammatory monocyte population, and neutrophils, in the blood after cigarette smoke exposure and KPN intervention. Cigarette smoke exposure induced no increase in blood Ly6CHI monocytes/macrophages or neutrophils (
FIG. 28C (a)-(b)). Surprisingly, KPN SSI intervention increased the blood Ly6CHI monocytes/macrophages and neutrophils in the cigarette smoke exposure groups (p<0.05) and the neutrophils in the air-exposed animals. The increase in systemic Ly6CHI monocytes/macrophages and neutrophils was correlated with similar patterns for a local increase in the lung tissue (FIG. 28C (c)-(d)), where KB induced an increase in these cell types, which was further exacerbated by cigarette smoke exposure (p<0.05). -
FIG. 28D includes three bar graphs for select lung gene expression profiles, illustrating that QBKPN decreases the expression of three important inflammatory cytokine genes (IL-6, IL-1beta, and IL-17A) in the lung tissue after smoke exposure. -
FIG. 29 illustrates select BAL cytokine expression profiles, with six bar graphs illustrating that QBKPN caused a significant decrease in G-CSF, IL-6 and IP-10 in the COPD model, and a downwards trend in IL-4, KC, MIG, TNFalpha. -
FIG. 30 illustrates serum cytokine expression profiles, identifying a number of markers for SSI efficacy, particularly elevated serum levels of IP-10, MIG and RANTES. These serum markers may accordingly be used as a biomarker for SSI efficacy, for example to identify responders or non-responders to a particular SSI, or as a marker of efficacious dosing in a dose adjustment protocol. - This Example illustrates that a QBKPN SSI decreased a number of markers of an inflammatory environment in a COPD model, in particular: decreased BAL total cells, lymphocytes and macrophages; decreased gene expression of cytokines that are usually elevated in COPD including IL-6, IL-1beta and IL-17A; and decreased levels of cytokines of importance in the BAL in COPD including IL-6, IP-10 and G-CSF. More particularly, these results demonstrate that KPN treatment attenuated cigarette smoke-induced TH1-skewed lung inflammation and BAL cellularity. In control air-exposed and experimental cigarette smoke-exposed animals, KPN SSI induced a systemic immune response that included immune mediator production, and mobilization of monocytes and neutrophils, which was mirrored in the local lung environment with an increase in Ly6CHI monocytes/macrophages and neutrophils. This Example therefore indicates that interventions with microbial components that enhance certain aspects of an immune response, rather than generally suppressing the immune responses, may be used to alter the course of cigarette smoke exposure related COPD pathogenesis.
- COPD has many underlying pathways with other inflammatory diseases, including asthma and inflammatory bowel disease (IBD). IBD and COPD share common observations including an altered microbiome, immune dysfunction, altered epithelial cell function, and chronic inflammation. There is also significant overlap between asthma and IBD including altered respiratory microbiome and immune dysfunction. Over all, the similarities between COPD and other inflammatory disease that benefit from SSIs, as evidenced herein, indicates that enhancing aspects of the immune response with a repertoire of PRR agonists, such as microbial products or synthetic formulations, may be employed as a therapeutic approach to COPD.
- In this Example of acute cigarette smoke exposure-induced inflammation, we observe an elevation in IFN-γ, CXCL9, CXCL10, CCL-5, IL-6, G-CSF and IL-17 in the BAL that is attenuated with KPN treatment. This reduction in TH1-skewed inflammatory mediators was associated with a concomitant reduction in lung macrophage and lymphocyte recruitment, with KPN treatment attenuating the quantity of BAL lymphocytes and macrophages. Interestingly, systemically, KPN induced a TH1-skewed chemokine signature (CXCL9, CXCL10, CCL-5) in both the air-exposed and cigarette smoke exposed animals, similar to what is seen in infection. In effect, in parallel to the attenuation of
T H1 lung inflammation, KPN treatment induced a systemic immune activation with increases in Ly6CHI monocytes/macrophages and neutrophils. This Example accordingly indicates that KPN SSI actively stimulates aspects of an immune response that may be adapted to lead to mobilization and recruitment of TH1-skewed immune cells systemically, but a reduction locally in the BAL. - Systemically, this Example indicates that KPN SSI administration increased pro-inflammatory cytokines (e.g. IL-1β) and blood inflammatory monocytes (defined as Ly6CHI) and neutrophils, similar to the response seen with an acute infection. We further identified an increase in the inflammatory monocytes and neutrophils in the lung tissue by flow cytometry. In the lung inflammation examples, Examples 15 and 16, in control mice (air exposed in the COPD study and saline exposed in asthma study) QBKPN SSI increases cytokine levels in the serum. These are accordingly available as biomarkers for efficacy, particularly IP-10 (CXCL10) which was increased in both the asthma and COPD examples in the QBKPN SSI treated control mice.
- In a murine B16 melanoma model of metastases to the lung, an SSI formulated with whole killed cells of Klebsiella phylogroup III (K. variicola) was effective in reducing tumour burden, as illustrated in
FIG. 31 (in which the K. variicola is identified as “QBKPN”). - CD25 is expressed on activated T cells, activated B cells, Tregs and resting memory T cells (cells involved in adaptive immunity). Utilizing an anti-CD25 antibody, this example illustrates QBKPN SSI efficacy in reducing lung nodules in the absence of CD25 positive cells, as shown in
FIG. 32 . This illustrates that aspects of SSI efficacy are independent of CD25 positive adaptive immune cells in the B16 melanoma model (SSI was administered prophylactically, with mice challenged with B16 melanoma cells injected IV and tumour foci counted 18 days post B16 injection). Accordingly, aspects of the invention relate to modulating an immune response that is not dependent upon CD25+ cells, for example an innate immune response. - In a murine B16 melanoma model of metastases to the lung, the dilution of a KPN SSI progressively reduced efficacy (with tumour burden measured by QPCR quantification of Trp-1 expression).
FIG. 33A shows the Ct (cycle threshold) values associated with a KPN SSI formulation (QBKPN), and progressive dilutions of the KPN SSI (10×, 100× and 1000×), onday 5 following B16 challenge. Ct values accordingly indicate the number of PCR cycles required for the fluorescent signal to cross the threshold (i.e. to exceed background level). Delta Ct values took into account of Ct values of a housekeeping gene, and the levels are accordingly inversely proportional to the amount of target nucleic acid in the sample. As illustrated, tumour burden increased with increasing dilution of the SSI. As shown inFIG. 33B , this dose dependency is also reflected in an assay of the number of B16 tumour nodules in the lung.FIG. 33C is a bar graph illustrating that a variety of dosing regimes provide a therapeutic effect, with intervals between injections varying from 1 to 7 days all providing a therapeutic effect. - Further analysis, as shown in
FIG. 34 , illustrated that the proportion of cells that express Rae-1 was inversely correlated with tumour burden, evidencing the fact that SSIs increase target tissue Rae-1 expression in a dose-dependent manner. The increased Rae-1 signal would facilitate immune stimulation through NKG2D (see below) receptors on innate lymphoid cells, such as NK cells, leading to increased cancer cell killing and the reduced tumour burden evidenced in this example. In effect, high SSI induced Rae-1 expression leads to decreased cancer burden. - As shown in
FIG. 34(B) , in NKG2D (natural-killer group 2, member D) knockout mice, the therapeutic efficacy of QBKPN in the B16 lung metastasis model is abrogated. This illustrates the significant role of NKG2D signalling in various aspects of a therapeutic SSI response, reinforcing the significance of the evidence of increased Rae-1 expression in target tissues. - In a murine Lewis lung carcinoma expressing red fluorescent protein (LLC-RFP), the efficacy of a KPN SSI (QBKPN) was compared to E. coli (QBECO) and Staphylococcus aureus (QBSAU) SSIs (KPN being a lung pathogen in mice while ECO and SAU are not). As illustrated in
FIG. 35 , QBKPN provided a markedly stronger effect in reducing tumour nodules in the lung. As illustrated inFIG. 36 , there was a concomitant reduction in the number of LLC-RFP cells in the lungs atday 15 after inoculation with LLC. - Alternative data illustrates that while immune infiltrates with QBKPN and QBECO may be comparable at early time points in some systems, neutrophil levels are enhanced at day 7 (flow data) with QBKPN compared to QBECO. Also, gene array analyses evidences prolonged persistence of innate infiltrates in QBKPN vs QBECO (˜72 hrs). These data further indicate that the ongoing immune response in lungs is different in response to QBKPN vs QBECO.
- In an MC38 colon cancer model, QBECO conferred a greater survival advantage than did either QBKPN or 10× concentrated QBSAU (QBSAUR), as illustrated in
FIG. 37 . - In a B16 melanoma model, 100,000 B16 melanoma cells were injected into the right flank of C57BL/6 mice in a volume of 100 μl on
Day 0, SSI treatment started on Day −10 and continued till Day +12. Tumour volume was monitored starting onDay 7, with the endpoint reached atDay 14. As shown inFIG. 5 , 10× concentrated QBSAU or QBSAUR was much more effective than either QBKPN or QBECO at reducing B16 tumour volume in the skin. - The B16 melanoma model was used to seed lung tumours by IV administration, and to seed a skin tumour by subcutaneous dorsal injection, so that each animal has both cancer situated in the skin and cancer situated in the lung. In this study, mice (N=5/group) in the experimental group were injected SQ with the placebo (30 μl), QBKPN (30 μl of 4.91 OD600), or 10×QBSAU (30 μl of 8.6 OD600) every other day on day −8, −6, −4 and −2 prior to being implanted with the B16 melanoma cells (1×105 cells/100 μl/mouse) both IV and SQ. Mice (N=5/group) in the 4 control groups were injected SQ with either QBKPN or 10×QBSAU on day −8, −6, −4, and −2: 2 groups of these control mice were inoculated with the B16 tumour either IV (QBKPN single positive control) or SQ (10×QUSAU single positive control) on
day 0, serving as single positive controls, whereas 2 groups of these control mice did not receive any tumour inoculation, serving as negative controls. SQ administration of either the SSI treatment or the placebo control was given to mice continuously every other day until the experiment was terminated onday 5 post tumour implant. Tumour burden in the lung and the skin were enumerated onday 5. - Mice treated with QBKPN, but not 10×QBSAU, exhibited elevated lung-specific Rae-1 expression (
FIG. 38 ) and recruitment of monocytes and neutrophils to the lung. There was also decreased PD-1 expression in the lung of QBKPN-treated mice as compared to placebo-treated mice in the same model (FIG. 39 ). In contrast, PD-L1 expression was not different among the groups in the lung. Treating mice with 10×QBSAU, but not QBKPN, led to a decrease in the skin tumour burden as compared to placebo control in the B16 skin and lung tumour model (FIG. 40 ). - Accordingly, QBKPN demonstrated site specificity in the lung by elevating Rae-1 expression and the recruitment of monocytes and neutrophils in animals having both skin and lung tumours. Similarly, 10×QBSAU demonstrated site-specific efficacy by reducing skin tumour in these animals.
- Intravenous SSI vs. Subcutaneous SSI
- In this example, a KPN SSI (QBKPN) was administered either IV or SQ in a B16 lung metastasis model. On
day 0, B16 cells were administered IV to seed tumours. Ondays FIG. 41 , both routes of administration provide therapeutic benefit. - In this example, the scheduling of SSI treatment, either before challenge with cancer cells (prophylaxis) or after challenge (treatment) was compared. This example also demonstrates immune correlates linked with efficacy, particularly the M1/M2 ratio of macrophages.
FIG. 42 is a schematic illustration of the study design, based on efficacy of QBKPN in a treatment versus prophylactic regimen in the B16 lung cancer model. As illustrated inFIG. 43 , while the prophylactic regimen provided earlier therapeutic benefit, byday 17 the treatment regimen shows a very strong trend of efficacy. The efficacy of both prophylactic and treatment regimens was reflected in common correlates of efficacy in the M1/M2 macrophage ratios in the lung with alternative M2 marker CD206, as illustrated for the treatment group atday 10 and the prophylactic group atday 17 inFIG. 44 . - This example illustrates aspects of how quickly SSI therapies have detectable therapeutic effects involving myeloid cell populations, providing examples of therapeutic biomarkers. As illustrated in
FIG. 45 , neutrophils increase at all time points for QBKPN and QBECO SSIs, with significant increases seen even within 3 hours post injection. As illustrated inFIG. 46 , Ly6CHILy6G+CD11b+ cells (Ly6C monocytes) were significantly increased at both 3 and 7 hours, with a decreasing trend that falls back to placebo levels by around 24 hours. The cellular immune response provoked by an SSI therapy may accordingly be characterized by a rapid onset, within hours, followed by a resolution within days. This pattern of cellular response supports a dosing schedule with repeated administrations at an interval that is measured in days, for example one administration every 1, 2, 3, 4, 5, 6, or 7 days. - This example illustrates that an SSI (QBKPN) can directly cause an increase in cancer cell death at high doses. NCI-H358 cells (a human lung cell line) were incubated in vitro with successive dilutions of QBKPN for 24 hours. Efficacy was assessed using a carboxyfluorescein succinimidyl ester (CFSE) labelling assay (a green fluorescent cell staining dye to label target cells) with the red live/dead viability dye 7-AAD (7-aminoactinomycin D) used to identify the killed/dead cells present in the cytotoxicity assay sample. As illustrated in
FIG. 48 , QBKPN increases NCI-H358 cancer cell death at high doses (1/20, 1/200 dilution) in this 24 hour killing assay. Using the same assay, it was also shown that the KPN SSI increases γδ T cell mediated killing of the NCI-H358 cancer cells at similar doses (1/20 dilution, 1/200 dilution) in the 24 hour killing assay, as illustrated inFIG. 49 . In addition, the KPN SSI (QBKPN) potentiated the effect of zoledronate in inducing γδ T cell mediated cancer cell lysis, at 1/200 and 1/2000 dilutions, as shown inFIG. 50 . - As this example illustrates, in select embodiments, SSIs can be administered directly to cancerous tissues, for example at the site of surgical resection of a cancer. For example, an SSI, such as QBSAU, may be applied topically to a melanoma in the skin or to the site of a surgical excision of a skin melanoma.
- This example illustrates the involvement of the NKG2D receptor in mediating a therapeutic response to an SSI. This was shown in a murine survival study after IP injection of MC-38 cells (a murine adenocarcinoma cell line derived from a primary mouse colon carcinoma). The tumour cells were injected intraperitoneally in order to allow the tumour cells to seed the gut, creating a MC-38 cell colon cancer model. QBECO treatment was compared to placebo in wildtype mice (C57BL/6 mice) and NKG2D knockout mice (on a C57BL/6 background). Wildtype and NKG2D mice were treated with either QBECO or placebo (10 per group) for 10 days every second day before MC-38 injection. Treatment was continued throughout the survival study every second day.
- As illustrated in
FIG. 51 , this study confirmed the therapeutic efficacy of QBECO in the MC-38 colon cancer model, showing in the wildtype mice a statistically significant increase in survival with QBECO treatment compared to placebo treatment. As illustrated inFIG. 52 , NKG2D expression is correlated with QBECO efficacy, as there was no statistical difference in survival between NKG2D knockout mice treated with either QBECO or placebo. Immunophenotyping confirmed that the NKG2D knockout mice had reduced levels of NKG2D positive cells. Interestingly, QBECO caused a decrease in NKG2D at each time point within the wildtype mice (illustrating the use of NKG2D expression as a biomarker for SSI efficacy). Immunophenotyping also showed a characteristic increase in neutrophils by day −9 and monocytes by day −1 in both wildtype and NKG2D KO mice treated with QBECO compared to placebo. There was also an increase in PDL1+ after QBECO treatment, with QBECO causing an increase in PDL1+ cells in the blood throughout the experiment, with significance in wildtype mice at day −9 and −1, and a similar by attenuated pattern in NKG2D knockout mice. In wildtype mice, QBECO caused an increase in PD1+ cells in the blood in non-tumour bearing mice (Day −9, Day −1), while in tumour bearing mice QBECO induced an initial increase in PD1+ cells which was attenuated by Day 11 in a trend that continued so that at survival QBECO caused a decrease in PD1+ cells in the blood. NKG2D knockout mice follow this trend with less magnitude and no significance. Together, this data illustrates that PD1 and PDL1 may be used as biomarkers indicative of SSI efficacy. - This example illustrates the use of an SSI to treat neutropenia in a mouse model. Neutrophil populations were assessed in spleen (in mouse, representative of circulation) and lungs in response to SSI treatment (QBKPN) and neutrophil-depleting (anti-Ly6G) monoclonal antibody, as illustrated in the treatment schema in
FIG. 53 . In indicated mice, SSI treatment was performed every two days from Day −10 to Day +10. SSI (QBKPN) was injected SC in alternating sites at a dose of 0.03 ml of an OD5.0 solution. In indicated mice, anti-Ly6G treatment was performed every three days from Day −1 to Day +11. Antibody (Bio-X-Cel clone 1A8) was injected IP at a dose of 200 μg/mouse. All mice were IV injected with B16 melanoma (200,000 cells/mouse) atDay 0. On Day +12, mice were sacrificed. Single cell suspensions were generated from spleen and lungs. Neutrophil populations (CD45+CD11b+Ly6G-hi Ly6C-intermediate) were assessed by flow cytometry, using monoclonal antibodies (BioLegend) and a Miltenyi MacsQuant cytometer, and analyzed using FlowJo software. Representative staining data from lungs is illustrated inFIG. 54 , from lung samples, gated on live, CD45+CD11b+ cells. The proportions of neutrophils in lungs (FIG. 55A , showing % of live CD45+CD11b+ cells) and spleen (FIG. 56A ) were calculated from primary cytometry data. Numbers of neutrophils (CD45+CD11b+Ly6G+Ly6C+ cells) in the lungs (FIG. 55B ) and spleen (FIG. 56B ) were calculated by multiplying the proportion of cells by the total cellularity. - In both lungs and spleen, QBKPN treatment significantly increased the proportion (
FIG. 55A andFIG. 56A ) of neutrophils. QBKPN treatment significantly increased the number of neutrophils in spleen (FIG. 56B ). These data illustrate that QBKPN SSI induces an expansion in the proportion and number of circulating neutrophils. - Parallel cohorts of mice were treated with anti-Ly6G monoclonal antibody. Absent QBKPN treatment, anti-Ly6G completely depleted the neutrophils in lungs and spleen, both in terms of proportions and numbers (
FIGS. 55 and 56 ). However, neutrophil populations in lung (FIG. 55 ) and spleen (FIG. 56 ) remained at high levels in QBKPN-treated mice, despite anti-Ly6G monoclonal antibody treatment. As neutrophils were detected using a fluorescently-labeled anti-Ly6G antibody (indicating expression of the antigen), the data indicate that the QBKPN treatment did not render neutrophils resistant to anti-Ly6G-mediated depletion. Thus, these data illustrate QBKPN SSI-induced expansion of the neutrophil compartment in a model of neutropenia. - A number of common therapies, including chemotherapy drugs used to treat cancers, suppress bone marrow function and reduce neutrophil counts, causing neutropenia. As illustrated herein, an SSI may accordingly be given so as to restore neutrophil counts. There are additional therapeutic benefits available in SSI therapies of this kind. In addition to treating neutropenia, in the context of treating an underlying disease, the selection of a targeted SSI, with a PRR agonist signature that recapitulates a distinct portion of a PRR agonist signature of a microbial pathogen that is pathogenic in the target tissue, results in site specific restoration of innate immune function in the target tissue. This may for example involve an anti-cancer immune response, or an anti-inflammatory immune response mediated by the SSI (in addition to the effect of treating the neutropenia).
- Chemotherapy commonly produces myelosuppression, of which the most clinically relevant component is neutropenia occurring between 2-10 days post-chemotherapy. The clinical implications of this are serious, interfering with the ability to maintain a chemotherapeutic dose and schedule, and giving rise to the risk of neutropenic sepsis. Accordingly, an SSI may be given to patients undergoing a myelosuppressive chemotherapy as a prophylaxis or treatment for neutropenia, for example being administered every other day between cycles of chemotherapy.
- This Example provides clinical data illustrating the efficacy of an SSI acting to down-regulate PD1 and PDL1 expression in neoplastic disease. This also illustrates the use of PD1 and PDL1 as markers of SSI efficacy, augmenting the NKG2D mouse model data in Example 23. This is significant, given the understanding that PD1 (expressed on T-cells) and it's ligand PD-L1 play a role in preventing T-cell activation and mediating pathological immunosuppression.
- In a lung cancer clinical trial of a KPN SSI, 6 patients presented in two distinct disease groups: pre-neoplastic and neoplastic (2 of the 6 patients were neoplastic). This Example provides data obtained from blood samples, analyzed by flow cytometry.
- As shown in Table 21, the 2 neoplastic patients presented with elevated PDL1 and PD1 expression compared to the pre-neoplastic patients. This is shown in the bar graph of
FIG. 57 as a percentage of the distinct cell populations, and inFIG. 58 as the relative number of cells having the denoted characteristics. The neoplastic patients (01-001 and 01-002) express higher levels of PD1 and PDL1, ad have a lower level of M4 macrophages than the pre-neoplastic patients. -
TABLE 21 PD1 and PDL1 Markers in Patients Prior to SSI Treatment Subject # Pre- Pre- Pre- Pre- neoplastic neoplastic neoplastic neoplastic Neoplastic Neoplastic 01-007 01-006 01-005 01-004 01-002 01-001 % of CD45+ 6.9 4.9 12.8 53.0 44.8 83.9 PDL1+ cells % of CD3+ 7.6 10.7 19.0 14.2 36.3 70.8 PD1+ cells M1 2.9 1.8 6.0 3.2 1.0 0.0 macrophages % of cell CD45+ CD14+ HLA- DR+ CD86+ M2 85.4 96.7 80.8 87.8 79.9 99.1 macrophages % of CD14+ cells CD163+ - With SSI treatment, the neoplastic patients showed a significant decrease in PD1 and PDL1 expression, as well as a significant increase in the percentage of M1 (CD45+ CD14+ HLA-DR+ CD86+) macrophage cells.
FIGS. 59A-59B illustrate the reduction of PD-L1 expression in Patient 01-001 (panel A) and Patient 01-002 (panel B), at:week 1, day 4 (W1D4);week 1, day 5 (W1D5); week 2 (W2); week 4 (W4), week 12 (W12) and week 16 (W16); during the course of SSI treatment every other day.FIGS. 60A-60B illustrate the reduction in PD-1 expression in these patients at these time points.FIGS. 61A-61B illustrate the increase in the proportion of M1 macrophages in these patients at these time points. As illustrated, with SSI treatment, over time, PDL1 expression decreases on CD45+ cells (all white blood cells), PD1 expression decreases in CD3+ cells (lymphocytes), and M1 macrophages increase in the blood (CD45+ CD14+ HLA-DR+ CD86+). In these patients, SSI treatment was discontinued at week 12 (W12), and the assays indicated that the relative M2 macrophage populations (CD14+CD163+) generally decreased until the cessation of treatment, and then rebounded. - This Example illustrates the relationship between SSI dosage, tumour load, and expression of granzyme A, granzyme B, and perforin in B16 melanoma mouse lung models, providing evidence that eficatious SSI therapy elevates granzyme and perforin levels while reducing tumour load.
- Mice were intravenously injected with B16 melanoma cells to provide a mouse lung cancer model. Five groups of mice (n=5) were subcutaneously injected as follows: placebo (saline), 1×QBKPN, 1/50×QBKPN, 1/500×QBKPN, or 1/5000×QBKPN (a series of dilutions of the 1×KPN SSI). SSIs were administered prophylactically ten days prior to tumour inoculation at every second day. Mice were continually injected with SSIs every two days until they were euthanized at fourteen days post-tumour injection. The right lung post-caval lobe was removed and stored in RNAlater®.
- The entire mouse right lung post-caval lobe was homogenized in lysis buffer by a small bead mill (Qiagen, Cat No. 85600). All of the homogenate was extracted for RNA using the PureLink® RNA Mini Kit (ThermoFisher Scientific, Cat No. 12183018A). A Nanodrop™ spectrophotometer was used to quantify the RNA concentrations and purity. One microgram of RNA was reverse transcribed into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad, Cat no. 170-8891). For quantitative PCR, fifty nanograms of cDNA were loaded into each well of the reaction plate. In addition to cDNA, the wells contained TaqMan® Fast Advanced Master Mix (ThermoFisher Scientific, Cat No. 4444554), and TaqMan® Gene Expression Assays probes. Samples were quantified for granzyme A (ThermoFisher Scientific, Mm01304452_m1), granzyme B (ThermoFisher Scientific, Mm00442837_m1), perforin (ThermoFisher Scientific, Mm00812512_m1), tyrosinase (ThermoFisher Scientific, Mm00495817_m1), and GAPDH (ThermoFisher Scientific, Mm99999915_g1) as the housekeeping gene. Two technical replicates were plated for the genes of interest (GOI), and in singlicate for the housekeeping gene.
- The ddCt method was used to calculate gene expression fold changes. Technical replicates for the GOI were averaged, and biological replicates were tested for outliers using the ROUT method on GraphPad Prism 7.00 at 95% confidence. The technical outliers for GzmB: 1/500x-3 and Prf1: 1/500x-3 were removed from further analyses. The dCt value was calculated by subtracting Ct,GOI by Ct,GAPDH. The ddCt values were calculated by subtracting dCt of the sample by average dCt of the placebo group. Fold change was calculated by taking the negative exponent of ddCt with base two (2-ddCt). The average fold change of each treatment group was analyzed for significance using a one-way Tukey's multiple comparison ANOVA test at 95% confidence.
-
FIGS. 62A-62B illustrate the results of the foregoing assays, showing RT-qPCR fold changes in (A) GzmA, GzmB, Prf1, and (B) Tyr in lungs of B16 inoculated mice euthanized onday 14 with differing QBKPN doses. Taqman® Gene Expression Assays were performed on 50 ng of cDNA isolated from the right lung post-caval lobe of mice. Values are normalized to GAPDH, and relative to the gene expression of the placebo group, which were mice injected with saline. Data points are mean+/−SD. All data points have n=5 except GzmB-1/500X and Prf1-1/500X, which have n=4 after removal of dCt outliers. Significance was calculated using a one-way Tukey's multiple comparison ANOVA test. **p<0.01, *p<0.001 and ****p<0.0001. - In accordance with one aspect of this Example, SSIs may be formulated and administered in a dosage regime that is effective in a target organ or tissue to mediate increased expression of one or more granzyme or perforin, such as of granzyme A, granzyme B, and perforin.
- This Example illustrates that both QBECO and QBKPN SSIs activate multiple PRRs, and QBECO and QBKPN each activate different PRRs, with different PRR repertoire fingerprints being identified for each SSI.
- This data in this Example was obtained from assays of QBKPN and QBECO PRR activation in cell lines that have a single PRR. The cell lines used were HEK293 cells lines that express a single human Toll-Like Receptor (TLR2, 3, 4, 5, 7, 8 and 9), NOD-Like Receptor (NOD1 and NOD2), C-Type Lectin (
Dectin 1a,Dectin 1b, and Mincle) or RIG-1-like receptor (RIG-1 and MDA5). - As illustrated in
FIG. 63 , two TLRs were highly activated by both QBECO and QBKPN (TLR 2 and TLR4). One TLR was highly activated by just QBKPN (TLR5). 1 PRR was moderately activated by bother QBECO and QBKPN (NOD2). 4 were moderately activated by only QBECO (TLR3, TLR7, TLR8, TLR9) while 2 were moderately activated by only QBKPN (Dectin 1a,Dectin 1b). NOD1, Mincle, RIG-1 and MDA5 were not activated by either QBECO or QBKPN. - TLR2 and TLR4 are localized on the plasma membrane and primarily recognize lipoprotein and LPS respectively. TLR5 is a plasma membrane receptor that responds to Flagellin. Of the RNA/DNA recognition TLR's, TLR3 was only slightly activated by QBECO (and not by QBKPN). TLR3 is primarily a dsRNA receptor for viral RNA. TLR7 and 8, which are located in the endolysosome and also recognize RNA (bacterial and viral) were activated by only QBECO. Finally, TLR9 which recognized CpG-DNA and is located in the endolysosome was also activated by only QBECO. In this context, it is relevant that HEK cells are not known to highly uptake bacteria in endolysosomes. Therefore, the lack of QBKPN activation for
TLR Dectin 1a andDectin 1b are primarily fungi receptors for beta-Glucans but can also see bacteria carbohydrates. - When graphed as either bar graphs (
FIG. 64 ) or radar graphs (FIG. 65 ), an overall PRR repertoire fingerprint appears. These results are all derived from the 1/10 dilution of the relevant SSI, with the negative control subtracted from the absorbance value. - This Example illustrates that viral SSIs induce immune changes are similar to bacterial SSIs, as evidenced by immune correlates in the blood after 7 days of Viral SSI treatment compared to QBKPN SSI treatment. Mice were treated with Placebo, QBKPN, or three viral SSI models: Rabies Vaccine, Feline Rhinotracheitis-Calici-Panleukopenia Vaccine and Canine Influenza Vaccine. 30 μL of the treatments were injected subcutaneously every second day. The endpoint was 24 hours after the 4th SSI injection (day 7). At endpoint, blood was collected and stained for flow cytometry to determine the numbers of neutrophils and Ly6CHI monocytes in the blood as a percentage of CD45+ cells.
- As illustrated in
FIG. 66 , Rabies vaccine (killed rabies virus) increased neutrophil levels when compared to placebo, to levels comparable to levels seen with QBKPN treatment. As illustrated inFIG. 67 , treatment with Rabies vaccine, Fel-O-Vac (Feline Rhinotracheitis-Calici-Panleukopenia virus) and Nobivac (Canine Influence H3H8 virus) all had similar increases in Ly6CHI monocytes, comparable to QBKPN treatment. - This data illustrates that SSIs produced from viral compositions induce similar immune response to SSIs produced from bacterial compositions. Viral SSIs are demonstrated to provide an equivalent response in neutrophil and Ly6CHI monocyte levels in the blood as does QBKPN.
- This Example illustrates that SSIs potentiate an immune response when used in combination with cancer antigens. As set out below in more detail, the lung-targeted SSI QBKPN mediated a reduction in tumour burden, and when used in combination therapy with a melanoma-associated antigen (gp100) further reduced tumour burden. This effect was specific to the use of the cancer antigen, as evidenced by the fact that an irrelevant (immunogenic but non tumour-associated) antigen did not impact tumour burden. The SSI cancer antigen combination therapy was effective both as co-formulated compositions and as separate injections of SSI and antigen. This evidences the use of an SSI as a adjuvant to drive immune responses to immunogenic cancer antigens.
- The anti-tumour efficacy of QBKPN SSI in combination with the melanoma-specific antigen gp100 was compared to the irrelevant control antigen OVA (also called SIINFEKL) in C57Bl/6 mice sourced from Jackson Laboratories. On ˜day −31, mice were infected with K. pneumoniae (2.5×105 cells/mouse, by oropharyngeal instillation after being anaesthetized with isofluorane), then rested. Within 5-7 days, all mice were fully recovered from K. pneumoniae challenge. Starting on day −10, some mice were S.C. injected with QBKPN SSI; mice were injected every other day from Day −10 to day +12. Injections were performed in rotating sites (in accordance with the typical protocol in the Examples herein) at a dose of 0.03 ml of a 5.0 OD suspension.
- On days −10, −6, and −4, some mice were also treated with indicated antigens and/or adjuvants, either co-mixed with SSI or s.c. in a distal site (nape). Peptide vaccines consisted of the melanoma-specific antigen gp10025-33 (KVPRNQDWL, 100 μg/mouse) or the immunogenic control antigen from OVA (OVA257-264, SIINFEKL, 100 μg/mouse). Adjuvant consisted of commercial CpG (ODN 1585 VacciGrade, 30 μg/mouse s.c). On
day 0, mice were challenged with B16 melanoma (3×105 cells/mouse, i.v.). On day +14, mice were sacrificed, surface metastases enumerated, and spleens and blood collected. Splenocytes were pooled among each group. Splenocytes (1×106 cells/well) were cultured with gp10025-33, OVA257-264, or control peptide (influenza NP366-374) (all peptides at 10 μg/ml) for 5 days, then supernatants assessed for IFN-γ (by specific ELISA) as a readout of immunogenicity. Blood was collected into heparin-containing tubes, then centrifuged to remove cells. ELISA (RND Systems DuoSet DY485, limit of detection 31.2 μg/ml) was performed per the manufacturer's protocol. ELISA was performed with technical replicates (n=3) on all samples to generate a cytokine value for each culture condition (restimulated splenocytes) or animal (serum analyses); cytokine data are reported as group mean+/−standard deviation. Statistical differences were evaluated by unpaired T test (GraphPad PRISM). - As illustrated in
FIG. 68 , QBKPN treatment of K. pneumoniae-pre-exposed mice significantly (p<0.0001) reduced metastatic-like B16 melanoma in the lungs. Administration of cancer antigen (gp100) without adjuvant had no significant effect, in keeping with the relative paucity of response to non-adjuvanted vaccines in murine systems. Administration of cancer antigen with adjuvant (CpG) reduced tumour burden (p=0.0023), to a lesser extent that SSI alone. Combination of QBKPN SSI with gp100 (tumour-associated antigen) significantly (p<0.05) enhanced anti-tumour efficacy, compared with QBKPN alone. There was no statistical difference in anti-tumour efficacy between SSI/antigen combination used as a coformulation vs separate injection. Combining the SSI with a non-specific antigen (OVA) did not enhance anti-tumour efficacy, beyond the level of QBKPN SSI alone. - These data illustrate that QBKPN SSI can act as an adjuvant to induce/enhance the efficacy of cancer vaccines, and this adjuvant effect may be utilized either as a coformulation or separate administration. These results evidence an anti-cancer effect in which the SSI (alone or with antigen) was superior to adjuvanted antigen (gp100+CpG). Consistent with this, SSI treatment, without or with antigen, enhanced circulating levels of IFN-γ.
- This Example illustrates enhanced efficacy of a microbial SSI augmented with an additional PRR agonist, in this case a STING agonist. These formulations constitute a class of artificial PRR agonist repertoires in which a microbial PRR agonist repertoire is augmented with one or more additional heterologous PRR agonists.
- The anti-tumour efficacy of QBKPN SSI in combination with the
STING agonist 2′2′-cGMAP (inVivoGen) was evidenced in C57BV/6 mice, as follows. On ˜day −31, mice were infected with K. pneumoniae (2.5×105 cells/mouse) by oropharyngeal instillation after being anaesthetized with isofluorane, then rested. Within 5-7 days, all mice were fully recovered from K. pneumonia challenge. Starting on day −10, some mice were S.C. injected with QBKPN SSI; mice were injected every other day from Day −10 to day +12. Injections were performed in rotating sites at a dose of 0.03 ml of a 5.0 OD suspension. On days −10, −6, and −4, some mice were also treated with STING agonist (SC injection of 10 μg/mouse in 20 μl of saline), either co-mixed with SSI or s.c. in a distal site (nape). OnDay 0, mice were challenged with B16 melanoma by tail-vein (I.V.) injection of single cell suspensions of tumour cells (2.0×105 cells/mouse). On day +14, plasma was collected for ELISA, then mice were sacrificed and visual metastases counted and recorded. Serum was collected into heparin-containing tubes, then centrifuged to remove cells. ELISA (RND Systems DuoSet DY485, limit of detection 31.2 pg/ml) was performed per the manufacturer's protocol. ELISA was performed with technical replicates (n=3) on all plasma samples to generate a cytokine value for each animal; cytokine data are reported as group mean+/−standard deviation (n=7 mice/group). Statistical differences were evaluated by unpaired T test (GraphPad PRISM). - As illustrated in
FIG. 69 , QBKPN treatment of K. pneumoniae-pre-exposed mice significantly (p<0.0001) reduced metastatic-like B16 melanoma in the lungs. Administration of STING agonist alone also reduced tumour burden (p=0.0038). The combination of SSI and STING agonist further reduced tumour burden; the number of tumour nodules was significantly reduced following coinjection of SSI and agonist, compared with untreated (p<0.0001), SSI alone (p=0.0206), or STING agonist alone (p=0.0006) (FIG. 1 ). Likewise, simultaneous therapy (separate injection sites) with SSI and STING agonist reduced tumour burden, compared with untreated (p<0.0001) or agonist alone (p=0016). - As shown in
FIG. 70 , both SSI treatment and STING agonist treatment enhanced circulating levels of IFN-γ (p<0.0001 and p=0.0038, respectively). The combination of SSI and STING agonist further increased cytokine levels, even though STING agonist treatment had not occurred for 18 days. Cytokine levels following combination treatment were statistically greater than single agent treatment. There was a significant inverse correlation between tumour burden and plasma IFN-γ levels. In sum, this data illustrate effective combination therapy using a STING agonist and an SSI. - This Example provides a genetic analysis of subjects with IBD undergoing treated with an SSI therapy, illustrating the use of genetic markers associated with IBD to identify patient populations amenable to SSI treatments. In this Example there were 48 subjects with IBD and approximately 2.4 million single nucleotide polymorphisms (SNPs) which were the subject of analyses following genotyping on the Infinium Omni2.5-8 bead chip. The end-points used for these genetic analyses were varied and encompassed both clinical response and also the use of object markers of disease activity. Following standard quality control measures (including call frequency, minor allele frequency, and Hardy-Weinberg equilibrium test) a total of 1,271,655 SNPs were available for analyses. 113 known IBD loci were represented on the chip and passed quality control. Of the study subjects there were 31 Crohn's disease (CD) and 12 ulcerative colitis (UC) cases included.
- A number of IBD-associated SNPs are associated with SSI treatment outcomes in IBD cases, using p=0.05 as a nominal significance, for example:
-
-
- Last recorded response in CD (response vs no response)—a SNP tagging the FASLG, TNFSF18 genes was the top association (p=0.0033).
- The same FASLG, TNFSF18 locus was also associated with drop in CDAI in CD cases (p=0.018).
- CD drop in calprotectin was associated with a number of SNPs tagging 4 loci:
- NEXN, FUBP1, DNAJB4, GIPC2, MGC27382;
- ATF4, TAB1;
- IL23R;
- IL8, CXCL1, CXCL6, CXCL3, PF4, CXCL5, CXCL2 (all p<0.05).
- 8 week drop in CRP was associated with a SNP tagging NOTCH2 (p=0.002).
-
-
- Mayo score drop at 16 weeks associated with SNPs tagging:
- HNF4A
- IRFI
- GPR12
- nd FOXO1 (all p<0.05)
- HNF4A, and GPR12 are also associated with drop in CRP in UC after 16 weeks of treatment.
- Mayo score drop at 16 weeks associated with SNPs tagging:
-
-
- Last response in all IBD cases combined showed associations with SNPs that tagged loci tagging FASLG, TNFSF18 (p=0.02) and also JAK2 (p=0.04).
- An analyses of all the SNPs across the chip against the phenotypes listed above revealed a number of associations as summarized in the Table 22:
-
TABLE 22 Unbiased analyses of all SNPs across the genotyping platform SNP ID P value Genes kgp10600643 0.00037 BMPR1B rs1998639 0.00043 CD1D, KIRREL rs9578586 0.00046 SGCG, SACS rs1467073 0.00055 DENND3, SLC45A4 rs12364461 0.00062 P2RY2, P2RY6, ARHGEF17, FCHSD2 kgp8836175 0.00069 ZFHX3 - Using a cumulative gene-risk score (GRS; see Jostins et al., (2013) PLoS ONE 8(10): e76328) based on all known IBD associated SNPs, a highly significant association was identified with CD responders to SSI treatment having higher GRS developed from 112 IBD-associated SNPs (listed below) than non-responders (p=2.43×10−5), as illustrated in
FIG. 71A . Using just 3 of these SNPs, with raw p-values <0.05 (rs9286879, rs7517810, rs17391694), also evidenced a significant association (P-value: 1.385E-04) with CD responders, as illustrated inFIG. 71B . Similarly there was an association with higher GRSs observed in UC responders than non-responders, as illustrated inFIG. 72 (p=0.012), providing an independent verification of the CD phenotype and GRS finding summarized above. Given that the overwhelming majority of IBD-associated loci are shared between CD and UC combining these data as cumulative GRS in all IBD cases is valid. Despite the small number of cases there is a very significant association between GRS and response at last follow up, as illustrated inFIG. 73 (p=8.18×10−7). - The remarkable association of the cumulative GRS with last documented response in CD, UC, and combined IBD patient populations indicates that individuals with IBD that are genetically enriched for genetic markers associated with IBD are more likely to respond to SSI. Furthermore, since the majority of these genetic variants are associated with other immune-mediated diseases, this indicates that this approach may be extended to other patient cohorts beyond IBD when treated with an SSI. These findings indicate that it is possible to identify subjects, such as IBD subjects, more likely to respond to an SSI treatment. Accordingly, an aspect of the present invention involves the provision of companion diagnostic genetic testing assays in association with an SSI therapy. SNPs and genetic loci that may be used in such assays are set out below.
-
- List of 243 IBD susceptibility SNPs: rs1748195, rs34856868, rs11583043, rs6025, rs10798069, rs7555082, rs11681525, rs4664304, rs3116494, rs7556897, rs111781203, rs35320439, rs113010081, rs616597, rs724016, rs2073505, rs4692386, rs6856616, rs2189234, rs395157, rs4703855, rs564349, rs7773324, rs13204048, rs7758080, rs1077773, rs2538470, rs17057051, rs7011507, rs3740415, rs7954567, rs653178, rs11064881, rs9525625, rs3853824, rs17736589, rs9319943, rs7236492, rs727563, rs17391694, rs6679677, rs3897478, rs9286879, rs1728918, rs10865331, rs6716753, rs12994997, rs6837335, rs13126505, rs10065637, rs7702331, rs17695092, rs12663356, rs9264942, rs9491697, rs13204742, rs212388, rs10486483, rs864745, rs7015630, rs6651252, rs3764147, rs16967103, rs2066847, rs2945412, rs2024092, rs4802307, rs516246, rs2284553, rs10797432, rs6426833, rs2816958, rs1016883, rs17229285, rs9847710, rs3774959, rs11739663, rs254560, rs6927022, rs798502, rs4722672, rs4380874, rs4728142, rs483905, rs561722, rs28374715, rs11150589, rs1728785, rs7210086, rs1126510, rs6088765, rs6017342, rs12103, rs35675666, rs12568930, rs11209026, rs2651244, rs4845604, rs670523, rs4656958, rs1801274, rs2488389, rs7554511, rs3024505, rs6545800, rs925255, rs10495903, rs7608910, rs6740462, rs917997, rs2111485, rs1517352, rs2382817, rs3749171, rs4256159, rs3197999, rs2472649, rs7657746, rs2930047, rs11742570, rs1363907, rs4836519, rs2188962, rs6863411, rs11741861, rs6871626, rs12654812, rs17119, rs9358372, rs1847472, rs6568421, rs3851228, rs6920220, rs12199775, rs1819333, rs1456896, rs9297145, rs1734907, rs38904, rs921720, rs1991866, rs10758669, rs4743820, rs4246905, rs10781499, rs12722515, rs1042058, rs11010067, rs2790216, rs10761659, rs2227564, rs1250546, rs6586030, rs7911264, rs4409764, rs907611, rs10896794, rs11230563, rs4246215, rs559928, rs2231884, rs2155219, rs6592362, rs630923, rs11612508, rs11564258, rs11168249, rs7134599, rs17085007, rs941823, rs9557195, rs194749, rs4899554, rs8005161, rs17293632, rs7495132, rs529866, rs7404095, rs26528, rs10521318, rs3091316, rs12946510, rs12942547, rs1292053, rs1893217, rs7240004, rs727088, rs11879191, rs17694108, rs11672983, rs6142618, rs4911259, rs1569723, rs913678, rs259964, rs6062504, rs2823286, rs2836878, rs7282490, rs2266959, rs2412970, rs2413583, rs2641348, rs7517810, rs1260326, rs7438704, rs10061469, rs2503322, rs5743289, rs6667605, rs1440088, rs3774937, rs477515, rs1182188, rs17780256, rs11083840, rs3766606, rs13407913, rs6708413, rs2457996, rs10051722, rs4976646, rs7746082, rs38911, rs13277237, rs2227551, rs7097656, rs12778642, rs11229555, rs174537, rs568617, rs2226628, rs566416, rs11054935, rs3742130, rs1569328, rs2361755, rs3091315, rs1654644, rs4243971, rs6087990, rs6074022, rs5763767.
- Subset of 112 SNPs which together generated the GRS of
FIG. 71A : rs10065637, rs1016883, rs1042058, rs10521318, rs10758669, rs1077773, rs10781499, rs10865331, rs10896794, rs11054935, rs11083840, rs11150589, rs11168249, rs11209026, rs11583043, rs11672983, rs11739663, rs11742570, rs1182188, rs1260326, rs12778642, rs13204048, rs13277237, rs1517352, rs1569723, rs1654644, rs17085007, rs17119, rs17229285, rs1728918, rs1734907, rs17391694, rs1748195, rs17780256, rs1801274, rs1847472, rs1893217, rs194749, rs2024092, rs2111485, rs212388, rs2155219, rs2188962, rs2189234, rs2227551, rs2231884, rs2413583, rs2472649, rs2641348, rs2651244, rs26528, rs2816958, rs2823286, rs2836878, rs2930047, rs3024505, rs35320439, rs3742130, rs3764147, rs3766606, rs38904, rs395157, rs4243971, rs4409764, rs4692386, rs4728142, rs477515, rs4802307, rs4836519, rs483905, rs4976646, rs516246, rs559928, rs564349, rs566416, rs568617, rs6017342, rs6088765, rs616597, rs6426833, rs6651252, rs6667605, rs6856616, rs6863411, rs6920220, rs7097656, rs7134599, rs7210086, rs7236492, rs7240004, rs724016, rs7282490, rs7495132, rs7517810, rs7702331, rs7758080, rs864745, rs917997, rs921720, rs925255, rs9264942, rs9286879, rs9297145, rs9319943, rs941823, rs9491697, rs9847710, rs12199775, rs12654812, rs1292053, rs2227564, rs3197999, rs6074022.
- The foregoing subset of 112 SNPs exhibited varying degrees of association with response to SSI therapy, as set out in Tables 23A and 236, which identifies the relevant allele for each SNP and the odds ratio reflecting the association of that allele with SSI response. In Table 23A, odds ratios greater than 1 indicate that the designated allele is positively associated with response to SSI therapy, odds ratios less 1 indicate that alternative allele is positively associated with response to SSI therapy and the allele set out in the Table is negatively associated with response to SSI therapy. In Table 23B, the odds ratios that are negative in Table 23A have been converted to positive odds ratios for the alternative allele, so that all odds ratios are greater than one and the Response Allele is the allele associated with response to SSI therapy.
-
TABLE 23A SNP alleles associated (or negatively associated) with Response to SSI Therapy rsID Response Allele Odds Ratio rs7517810 G 19.83 rs17391694 G 12.00 rs2413583 G 5.67 rs13204048 G 3.84 rs11209026 G 3.64 rs1734907 G 3.56 rs212388 G 3.19 rs11739663 G 3.19 rs3742130 G 3.00 rs11672983 G 2.99 rs1801274 G 2.94 rs559928 G 2.68 rs1042058 G 2.68 rs9847710 G 2.66 rs4802307 C 2.49 rs4836519 G 2.37 rs194749 G 2.31 rs4243971 C 2.28 rs10781499 G 2.26 rs26528 G 1.99 rs864745 G 1.90 rs516246 G 1.87 rs2472649 G 1.87 rs12654812 G 1.85 rs3764147 G 1.85 rs2155219 C 1.79 rs12199775 G 1.69 rs4728142 G 1.63 rs1182188 G 1.63 rs17119 G 1.60 rs2189234 C 1.59 rs483905 G 1.58 rs925255 G 1.49 rs7702331 G 1.48 rs564349 G 1.44 rs35320439 G 1.43 rs10865331 G 1.37 rs7495132 G 1.33 rs1016883 G 1.33 rs1292053 G 1.29 rs1260326 G 1.27 rs724016 G 1.25 rs9264942 G 1.23 rs11742570 G 1.21 rs3024505 G 1.20 rs11083840 C 1.20 rs6863411 T 1.18 rs11150589 G 1.16 rs2188962 G 1.15 rs38904 G 1.15 rs2231884 G 1.14 rs568617 G 1.14 rs566416 C 1.09 rs941823 G 1.09 rs2930047 G 1.08 rs1748195 G 1.06 rs2227564 G 1.05 rs9491697 G 1.00 rs7240004 G 0.98 rs3766606 C 0.96 rs2227551 C 0.95 rs11054935 G 0.95 rs7758080 G 0.95 rs477515 G 0.94 rs1847472 C 0.93 rs10896794 G 0.92 rs6426833 G 0.91 rs1893217 G 0.90 rs4409764 C 0.89 rs13277237 G 0.86 rs6017342 C 0.82 rs1517352 C 0.82 rs11583043 G 0.81 rs4692386 G 0.79 rs2823286 G 0.79 rs2111485 G 0.77 rs395157 G 0.76 rs17780256 C 0.76 rs7210086 C 0.76 rs921720 G 0.75 rs616597 C 0.74 rs10521318 G 0.71 rs9319943 G 0.71 rs7282490 G 0.70 rs1569723 C 0.69 rs4976646 G 0.68 rs9297145 C 0.67 rs6074022 G 0.67 rs7097656 G 0.66 rs1077773 G 0.66 rs11168249 G 0.63 rs10758669 C 0.62 rs1728918 G 0.61 rs2651244 G 0.59 rs12778642 C 0.58 rs17229285 G 0.56 rs2836878 G 0.56 rs6667605 G 0.50 rs1654644 C 0.48 rs10065637 G 0.48 rs2641348 G 0.44 rs2816958 G 0.43 rs7134599 G 0.41 rs6651252 G 0.40 rs917997 G 0.38 rs6088765 C 0.38 rs2024092 G 0.38 rs3197999 G 0.34 rs7236492 G 0.32 rs17085007 G 0.24 rs6920220 G 0.21 rs9286879 G 0.05 -
TABLE 23B SNP alleles associated with Response to SSI Therapy rsID Response Allele Odds Ratio rs9286879 A 19.83 rs7517810 G 19.83 rs17391694 G 12.00 rs2413583 G 5.67 rs6920220 A 4.87 rs17085007 A 4.20 rs13204048 G 3.84 rs11209026 G 3.64 rs1734907 G 3.56 rs212388 G 3.19 rs11739663 G 3.19 rs7236492 A 3.08 rs3742130 G 3.00 rs11672983 G 2.99 rs3197999 A 2.98 rs1801274 G 2.94 rs559928 G 2.68 rs1042058 G 2.68 rs2024092 A 2.67 rs6088765 T 2.66 rs9847710 G 2.66 rs917997 A 2.64 rs6651252 A 2.52 rs4802307 C 2.49 rs7134599 A 2.46 rs4836519 G 2.37 rs2816958 A 2.33 rs194749 G 2.31 rs2641348 A 2.29 rs4243971 C 2.28 rs10781499 G 2.26 rs10065637 A 2.10 rs1654644 T 2.06 rs26528 G 1.99 rs6667605 A 1.99 rs864745 G 1.90 rs516246 G 1.87 rs2472649 G 1.87 rs12654812 G 1.85 rs3764147 G 1.85 rs2836878 A 1.80 rs17229285 A 1.79 rs2155219 C 1.79 rs12778642 T 1.73 rs2651244 A 1.71 rs12199775 G 1.69 rs1728918 A 1.65 rs4728142 G 1.63 rs1182188 G 1.63 rs10758669 T 1.60 rs17119 G 1.60 rs2189234 C 1.59 rs483905 G 1.58 rs11168249 A 1.58 rs1077773 A 1.53 rs7097656 A 1.51 rs6074022 A 1.50 rs925255 G 1.49 rs9297145 T 1.48 rs7702331 G 1.48 rs4976646 A 1.46 rs1569723 T 1.45 rs564349 G 1.44 rs35320439 G 1.43 rs7282490 A 1.42 rs9319943 A 1.41 rs10521318 A 1.40 rs10865331 G 1.37 rs616597 T 1.35 rs7495132 G 1.33 rs1016883 G 1.33 rs921720 A 1.33 rs17780256 T 1.32 rs7210086 T 1.32 rs395157 A 1.32 rs2111485 A 1.30 rs1292053 G 1.29 rs1260326 G 1.27 rs2823286 A 1.27 rs4692386 A 1.26 rs724016 G 1.25 rs11583043 A 1.23 rs9264942 G 1.23 rs1517352 T 1.21 rs6017342 T 1.21 rs11742570 G 1.21 rs3024505 G 1.20 rs11083840 C 1.20 rs6863411 T 1.18 rs13277237 A 1.16 rs11150589 G 1.16 rs2188962 G 1.15 rs38904 G 1.15 rs2231884 G 1.14 rs568617 G 1.14 rs4409764 T 1.13 rs1893217 A 1.11 rs6426833 A 1.10 rs566416 C 1.09 rs941823 G 1.09 rs10896794 A 1.09 rs2930047 G 1.08 rs1847472 T 1.07 rs1748195 G 1.06 rs477515 A 1.06 rs7758080 A 1.06 rs11054935 A 1.05 rs2227564 G 1.05 rs2227551 T 1.05 rs3766606 T 1.05 rs7240004 A 1.02 rs9491697 G 1.00 - Within the foregoing subset of 112 SNPs, a number were individually associated with particular markers of clinical efficacy, and these SNPs are in turn spacially associated with genes, so that alternative markers, such as SNPs, associated with these genes may also serve as markers of SSI efficacy, as set out in Table 24.
-
TABLE 24 Select SNPs and associated Genes Efficacy Metric SNP Raw p-value Important genes in area CD - rs9286879 3.32E−03 TNFSF18, TNFSF4, FASLG Response rs7517810 3.32E−03 TNFSF18, TNFSF4, FASLG score - rs17391694 4.06E−02 DNAJB4 (HSP-40 family member), Comparing GIPC2, NEXN, FUBP1, MGC27382 last recorded response for all CD subjects CD - CDAI: rs1734907 1.43E−02 EPHB4, EPO, GNB2, TFR2, ZAN, Comparing POP7, ACTL6B, GIGYF drop in CADI rs9286879 1.84E−02 See CD - response after 8 weeks rs7517810 1.84E−02 See CD - response of treatment for rs4836519 4.37E−02 all CD subjects CD - rs17391694 7.21E−03 See CD - response Calprotectin: rs2413583 1.09E−02 MAP3K7IP1, PDGFB, RPL3, Comparing SYNGR1, SNORD43, SNORD83A, drop in fecal SNORD83B, FLJ23865, TAB1, calprotectin ATF4 after 8 weeks rs11209026 1.62E−02 IL12RB2, IL23R of treatment for rs2472649 2.85E−02 CXCL3, PF4, PPBP, CXCL5, all CD subjects PPBPL2, IL8, CXCL1, CXCL6, CXCL2 CD - CRP: rs2641348 2.20E−03 NOTCH2, ADAM30, REG4, NBPF7 Comparing drop in CRP after 8 weeks of treatment for all CD subjects UC - Mayo: rs17085007 1.81E−02 GPR12 Comparing rs2024092 2.50E−02 CNN2, GPX4, POLR2E, STK11, drop in Mayo ABCA7, SBNO2, HMHA1 score after 16 rs6017342 2.50E−02 HNF4A, SERINC3, PKIG, TTPAL, weeks of R3HDM treatment for rs2188962 3.65E−02 IRF1, SLC22A4, SLC22A5, C5orf56 all UC subjects rs941823 3.71E−02 LOC646982, FOX01 UC-CRP: rs17085007 1.95E−02 see UC-Mayo Comparing rs2024092 1.95E−02 see UC-Mayo drop in CRP rs6017342 3.81E−02 see UC-Mayo after 16 weeks rs17229285 3.96E−02 of treatment for all UC subjects - The foregoing IBD associated SNPs are spacially associated with genes (Liu et al., Nature Genetics. 47.9 (September 2015): p 979), so that alternative markers, such as SNPs, associated with these genes may also serve as markers of SSI efficacy, as set out in Table 25:
-
TABLE 25 Additional SNPs and associated Genes SNP Candidate Gene GRAIL gene rs1748195 USP1 rs34856868 BTBD8 rs11583043 SLC30A, EDG1 EDG1 rs6025 SELP, SELE, SELL SELP, SELE, SELL NA (rs10798069) PTGS2, PLA2G4A NA (rs7555082) PTPRC rs11681525 — rs4664304 MARCH7, LY75, PLA2R1 LY75 rs3116494 ICOS, CD28, CTLA4 ICOS, CD28, CTLA4 rs7556897, CCL20 CCL20 rs111781203 rs35320439 PDCD1, ATG4B PDCD1, ATG4B rs113010081 FLJ78302, LTF, FLJ78302, LTF, CCR1/2/3/5 CCR1, CCR3, CCR5 rs616597 NFKBIZ NFKBIZ rs724016 — rs2073505 HGFAC rs4692386 — rs6856616 — rs2189234 — rs395157 OSMR, FYB, LIFR OSMR, FYB rs4703855 — rs564349 C5orf4, DUSP1 DUSP1 rs7773324 IRF4, DUSP22 IRF4, DUSP22 rs13204048 — rs7758080 MAP3K7IP2 MAP3K7IP2 rs1077773 AHR AHR rs2538470 CNTNAP2 rs17057051 PTK2B, TRIM35, EPHX2 PTK2B rs7011507 — rs3740415 NFKB2, TRIM8, TMEM180 NFKB2 rs7954567 CD27, TNFRSF1A, LTBR CD27, TNFRSF1A, LTBR rs653178 SH2B3, ALDH2, ATXN2 SH2B3 rs11064881 PRKAB1 rs9525625 AKAP1, TNFSF11 TNFSF11 rs3853824 — rs17736589 — rs9319943 — rs7236492 NFATC1, TST NFATC1 rs727563 TEF, NHP2L1, PMM1, L3MBTL2, CHADL - The foregoing IBD associated SNPs are spacially associated with genes (Jostins, et al., Nature. 2012; 491: 119-124), so that alternative markers, such as SNPs, associated with these genes may also serve as markers of SSI efficacy, as set out in Table 26:
-
TABLE 26 Further SNPs and associated Genes SNP IC_SNP Key Genes (N) rs17391694 rs17391694 (5) rs6679677 rs6679677 PTPN22, (8) rs3897478 rs2641348 ADAM30, (6) rs9286879 rs7517810 TNFSF18, FASLG rs1728918 rs1260326 UCN, (22) rs10865331 rs10865331 (3) rs6716753 rs6716753 SP140, (5) rs12994997 rs12994997 ATG16L1, (8) rs6837335 rs7438704 TEC, TXK, SLC10A4, (3) rs13126505 rs13126505 (1) rs10065637 rs10065637 IL6ST, IL31RA, (2) rs7702331 rs10061469 (4) rs17695092 rs17695092 CPEB4, (2) rs12663356 rs12663356 (2) rs9264942 rs9264942 HLA-C, PSORS1C1, (1) rs9491697 rs2503322 (3) rs13204742 rs13204742 (2) rs212388 rs212388 (6) rs10486483 rs10486483 (2) rs864745 rs864745 CREB5, JAZF1 rs7015630 rs7015630 RIPK2, (4) rs6651252 rs6651252 (0) rs3764147 rs3764147 LACC1, FLJ38725, (2) rs16967103 rs16967103 RASGRP1, SPRED1, (2) rs2066847** rs5743289 NOD2, (?) rs2945412 rs2945412 LGALS9, NOS2, (4) rs2024092 rs2024092 APC2, GPX4, (21) rs4802307 rs4802307 (11) rs516246 rs516246 DBP, IZUMO1, FUT2, SPHK2, (22) rs2284553 rs2284553 IFNGR2, IFNAR1, IL10RB, TMEM50B, IFNAR2, GART, (7) - The foregoing IBD associated SNPs are spacially associated with genes (Jostins, eta, Nature. 2012; 491: 119-124), so that alternative markers, such as SNPs, associated with these genes may also serve as markers of SSI efficacy, as set out in Table 27a:
-
TABLE 27a Further Select SNPs and associated Genes SNP IC_SNP All Genes rs17391694 rs17391694 NEXN, FUBP1, DNAJB4, GIPC2, MGC27382 rs6679677 rs6679677 MAGI3, PHTF1, RSBN1, PTPN22, BCL2L15, AP4B1, DCLRE1B, HIPK1, OLFML3 rs3897478 rs2641348 PHGDH, HMGCS2, REG4, NBPF7, ADAM30, NOTCH2 rs9286879 rs7517810 FASLG, TNFSF18 rs1728918 rs1260326 SLC5A6, C2orf28, CAD, SLC30A3, DNAJC5G, TRIM54, UCN, MPV17, GTF3C2, EIF2B4, SNX17, ZNF513, PPM1G, FTH1P3, NRBP1, KRTCAP3, IFT172, FNDC4, GCKR, C2orf16, ZNF512, CCDC121, GPN1, SUPT7L rs10865331 rs10865331 COMMD1, B3GNT2, TMEM17 rs6716753 rs6716753 FBXO36, SLC16A14, SP110, SP140, SP140L, SP100 rs12994997 rs12994997 NGEF, NEU2, INPP5D, ATG16L1, SCARNA5, SCARNA6, SAG, DGKD, USP40 rs6837335 rs7438704 TXK, TEC, SLAIN2, SLC10A4, ZAR1, FRYL rs13126505 rs13126505 BANK1 rs10065637 rs10065637 IL31RA, IL6ST, ANKRD55 rs7702331 rs10061469 FCHO2, TMEM171, TMEM174, FOXD1 rs17695092 rs17695092 CPEB4, C5orf47, HMP19 rs12663356 rs12663356 CDKAL1, SOX4, FLJ22536 rs9264942 rs9264942 HCG22, C6orf15, PSORS1C1, CDSN, PSORS1C2, CCHCR1, TCF19, POU5F1, PSORS1C3, HCG27, HLA-C, HLA-B, MICA, HCP5, HCG26, MICB, MCCD1, DDX39B, SNORD117, SNORD84, ATP6V1G2, NFKBIL1 rs9491697 rs2503322 RSPO3, RNF146, ECHDC1 rs13204742 rs13204742 THEMIS, PTPRK rs212388 rs212388 EZR, OSTCP1, C6orf99, RSPH3, TAGAP, FNDC1 rs10486483 rs10486483 C7orf71, SKAP2 rs864745 rs864745 JAZF1, LOC100128081, CREB5 rs7015630 rs7015630 RIPK2, OSGIN2, NBN, DECR1, CALB1 rs6651252 rs6651252 rs3764147 rs3764147 ENOX1, CCDC122, LACC1, LINC00284 rs16967103 rs16967103 SPRED1, FAM98B, RASGRP1, C15orf53 rs2066847** rs5743289 ADCY7, BRD7, NKD1, SNX20, NOD2, CYLD rs2945412 rs2945412 WSB1, LOC440419, KSR1, LGALS9, NOS2 rs2024092 rs2024092 MED16, R3HDM4, KISS1R, ARID3A, WDR18, GRIN3B, C19orf6, CNN2, ABCA7, HMHA1, POLR2E, GPX4, SBNO2, STK11, C19orf26, ATP5D, MIDN, CIRBP-AS1, CIRBP, C19orf24, EFNA2, MUM1 rs4802307 rs4802307 IGFL3, IGFL2, DKFZp434J0226, IGFL1, HIF3A, PPP5C, CCDC8, PNMAL1, PNMAL2 rs516246 rs516246 GRWD1, KCNJ14, CYTH2, LMTK3, SULT2B1, FAM83E, SPACA4, RPL18, SPHK2, DBP, CA11, SEC1, NTN5, FUT2, MAMSTR, RASIP1, IZUMO1, FUT1, FGF21, BCAT2, HSD17B14, PLEKHA4, PPP1R15A, TULP2, NUCB1, DHDH rs2284553 rs2284553 C21orf54, IFNAR2, IL10RB, IFNAR1, IFNGR2, TMEM50B, DNAJC28, GART, SON, DONSON, CRYZL1, ITSN1 - The correlation coefficient between pairs of loci may be reflected by the term r-squared (r2), which may be used a measure of the degree to which alternative genetic markers provide similar diagnostic or prognostic information. The value of r2 ranges between 0 and 1 (1 when two markers provide identical information, and 0 when they are in perfect equilibrium). Conventionally, markers with r2>0.8 may be considered to be in high linkage disequilibrium, so that they may provide similar diagnostic or prognostic information. Accordingly, an aspect of the assays described herein involves the use of makers that are in linkage disequilibrium with the markers identified above, having for example r2>0.7, r2>0.8, r2>0.9 or r2>0.95. In addition, markers that provide related information may be characterized by physical proximity in the genome, for example being within 1 Mbp of each other, for example within 50 Kb, 60 Kb, 70 Kb, 80 Kb, 90 Kb, 100 Kb, 200 Kb, 300 Kb, 400 Kb or 500 Kb of each other.
- In accordance with the foregoing, a “genetic SSI response marker” means a genetic biomarker, the presence of which is correlated with the probability of response to a treatment with an SSI. Exemplary genetic SSI response markers are disclosed in this Example, evidencing a correlation with response to an SSI in IBD patients. Genetic SSI response markers may be detected by a wide range of genomic assays, and may also be detected by assays that interrogate the transcription or translation products of a genome, for example protein isoforms associated with a particular genomic allele. Similarly, “biochemical SSI response markers” are disclosed herein that provide a biochemical indication of response to an SSI therapy, these for example include temporal or special changes in cellular populations or in the abundance or concentration of biologically relevant molecules. Biochemical and genetic SSI response markers may be used as diagnostic or prognostic indicators in the context of an SSI treatment, for example for IBD in general, or for specific forms of IBD such as Crohn's Disease and ulcerative colitis. Exemplary genetic SSI response markers are set out in Table 27b, as well as Tables 23 to 26.
-
TABLE 27b Genetic SSI Response Markers Response SNP Allele SNP related allele (or isoform) IBD rs9286879 A TNFSF18, TNFSF4, FASLG Crohn's rs7517810 G TNFSF18, TNFSF4, FASLG Crohn's rs17391694 G DNAJB4 (HSP-40 family member), Crohn's GIPC2, NEXN, FUBP1, MGC27382 rs17085007 A GPR12 UC rs2024092 A CNN2, GPX4, POLR2E, STK11, UC ABCA7, SBNO2, HMHA1 rs6017342 T HNF4A, SERINC3, PKIG, TTPAL, UC R3HDM - This Example provides an analysis of the PRR receptors that are the targets for alternative SSIs.
-
TABLE 28 List of PRRs stimulated by select SSIs, including QBKPN, QBECO and QBSAU. Where a PRR is “Optional”, this indicates that some embodiments may be designed to include agonists for the specificed PRR. Pattern Recognition Receptor Major Agonists QBECO QBKPN QBSAU TLRs (Toll-Like Receptors) TLR1 Triacyl lipoprotein/peptidoglycan Yes Yes Yes TLR2 Glycolipds, Lipoprotein, Yes Yes Yes lipopeptides, lipoteichoic acid, others TLR3 dsRNA (viral) No No No TLR4 Lipopolysaccharide (LPS), heat Yes Yes No shock proteins, others TLR5 Flagellin, Profilin Yes No No TLR6 Diacyl lipoprotein Yes Yes Yes TLR7 ssRNA No No No TLR9 CpG-DNA Yes Yes Yes TLR10 Unclear Optional Optional Optional CLR (C-Type Lectin Receptors) (PMID 21616435) Mannose Mannose, N-acetylglucosamine Optional Optional Optional Receptor (MR) and fucose on glycans DEC-205 Promiscuous antigen receptor - Optional Optional Optional Class B CpG-DNA (Lahoud et al. 2012. PNAS) Macrophage α- or β-N-acetylgalactosamine Optional Optional Optional galactose-type (GalNAc, Tn) residues of N- lectin (MGL) and O-glycans carried by glycoproteins and/or glycosphingolipids (PMID 15802303) DC-SIGN (CD- High-mannose-containing Optional Optional Optional 209) glycoproteins Langerin (CD207) Similar to CD-209 Optional Optional Optional Mannose Binding Mannose and N- Optional Optional Optional Lectin (MBL) acetylucosamine Myeloid DAP12- Unclear, dengue viral particles Optional Optional Optional associating lectin (PMC3204838) (MDL-1/CLEC5A) Dectin1/CLEC7A B glucans on fungi, Optional Optional Optional mycobacteria DNGR1/CLEC9A Actin filaments (no microbial Optional Optional Optional ligands identified) SIGNR3 Mycobacterium tuberculosis Optional Optional Optional CLEC4B1 Not Determined Optional Optional Optional CLEC4B2 Not Determined Optional Optional Optional CLEC2 Endogenous (prodoplanin), Optional Optional Optional snake venom, HIV CLEC12B Not Determined Optional Optional Optional CLEC12A Not Determined Optional Optional Optional DCIR/CLEC4A HIV-1 Optional Optional Optional Dectin 2/CLEC6A Mannose-type carbohydrates Optional Optional Optional CLEC4C Unclear Optional Optional Optional CLEC4E (Mincle) Fungal a-mannose and others Optional Optional Optional NLR (Nod-Like Receptors) NOD1 diaminopimelatic acid (DAP)- Optional Optional Optional containing muropeptide NOD2 muramyl dipeptide (MDP) Yes Yes Optional moieties universal to all bacterial peptidoglycan NLRC3 (NOD3) Cytosolic DNA, cyclic di-GMP, Optional Optional Optional DNA viruses (PMID 24560620) This is an inhibitory PRR. NLRC4 (NOD4) Flagellin, components of the Optional Optional Optional type three secretion system, others NLRC6 Unclear Optional Optional Optional NLRX1 (NOD5) Unclear Optional Optional Optional NALP1-14 Pathway unclear (Anthrax and Optional Optional Optional muramyldipeptide for NALP1) NAIP Unclear Optional Optional Optional CIITA (NLRA) Unclear (does not directly bind Optional Optional Optional DNA) RLR (Rig-1 Like Receptors) RIG-1 dsRNA (viral), maybe bacterial Optional Optional Optional MDA5 dsRNA (viral) Optional Optional Optional LGP2 dsRNA (viral) Optional Optional Optional Others DAI (DNA- DNA Optional Optional Optional dependent activator of IRFs) (PMID 20098460) AIM2 (PMID dsDNA Optional Optional Optional 20098460) Caspase 11 LPS Optional Optional Optional (PMID 25145754) LBP LPS Optional Optional Optional (Lipopolysaccharide Binding Protein CD14 LPS Optional Optional Optional Scavenger Receptors LPS Optional Optional Optional Beta2 Integrins LPS Optional Optional Optional Peptidoglycan Peptidoglycan Minor Minor Major receptor proteins (4 different receptors) -
TABLE 29 PRR agonists in select fractionated SSIs, particularly in the DNA fractions Examplified herein. DNA Fractions Component QBECO QBKPN DNA TLR9 TLR9 AIM2 AIM2 DAI DAI RIG-1 RIG-1 DEC205 DEC205 NLRC3 NLRC3 -
TABLE 30 PRR agonists in select fractionated SSIs, particularly in the outer membrane fractions as Examplified herein. Outer Membrane Fractions Component QBECO QBKPN LPS TLR4 TLR4 LBP LBP CD14 CD14 Caspase 11 Caspase 11 Other Scavenger Other Scavenger Receptors Receptors Lipoprotein TLR1 TLR1 TLR2 TLR2 TLR6 TLR6 Flagellin TLR5 N/A NOD4 NOD4 Peptidoglycan NOD2 NOD2 Capsule N/A TLRs and CLRs Other Collection of CLRs - Accordingly, in select embodiments, SSI therapies are provided that target a select subset of PRRs, using microbial PRR agonists derived from microbial pathogens of a target tissue. For example, an immunogenic composition is provided that comprises microbial agonists for at least a select number of distinct PRRs, for use so as to illicit an innate response in a target tissue, wherein the PRR agonists are microbial components from a single species of microbe that is selectively pathogenic in the target tissue. The number of distinct PRRs targeted by the agonists may for example be a number from 5 to 25, or at least a number within that range of integers, for example at least 5, 6, etc. The distinct PRRs may for example be selected from the PRRs set out in Tables 28, 29 and/or 30.
- This Example provides an indication of cytokine markers indicative of various facets of SSI therapies. This data reflects the analysis of 42 cytokines/chemokines from a cohort of Crohn's Disease patients undergoing SSI therapy with QBECO, at baseline,
week 4,week 8,week 16, andweek 24, of a randomized placebo-controlled trial involving 68 patients. - Cytokines Changes with QBECO Exposure
- QBECO exposure increased IL-18 and IP-10 at both the 8 week and 16 week time points. Serum levels of IL-18 showed the most significant differences between patients treated with QBECO vs. Placebo at week 8 (
median change 24 pg/mL, adjusted p=0.0256) (FIG. 74 ). This increase in IL-18 was evident at theweek 16 time point as well. The second serum biomarker to show significant differences was IFNγ-inducible protein 10 (IP-10, also known as CXCL10) which showed greater increases in QBECO exposed patients at both week 8 (median change 7 pg/mL, adjusted p=0.036) and week 16 (median change 22 pg/mL, adjusted p=0.0151). - Vascular endothelial growth factor A (VEGF-A) showed some increase in the QBECO group at the
week 8 mark (median change 14 pg/mL, adjusted p=0.0483), but this difference was lost at the end of theweek 16 treatment point. A number of other immune factors showed strong trends in being increased from baseline to 8 weeks of QBECO exposure; these included: granulocyte colony stimulating factor (GCSF), IFNγ, IL-17A, IL-6, IL-7, and transforming growth factor-α (TGFα). - None of the serum immune factors remained elevated after patients were taken off all treatment after
week 16 and evaluated again atweek 24, illustrating that these biomarkers are most helpful to assess the immune responsiveness to QBECO while on treatment. - Serum Biomarker Cytokine Concentration Changes that Associate with Clinical Response
- A sub-analysis was performed in patients exposed to QBECO (N=42, including those initially randomized to QBECO and those who were switched from placebo at week 8) to assess whether any of the immune changes over time associated with clinical outcome. Il-18 increased less among those with clinical response and remission, compared to non responders. IP-10 increased less among those with clinical response and remission, compared to non responders. IFNγ, IL-12p70, IL-17A and TGFα showed a significant difference in increase over time for responders compared to non responders. In particular, IFNγ, IL-12p70, IL-17A and TGFα, had greater increases over-time (adjusted p=0.0344) in patients who experienced a clinical response to QBECO in comparison to non-responders at week 8 (
FIG. 75 ). - Baseline Serum Immune Factors that Associate with Clinical Response
- Lower Eotaxin 1 was a predictive biomarker for remission in response to QBECO treatment. In particular, baseline serum levels of Eotaxin-1 (C-C chemokine 11) had the strongest link to clinical remission (adjusted p=0.0016), with patients who had higher levels at baseline being less likely to go into clinical into clinical remission by
week 8 with QBECO treatment (FIG. 76 ). Although not reaching statistical significance after correcting for multiple comparisons, patients with higher baseline IL-10 and IL-12p40 were also less likely to have a clinical response to QBECO treatment by week 8 (FIG. 76 ). - Trial results indicate that patients who had been previously exposed to TNFα inhibitors, such as Remicade™ or Humera™, were less likely to experience clinical remission or response after 8 weeks of QBECO treatment. This more difficult to treat group may have more severe immune dysfunction, due to their exposure to these immunosuppressive drugs and/or by virtue of the nature of their condition. Stratifying the mean baseline serum levels of the immune factors that associated with clinical outcome by previous TNFα inhibitor exposure provides evidence to support this. The baseline serum immune factors that inversely associated with patient response to QBECO, Eoxtaxin-1, IL-10 and IL-12p40, were higher in patients previously exposed to anti-TNFα therapy relative to unexposed patients (Table 31).
-
TABLE 31 Mean baseline serum levels of Eotaxin-1, IL-10 and IL- 12p40 stratified by previous TNFα inhibitor exposure Previous 95% anti- Mean Confidence TNFα Mean ± Difference ± Interval of the therapy N* SD SD Difference Eotaxin-1 No 39 84 ± 43 −17 ± 12 (−41, 7) Yes 26 100 ± 54 IL-10 No 28 6 ± 14 −5 ± 5 (−14, 4) Yes 17 11 ± 17 IL- 12p40 No 36 19 ± 67 −52 ± 36 (−123, 20) Yes 24 70 ± 198 *20 reads from the IL-10 assay and 5 reads from the IL-12p40 were out of range of the assay or unreliable - In anti-TNFα naïve patients, treatment with QBECO SSI for 8 weeks resulted in a statistically significant response rate of 64% compared to 27% in the placebo control (p=0.041). Clinical remission rates after 8 weeks of treatment were also impressive at 50%, more than double the placebo rate of 23% (p=0.16). Clinical response and remission rates were assessed using the standard Crohn's Disease Activity Index (CDAI), defined as a decrease in CDAI of ≥70 points (response) and CDAI score ≤150 points (remission). Anti-TNFα naïve patients include, for example, patients who have not been treated with the immunosuppressive drugs Remicade®, Humira®, Cimzia® and Simponi®. In patients previously been treated with TNFα inhibitors who completed 16 weeks of SSI treatment, 40% were in remission, indicating that this more challenging patient group may respond to QBECO SSI with longer treatment.
- Using a Regularized Logistic Regression modelling approach, which simultaneously selects variables with the strongest association with response and optimally weights them to generate a prediction score, a composite prediction model was built including both the baseline biomarker measures (i.e. the 42 immune factors including cytokines, chemokines and growth factors) and baseline clinical and demographic characteristics. The variables available for the latter included enrollment year, age at randomization, age at diagnosis, time from diagnosis to randomization, sex, race (Caucasian or not), site (Vancouver or not), prior anti-TNFα therapy, baseline Crohn's Disease Activity Index (CDAI) score, baseline fecal calprotectin levels, and baseline C-reactive protein levels.
- An “optimism-adjusted” area-under the receiver operating curve (AUROC) was made to correct for the potential over-estimation of the model fit. This “optimism-adjusted” AUROC can thus be more readily reliably applied to future independent data.
- As shown in the analysis in this Example, high baseline serum Eotaxin-1 was the strongest negative biomarker predictor for clinical response after 8 weeks of QBECO treatment and was included in all models generated. Of the clinical/demographic variables—sex (females were more likely to respond to QBECO treatment) and previous anti-TNFα therapy (those previously exposed less likely to respond to QBECO) were the strongest predictors. Table 32 summarizes the different models generated. Typical commercial biomarker standards require an AUROC >7 for commercial viability of a prediction model. After optimism-adjustment, the composite model generated from this data achieved this level of predictive value with the inclusion of the following variables: sex, prior TNFα therapy, and baseline levels of Eotaxin-1, GROα (also called CXCL1—a neutrophil chemokine), IL-10, PDGF AA and RANTES (also called CCL5—a chemokine for activated T cells, eosinophils, basophils). Alternatively, a predictive model may also be developed using Eotaxin, GROα, IL10, PDGF AA, RANTES, Sex and prior aTNFα, predicting response with high confidence.
-
TABLE 32 Performance of four prediction models for clinical response and clinical remission following 8 weeks of QBECO treatment Clinical Response @ 8 Weeks Clinical Remission @ 8 Weeks Optimism- Optimism- Variables Raw Adjusted Variables Raw Adjusted Candidates Included AUROC AUROC Included AUROC AUROC Reliable Eotaxin 1 0.737 0.591 Eotaxin 10.846 0.644* Cytokines PDGF AA (0.59, 0.88) (0.44, 0.73) GRO α (0.72, 0.97) (0.52, 0.77) Only PDGF AA All Eotaxin 1 0.753 0.588 Eotaxin 10.842 0.612 Cytokines IL 10 (0.60, 0.90) (0.43, 0.73) GRO α (0.71, 0.97) (0.50, 0.74) PDGF AA PDGF AA Clinical/ Sex Prior 0.760 0.642 Sex 0.674 0.627 Demographic aTNFα (0.62, 0.90) (0.50, 0.78) (0.53, 0.81) (0.48, 0.76) Variables All Eotaxin 10.858 0.700* Eotaxin 10.881 0.707* Cytokines GRO α (0.75, 0.97) (0.59, 0.81) GRO α (0.77, 0.99) (0.60, 0.82) and All IL 10PDGF AA Clinical/ PDGF AA RANTES Demographic RANTES Sex Variables Sex Prior aTNFα *significant at 0.05 level. - Cytokine change with QBECO exposure: IL-18 (adjusted p=0.011 @ 8 weeks and 0.067 @ 16 weeks) and IP-10 (adjusted p=0.036 @ 8 weeks and 0.015 @16 Weeks) demonstrated a substantial and statistically significant increase with exposure to QBECO. These two cytokines also demonstrated significantly different trajectories for Clinical Responders vs Non-Responders (adjusted p=0.0328 for both) and those in and not in Clinical Remission (adjusted p=0.0368 for both) at
week 8. Further, IL-18 demonstrated significantly different trajectory for those randomized to QBECO vs Placebo (adjusted p=0.0256). - Cytokine Association with Outcome: Baseline Eotaxin-1 concentration was most strongly associated with clinical outcome among QBECO exposed subjects; those with higher Eotaxin-1 concentration at baseline were more likely to achieve Clinical Remission (adjusted p=0.0016) following 8 weeks of QBECO exposure.
- Composite Biomarker: Baseline concentration of Eotaxin-1, GRO-α, IL-10, PDGF AA and RANTES, combined with clinical variables Sex, and Prior anti-TNFAα exposure provided predictions of 8-week clinical outcomes that were significantly better than chance (optimism-adjusted AUROC=0.70, 95% CI [0.59, 0.81] for Response and 0.71, 95% CI [0.60,0.82] for Remission). This model had some observable predictive ability for subjects in the Placebo group (AUROC=0.67 95% CI [0.45, 0.89] for Response and 0.70 [0.47, 0.93] for Remission.
- QBECO SSI therapy provokes a biological response by increasing certain cytokines (IL-18 and IP-10) over time. Surprisingly, although both cytokines are increased after QBECO treatment, patients who were responders increased less. Treatment protocols, such as dosing, may accordingly be adjusted to achieve this result.
- IFNg, IL-12P70, IL-17A and TGFa increased more in responders than non responders. Treatment protocols, such as dosing, may accordingly be adjusted to achieve this result. TGFa may for example be used as a marker of mucosal healing.
-
Lower Eotaxin 1 levels may be used as an indicator of patients more amenable to SSI treatment. - In conclusion:
-
- an increase in serum IL-18 from baseline to
week - a subsequent rise in serum levels of IFNγ, IL-12p70, IL-17A and TGFα after 8 weeks of QBECO treatment associated with clinical response;
- Crohn's patients with higher baseline levels of Eotaxin-1 (and to a lesser extent, IL-10 and IL-12p40) were less likely to experience a clinical response or remission to QBECO after 8 weeks of treatment; previous anti-TNFα therapy may predispose to having higher levels of these factors, and anti-TNFα naïve patients represent a distinct Crohn's patient population amenable to QBECO SSI therapy;
- a composite model that includes baseline serum biomarkers and clinical/demographic data would be able to predict, after optimism-adjustment (AUROC ≥7), a patient's likelihood to respond to 8 weeks of QBECO treatment; the variables in the final model includes sex, previous anti-TNFα therapy and baseline serum levels of Eotaxin-1, GROα, IL-10, PDGF AA and RANTES.
- an increase in serum IL-18 from baseline to
- This biomarker analysis illustrates the formulation of a viable predictive composite model that can provide personalized treatment for Crohn's disease. This biomarker analysis maybe useful alone, or in combination with the genetic analysis exemplified herein, which showed significant stratification between responders and non-responders based on a derivation of a gene score.
- This Example illustrates results from a mouse model of chemically induced colitis, used to assess the efficacy of QBECO SSI therapy. Mice were given dextran sodium sulfate (DSS) in drinking water to induce colitis that mimics human ulcerative colitis. In the disease model, one cohort of mice was exposed to DSS for 7 days, a second cohort was exposed to DSS for 7 days followed by 3 days of water. Mice were given SSI injections every other day during a 10 day period prior to DSS exposure. The SSI injections continued every other day during DSS exposure. The results, as illustrated, indicate that SSI treatment with QBECO ameliorates disease severity by limiting weight loss (
FIG. 77 ), lowering disease severity (FIG. 78 ) and maintaining mucosal barrier function (FIG. 79 ). The pharmacodynamics of QBECO SSI treatment in this model are illustrated by the blood neutrophil (FIG. 80 ) and blood cytokine (FIG. 81 ) levels in disease-free mice treated with QBECO or placebo, with the pharmacokinetics of QBKPN (FIG. 82 ) used to model the pharmacokinetics of SSIs in general, including QBECO (QBKPN SSI was fluorescently labelled and subcutaneously injected into disease-free mice, mice were bled at different timepoints over 48 hours). - This Example illustrates results from a mouse cancer model, showing a tissue-specific biomarker response to SSI therapy. As illustrated in
FIG. 83 , gene expression in the lung tissues evidences tissue-specific SSI responses for CXCL10 (IP-10), CCL2 (MCP-1) and CCR2. In this Example, mice were treated every second day for 10 days with Placebo, QBKPN or QBECO before B16F10 tumour implantation into the lungs via tail vein injection. Treatment continued every second day after tumour inoculation. Mice were euthanized on day 5 (A, C, E) or day 17 (B, D, F). Accordingly, in alternative embodiments, CXCL10 (IP-10), CCL2 (MCP-1) and/or CCR2 may be used as biochemical SSI response markers, for example in biopsy tissue sample assays.
Claims (17)
1-8. (canceled)
9. The method according to claim 36 , wherein the therapeutic vehicle further comprises one or more of: GMCSF, vitamin D, NOHA, alph1 antitrypsin, glutathione, an isoprenoid, or α-galactosylceramide.
10-19. (canceled)
20. The method according to claim 36 , wherein therapeutic vehicle is administered at an administration site that is the skin or subcutaneous tissue.
21-24. (canceled)
25. The method according to claim 36 , wherein the therapeutic vehicle is administered in a plurality of doses over a dosage duration, and the dosage duration is at least two weeks.
26. The method according to claim 25 , wherein the doses are administered subcutaneously every day, or every other day.
27. (canceled)
28. The method according to claim 36 , wherein the patient is immunosuppressed or immunocompromised.
29. The method according to claim 36 , wherein the patient is a geriatric patient.
30. The method according to claim 36 , wherein the patient is a pediatric patient.
31-32. (canceled)
33. The method of claim 36 , wherein the Klebsiella spp. is a K. variicola or K. pneumonia that is a pathogenic strain of K. variicola or K. pneumonia.
34-35. (canceled)
36. A method of treating neutropenia in a human patient, comprising administering to the patient an effective amount of a therapeutic vehicle, comprising a whole killed or attenuated cell of a Klebsiella spp.
37. The method of claim 36 , wherein the neutropenia is caused by a myelosuppressive chemotherapy.
38-73. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/542,820 US20220236284A1 (en) | 2016-04-26 | 2021-12-06 | Therapeutically Triggering an Innate Immune Response in a Target Tissue |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662327953P | 2016-04-26 | 2016-04-26 | |
US201662385798P | 2016-09-09 | 2016-09-09 | |
US201662395783P | 2016-09-16 | 2016-09-16 | |
US201662421511P | 2016-11-14 | 2016-11-14 | |
US201762442759P | 2017-01-05 | 2017-01-05 | |
US201762457618P | 2017-02-10 | 2017-02-10 | |
US201762472394P | 2017-03-16 | 2017-03-16 | |
PCT/CA2017/050513 WO2017185180A1 (en) | 2016-04-26 | 2017-04-26 | Therapeutically triggering an innate immune response in a target tissue |
US201816096120A | 2018-10-24 | 2018-10-24 | |
US17/542,820 US20220236284A1 (en) | 2016-04-26 | 2021-12-06 | Therapeutically Triggering an Innate Immune Response in a Target Tissue |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2017/050513 Continuation WO2017185180A1 (en) | 2016-04-26 | 2017-04-26 | Therapeutically triggering an innate immune response in a target tissue |
US16/096,120 Continuation US11226340B2 (en) | 2016-04-26 | 2017-04-26 | Therapeutically triggering an innate immune response in a target tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220236284A1 true US20220236284A1 (en) | 2022-07-28 |
Family
ID=60161769
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/096,120 Active US11226340B2 (en) | 2016-04-26 | 2017-04-26 | Therapeutically triggering an innate immune response in a target tissue |
US17/542,820 Pending US20220236284A1 (en) | 2016-04-26 | 2021-12-06 | Therapeutically Triggering an Innate Immune Response in a Target Tissue |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/096,120 Active US11226340B2 (en) | 2016-04-26 | 2017-04-26 | Therapeutically triggering an innate immune response in a target tissue |
Country Status (6)
Country | Link |
---|---|
US (2) | US11226340B2 (en) |
EP (1) | EP3448397A4 (en) |
JP (2) | JP2019514939A (en) |
CN (1) | CN109414461A (en) |
CA (1) | CA3061077A1 (en) |
WO (1) | WO2017185180A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10130663B2 (en) | 2015-02-11 | 2018-11-20 | The John Hopkins University | Bacteria over-expressing c-di-AMP and therapeutic methods |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
WO2018085937A1 (en) * | 2016-11-14 | 2018-05-17 | Qu Biologics Inc. | Managing site specific ibd immunotherapies |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
CN108254571A (en) * | 2018-01-02 | 2018-07-06 | 江苏浩欧博生物医药股份有限公司 | A kind of detection kit and its detection method of anti-dsDNA antibody IgG |
CA3086832A1 (en) * | 2018-01-03 | 2019-07-11 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
US10907161B2 (en) | 2018-04-19 | 2021-02-02 | Checkmate Pharmaceuticals, Inc. | Synthetic RIG-I-like receptor agonists |
CA3124970A1 (en) * | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
WO2020163713A1 (en) * | 2019-02-08 | 2020-08-13 | Cedars-Sinai Medical Center | Methods, systems, and kits for treating inflammatory disease targeting skap2 |
JP7106487B2 (en) * | 2019-04-23 | 2022-07-26 | ジェネシスヘルスケア株式会社 | How to determine your risk of ulcerative colitis |
CA3137119A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
CN113679829B (en) * | 2020-05-18 | 2024-01-02 | 北京繁易纳维科技有限公司 | Tumor vaccine for preventing postoperative recurrence of cancer, and preparation method and application thereof |
CN113801931B (en) * | 2020-09-01 | 2024-03-08 | 吉林大学 | CEBPA, PPARgamma, CREBBP gene SNP detection substance related to ONFH risk and application thereof |
CN112362640B (en) * | 2020-10-11 | 2021-10-26 | 华中农业大学 | Screening method and application of streptococcus suis c-di-AMP synthetase inhibitor |
CN112772560A (en) * | 2021-01-07 | 2021-05-11 | 昆明医科大学 | Method for establishing animal model of caenorhabditis elegans for pathogenic bacteria forgetting |
JP2024510510A (en) * | 2021-03-24 | 2024-03-07 | クー バイオロジックス インコーポレイテッド | Perioperative innate immune priming in cancer treatment |
US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
CN114592051B (en) * | 2022-03-30 | 2023-04-21 | 邢珺月 | Biomarker and kit for auxiliary diagnosis of myocardial injury |
KR20230144870A (en) * | 2022-04-08 | 2023-10-17 | 전남대학교산학협력단 | A Pharmaceutical composition for treating neuropathic pain comprising Mincle inhibitor |
CN116593700B (en) * | 2023-05-24 | 2024-02-06 | 中日友好医院(中日友好临床医学研究所) | Molecular marker for identifying MDA 5-resistant positive dermatomyositis patient |
CN118006765B (en) * | 2024-04-08 | 2024-06-25 | 北京大学第三医院(北京大学第三临床医学院) | Kit for detecting BCAT2 rs493841 polymorphism and application thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010420A1 (en) * | 1994-10-04 | 1996-04-11 | Sotomayor, Tevic, Emar | Composition and treatment for hyperimmunization with non heat-killed bacteria |
US6893815B1 (en) | 1997-06-30 | 2005-05-17 | Isis Pharmaceuticals, Inc. | Nucleobase heterocyclic combinatorialization |
WO1999018206A2 (en) * | 1997-10-08 | 1999-04-15 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Human cancer antigen ny eso-1/cag-3 and gene encoding same |
EP1806403A3 (en) * | 1997-10-08 | 2008-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Human cancer antigen NY ESO 1/CAG-3 and gene encoding same |
AU2001286405B2 (en) | 2000-07-31 | 2007-05-10 | Yale University | Innate immune system-directed vaccines |
AU2002361682A1 (en) | 2001-12-14 | 2003-06-30 | Elizabeth Kopp | Innate immune system-directed vaccines |
US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
US8034359B2 (en) | 2004-06-07 | 2011-10-11 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to cancers |
US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
EP1765391B1 (en) | 2004-06-07 | 2013-03-06 | Qu Biologics Inc | Bacterial compositions for the treatment of cancer |
US8858930B2 (en) * | 2004-10-26 | 2014-10-14 | Chengru Zhu | Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic Escherichia coli in cattle |
US20060205012A1 (en) * | 2004-12-09 | 2006-09-14 | Meso Scale Technologies, Llc | Diagnostic test |
US20070059319A1 (en) | 2005-09-15 | 2007-03-15 | Caliper Life Sciences, Inc. | Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants |
NZ576590A (en) | 2006-10-27 | 2012-08-31 | Qu Biolog Inc | Tissue targeted antigenic activation of the immune response to treat cancers |
WO2008092134A2 (en) * | 2007-01-26 | 2008-07-31 | Memorial Sloan-Kettering Cancer Center | Tumor-specific antigens, cytotoxic t lymphocytes responsive thereto, and methods of using the same |
EP2170931A4 (en) * | 2007-06-15 | 2010-06-30 | Immurx Inc | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
WO2009003905A2 (en) | 2007-06-29 | 2009-01-08 | Biomonitor A/S | Prognostic method for the determination of the suitability of biopharmaceutical treatment |
WO2010062960A2 (en) * | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
US8980279B2 (en) * | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
WO2012012874A1 (en) | 2010-07-26 | 2012-02-02 | Qu Biologics Inc. | Immunogenic anti-inflammatory compositions |
MX362132B (en) * | 2011-05-10 | 2019-01-07 | Nestec Sa | Methods of disease activity profiling for personalized therapy management. |
WO2013030670A2 (en) | 2011-08-29 | 2013-03-07 | Qu Biologics | Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers |
SG11201606625RA (en) * | 2014-02-14 | 2016-09-29 | Immune Design Corp | Immunotherapy of cancer through combination of local and systemic immune stimulation |
CN106456740B (en) | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | Antimicrobial immunomodulation |
EP3402498A1 (en) * | 2016-01-11 | 2018-11-21 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
WO2018085937A1 (en) | 2016-11-14 | 2018-05-17 | Qu Biologics Inc. | Managing site specific ibd immunotherapies |
CA3086832A1 (en) * | 2018-01-03 | 2019-07-11 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
-
2017
- 2017-04-26 US US16/096,120 patent/US11226340B2/en active Active
- 2017-04-26 EP EP17788461.6A patent/EP3448397A4/en active Pending
- 2017-04-26 CA CA3061077A patent/CA3061077A1/en active Pending
- 2017-04-26 WO PCT/CA2017/050513 patent/WO2017185180A1/en unknown
- 2017-04-26 JP JP2018556963A patent/JP2019514939A/en active Pending
- 2017-04-26 CN CN201780039137.XA patent/CN109414461A/en active Pending
-
2021
- 2021-12-06 US US17/542,820 patent/US20220236284A1/en active Pending
-
2023
- 2023-03-22 JP JP2023044841A patent/JP2023068095A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3448397A4 (en) | 2020-01-08 |
JP2023068095A (en) | 2023-05-16 |
US20190134172A1 (en) | 2019-05-09 |
CN109414461A (en) | 2019-03-01 |
WO2017185180A1 (en) | 2017-11-02 |
US11226340B2 (en) | 2022-01-18 |
JP2019514939A (en) | 2019-06-06 |
CA3061077A1 (en) | 2017-11-02 |
EP3448397A1 (en) | 2019-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220236284A1 (en) | Therapeutically Triggering an Innate Immune Response in a Target Tissue | |
Brown et al. | Memory Th1 cells are protective in invasive Staphylococcus aureus infection | |
McAleer et al. | Directing traffic: IL‐17 and IL‐22 coordinate pulmonary immune defense | |
KR20160079122A (en) | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment | |
Matthijs et al. | Systems immunology characterization of novel vaccine formulations for Mycoplasma hyopneumoniae bacterins | |
Ray et al. | Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A | |
Bi et al. | The combinations chitosan-Pam3CSK4 and chitosan-monophosphoryl lipid A: promising immune-enhancing adjuvants for anticaries vaccine PAc | |
US20210052645A1 (en) | Innate Targeting of Adoptive Cellular Therapies | |
Braverman et al. | Staphylococcus aureus specific lung resident memory CD4+ Th1 cells attenuate the severity of influenza virus induced secondary bacterial pneumonia | |
Senevirathne et al. | Prospective lipid-A altered live attenuated Salmonella Gallinarum confers protectivity, DIVA capability, safety and low endotoxicity against fowl typhoid | |
KR20180119864A (en) | Pharmaceutical composition containing attenuated streptococcus pneumoniae and uses thereof | |
Sutton et al. | Helicobacter pylori vaccines spiral into the new millennium | |
Jiang et al. | An attenuated multiple genetic mutant of Mycoplasma pneumoniae imparts good immuno-protection against M. pneumoniae pneumonia in BALB/c mice | |
WO2018085937A1 (en) | Managing site specific ibd immunotherapies | |
Kopitar et al. | Specific T cell responses to Helicobacter pylori predict successful eradication therapy | |
US20240091277A1 (en) | Perioperative Innate Immune Priming in Cancer Therapy | |
US20190374632A1 (en) | Compositions and methods of treating autoimmune disease by reducing enterococcus | |
Lévy et al. | Analysis of the impact of corticosteroids adjuvant treatment during experimental invasive meningococcal infection in mice | |
US20230346925A1 (en) | Triple vaccine protects against bacterial and fungal pathogens via trained immunity | |
US20240082393A1 (en) | Adjuvants to stimulate broad and persistent innate immunity against diverse antigens | |
Orgel | Advances in Treatments and Animal Models of Peanut Allergy | |
Maisonneuve | The Innate Immune Receptor Nod1 in Reprogramming the Myeloid Compartment: Implications for Colorectal Cancer | |
Kyburz | Exploiting the Intergenerational Immunomodulatory Properties of Helicobacter Pylori for the Treatment of Allergic Disorders | |
Blanco et al. | IgA response by oral infection with an attenuated Yersinia enterocolitica mutant: Implications for its use as oral carrier vaccine | |
Blaecher | Helicobacter suis and the stomach-brain axis: epidemiological, pathogenetic and diagnostic aspects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: QU BIOLOGICS INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GUNN, HAROLD DAVID;MULLINS, DAVID W.;KALYAN, SHIRIN;AND OTHERS;SIGNING DATES FROM 20180411 TO 20180515;REEL/FRAME:059325/0275 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |